<SEC-DOCUMENT>0001104659-24-041120.txt : 20240329
<SEC-HEADER>0001104659-24-041120.hdr.sgml : 20240329
<ACCEPTANCE-DATETIME>20240329153330
ACCESSION NUMBER:		0001104659-24-041120
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		5
FILED AS OF DATE:		20240329
DATE AS OF CHANGE:		20240329

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Adagene Inc.
		CENTRAL INDEX KEY:			0001818838
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-264486
		FILM NUMBER:		24803955

	BUSINESS ADDRESS:	
		STREET 1:		4F, BUILDING C14, NO. 218, XINGHU STREET
		STREET 2:		SUZHOU INDUSTRIAL PARK
		CITY:			JIANGSU
		STATE:			F4
		ZIP:			00000
		BUSINESS PHONE:		86-512-87773632

	MAIL ADDRESS:	
		STREET 1:		4F, BUILDING C14, NO. 218, XINGHU STREET
		STREET 2:		SUZHOU INDUSTRIAL PARK
		CITY:			JIANGSU
		STATE:			F4
		ZIP:			00000
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>tm2213007-9_424b5.htm
<DESCRIPTION>424B5
<TEXT>
<html>
  <head>
    <title>tm2213007-9_424b5 - none - 9.5570855s</title>
  </head>
  <body style="margin-left:auto;margin-right:auto;width:595.31pt;">
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;margin-bottom:21.86pt;margin-left:27pt;width:541.31pt;">
        <div style="text-align:right; width:541.31pt; line-height:10pt;font-weight:bold;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">&#8202;As Filed Pursuant to Rule&#160;424(b)(5)</font>&#8203;</div>
        <div style="margin-top:-0.1pt; text-align:right; width:541.31pt; line-height:12pt;font-weight:bold;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">&#8202;Registration No. 333-264486</font>&#8203;</div>
        <div style="margin-top:1.9pt; width:541.31pt; line-height:10.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.18pt;">PROSPECTUS SUPPLEMENT </font> <br ><font style="letter-spacing:0.18pt;">(To Prospectus dated May&#160;26, 2022 ) </font></div>
        <div style="position:relative;margin-top:6.9pt; text-align:center; width:541.31pt;">
          <img src="lg_adagene-4clr.jpg" alt="[MISSING IMAGE: lg_adagene-4clr.jpg]" height="44" width="204" >
        </div>
        <div style="margin-top:9.5pt; text-align:center; width:541.31pt; line-height:19.5pt;font-weight:bold;font-size:18pt;">
          <font style="letter-spacing:-0.36pt;">Adagene Inc.</font><font style="font-weight:normal;letter-spacing:0.36pt;"> </font>
        </div>
        <div style="margin-top:1pt; text-align:center; width:541.31pt; line-height:15.5pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">Up to US$100,000,000 of American Depositary Shares</font>
          <br >
          <font style="letter-spacing:-0.28pt;">Representing Ordinary Shares</font>
        </div>
        <div style="text-indent:20pt; margin-top:5pt; width:541.31pt; line-height:10.5pt;">
          <font style="letter-spacing:0.18pt;">We have entered into a Sales Agreement, or sales agreement, with Leerink Partners LLC, or Leerink Partners, dated March&#160;29, 2024, relating to the sale of American depositary shares, or ADSs, each representing one and one quarter (1.25) of our ordinary shares, par value US$0.0001 per share, or Ordinary Shares, offered by this prospectus supplement. In accordance with the terms of the sales agreement, under this prospectus supplement we may offer and sell our ADSs, having an aggregate offering price of up to US$100&#160;million from time to time through Leerink Partners LLC, acting as our agent. </font>
        </div>
        <div style="text-indent:20pt; margin-top:5pt; width:541.31pt; line-height:10.5pt;">
          <font style="letter-spacing:0.18pt;">Sales of our ADSs, together with the underlying Ordinary Shares, if any, under this prospectus supplement will be made by any method permitted that is deemed an &#8220;at the market offering&#8221; as defined in Rule&#160;415 under the Securities Act of 1933, as amended, or the Securities Act, including sales made directly on or through The Nasdaq Global Market, on or through any other existing trading market for our ADSs or to or through a market maker or otherwise, through block transactions and/or any other method permitted by law, in each case at market price. Leerink Partners is not required to sell any specific number or dollar amount of securities but will act as our sales agent using commercially reasonable efforts consistent with its normal trading and sales practices and applicable state and federal laws, rules and regulations and the rules of the Nasdaq, on mutually agreed terms between Leerink Partners and us. There is no minimum sale requirements, and there is no arrangement for funds to be received in any escrow, trust or similar arrangement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:5pt; width:541.31pt; line-height:10.5pt;">
          <font style="letter-spacing:0.18pt;">Leerink Partners will be entitled to compensation at a commission rate of up to 3.0% of the gross proceeds of any ADSs sold pursuant to the sales agreement. See &#8220;Plan of Distribution&#8221; beginning on page&#160;S-16 for additional information regarding the compensation to be paid to Leerink Partners. </font>
        </div>
        <div style="text-indent:20pt; margin-top:5pt; width:541.31pt; line-height:10.5pt;">
          <font style="letter-spacing:0.18pt;">In connection with the sale of the ADSs on our behalf, Leerink Partners may be deemed to be an &#8220;underwriter&#8221; within the meaning of the Securities Act, and the compensation of Leerink Partners may be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contribution to Leerink Partners with respect to certain liabilities, including liabilities under the Securities&#160;Act. </font>
        </div>
        <div style="text-indent:20pt; margin-top:5pt; width:541.31pt; line-height:10.5pt;">
          <font style="letter-spacing:0.18pt;">Our ADSs trade on The Nasdaq Global Market, or Nasdaq, under the trading symbol &#8220;ADAG&#8221;. On March&#160;28, 2024, the last sale price of our ADSs as reported on Nasdaq was US$2.80 per ADS. </font>
        </div>
        <div style="text-indent:20pt; margin-top:5pt; width:541.31pt; line-height:10.5pt;">
          <font style="letter-spacing:0.18pt;">We are an emerging growth company as that term is used in the Jumpstart Our Business Startups Act of 2012, and, as such, are subject to certain reduced public company reporting requirements. See &#8220;Prospectus Supplement Summary&#8201;&#8212;&#8201;Implications of Being an Emerging Growth Company&#8221; on page S-9 of this prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:5pt; width:541.31pt; line-height:10.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.18pt;">Investing in the ADSs involves risk. See &#8220;Risk Factors&#8221; beginning on page <a href="#bRIFA">S-12</a> of this prospectus supplement and in the documents incorporated by reference into this prospectus supplement and the accompanying prospectus for a discussion of certain risks that you should consider in connection with an investment in the ADSs.</font><font style="font-weight:normal;letter-spacing:0.18pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:5pt; width:541.31pt; line-height:10.5pt;">
          <font style="letter-spacing:0.18pt;">Investors in the ADSs are purchasing securities of a Cayman Islands holding company rather than securities of our subsidiaries that have substantive business operations in the United States or China. Adagene Inc. is a Cayman Islands holding company that conducts its operations and operate its business in the U.S. through its U.S. subsidiary, Adagene Incorporated. In addition, Adagene Inc. conducts its operations in China through its PRC subsidiary, Adagene (Suzhou) Limited, or Adagene Suzhou. Such structure involves unique legal and operational risks to investors in the ADSs and Ordinary Shares. In particular, the PRC government has significant authority to exert influence on the ability of a company with substantive operations in China, such as us, to conduct its business, accept foreign investments or list on a U.S. or other foreign exchanges. For example, we face risks associated with regulatory approvals of offshore offerings, anti-monopoly regulatory actions, oversight on cybersecurity and data privacy. Such risks could result in a material change in our operations and/or the value of the ADSs representing our Ordinary Shares or could significantly limit or completely hinder our ability to offer or continue to offer our Ordinary Shares represented by ADSs to investors and cause the value of such securities to significantly decline or become worthless. As we are a holding company with substantive business operations in China, you should pay special attention to disclosures included in our most recent annual report on Form 20-F incorporated by reference in this prospectus supplement and risk factors included herein. </font>
        </div>
        <div style="text-indent:20pt; margin-top:5pt; width:541.31pt; line-height:10.5pt;">
          <font style="letter-spacing:0.18pt;">In addition, our auditor is headquartered in mainland China, a jurisdiction where the Public Company Accounting Oversight Board, or PCAOB, was unable to conduct inspections without the approval of the Chinese authorities. Trading in our ADSs on the Nasdaq or over-the-counter may be prohibited, and as a result, our ADSs may be delisted under the Holding Foreign Companies Accountable Act, or HFCAA, if the PCAOB determines that it has been unable to inspect or investigate completely our auditor located in China for two consecutive&#160;years. On December&#160;16, 2021, the PCAOB issued the HFCAA Determination Report to notify the SEC of its determinations, or 2021 Determinations, that the PCAOB was unable to inspect or investigate completely registered public accounting firms headquartered in mainland China and Hong Kong, including our auditor. On December&#160;15, 2022, the PCAOB issued a report that vacated its December&#160;16, 2021 determination and removed mainland China and Hong Kong from the list of jurisdictions where it is unable to inspect or investigate completely registered public accounting firms. As a result, we do not expect to be identified as a &#8220;Commission-Identified Issuer&#8221; under the HFCAA upon filing of our annual report on Form 20-F for the year ended December&#160;31, 2023. However, whether the PCAOB will continue to be able to satisfactorily </font>
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;min-height:706pt;margin-bottom:21.86pt;margin-left:27pt;width:541.31pt;">
        <div style="width:541.31pt; line-height:10.5pt;">
          <font style="letter-spacing:0.18pt;">conduct inspections and investigations of PCAOB-registered public accounting firms headquartered in mainland China and Hong Kong is subject to uncertainty and depends on a number of factors out of our, and our auditor&#8217;s, control, including positions taken by authorities of the PRC. The PCAOB is expected to continue to demand complete access to inspections and investigations against accounting firms headquartered in mainland China and Hong Kong in the future. The PCAOB is required under the HFCAA to make its determination on an annual basis with regards to its ability to inspect and investigate completely accounting firms based in the mainland China and Hong Kong. The possibility of being a &#8220;Commission- Identified Issuer&#8221; and risk of delisting could continue to adversely affect the trading price of our securities. If the PCAOB determines in the future that it no longer has full access to inspect and investigate accounting firms headquartered in mainland China and Hong Kong and we continue to use such accounting firm to conduct audit work, we would be identified as a &#8220;Commission-Identified Issuer&#8221; under the HFCAA following the filing of the annual report for the relevant fiscal year, and if we were so identified for two consecutive&#160;years, trading in our securities on U.S. markets would be prohibited under the HFCAA. </font>
        </div>
        <div style="text-indent:20pt; margin-top:5pt; width:541.31pt; line-height:10.5pt;">
          <font style="letter-spacing:0.18pt;">The PRC government has oversight over the conduct of our business and its laws, regulations and policies may affect our operations. The PRC government has recently published new policies that affected certain industries with respect to matters such as cybersecurity, data privacy, antitrust and competition, foreign investments, and overseas listings, and we cannot rule out the possibility that it will in the future release regulations or policies regarding our industry that could adversely affect our business, financial condition and results of operations. Furthermore, the PRC regulatory authorities have recently issued new laws and regulations to exert more oversight and control over overseas securities offerings and other capital markets activities and foreign investment in China-based companies like us. Any such action, once taken by the PRC regulatory authorities, could significantly limit or completely hinder our ability to offer or continue to offer securities to investors and cause the value of such securities to significantly decline or in extreme cases, become worthless. For additional information, see &#8220;Item&#160;3. Key Information&#8201;&#8212;&#8201;3.D. Risk Factors&#8201;&#8212;&#8201;Risks Related to Doing Business in China&#8221; in our most recent annual report on Form 20-F incorporated by reference in this prospectus supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:5pt; width:541.31pt; line-height:10.5pt;">
          <font style="letter-spacing:0.18pt;">As used in this prospectus supplement, &#8220;Adagene&#8221; refers to Adagene Inc., a Cayman Islands exempted company with limited liability, &#8220;Adagene Incorporated&#8221; refers to Adagene Incorporated, our U.S. subsidiary, &#8220;Adagene Suzhou&#8221; refers to Adagene (Suzhou) Limited, a PRC incorporated company with limited liability, &#8220;Adagene Hong Kong&#8221; refers to Adagene (Hong Kong) Limited, our Hong Kong intermediary holding company, , and &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our company,&#8221; or &#8220;our&#8221; refers to Adagene Inc. and its subsidiaries. </font>
        </div>
        <div style="text-indent:20pt; margin-top:5pt; width:541.31pt; line-height:10.5pt;">
          <font style="letter-spacing:0.18pt;">With a holding company structure, we currently rely principally on equity financing for our cash requirements, including the funds necessary to pay cash considerations for services we may incur. In the future, if we become profitable and generate cash flows from operating activities, we may rely principally on dividends and other distributions on equity from our U.S., PRC and other subsidiaries for our cash requirements, including the funds necessary to pay dividends and other cash distributions to our shareholders or for services of any debt we may incur. If any of our subsidiaries or any newly formed subsidiaries incur debt on their own behalf in the future, the instruments governing their debt may restrict their ability to pay dividends or make other distributions to us. In 2021, 2022 and 2023, Adagene Inc. made payments of US$30.0&#160;million, US$24.5&#160;million and US$20.5&#160;million respectively, in cash to Adagene Suzhou as consideration for providing services associated with research and development activities related to those intellectual properties owned by Adagene Inc. There were no intercompany loans provided by Adagene Inc. to Adagene Suzhou during the&#160;years ended and as of December&#160;31, 2021, 2022 and 2023. As advised by our PRC legal counsel, Jingtian &amp; Gongcheng, Adagene Suzhou is able to mark up and charge to Adagene Inc., its ultimate parent, for providing services associated with research and development activities related to those intellectual properties owned by Adagene Inc. and Adagene Inc. is able to make cash payments to Adagene Suzhou for considerations of such services. In the future, cash proceeds raised from overseas financing activities, including this offering, may be transferred by Adagene Inc., the Cayman holding company, (i)&#160;to Adagene Incorporated, our U.S. subsidiary, (ii)&#160;through Adagene (Hong Kong) Limited, our Hong Kong subsidiary, to Adagene Suzhou, our PRC subsidiary and (iii)&#160;to other subsidiaries, via capital contribution, shareholder loans or consideration for the services rendered, as the case may be. Other than the above disclosed transfer of funds, we did not transfer any type of assets between Adagene Suzhou and other Adagene subsidiaries in 2021, 2022 or 2023. For risks associated with this structure, see &#8220;Item&#160;3. Key Information&#8201;&#8212;&#8201;3.D. Risk Factors&#8201;&#8212;&#8201;Risks Related to Doing Business in China&#8201;&#8212;&#8201;We may rely on dividends and other distributions on equity paid by our PRC subsidiary to fund any cash and financing requirements that we may have, and any limitation on the ability of our PRC subsidiary to make payments to us could have material and adverse effect on our ability to conduct our business&#8221; and &#8220;&#8212; PRC regulation of loans to and direct investment in PRC entities by offshore holding companies and governmental control of currency conversion may delay or prevent us from using the proceeds of our public offering to make loans or additional capital contributions to our PRC subsidiary, which could materially and adversely affect our liquidity and our ability to fund and expand our business&#8221; in our most recent annual report on Form 20-F incorporated by reference in this prospectus supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:5pt; width:541.31pt; line-height:10.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.18pt;">Neither the Securities and Exchange Commission nor any state securities commission nor any other regulatory body has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.</font><font style="font-weight:normal;letter-spacing:0.18pt;"> </font>
        </div>
        <div style="margin-top:57.2pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 40.024%; margin-right: 40.024%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:8.7pt; text-align:center; width:541.31pt; line-height:19.5pt;font-weight:bold;font-size:18pt;">
          <font style="letter-spacing:-0.36pt;">Leerink Partners</font><font style="font-weight:normal;letter-spacing:0.36pt;"> </font>
        </div>
        <div style="margin-top:4pt; text-align:center; width:541.31pt; line-height:10.5pt;">
          <font style="letter-spacing:0.18pt;">March&#160;29, 2024</font>
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="TOC">&#8203;</a><a name="TOC2">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">TABLE OF CONTENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:10.5pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:10pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PROSPECTUS SUPPLEMENT</font>
        </div>
        <table style="width:456pt;height:218.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:425.15pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Page </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#bATPS"><font style="letter-spacing:0.2pt;">About This Prospectus Supplement </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#bATPS">S-ii</a></font> <a href="#bATPS"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#bSNRF"><font style="letter-spacing:0.2pt;">Special Note Regarding Forward-Looking Statements </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#bSNRF">S-iii</a></font> <a href="#bSNRF"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#bSSS"><font style="letter-spacing:0.2pt;">Prospectus Supplement Summary </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#bSSS">S-1</a></font> <a href="#bSSS"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#bTHOF"><font style="letter-spacing:0.2pt;">The Offering </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#bTHOF">S-11</a></font> <a href="#bTHOF"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#bRIFA"><font style="letter-spacing:0.2pt;">Risk Factors </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#bRIFA">S-12</a></font> <a href="#bRIFA"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#bUOP"><font style="letter-spacing:0.2pt;">Use of Proceeds </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#bUOP">S-15</a></font> <a href="#bUOP"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#bDIPO"><font style="letter-spacing:0.2pt;">Dividend Policy </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#bDIPO">S-16</a></font> <a href="#bDIPO"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#bCAP"><font style="letter-spacing:0.2pt;">Capitalization </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#bCAP">S-17</a></font> <a href="#bCAP"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#bTAX"><font style="letter-spacing:0.2pt;">Taxation </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#bTAX">S-19</a></font> <a href="#bTAX"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#bPODF"><font style="letter-spacing:0.2pt;">Plan of Distribution </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#bPODF">S-25</a></font> <a href="#bPODF"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#bLEMA"><font style="letter-spacing:0.2pt;">Legal Matters </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#bLEMA">S-27</a></font> <a href="#bLEMA"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#bEXP"><font style="letter-spacing:0.2pt;">Experts </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#bEXP">S-28</a></font> <a href="#bEXP"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#bWYCF"><font style="letter-spacing:0.2pt;">Where You Can Find More Information </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#bWYCF">S-29</a></font> <a href="#bWYCF"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#bIBR"><font style="letter-spacing:0.2pt;">Incorporation by Reference </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#bIBR">S-30</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PROSPECTUS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:308.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:427.33pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Page </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tATP"><font style="letter-spacing:0.2pt;">About This Prospectus </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tATP">1</a></font> <a href="#tATP"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tOUCO"><font style="letter-spacing:0.2pt;">Our Company </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tOUCO">3</a></font> <a href="#tOUCO"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tRIFA"><font style="letter-spacing:0.2pt;">Risk Factors </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tRIFA">17</a></font> <a href="#tRIFA"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tCNRF"><font style="letter-spacing:0.2pt;">Cautionary Note Regarding Forward-Looking Statements </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tCNRF">37</a></font> <a href="#tCNRF"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tUOP"><font style="letter-spacing:0.2pt;">Use of Proceeds </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tUOP">39</a></font> <a href="#tUOP"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tCAI"><font style="letter-spacing:0.2pt;">Capitalization and Indebtedness </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tCAI">40</a></font> <a href="#tCAI"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDOSC"><font style="letter-spacing:0.2pt;">Description of Share Capital and Memorandum and Articles of Association </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDOSC">41</a></font> <a href="#tDOSC"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDOW"><font style="letter-spacing:0.2pt;">Description of Warrants </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDOW">51</a></font> <a href="#tDOW"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDOU"><font style="letter-spacing:0.2pt;">Description of Units </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDOU">52</a></font> <a href="#tDOU"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tFOS"><font style="letter-spacing:0.2pt;">Forms of Securities </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tFOS">53</a></font> <a href="#tFOS"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDOAD"><font style="letter-spacing:0.2pt;">Description of American Depositary Shares </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDOAD">55</a></font> <a href="#tDOAD"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tEOC"><font style="letter-spacing:0.2pt;">Enforceability of Civil Liabilities </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tEOC">70</a></font> <a href="#tEOC"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tTAX"><font style="letter-spacing:0.2pt;">Taxation </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tTAX">72</a></font> <a href="#tTAX"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tSESH"><font style="letter-spacing:0.2pt;">Selling Shareholders </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tSESH">73</a></font> <a href="#tSESH"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tPOD"><font style="letter-spacing:0.2pt;">Plan of Distribution </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tPOD">74</a></font> <a href="#tPOD"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tEXP"><font style="letter-spacing:0.2pt;">Expenses </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tEXP">78</a></font> <a href="#tEXP"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tIOCD"><font style="letter-spacing:0.2pt;">Incorporation of Certain Documents by Reference </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tIOCD">79</a></font> <a href="#tIOCD"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tLEMA"><font style="letter-spacing:0.2pt;">Legal Matters </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tLEMA">80</a></font> <a href="#tLEMA"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tEPTR"><font style="letter-spacing:0.2pt;">Experts </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tEPTR">81</a></font> <a href="#tEPTR"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tWYCF"><font style="letter-spacing:0.2pt;">Where You Can Find More Information </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tWYCF">82</a></font>
            </td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-i</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="bATPS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:24pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ABOUT THIS PROSPECTUS SUPPLEMENT</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus supplement and the accompanying base prospectus are part of a shelf registration statement on Form F-3 that we filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;). Under the shelf registration process, we may sell or issue any of the combination of securities described in the accompanying base prospectus in one or more offerings with a maximum aggregate offering price of up to US$200,000,000 from time to time, at prices and on terms to be determined by market conditions at the time of the offering, subject in certain cases to the receipt of regulatory approval. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We provide information to you about this offering of our ADSs in two separate documents that are bound together: (1)&#160;this at-the-market sales agreement prospectus supplement, which describes the specific details regarding this offering of our ADSs and supplements information contained in the accompanying base prospectus and the documents incorporated by reference in the accompanying base prospectus; and (2)&#160;the accompanying base prospectus, which provides more general information about us and the securities we may offer from time to time under our shelf registration statement, some of which may not apply to this offering. Generally, when we refer to this &#8220;prospectus,&#8221; we are referring to both the at-the-market sales agreement prospectus supplement and the accompanying base prospectus combined. If information in this at-the-market sales agreement prospectus supplement is inconsistent with the accompanying base prospectus, you should rely on this prospectus supplement. However, if any statement in one of these documents is inconsistent with a statement in another document having a later date&#8201;&#8212;&#8201;for example, a document incorporated by reference in this prospectus supplement&#8201;&#8212;&#8201;the statement in the document having the later date modifies or supersedes the earlier statement as our business, financial condition, results of operations and prospects may have changed since the earlier dates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You should rely only on the information contained in, or incorporated by reference into, this prospectus and in any free writing prospectus that we may authorize for use in connection with this offering. We have not, and Leerink Partners has not, authorized any other person to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. We are not, and Leerink Partners is not, making an offer to sell or soliciting an offer to buy our securities in any jurisdiction in which an offer or solicitation is not authorized or in which the person making that offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make an offer or solicitation. You should assume that the information appearing in this prospectus, the documents incorporated by reference into this prospectus, and in any free writing prospectus that we may authorize for use in connection with this offering, is accurate only as of the date of those respective documents. Our business, financial condition, results of operations and prospects may have changed since those dates. You should read this prospectus, the documents incorporated by reference into this prospectus, and any free writing prospectus that we may authorize for use in connection with this offering, in their entirety before making an investment decision. You should also read and consider the information in the documents to which we have referred you in the sections of this prospectus entitled &#8220;Where You Can Find More Information&#8221; and &#8220;Incorporation by Reference.&#8221; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are offering to sell, and seeking offers to buy, our ADSs only in jurisdictions where offers and sales are permitted. The distribution of this prospectus and the offering of the ADSs in certain jurisdictions may be restricted by law. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the ADSs and the distribution of this prospectus outside the United States. This prospectus does not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by this prospectus by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Unless otherwise indicated or the context otherwise requires, all references in this prospectus supplement to &#8220;Adagene Inc.,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; &#8220;ours,&#8221; &#8220;us&#8221; or similar terms refer to Adagene Inc., a Cayman Islands exempted company and its subsidiaries. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-ii</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="bSNRF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This prospectus supplement and the financial statements and other documents incorporated by reference in this prospectus supplement contain forward-looking statements, including statements concerning our industry, our operations, our anticipated financial performance and financial condition, and our business plans and growth strategy and product development efforts. These statements constitute forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&#160;21E of the Exchange Act. Many of the forward-looking statements contained in this prospectus supplement can be identified by the use of forward-looking words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;expect,&#8221; &#8220;should,&#8221; &#8220;plan,&#8221; &#8220;intend,&#8221; &#8220;estimate&#8221; and &#8220;potential,&#8221; among others. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. These forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain and subject to a number of risks and uncertainties. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">These forward-looking statements include, but are not limited to, statements about: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our goals and growth strategies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our future business development, results of operations and financial condition; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the timing of the initiation, progress and potential results of our preclinical studies, clinical trials and our discovery programs; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to utilize our proprietary Dynamic Precision Library platform, or DPL, to design, construct and develop next-generation antibodies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to advance product candidates into, and successfully complete, clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the timing or likelihood of regulatory filings and approvals; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our estimates of the number of patients who suffer from the diseases we are targeting and the number of patients that may enroll in our clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the commercializing of our product candidates, if approved; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability and the potential to successfully manufacture and supply our product candidates for clinical trials and for commercial use, if approved; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">future strategic arrangements and/or collaborations and the potential benefits of such arrangements; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our anticipated use of our existing resources and the proceeds from our initial public offering; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing and our ability to obtain additional capital; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure requirements; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to retain the continued service of our key personnel and to identify, hire and retain additional qualified professionals; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the implementation of our business model, strategic plans for our business and product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the scope of protection we are able to establish and maintain for intellectual property rights, such as our proprietary DPL, which includes NEObody platform, SAFEbody platform and POWERbody technology platforms, product candidates and discovery programs; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our potential to enter into new collaborations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the pricing, coverage and reimbursement of our product candidates, if approved; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">developments relating to our competitors and our industry, including competing product candidates and therapies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-iii</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:410pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the direct and indirect impact of the COVID-19 pandemic on our business and operations and on development of our clinical and preclinical programs, and the duration and impact of COVID-19 or any of its variants that may affect, precipitate or exacerbate one or more of any of the risks and uncertainties mentioned in this annual report; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">relevant government policies and regulations relating to our business and industry; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">general economic and business condition in the markets we have businesses; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">assumptions underlying or related to any of the foregoing. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We would like to caution you not to place undue reliance on these forward-looking statements and you should read these statements in conjunction with the risk factors disclosed herein, in the accompanying prospectus, and in the documents incorporated by reference therein, and other risks outlined in our other filings with the Securities and Exchange Commission, or the SEC. Those risks are not exhaustive. We operate in an evolving environment. New risks emerge from time to time and it is impossible for our management to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. We qualify all of our forward-looking statements by these cautionary statements.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-iv</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="bSSS">&#8203;</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">PROSPECTUS SUPPLEMENT SUMMARY</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">This summary highlights selected information contained elsewhere in this prospectus and in the documents we incorporate by reference. This summary does not contain all of the information you should consider before making an investment decision. You should read this entire prospectus supplement carefully, especially the risks of investing in our Ordinary Shares or ADSs discussed under &#8220;Risk Factors&#8221; beginning on page S-12 of this prospectus supplement, along with our consolidated financial statements and notes to those consolidated financial statements and the other information incorporated by reference in this prospectus supplement.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">OVERVIEW</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We are a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based cancer immunotherapies. We leverage computational biology to design and develop novel antibodies that address unmet patient needs. Powered by our proprietary Dynamic Precision Library (DPL) platform, which fuels our NEObody&#8482;, SAFEbody</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, and POWERbody&#8482; technologies, we are developing a highly differentiated pipeline of novel immunotherapies. Our lead candidate is an anti-CTLA-4 SAFEbody, ADG126, which is currently in phase 1b/2 development, initially focused on metastatic microsatellite-stable (MSS) colorectal cancer (CRC). We also have a robust pipeline of earlier stage candidates that apply our NEObody and SAFEbody technologies to targets associated with toxicity challenges, including modalities with potent efficacy features, such as Fc-empowered antibodies (e.g., IgG1 isotype and its enhanced version) and bi/multispecific T-cell engagers. Additionally, we have forged strategic collaborations with reputable global partners that leverage our technology in multiple approaches at the vanguard of science. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We aim to push the boundaries of antibody discovery and engineering through the precise design, construction, and selection of antibody product candidates intractable to traditional antibody technology. We have pioneered a dynamic antibody technology interface to harness the conformational diversity of antibodies, which enlarges epitope sampling of a given drug target for differentiated therapeutic antibody development. Additionally, we have proprietary precision masking technology and specialized antibody engineering capabilities which enable us to design therapeutics with unique features. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Our DPL fuels&#160;three antibody technology platforms, which can be used alone or together to create novel, differentiated antibody-based therapeutic candidates: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">The NEObody technology platform is a fully synthetic phage display and yeast display-based antibody discovery technology, which we believe is differentiated from other synthetic antibody technologies through its innovative designs and precise constructions. NEObody technology enables the generation of antibodies designed with dynamic binding sites that adapt kinetically to unique epitopes, triggering a novel MOA. The species cross-reactive antibodies generated by NEObody technology not only have the potential to reveal new biological functions of the targets, but also facilitate preclinical studies using various immune system intact animal models, resulting in high fidelity translation from preclinical to clinical studies. We refer to antibodies generated by our NEObody technology as NEObodies. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">The SAFEbody technology platform is designed to mask an antibody binding interface with a masking motif, which then prevents an antibody from binding to its target in healthy tissues, minimizing on target, off tumor toxicities. The masking motif is designed to activate, or unmask, the antibody to allow binding in the tumor microenvironment, or TME, where certain activation conditions such as a protease is upregulated as compared to healthy tissues, allowing the antibody to bind to its target for tumor killing. Our SAFEbody enabled therapeutic candidates are therefore designed to be activated predominantly in the TME while remaining largely in an inactive state in healthy tissues. Our SAFEbody technology can be applied to mask the binding sites of any antibodies including but not limited to NEObodies. We refer to such masked antibodies as SAFEbodies. Notably, SAFEbody technology can be applied to our NEObodies, such as what we did with ADG116 to potentially achieve an increased therapeutic index with ADG126. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">The POWERbody technology platform enables the creation of new versions of antibodies, which may be bi/multispecific T-cell engagers, or TCEs, or Fc-enhanced antibodies, antibody-drug conjugates, or ADCs, or antibodies that are designed to reach beyond the therapeutic potency of traditional </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="margin-left:30pt; width:426pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">monospecific antibodies. Our POWERbody candidates incorporate SAFEbody precision masking technology and are designed to improve antitumor activity while maintaining the enhanced safety profile for potentially safe and durable immunotherapies. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">These proprietary technology platforms allow us to engineer and select species cross-reactive antibodies designed to dynamically adapt to unique and evolutionally conserved epitopes. We believe that comprehensive </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> preclinical evaluations using these species cross-reactive antibodies are the key to assess the efficacy and safety potential of tailor-made antibody candidates before progressing them into lengthy and costly clinical trials. Our NEObody, SAFEbody and POWERbody technology platforms are all designed to facilitate favorable druggability, manageable CMC attributes, and reduced immunogenicity. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">Our Robust, Transformative Pipeline</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">By leveraging our proprietary DPL and three platform technologies, we have developed a robust pipeline of innovative product candidates in various stages of development, including our lead candidate, ADG126 SAFEbody, which is currently in phase 1b/2 clinical development. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">ADG126 is a fully human anti-CTLA-4 SAFEbody, which applies SAFEbody precision masking technology to its parental unmasked version, ADG116, to further enhance safety and efficacy profiles by masking the antibody binding site which is then conditionally activated in the TME to limit on target, off tumor toxicity. ADG126 targets a unique epitope to CTLA-4 and is designed to provide an enhanced therapeutic window and optimize efficacy by enabling higher, more frequent and repeated doses of anti-CTLA-4 therapy with constant target engagement that may unlock the full potential of CTLA-4 as a proven target for strong ADCC-mediated Treg depletion in the TME. ADG126 has shown a potential best-in-class profile in clinic, which is consistent with and enabled by the broad species cross-reactivity of ADG126 for extensive preclinical evaluation from mouse, rats and monkeys, including GLP toxicology data. ADG126 is currently in phase 1b/2 evaluation, with a focus on phase 2 dose expansion in combination with pembrolizumab in patients with advanced/metastatic MSS CRC. See &#8220;Item&#160;4.B. Business Overview&#8201;&#8212;&#8201;</font>
            <br >
            <font style="letter-spacing:0.2pt;">ADG126 SAFEbody: A Potential Best-in-Class&#160;Anti-CTLA-4 Therapy&#8221; in our latest annual report incorporated by reference. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Earlier stage candidates that apply our SAFEbody precision masking technology include ADG206, a masked, Fc-enhanced anti-CD137 agonistic POWERbody. ADG206 incorporates SAFEbody precision masking technology and is designed to achieve improved safety and efficacy. ADG206 has demonstrated enhanced crosslinking by FcgRIIb in vitro upon activation and antitumor activity in vivo, while the SAFEbody masking technology limits on-target off-tumor toxicities by preferential activation in the TME. Preclinical data demonstrated that ADG206 was well tolerated, with normal pharmacokinetic properties and minimal activation in circulation. It also had robust anti-tumor activity as a single agent in multiple tumor models, with 4-fold stronger anti-CD137 agonistic activity of its activated form than a benchmark antibody (urelumab analog). ADG206 is currently in Phase&#160;1 development with monotherapy dose escalation ongoing. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Additionally, we have two IND-ready preclinical programs (ADG153, a masked, IgG1 anti-CD47 SAFEbody, and ADG138, a novel HER2xCD3 POWERbody bispecific TCE that is masked on both arms), as well as another preclinical program (ADG152, a CD20xCD3 POWERbody with masking on the CD3&#160;arm) in the IND-enabling phase. We are developing anti-CD28 bispecific POWERbody TCEs enabled by our suite of antibody platform technologies. We have previously published preclinical data showing the scientific rationale for these differentiated programs. See &#8220;Item&#160;4.B. Business Overview&#8201;&#8212;&#8201;IND-Ready Candidates &amp; Preclinical Pipeline&#8221; in our latest annual report incorporated by reference. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We also have two clinical-stage NEObody product candidates, ADG116 and ADG106, for which we have conducted previous clinical studies that demonstrate the potential clinical benefits of targeting a unique epitope with our NEObody platform. Both of these candidates are currently in phase 1b/2 evaluation. See &#8220;Item 4.B. Business Overview&#8201;&#8212;&#8201;ADG116 NEObody: A Unique Entry Point for Anti-CTLA-4 Therapy&#8221; and &#8220;&#8212; ADG106 NEObody: A Novel Agonistic Anti-CD137&#8221; in our latest annual report incorporated by reference. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Further, we have out-licensed the Greater China rights of ADG104, an anti-PD-L1 mAb currently in Phase&#160;2 clinical development, to Sanjin, and the Greater China rights of ADG125, a novel anti-CSF-1R </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">mAb in Phase&#160;1 development, to Dragon Boat Biopharmaceuticals. We have the right to apply for the patents derived from our core and key technologies pertaining to ADG104 and ADG125 in the rest of the world, where we retain a majority of the economic benefits. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Our Global Partnerships and Collaborations</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We have a successful track record of collaborations and partnerships with global biopharmaceutical companies and academic institutions. So far, we have established multiple collaborations and we continue to seek partnership opportunities where we can leverage our proprietary technology platform to develop novel antibodies to address unmet medical needs. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We enter into collaborations with biotechnology and pharmaceutical companies to leverage the power of our technology platforms, creating a network of potential future revenue streams that complement future long-term value from our wholly-owned pipeline. These collaborations include both technology licensing agreements and outlicensing of product candidates, both of which allow us to retain significant future participation in product sales through royalties paid on net sales. In the future, we may also enter into strategic collaborations which may involve joint development for our preclinical and/or clinical assets to both accelerate the path to clinic and drive global commercialization. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Our technology licensing agreements with Sanofi and Exelixis focus on developing antibody-based therapeutics against tumor targets using our SAFEbody technology. We have also out-licensed the Greater China rights for two antibody candidates to Sanjin and its affiliates. To further advance our pipeline, we have also put in place various clinical collaborations, including an agreement with Roche who is sponsoring and conducting a randomized combination trial with ADG126, atezolizumab and bevacizumab in first-line hepatocellular carcinoma (HCC), clinical collaborations and supply agreements with Merck who will provide pembrolizumab for certain of our combination clinical trials, and an agreement with research organizations in Singapore for investigator-initiated trials of our ADG106 clinical candidate in combination settings. See &#8220;Item&#160;4.B. Business Overview&#8201;&#8212;&#8201;Clinical Collaboration Agreements&#8221; in our latest annual report incorporated by reference. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Our collaborations empower our growth by generating cash flow and revenues that partially offset expenditures on our internal research and development programs, expand our knowledge base regarding antibody technology across multiple targets and antibodies provided by our partners, and provide us with future joint development opportunities. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">OUR CHALLENGES</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Investors are purchasing securities of a Cayman Islands holding company rather than securities of our subsidiaries that have substantive business operations in the United States or China. Adagene Inc. is a Cayman Islands holding company that conducts its operations and operate its business in the U.S. through its U.S. subsidiary, Adagene Incorporated. In addition, Adagene Inc. conducts its operations in China through its PRC subsidiary, Adagene Suzhou. Such structure involves unique risks to investors in the ADSs and Ordinary Shares. You should carefully consider all of the information in this prospectus supplement and in any documents incorporated by reference to this prospectus supplement, including disclosures included in our most recent annual report on Form 20-F incorporated by reference in this prospectus supplement, before making an investment in our ADSs. In particular, as we are a holding company with substantial business operations in China, you should pay special attention to subsections headed &#8220;Recent Regulatory Developments&#8221; in this prospectus supplement and &#8220;Item&#160;5.B.&#8201;&#8212;&#8201; Liquidity and Capital Resources Holding Company Structure&#8221; and &#8220;Item&#160;3. Key Information&#8201;&#8212;&#8201;3.D. Risk Factors&#8201;&#8212;&#8201; Risks Related to Doing Business in China&#8221; in our most recent annual report on Form 20-F incorporated by reference in this prospectus supplement, including but not limited to risk factor such as &#8220;uncertainties with respect to the PRC legal system, including uncertainties regarding the enforcement of laws, and sudden or unexpected changes in policies, laws and regulations in China could adversely affect us.&#8221; </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">The PRC government has significant authority to exert influence on the ability of a China-based company, such as us, to conduct its business, accept foreign investments or list on a U.S. or other foreign exchanges. For example, we face risks associated with regulatory approvals of offshore offerings, anti-monopoly regulatory actions, oversight on cybersecurity and data privacy, as well as the lack of PCAOB </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">inspection on our auditor. Such risks could result in a material change in our operations and/or the value of our ADSs or could significantly limit or completely hinder our ability to offer or continue to offer ADSs and/or other securities to investors and cause the value of such securities to significantly decline or be worthless. The PRC government also has significant oversight and discretion over the conduct of our business and as such may influence our operations at any time, which could result in a material adverse effect on our operations. The PRC government has recently published new policies that significantly affected certain industries, and we cannot rule out the possibility that it will in the future release regulations or policies regarding the industry where we operate, which could adversely affect our business, financial condition and results of operations. Furthermore, the PRC government has recently indicated an intent to exert more oversight and control over overseas securities offerings and other capital markets activities and foreign investment in China-based companies like us. These risks could result in a material change in our operations and the value of our Ordinary Shares or the ADSs, or could significantly limit or completely hinder our ability to offer or continue to offer securities to investors and cause the value of such securities to significantly decline or become worthless. Below please find a summary of the principal risks we face, organized under relevant headings. These risks are discussed more fully in the section titled &#8220;Risk Factors&#8221; in this prospectus and the most recent annual report on Form 20-F incorporated by reference. </font>
          </div>
          <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Risks Related to Doing Business in the PRC</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Risks and uncertainties related to doing business in China include, but are not limited to, the following: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">uncertainties with respect to the PRC legal system, including uncertainties regarding the enforcement of laws, and sudden or unexpected changes in policies, laws and regulations in China could adversely affect us; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">PRC government has significant oversight over the conduct of our business and as such may influence our operations at any time, which may potentially result in a material adverse effect on our operations; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">the PCAOB had historically been unable to inspect our auditor in relation to their audit work performed for our financial statements and the inability of the PCAOB to conduct inspections of our auditor in the past has deprived our investors with the benefits of such inspections; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">our ADSs may be prohibited from trading in the United States under the HFCAA in the future if the PCAOB is unable to inspect or investigate completely auditors located in China. The delisting of the ADSs, or the threat of their being delisted, may materially and adversely affect the value of your investment; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">the enactment of the Accelerating Holding Foreign Companies Accountable Act decreases the number of non-inspection&#160;years from three&#160;years to two, thus reducing the time period before our ADSs will be prohibited from trading on the Nasdaq Stock Market or OTC or delisted; and </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">the report and filing with the China Securities Regulatory Commission will be required in connection with the offering under this prospectus supplement, and, we cannot predict if we will be able to complete such report and filing process. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Risks Related to Our Financial Prospects and Need for Additional Capital</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Risks and uncertainties related to our financial prospectus and need for additional capital include, but are not limited to, the following: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">we have a limited operating history, which may make it difficult to evaluate our current business and predict our future performance; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">we have incurred net losses historically and we may continue to incur net losses in the near future; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">we may need to obtain substantial additional financing to fund our growth and operations, which may not be available on acceptable terms, if at all; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">raising additional capital may lead to dilution of shareholdings by our existing shareholders and restrict our operations or require us to relinquish rights to our technologies or product candidates; and </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">we have certain shareholders who have board representation rights and their individual interests may differ from yours. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Risks Related to Clinical Development of Our Product Candidates</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Risks and uncertainties related to clinical development of our product candidates include, but are not limited to, the following: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">we may not be able to identify or discover new product candidates, and may allocate our limited resources to pursue a particular product candidate and fail to capitalize on product candidates that may later prove to be more profitable, or for which there is a greater likelihood of success; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">we may not be successful in our efforts to use and expand our proprietary platforms to build a pipeline of product candidates; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">any failures or setbacks in our platforms or our other proprietary technologies could negatively affect our business and financial condition; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">our product candidates, for which we intend to seek approval as biologic products, may face competition sooner than anticipated; and </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">we depend substantially on the success of our product candidates, particularly our anti-CTLA-4 franchise, including our lead product candidate, ADG126, and ADG116, which are in clinical development, and our ability to identify additional product candidates. Clinical trials of our product candidates may not be successful. If we are unable to successfully identify new product candidates, complete clinical development, obtain regulatory approval and commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Risks Related to Obtaining Regulatory Approval of Our Drug Candidates</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Risks and uncertainties related to obtaining regulatory approval of our drug candidates include, but are not limited to, the following: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">the regulatory approval processes of the FDA, NMPA and other comparable regulatory authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approvals for our product candidates, our business will be substantially harmed; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">even if we obtain FDA approval of any of our product candidates, we may never obtain approval or commercialize such products outside of the United States, which would limit our ability to realize their full market potential; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">we are conducting clinical trials and may in the future conduct additional clinical trials for our product candidates outside the United States and/or China, and FDA, NMPA and similar foreign regulatory authorities may not accept data from such trials; and </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">our product candidates may cause undesirable adverse events, side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following any regulatory approval. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Risks Related to Our Intellectual Property</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Risks and uncertainties related to our intellectual property include, but are not limited to, the following: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">it is difficult and costly to protect our proprietary rights and technology, and we may not be able to protect our intellectual property rights throughout the world; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">we may not be successful in obtaining or maintaining necessary rights for our development pipeline through acquisitions and licensing deals; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">we may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful, and any unfavorable outcome from such litigation could limit our research and development activities and/or our ability to commercialize our product candidates; and </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">our commercial success depends significantly on our ability to operate without infringing upon, misappropriating or otherwise violating the intellectual property rights of third parties. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Risks Related to the ADSs</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Risks and uncertainties related to the ADSs include, but are not limited to, the following: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">our business and financial results, including our ability to raise capital or raise capital on favorable terms and the market price of our ADSs, may be adversely affected by the geopolitical factors arising in connection with Russia&#8217;s invasion of Ukraine, including particularly how countries like the United States and China choose to respond to this war. As a result, the value of our ADSs may significantly decline; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">you may be subject to limitations on transfer of your ADSs; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">the trading price of the ADSs is likely to be volatile, which could result in substantial losses to investors; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">we are an emerging growth company within the meaning of the Securities Act and may take advantage of certain reduced reporting requirements; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">if securities or industry analysts cease to publish research or reports about our business, or if they adversely change their recommendations regarding the ADSs, the market price for the ADSs and trading volume could decline; and </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">the sale or availability for sale, or perceived sale or availability for sale, of substantial amounts of the ADSs could adversely affect their market price. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">RECENT REGULATORY DEVELOPMENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Cybersecurity Review</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">On December&#160;28, 2021, the Cyberspace Administration of China, or the CAC, and 12 other relevant PRC government authorities published the amended Cybersecurity Review Measures, or the Cybersecurity Review Measures, which went on February&#160;15, 2022 and supersede and replace the current Cybersecurity Review Measures previously promulgated on April&#160;13, 2020. The Cybersecurity Review Measures provide that the purchase of network products and services by a &#8220;critical information infrastructure operator&#8221; and the data processing activities of a &#8220;network platform operator&#8221; that affect or may affect national security shall be subject to the cybersecurity review. Furthermore, if a &#8220;network platform operator&#8221; that possesses personal information of more than one million users intends to go public in a foreign country, it must apply for a cybersecurity review with the Cybersecurity Review Office. In addition, the relevant PRC governmental authorities may initiate cybersecurity review if they determine certain network products, services, or data processing activities affect or may affect national security. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">On November&#160;14, 2021, the CAC released the Regulations for the Administration of Network Data Security (Draft for Comment), or the Draft Data Security Regulations, for public comments. The Draft Data Security Regulations provide that (i)&#160;a data processor who processes personal information of more than one million individuals must complete a cybersecurity review if it intends to be listed in a foreign country, and (ii)&#160;a data processor who carries out other data processing activities which affect or may affect national security should also complete the cybersecurity review. The Draft Data Security Regulations provide a broad definition of &#8220;data processing activities,&#8221; including collection, storage, usage, processing, transfer, provision, publication, deletion and other activities, which covers the entire life cycle of data processing. The Draft Data Security Regulations also provide a broad definition of &#8220;data processors&#8221; as individuals and </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">entities that may autonomously determine the purpose and method of data processing activities. In addition, the Draft Data Security Regulations require data processors who process important data or whose securities are listed outside of China to carry out annual data security assessment either by itself or through a third party data security service provider and submit the assessment report to a local agency of the CAC. On March 22, 2024, the CAC issued the Provisions on Promoting and Regulating Cross-border Flow of Data, which provide that unless otherwise stipulated, data processors shall apply for security assessment for cross-border data transfer in any of the following circumstances: (i) outbound transfer of personal information or important data by critical information infrastructure operators; or (ii) outbound transfer of important data by a data processor other than critical information infrastructure operators, or outbound transfer of personal information (other than sensitive personal information) of more than one million people or sensitive personal information of more than 10,000 people by a data processor other than critical information infrastructure operators since January 1 of the same year. See &#8220;Item&#160;4. Information of the Company&#8201;&#8212;&#8201;4.B. Business Overview&#8201;&#8212;&#8201;Regulation&#8201;&#8212;&#8201;Other PRC Government Regulations&#8201;&#8212;&#8201;Regulations on Information Security and Data Protection&#8221; in the most annual report incorporated by reference for detailed discussion. As advised by our PRC legal counsel, Jingtian &amp; Gongcheng, the Draft Data Security Regulations were released for public comment only with the deadline of submitting public comments or opinions by December&#160;13, 2021, and its provisions and anticipated adoption or effective date are subject to changes and thus its interpretation and implementation remain substantially uncertain. We cannot predict the impact of the Draft Data Security Regulations, if any, at this stage, and we will closely monitor and assess any development in the rule-making process. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">As advised by our PRC legal counsel, Jingtian &amp; Gongcheng, given the nature of our business, since we do not possess or process personal information of more than one million users/individuals, and we do not believe we are a &#8220;critical information infrastructure operator,&#8221; &#8220;network platform operator&#8221; or a data processor whose purchase of network products and services or data processing activities affect or may affect national security, the listing of our ADSs on the Nasdaq and future potential offering of our ADSs pursuant to this prospectus supplement will not be subject to the cybersecurity review process under the Cybersecurity Review Measures, although we cannot guarantee that the relevant PRC regulatory authority will agree with our interpretation. Currently, the Cybersecurity Review Measures, the Provisions on Promoting and Regulating Cross-border Flow of Data and the Draft Data Security Regulations have not materially affected our business and operations, but in anticipation of the strengthened implementation of cybersecurity laws and regulations and the continued expansion of our business, we face potential risks if we are deemed as a critical information infrastructure operator, a network platform operator or data processing operator under the PRC cybersecurity laws and regulations. In such case, we must fulfill certain obligations as required under the PRC cybersecurity laws and regulations, including, among others, storing personal information and other important data collected and produced within the PRC territory as we advance our drug discovery pipelines as part of our future operations in China, and we may be subject to lengthy cybersecurity review, annual data security assessment and other enhanced regulatory requirements when purchasing network products and services or conducting other data processing activities. We may face challenges in addressing such enhanced regulatory requirements and be required to make necessary changes to our internal policies and practices in data privacy and cybersecurity matters. As advised by our PRC legal counsel, Jingtian &amp; Gongcheng, as of the date of this prospectus supplement, no detailed rules or implementation of the Cybersecurity Review Measures have been issued by the CAC and the Draft Data Security Regulations were only released for public comments, and the PRC governmental authorities have broad discretion in the interpretation and enforcement of these laws and regulations. It also remains uncertain whether the future regulatory changes will impose additional restrictions on companies like us. We cannot predict the impact of the Cybersecurity Review Measures and/or the Draft Data Security Regulations, if any, at this stage, and we will closely monitor and assess any development in the rule-making process. If the future enacted laws and regulations, including the enacted version of the data security regulations mandate clearance of cybersecurity review and other specific actions to be completed by companies like us before we are able to complete this offering, we will face uncertainties as to whether such clearance and/or other specific actions can be timely obtained or completed, or at all. If we are not able to comply with the cybersecurity and data privacy requirements in a timely manner, or at all, we may be subject to government enforcement actions and investigations, fines, penalties, or suspension of our non-compliant operations, among other sanctions, which could materially and adversely affect our business and results of operations. Any failure to complete the required cybersecurity review may result in administrative penalties, including fines, a shut-down of our </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-7</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">business, revocation of requisite licenses, as well as reputational damage or legal proceedings or actions against us, which may have material adverse effects on our business, financial condition and results of operations. As of the date of this prospectus supplement, we have not been involved in any investigation on cybersecurity review made by the CAC on such basis, and we have not received any inquiry, notice, warning, or sanction in such respect, and we have not been subject to any material fines or other material penalties due to non-compliance with cybersecurity or data privacy laws or regulations. Our PRC legal counsel does not expect that, as of the date of this prospectus supplement, we are required to file an application for the cybersecurity review by CAC in connection with our previous issuance of securities to foreign investors or maintaining our listing status on Nasdaq. We have been making continuous efforts to comply with the relevant cybersecurity and data protection laws and regulations of the PRC, and will endeavor to comply with any updated applicable laws, regulations or guidelines as issued by any relevant regulatory authority in the PRC. See &#8220;Item&#160;3 Key Information&#8201;&#8212;&#8201;3.D.Risk Factors&#8201;&#8212;&#8201;Risks Related to Doing Business in the PRC&#8201;&#8212;&#8201;Failure to comply with existing or future laws and regulations related to privacy or data security could lead to government enforcement actions, which could include civil or criminal fines or penalties, investigation or sanction by regulatory authorities, private litigation, other liabilities, and/or adverse publicity&#8221; in the most recent annual report incorporated by reference. </font>
          </div>
          <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Post-Offering CSRC Filings Required for the Offering of Our ADSs</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">On February&#160;17, 2023, the China Securities Regulatory Commission, or CSRC, issued the Notice on Filing Arrangements for Overseas Securities Offering and Listing by Domestic Companies (the &#8220;CSRC Filing Notice&#8221;), stating that the CSRC has published the Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Companies (the &#8220;Trial Measures&#8221;) and five supporting guidelines (the &#8220;Listing Guidelines&#8221;), collectively the Trial Measures and Listing Guidelines, which came into effect on March&#160;31, 2023. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Under the Trial Measures and Listing Guidelines, subsequent securities offerings of an issuer in (i)&#160;the same overseas market where it has previously offered and listed securities, and (ii)&#160;an overseas market other than one where the issuer has previously offered and listed securities shall be (a)&#160;filed with the CSRC within three working days after offerings are completed, and (b)&#160;within three working days after the submission of the application documents for overseas issuance and listing, respectively. Further, the CSRC Filing Notice states that, beginning from March&#160;31, 2023, PRC domestic enterprises which have already issued and listed securities overseas and fall within the scope of filing under the Trial Measures shall be considered &#8220;existing enterprises,&#8221; or Existing Listed Enterprises. Existing Listed Enterprises are not required to complete filings immediately; rather, Existing Listed Enterprises should complete filings if they are subsequently involved in matters require filings, such as follow-on financing activities, in accordance with the Trial Measures. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">As advised by our PRC legal counsel, Jingtian &amp; Gongcheng, we are required to complete the initial filing with the CSRC in connection with the offering of securities under this prospectus supplement within three (3)&#160;working days upon completion of the initial sale under this prospectus supplement, and upon completion of the final sale under this prospectus supplement, we shall file a record of the issuance with CSRC within three (3)&#160;working days. We intend to comply with such requirements imposed by the Trial Measures and Listing Guidelines. </font>
          </div>
          <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Material Licenses and Approvals</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Our PRC subsidiary has obtained all material licenses and approvals required for our operations in China. For details of our material licenses and approvals, see &#8220;Item&#160;4. Information of the Company&#8201;&#8212;&#8201;4.B. Business Overview&#8201;&#8212;&#8201;Material Licenses and Approvals&#8221; in the most recent annual report incorporated by reference. For risks relating to licenses and approvals required for our operations in China, see &#8220;Item&#160;3. Key Information&#8201;&#8212;&#8201;3.D. Risk Factors&#8201;&#8212;&#8201;Risks Related to Doing Business in the PRC,&#8221; &#8220;&#8212; Risks Related to Clinical Development of Our Product Candidates,&#8221; and &#8220;&#8212; Risks Related to Obtaining Regulatory Approval of Our Drug Candidates&#8221; in the most recent annual report incorporated by reference. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Furthermore, in connection with our historical issuance of securities to foreign investors, under currently effective PRC laws, regulations and regulatory rules, as of the date of this annual report, we are not currently required to obtain permissions from the CSRC, and we have not received any formal notice from </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-8</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">any PRC authority indicating that we should apply for or are otherwise subject to cybersecurity review or security assessment. In addition, we have not been asked to obtain such permissions by any PRC authority or received any denial to do so. However, the PRC government has recently indicated an intent to exert more oversight and control over offerings that are conducted overseas and/or foreign investment in China-based issuers. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">If (i)&#160;we mistakenly conclude that certain regulatory filings, permissions and approvals are not required or (ii)&#160;applicable laws, regulations, or interpretations change and (iii)&#160;we are required to obtain such filings, permissions or approvals in the future, but fail to receive or maintain such filings, permissions or approvals, we may face sanctions by the CSRC, the CAC or other PRC regulatory agencies. In addition, rules and regulations in China can change quickly with little advance notice. These regulatory agencies may impose fines and penalties on our operations in China, limit our operations in China, limit our ability to pay dividends outside of China, limit our ability to list on stock exchanges outside of China or offer our securities to foreign investors or take other actions that could have a material adverse effect on our business, financial condition, results of operations and prospects, as well as the trading price of our securities. See also &#8220;Item&#160;3 Key Information&#8201;&#8212;&#8201;3.D.Risk Factors&#8201;&#8212;&#8201;Risks Related to Doing Business in the PRC&#8201;&#8212;&#8201;We may be required to obtain approval or complete filing or other requirements of the CSRC or other PRC government authorities in connection with our issuances of securities overseas, and, if required, we cannot predict whether we will be able to obtain such approval or complete such governmental procedure&#8221; in the most recent annual report incorporated by reference. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">CORPORATE INFORMATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Adagene was incorporated in the Cayman Islands in February&#160;2011. We conduct our operations in the U.S. primarily through our U.S. subsidiary, Adagene Incorporated, and in China through Adagene Suzhou, which was incorporated in February&#160;2012. The ADSs, each representing one and one quarter (1.25) of our Ordinary Shares, par value US$0.0001 per share, are currently traded on the Nasdaq under the symbol &#8220;ADAG&#8221;. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Our principal executive offices of our main operations are located at 4F, Building C14, No. 218, Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu Province, 215123, People&#8217;s Republic of China. Our San Diego office address is 6042 Cornerstone Court West Suite E, San Diego, CA&#160;92121. Our registered office is located at Vistra (Cayman) Limited, P. O. Box 31119 Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman, KY1&#8201;&#8212;&#8201;1205 Cayman Islands. Our telephone number is +86-512-8777-3632. Investors should contact us for any inquiries through the address and telephone number of our principal executive office. Our corporate website is </font><font style="font-style:italic;letter-spacing:0.2pt;">www.adagene.com</font><font style="letter-spacing:0.2pt;">. The reference to our website is an inactive textual reference only, and information contained therein or connected thereto is not incorporated into this prospectus or the registration statement of which it forms a part. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">IMPLICATIONS OF BEING AN &#8220;EMERGING GROWTH COMPANY&#8221;</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We qualify as an &#8220;emerging growth company&#8221; as defined in the Jumpstart our Business Startups Act of&#160;2012 (the &#8220;JOBS Act&#8221;). As an emerging growth company, we may take advantage of specified reduced reporting and other burdens that are otherwise applicable generally to public companies. These provisions include: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">an exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting pursuant to Section&#160;404 of the Sarbanes-Oxley Act of 2002 (the &#8220;Sarbanes-Oxley Act&#8221;); and </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">to the extent that we no longer qualify as a foreign private issuer, (i)&#160;reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and (ii)&#160;exemptions from the requirements of holding a non-binding advisory vote on executive compensation, including golden parachute compensation. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We may take advantage of these provisions for up to five&#160;years or such earlier time that we are no longer an emerging growth company. We will remain an emerging growth company until the earliest of (i)&#160;the last day of the fiscal year in which we have total annual gross revenues of at least US$1.235&#160;billion; (ii)&#160;the last day of our fiscal year following the fifth anniversary of the completion of our initial public </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-9</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;min-height:660pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">offering; (iii)&#160;the date on which we have issued more than US$1.0&#160;billion in non-convertible debt during the previous three&#160;years; or (iv)&#160;the date on which we are deemed to be a large accelerated filer under the rules of the SEC, which means the market value of our Ordinary Shares that are held by non-affiliates equals or exceeds US$700.0&#160;million as of the last business day of our most recently completed second fiscal quarter. We may choose to take advantage of some but not all of these reduced burdens. For example, Section&#160;107 of the JOBS Act also provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards applicable to public companies. This provision allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have decided not to &#8220;opt out&#8221; of such exemptions afforded to an emerging growth company. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">IMPLICATIONS OF BEING A FOREIGN PRIVATE ISSUER</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We are also considered as a &#8220;foreign private issuer.&#8221; Accordingly, we report under the Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), as a non-U.S. company with foreign private issuer status. This means that, even after we no longer qualify as an emerging growth company, as long as we qualify as a foreign private issuer under the Exchange Act, we will be exempt from certain provisions of the Exchange Act that are applicable to U.S. domestic public companies, including: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of a security registered under the Exchange Act; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">the sections of the Exchange Act requiring insiders to file public reports of their stock ownership and trading activities and liability for insiders who profit from trades made in a short period of time; and </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">the rules under the Exchange Act requiring the filing with the Securities and Exchange Commission, or SEC, of quarterly reports on Form 10-Q containing unaudited financial and other specified information, or current reports on Form 8-K, upon the occurrence of specified significant events. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We may take advantage of these exemptions until such time as we are no longer a foreign private issuer. We would cease to be a foreign private issuer at such time as more than 50% of our outstanding voting securities are held by U.S. residents and any of the following three circumstances applies: (i)&#160;the majority of our executive officers or directors are U.S. citizens or residents, (ii)&#160;more than 50% of our assets are located in the United States or (iii)&#160;our business is administered principally in the United States. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">In this prospectus supplement and in the documents incorporated by reference in this prospectus supplement, we have taken advantage of certain of the reduced reporting requirements as a result of being an emerging growth company and a foreign private issuer. Accordingly, the information contained in this prospectus supplement and in the documents incorporated by reference in this prospectus supplement may be different than the information you receive from other public companies in which you hold equity securities. </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-10</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="bTHOF">&#8203;</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;min-height:660pt;margin-left:12pt;width:456pt;">
          <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">THE OFFERING</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="width:168pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Ordinary Shares and/or ADSs Offered by Us </font>
            </div>
          </div>
          <div style="margin-left:192pt; margin-top:-12pt; width:264pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Ordinary shares and/or ADSs having an aggregate offering price of up to US$100&#160;million. </font>
          </div>
          <div style="width:168pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Ordinary Shares to be outstanding after this offering </font>
            </div>
          </div>
          <div style="margin-left:192pt; margin-top:-12pt; width:264pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Up to 94,208,339 Ordinary Shares, assuming the sale of US$100&#160;million of ADSs at a sales price of US$3.20 per ADS, which was the last sale price of our ADSs on February&#160;29, 2024 as reported on Nasdaq. The actual number of shares issued and outstanding will vary depending on the sales price under this offering. </font>
          </div>
          <div style="width:168pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Manner of Offering </font>
            </div>
          </div>
          <div style="margin-left:192pt; margin-top:-12pt; width:264pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Sales of our ADSs by Leerink Partners, if any, under this prospectus may be made by any method permitted by law and deemed to be an &#8220;at the market offering&#8221; as defined in Rule&#160;415(a)(4) promulgated under the Securities Act, from time to time through or to Leerink Partners, as sales agent or principal. See &#8220;Plan of Distribution&#8221; on page S-26 of this prospectus. </font>
          </div>
          <div style="width:168pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Use of Proceeds </font>
            </div>
          </div>
          <div style="margin-left:192pt; margin-top:-12pt; width:264pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We intend to use the net proceeds from this offering, together with our other cash resources, primarily to fund research and development expenses for our clinical and preclinical research and development activities and for working capital, repayment of debt and general corporate purposes. See &#8220;Use of Proceeds.&#8221; </font>
          </div>
          <div style="width:168pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Risk Factors </font>
            </div>
          </div>
          <div style="margin-left:192pt; margin-top:-12pt; width:264pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Investing in our securities involves a high degree of risk. See &#8220;Risk Factors&#8221; beginning on page <a href="#bRIFA">S-12</a> of this prospectus and the other information included in, or incorporated by reference into, this prospectus for a discussion of certain factors that you should carefully consider before deciding to invest in shares of our Ordinary Shares and/or ADSs. </font>
          </div>
          <div style="width:168pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Nasdaq Global Market Symbol </font>
            </div>
          </div>
          <div style="margin-left:192pt; margin-top:-12pt; width:264pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">ADAG</font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The number of shares of Ordinary Shares shown above to be outstanding immediately following this offering is based on 55,145,839 Ordinary Shares outstanding as of December&#160;31, 2023 and exclude 325,000 Ordinary Shares, issued but deemed to be not outstanding as of December&#160;31, 2023, held by Great Han Fortune LP. </font>
          </div>
          <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">This prospectus reflects and assumes no exercise of outstanding options.</font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-11</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="bRIFA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">RISK FACTORS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Investment in any securities offered pursuant to this prospectus supplement and the accompanying base prospectus involves risks. You should carefully consider the risk factors described below and in our annual report on Form 20-F for the year ended December&#160;31, 2023, incorporated by reference in this prospectus supplement, any amendment or update thereto reflected in subsequent filings with the SEC, including in our annual reports on Form 20-F, and all other information contained or incorporated by reference in this prospectus supplement, as updated by our subsequent filings under the Exchange Act. . In general, investing in the securities of issuers in emerging market countries such as the PRC involves certain risks not typically associated with investing in securities of U.S. companies. You should pay special attention to subsections headed &#8220;Recent Regulatory Developments,&#8221; &#8220;Holding Company Structure,&#8221; and &#8220;Risks Related to Doing Business in the PRC&#8221; in our most recent annual report on Form 20-F incorporated by reference. The risks and uncertainties we have described are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our operations. The occurrence of any of these risks might cause you to lose all or part of your investment in the offered securities.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to This Offering</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If you purchase the ADSs sold in this offering, you may experience immediate and substantial dilution in the net tangible book value of your ADSs. In addition, we may issue additional equity or debt securities in the future, which may result in additional dilution to you.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The price per ADS being offered may be higher than the net tangible book value per ADS prior to this offering. To the extent outstanding stock options are exercised or outstanding restricted share&#160;units are vested, there will be further dilution to new investors. In addition, to the extent we need to raise additional capital in the future and we issue additional Ordinary Shares or securities convertible or exchangeable for our Ordinary Shares, our then existing shareholders may experience dilution and the new securities may have rights senior to those of the ADSs offered in this offering. After this offering is completed, our effective Registration Statement on Form F-3 will remain available to cover the future public offering and sale of up to US$100,000,000 of our ADSs and, if no ADSs are sold in this offering, the full US$100,000,000 of our ADSs may be sold in other offerings pursuant to the accompanying base prospectus. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We have broad discretion over the use of the net proceeds from this offering and may not use them effectively or in a manner desired by our investors.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our management will have broad discretion in the application of the net proceeds from this offering, including for any of the purposes described in the section entitled &#8220;Use of Proceeds,&#8221; and you will not have the opportunity as part of your investment decision to assess whether the net proceeds are being used appropriately. Because of the number and variability of factors that will determine our use of the net proceeds from this offering, their ultimate use may vary substantially from their currently intended use. Our management might not apply our net proceeds in ways that ultimately increase the value of your investment. We expect to use the net proceeds from this offering for general corporate purposes, which may include the development and commercialization of our products, research and development, manufacturing, general and administrative expenses, license or technology acquisitions, and working capital and capital expenditures. The failure by our management to apply these funds effectively could harm our business. Pending their use, we plan to invest the net proceeds from this offering in short- and intermediate-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government. These investments may not yield a favorable return to our shareholders. If we do not invest or apply the net proceeds from this offering in ways that enhance shareholder value, we may fail to achieve expected financial results, which could cause the price of ADSs to decline. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Future sales or issuances of ADSs in the public markets, or the perception of such sales, could depress the trading price of the ADSs.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The sale of a substantial number of ADSs or other equity-related securities in the public markets, or the perception that such sales could occur, could depress the market price of the ADSs and impair our ability to raise capital through the sale of additional equity securities. We may sell large quantities of ADSs </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-12</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">at any time pursuant to this prospectus supplement or in one or more separate offerings. We cannot predict the effect that future sales of ADSs, Ordinary Shares or other equity-related securities would have on the market price of the ADSs. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The actual number of ADSs we will issue under the sales agreement, at any one time or in total, is uncertain.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Subject to certain limitations in the sales agreement and compliance with applicable law, we have the discretion to deliver a placement notice to Leerink Partners at any time throughout the term of the sales agreement. The number of ADSs that are sold by Leerink Partners after delivering a placement notice will fluctuate based on the market price of the ADSs during the sales period and limits we set with Leerink Partners. If the market price of our ADSs during the sales period declines, we would be able to potentially sell a higher number of ADSs than the number based on the current market price of our ADSs and, in any event, we may choose to sell a lower number of ADSs than the US$100&#160;million of our ADSs set forth on the cover of this prospectus. Because the price per ADS sold will fluctuate based on the market price of ADSs during the sales period, it is not possible at this stage to predict the number of Ordinary Shares that will be ultimately issued. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The ADSs offered hereby will be sold in &#8220;at the market offerings,&#8221; and investors who buy shares at different times will likely pay different prices.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Investors who purchase ADSs in this offering at different times will likely pay different prices, and so may experience different outcomes in their investment results. We will have discretion, subject to market demand, to vary the timing, prices, and numbers of ADSs sold, and there is no minimum or maximum sales price. Investors may experience a decline in the value of their ADSs as a result of ADS sales made at prices lower than the prices they paid. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The report and filing with the China Securities Regulatory Commission will be required in connection with the offering under this prospectus supplement, and, we cannot predict if we will be able to complete such report and filing process.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On February&#160;17, 2023, the China Securities Regulatory Commission, or CSRC, issued the Notice on Filing Arrangements for Overseas Securities Offering and Listing by Domestic Companies (the &#8220;CSRC Filing Notice&#8221;), stating that the CSRC has published the Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Companies (the &#8220;Trial Measures&#8221;) and five supporting guidelines (the &#8220;Listing Guidelines&#8221;), collectively the Trial Measures and Listing Guidelines, which came into effect on March&#160;31, 2023. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under the Trial Measures and Listing Guidelines, subsequent securities offerings of an issuer in (i)&#160;the same overseas market where it has previously offered and listed securities, and (ii)&#160;an overseas market other than one where the issuer has previously offered and listed securities shall be (a)&#160;filed with the CSRC within three working days after offerings are completed, and (b)&#160;within three working days after the submission of the application documents for overseas issuance and listing, respectively. Further, the CSRC Filing Notice states that, beginning from March&#160;31, 2023, PRC domestic enterprises which have already issued and listed securities overseas and fall within the scope of filing under the Trial Measures shall be considered &#8220;existing enterprises,&#8221; or Existing Listed Enterprises. Existing Listed Enterprises are not required to complete filings immediately; rather, Existing Listed Enterprises should complete filings if they are subsequently involved in matters require filings, such as follow-on financing activities, in accordance with the Trial Measures. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As advised by our PRC legal counsel, Jingtian &amp; Gongcheng, we are required to complete the initial filing with the CSRC in connection with the offering of securities under this prospectus supplement within three (3)&#160;working days upon completion of the initial sale under this prospectus supplement, and upon completion of the final sale under this prospectus supplement, we shall file a record of the issuance with CSRC within three (3)&#160;working days. We intend to comply with such requirements imposed by the Trial Measures and Listing Guidelines. We cannot assure you that we will be able to address the comments from the CSRC, if any, in connection with our initial filing in a timely and satisfactory manner. We may face adverse actions or sanctions by the CSRC or other PRC regulatory agencies if we are unable to comply with such requirements, which may result in fines and penalties, restrictions on our operations, having to delist from a </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-13</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">stock exchange outside of China, the halting of securities offerings to foreign investors and other actions that could materially and adversely affect our operations and the interest of our investors and cause a significant depreciation in the price of our ordinary shares and ADSs. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We were likely a passive foreign investment company, or PFIC, for 2023, and there is a significant risk that we will be a PFIC for 2024 and possibly subsequent taxable&#160;years, in which case U.S. investors will generally be subject to adverse U.S. federal income tax consequences.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In general, a non-U.S. corporation will be a PFIC for any taxable year in which (i)&#160;75% or more of its gross income consists of passive income, or the income test, or (ii)&#160;50% or more of the average value of its assets (generally determined on a quarterly basis) consists of assets that produce, or are held for the production of, passive income, or the asset test. For purposes of the above calculations, a non-U.S. corporation that directly or indirectly owns at least 25% by value of the shares of another corporation is treated as if it held its proportionate share of the assets of the other corporation and received directly its proportionate share of the income of the other corporation. Passive income generally includes interest, dividends, gains from certain property transactions, rents and royalties (other than certain rents or royalties derived in the active conduct of a trade or business). Cash is generally a passive asset for PFIC purposes. Goodwill and other intangible assets are active under the PFIC rules to the extent attributable to activities that produce active income. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The assets shown on our balance sheet are expected to consist primarily of cash and cash equivalents for the foreseeable future. Therefore, whether we will satisfy the asset test for any taxable year will depend largely on the value of our goodwill and other intangible assets and on how quickly we utilize the cash in our business. The value of our goodwill and other intangible assets for any taxable year may be determined in large part by reference to the average of our market capitalization for that year. Because our market capitalization has declined substantially in recent&#160;years, if the value of our goodwill is determined by reference to the average of our quarterly market capitalization, then it is our belief that we were likely a PFIC for our 2023 taxable year. Due to the volatility of our market capitalization there is a significant risk that we will also be a PFIC for 2024 and possibly future taxable&#160;years. In addition, the extent to which our goodwill and other intangible assets should be characterized as a non-passive asset is not entirely clear. We have not obtained any valuation of our assets (including goodwill). U.S. Holders of our ADSs or Ordinary Shares should consult their tax advisors regarding the value and characterization of our assets for purposes of the PFIC rules, which are subject to some uncertainties. In addition, we can give no assurance that we will not be a PFIC under the income test for any taxable year, particularly prior to the commercialization of any of our drug candidates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If we are a PFIC for any taxable year during which a U.S. investor owns our ADSs or Ordinary Shares, the U.S. taxpayer generally will be subject to adverse U.S. federal income tax consequences, including increased tax liability on disposition gains and &#8220;excess distributions,&#8221; and additional reporting requirements. This will generally continue to be the case even if we ceased to be a PFIC in a later taxable year, unless certain elections are made. See &#8220;Taxation&#8201;&#8212;&#8201;Material U.S. Federal Income Tax Considerations&#8221; below. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If a U.S. person is treated as owning 10% or more of our stock by vote or value, such person may be subject to adverse U.S. federal income tax consequences.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If a U.S. person is treated as owning (directly, indirectly or constructively) 10% or more of our stock (including our ADSs and Ordinary Shares) by value or voting power, such person generally will be treated as a &#8220;United States shareholder&#8221; with respect to each &#8220;controlled foreign corporation,&#8221; or CFC, in our group. A CFC is a non-U.S. corporation more than 50% of the stock (by voting power or value) of which is owned (directly, indirectly or constructively) by &#8220;United States shareholders.&#8221; We have not determined whether we are a CFC. However, even if we are not a CFC, under certain ownership attribution rules our non-U.S. subsidiaries would be treated as owned by our U.S. subsidiary and thus may be treated as CFCs. A United States shareholder of a CFC may be subject to additional U.S. federal income tax liabilities and reporting requirements. We do not intend to furnish any information that may be necessary for United States shareholders, if any, to comply with the CFC rules. U.S. investors that may be treated for purposes of the CFC rules as owning 10% of our stock by voting power or value should consult their tax advisors regarding the potential application of these rules in their particular circumstances. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-14</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="bUOP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:364pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">USE OF PROCEEDS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may offer and sell ADSs, each representing one and one quarter (1.25) of our Ordinary Shares, having aggregate sales proceeds of up to US$100&#160;million from time to time. Because there is no minimum offering amount required as a condition to close this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time. There can be no assurance that we will be able to sell any ADSs under or fully utilize the Sales Agreement with Leerink Partners as a source of financing. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We intend to use the net proceeds of this offering for general corporate purposes, which may include the development and commercialization of our products, research and development, manufacturing, general and administrative expenses, license or technology acquisitions, and working capital and capital expenditures. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The amounts and timing of our actual expenditures will depend on numerous factors, including the progress of our clinical trials and other development efforts and other factors described under &#8220;Risk Factors&#8221; in this prospectus supplement, the accompanying base prospectus and the documents incorporated by reference herein and therein, as well as the amount of cash used in our operations. We may find it necessary or advisable to use the net proceeds for other purposes, and we will have broad discretion in the application of the net proceeds. Pending the use of the net proceeds described above, we plan to invest the net proceeds from this offering in a variety of capital preservation investments, including short- and intermediate-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-15</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="bDIPO">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:280pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DIVIDEND POLICY</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have not previously declared or paid cash dividends and we have no plan to declare or pay any dividends in the near future on our Ordinary Shares or the ADSs representing our Ordinary Shares. We currently intend to retain most, if not all, of our available funds and any future earnings to operate and expand our business. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are a holding company incorporated in the Cayman Islands. In the future, we may rely on dividends from our subsidiaries, including our U.S. and PRC subsidiaries, for our cash requirements, including any payment of dividends to our shareholders. PRC regulations may restrict the ability of our PRC subsidiary to pay dividends to us. See &#8220;Item&#160;4 Information of the Company&#8201;&#8212;&#8201;B. Business Overview &#8212; Regulation &#8212; Regulations relating to Dividend Distribution&#8221; in our most recent annual report on Form 20-F incorporated by reference. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our board of directors has discretion as to whether to distribute dividends, subject to certain requirements of Cayman Islands law. In addition, our shareholders may, subject to the provisions of our post-offering articles of association, by ordinary resolution declare a dividend, but no dividend may exceed the amount recommended by our board of directors. Under Cayman Islands law, a Cayman Islands company may pay a dividend out of either profit, retained earnings or share premium account, provided that in no circumstances may a dividend be paid if this would result in the company being unable to pay its debts as they fall due in the ordinary course of business. Even if our board of directors decides to pay dividends, the form, frequency and amount will depend upon our future operations and earnings, capital requirements and surplus, general financial condition, contractual restrictions and other factors that the board of directors may deem relevant. If we pay any dividends on our Ordinary Shares, we will pay those dividends which are payable in respect of the Ordinary Shares underlying the ADSs to the depositary, as the registered holder of such Ordinary Shares, and the depositary then will pay such amounts to the ADS holders in proportion to the Ordinary Shares underlying the ADSs held by such ADS holders, subject to the terms of the deposit agreement, including the fees and expenses payable thereunder. See &#8220;Item&#160;12 Description of Securities Other Than Equity Securities&#8201;&#8212;&#8201;D. American Depositary Shares&#8221; in our most recent annual report on Form&#160;20-F incorporated by reference.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-16</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="bCAP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:229pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CAPITALIZATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth our capitalization as of December&#160;31, 2023, the latest date for which we have audited financial statements: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">on an actual basis; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">on an as adjusted basis to give effect to the issuance and sale of US$100,000,000 of ADSs in this offering at an assumed offering price of US$3.20 per ADS, which was the closing price of our ADSs on February&#160;29, 2024 after deducting estimated offering expenses payable by us. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The as adjusted information below is illustrative only. You should read this table together with our audited consolidated financial statements and the related notes and &#8220;Item&#160;5. Operating and Financial Review and Prospects&#8221; in our most recent annual report on Form 20-F, which is incorporated by reference in this prospectus supplement. </font>
        </div>
        <table style="width:416pt;height:214pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:315.97pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">As of December&#160;31, 2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:315.97pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Actual </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">As Adjusted </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:315.97pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">US$&#8217;000 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:315.97pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Cash and cash equivalents</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">109,934</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">206,234</td>
            <td style="padding:0pt;padding-left:1.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1.5pt 0pt; width:315.97pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Long-term borrowings </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">13,540 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.975pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">13,540</td>
            <td style="padding:0pt;padding-left:1.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:315.97pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Shareholders&#8217; equity</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:315.97pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Ordinary shares (par value of US$0.0001 per share; 640,000,000 shares authorized, and 55,145,839 shares issued and outstanding as of December&#160;31, 2023) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">6 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.975pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">9</td>
            <td style="padding:0pt;padding-left:1.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:315.97pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Treasury shares, at cost (1 share as of December&#160;31, 2023) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:315.97pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Additional paid-in capital </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">350,106 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">446,402</td>
            <td style="padding:0pt;padding-left:1.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:315.97pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Accumulated other comprehensive income </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">(1,800<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">(1,800<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:315.97pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Accumulated deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(277,751<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.975pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(277,751<font style="position:absolute;">) </font></td>
            <td style="padding:0pt;padding-left:1.975pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:315.97pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Total shareholders&#8217; equity</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">
              <div style="font-weight:bold;">&#8203;</div>
            </td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">70,559</div>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">
              <div style="font-weight:bold;">&#8203;</div>
            </td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">166,859</div>
            </td>
            <td style="padding:0pt;padding-left:1.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.5pt 0pt; width:315.97pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Total capitalization</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">
              <div style="font-weight:bold;">&#8203;</div>
            </td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">84,100</div>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.975pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">
              <div style="font-weight:bold;">&#8203;</div>
            </td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">180,400</div>
            </td>
            <td style="padding:0pt;padding-left:1.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-17</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:104pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DILUTION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If you invest in our Ordinary Shares or ADSs in this offering, your ownership interest will be diluted immediately to the extent of the difference between the price you pay in this offering and the net tangible book value per Ordinary Share after this offering. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our net tangible book value as of December&#160;31, 2023 was approximately US$70.4&#160;million, or US$1.3 per Ordinary Shares, based on 55,145,839 Ordinary Shares then outstanding. After giving effect to the assumed sale by us of our Ordinary Shares in the aggregate amount of US$100.0&#160;million at an assumed public offering price of US$3.20 per ADS (the last sale price of our ADSs on February&#160;29, 2024 as reported on Nasdaq), less the estimated commissions and estimated offering expenses payable by us, our net tangible book value at December&#160;31, 2023 would have been approximately US$166.7&#160;million, or US$1.77 per Ordinary Share. This represents an immediate increase in net tangible book value of US$0.49 per Ordinary Share to existing shareholders and an immediate dilution of US$0.79 per Ordinary Share to investors in this offering. The following table illustrates this per share dilution. The as adjusted information is illustrative only and will adjust based on the actual price to the public, the actual number of shares sold and other terms of the offering determined at the time our Ordinary Shares are sold pursuant to this prospectus supplement. The shares sold in this offering, if any, will be sold from time to time at various prices. </font>
        </div>
        <table style="width:416pt;height:129pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:222.18pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Per Ordinary</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Share </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Per ADS </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:222.18pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Assumed public offering price per share </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:36.45pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:36.45pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">US$2.56 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:36.45pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:36.45pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">US$3.20 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:222.18pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Net tangible book value per share as of December&#160;31, 2023 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:36.45pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">US$1.28 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:36.45pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:36.45pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">US$1.60 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:36.45pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:222.18pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Increase in net tangible book value per share to existing shareholders </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:36.45pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">US$0.49 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:36.45pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:36.45pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">US$0.61</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:36.45pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 1.833pt 0pt; width:222.18pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">As adjusted net tangible book value per share after giving effect to this offering </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:36.45pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt; width:36.45pt;">
              <div style="text-align:center;">
                <font style="border-bottom:1px solid #000000;letter-spacing:0.2pt;">US$1.77</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:36.45pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt; width:36.45pt;">
              <div style="text-align:center;">
                <font style="border-bottom:1px solid #000000;letter-spacing:0.2pt;">US$2.21</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:222.18pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Dilution per share to new investors </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:36.45pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:36.45pt;">
              <div style="text-align:center;">
                <font style="border-bottom:3pt double #000000;letter-spacing:0.2pt;">US$0.79</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:36.45pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:36.45pt;">
              <div style="text-align:center;">
                <font style="border-bottom:3pt double #000000;letter-spacing:0.2pt;">US$0.99</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The above discussion and table are based on our actual Ordinary Shares outstanding as of December&#160;31, 2023 and excludes the 325,000 Ordinary Shares, issued but deemed to be not outstanding as of December&#160;31, 2023, held by Great Han Fortune LP. The discussion and tables above also assume no exercise of any awards outstanding as of the date of this prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of the date of this prospectus, the aggregate number of our Ordinary Shares underlying our outstanding awards under the 2019 Plan and 2021 Plan is 2,536,570 and 6,229,557, respectively, issuable upon exercise of outstanding awards at a weighted average exercise price of US$ $1.79 and US$3.17 per Ordinary Share, respectively, excluding awards that were forfeited, cancelled or exercised after the relevant grant dates. To the extent that outstanding options are exercised, you will experience further dilution. In addition, we may choose to raise additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance of such securities may result in further dilution to our shareholders. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-18</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="bTAX">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">TAXATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The following discussion of Cayman Islands, PRC and United States federal income tax consequences of an investment in the ADSs or Ordinary Shares is based upon laws and relevant interpretations thereof in effect as of the date of this prospectus supplement, all of which are subject to change. This discussion does not deal with all possible tax consequences relating to an investment in the ADSs or Ordinary Shares, such as the tax consequences under U.S. state, or local laws or the tax laws of any jurisdiction other than the Cayman Islands, the PRC and the United States. To the extent that the discussion relates to matters of Cayman Islands tax law, it represents the opinion of Walkers (Hong Kong), our Cayman Islands counsel. To the extent that the discussion relates to matters of PRC tax law, it represents the opinion of Jingtian &amp; Gongcheng, our PRC legal counsel.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Cayman Islands Taxation</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">According to Walkers (Hong Kong), our Cayman Islands counsel, the Cayman Islands currently levies no taxes on individuals or corporations based upon profits, income, gains or appreciation, and there is no taxation in the nature of inheritance tax or estate duty. There are no other taxes likely to be material to us or holders of our ADSs or Ordinary Shares levied by the government of the Cayman Islands, except for stamp duties which may be applicable on instruments executed in, or after execution brought within the jurisdiction of the Cayman Islands. The Cayman Islands is not party to any double tax treaties that are applicable to any payments made to or by our company. There are no exchange control regulations or currency restrictions in the Cayman Islands. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Payments of dividends and capital in respect of the ADSs or Ordinary Shares will not be subject to taxation in the Cayman Islands and no withholding will be required on the payment of a dividend or capital to any holder of the ADSs or Ordinary Shares, nor will gains derived from the disposal of the ADSs or Ordinary Shares be subject to Cayman Islands income or corporation tax. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Material PRC Income Tax Considerations</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">According to Jingtian &amp; Gongcheng, our PRC legal counsel, under the PRC EIT Law, which became effective on January&#160;1, 2008 and was amended on December&#160;29, 2018, an enterprise established outside the PRC with &#8220;de facto management bodies&#8221; within the PRC is considered a &#8220;resident enterprise&#8221; for PRC enterprise income tax purposes and is generally subject to a uniform 25% enterprise income tax rate on its worldwide income. Under the implementation rules to the PRC EIT Law, a &#8220;de facto management body&#8221; is defined as a body that has material and overall management and control over the manufacturing and business operations, personnel and human resources, finances and properties of an enterprise. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, the SAT Circular 82 issued by the SAT in April&#160;2009 specifies that certain offshore incorporated enterprises controlled by PRC enterprises or PRC enterprise groups will be classified as PRC resident enterprises if the following are located or resident in the PRC: (a)&#160;senior management personnel and departments that are responsible for daily production, operation and management; (b)&#160;financial and personnel decision-making bodies; (c)&#160;key properties, accounting books, company seal, minutes of board meetings and shareholders&#8217; meetings; and (d)&#160;half or more of the senior management or directors having voting rights. Further to SAT Circular 82, the SAT issued the SAT Bulletin 45, which took effect in September&#160;2011, to provide more guidance on the implementation of SAT Circular 82. SAT Bulletin 45 provides for procedures and administration details of determination on resident status and administration on post-determination matters. Our company is a company incorporated outside the PRC. As a holding company, its key assets are its ownership interests in its subsidiaries, and its key assets are located, and its records (including the resolutions of its board of directors and the resolutions of its shareholders) are maintained, outside the PRC. As such, we do not believe that our company meets all of the conditions above or is a PRC resident enterprise for PRC tax purposes. For similar reasons, we believe our other entities outside China are not PRC resident enterprises either. However, the tax resident status of an enterprise is subject to determination by the PRC tax authorities and uncertainties remain with respect to the interpretation of the term &#8220;de facto management body.&#8221; There can be no assurance that the PRC government will ultimately take a view that is consistent with us. If the PRC tax authorities determine that our Cayman Islands holding company is a PRC resident enterprise for PRC enterprise income tax purposes, a number of unfavorable PRC tax consequences could follow. For example, a 10% withholding tax would be imposed </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-19</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">on dividends we pay to our non-PRC enterprise shareholders (including our ADS holders). In addition, nonresident enterprise shareholders (including our ADS holders) may be subject to PRC tax on gains realized on the sale or other disposition of ADSs or Ordinary Shares, if such income is treated as sourced from within the PRC. Furthermore, if we are deemed a PRC resident enterprise, dividends paid to our non-PRC individual shareholders (including our ADS holders) and any gain realized on the transfer of ADSs or Ordinary Shares by such shareholders may be subject to PRC tax at a rate of 20% (which, in the case of dividends, may be withheld at source by us). These rates may be reduced by an applicable tax treaty, but it is unclear whether in practice non-PRC shareholders of our company would be able to obtain the benefits of any tax treaties between their country of tax residence and the PRC in the event that we are treated as a PRC resident enterprise. See &#8220;Item&#160;3 Key Information&#8201;&#8212;&#8201;D. Risk Factors&#8201;&#8212;&#8201;Risks Related to Doing Business in the PRC&#8201;&#8212;&#8201;If we are classified as a PRC resident enterprise for PRC income tax purposes, such classification could result in unfavorable tax consequences to us and our non-PRC shareholders or ADS holders&#8221; of the latest annual report incorporated by reference. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Material U.S. Federal Income Tax Considerations</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following discussion describes U.S. federal income tax consequences to the U.S. Holders described below of the ownership and disposition of the ADSs or Ordinary Shares. This discussion is not a comprehensive description of all of the tax considerations that may be relevant to your decision to hold the ADSs or Ordinary Shares. This discussion applies to you only if you are a U.S. Holder that holds the ADSs or underlying Ordinary Shares as capital assets for U.S. federal income tax purposes. In addition, it does not describe all of the tax consequences that may be relevant in light of your particular circumstances, including the alternative minimum tax, the Medicare contribution tax on net investment income, and tax consequences applicable to you if you are subject to special rules, such as: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">one of certain financial institutions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a dealer or trader in securities that uses a mark-to-market method of tax accounting; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a person holding ADSs or Ordinary Shares as part of a straddle, conversion transaction, integrated transaction or similar transaction; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a person whose functional currency for U.S. federal income tax purposes is not the U.S. dollar; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">an entity classified as a partnership for U.S. federal income tax purposes (and investors therein); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a tax-exempt entity, &#8220;individual retirement account&#8221; or &#8220;Roth IRA&#8221;; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a person who acquired our ADSs or Ordinary Shares pursuant to the exercise of an employee stock option or otherwise as compensation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a person that owns or is deemed to own 10% or more of our stock by vote or value; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a person holding ADSs or Ordinary Shares in connection with a trade or business conducted outside the United States. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If you are a partnership for U.S. federal income tax purposes, the U.S. federal income tax consequences to your partners will generally depend on their status and your activities. Partnerships holding ADSs or Ordinary Shares and their partners should consult their tax advisors as to the particular U.S. federal income tax consequences of acquiring, owning or disposing of the ADSs or Ordinary Shares. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This discussion is based on the Internal Revenue Code of 1986, as amended, or the Code, administrative pronouncements, judicial decisions and final, temporary and proposed Treasury regulations, and the income tax treaty between the United States and the PRC, or the Treaty, all as of the date hereof, any of which is subject to change, possibly with retroactive effect. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For purposes of this discussion, you are a &#8220;U.S. Holder&#8221; if you are eligible for the benefits of the Treaty and are, for U.S. federal income tax purposes, a beneficial owner of ADSs or Ordinary Shares and: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a citizen or individual resident of the United States; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a corporation or other entity taxable as a corporation for U.S. federal income tax purposes, created or organized in or under the laws of the United States, any state therein or the District of Columbia; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-20</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">an estate or trust the income of which is subject to U.S. federal income taxation regardless of its source. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In general, if you own ADSs you will be treated as the owner of the underlying Ordinary Shares represented by those ADSs for U.S. federal income tax purposes. Accordingly, no gain or loss will be recognized if you exchange ADSs for the underlying Ordinary Shares represented by those ADSs. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Passive Foreign Investment Company Rules</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In general, a non-U.S. corporation will be a passive foreign investment company, or a PFIC, for any taxable year in which (i)&#160;75% or more of its gross income consists of passive income, or the income test, or (ii)&#160;50% or more of the average value of its assets (generally determined on a quarterly basis) consists of assets that produce, or are held for the production of, passive income, or the asset test. For purposes of the above calculations, a non-U.S. corporation that directly or indirectly owns at least 25% by value of the shares of another corporation is treated as if it held its proportionate share of the assets of the other corporation and received directly its proportionate share of the income of the other corporation. Passive income generally includes interest, dividends, gains from certain property transactions, rents and royalties (other than certain rents or royalties derived in the active conduct of a trade or business). Cash is generally a passive asset for PFIC purposes. Goodwill and other intangible assets are active under the PFIC rules to the extent attributable to activities that produce active income. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The assets shown on our balance sheet are expected to consist primarily of cash and cash equivalents for the foreseeable future. Therefore, whether we will satisfy the asset test for any taxable year will depend largely on the value of our goodwill and other intangible assets and on how quickly we utilize the cash in our business. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The value of our goodwill and other intangible assets for any taxable year may be determined in large part by reference to the average of our market capitalization for that year. Because our market capitalization has declined substantially in recent&#160;years, if the value of our goodwill is determined by reference to the average of our quarterly market capitalization then it is our belief that we were likely a PFIC for our 2023 taxable year. Due to the volatility of our market capitalization, there is a significant risk that we will also be a PFIC for 2024 and possibly future taxable&#160;years. In addition, the extent to which our goodwill and other intangible assets should be characterized as a non-passive asset is not entirely clear. We have not obtained any valuation of our assets (including goodwill). U.S. Holders of our ADSs or Ordinary Shares should consult their tax advisors regarding the value and characterization of our assets for purposes of the PFIC rules, which are subject to some uncertainties. In addition, we can give no assurance that we will not be a PFIC under the income test for any taxable year, particularly prior to the commercialization of any of our drug candidates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If we are a PFIC for any taxable year and any of our subsidiaries is also a PFIC (any such entity, a &#8220;Lower-tier PFIC&#8221;), U.S. Holders will be deemed to own a proportionate amount (by value) of the shares of each Lower-tier PFIC and will be subject to U.S. federal income tax according to the rules described in the subsequent paragraph on (i)&#160;certain distributions by a Lower-tier PFIC and (ii)&#160;dispositions of shares of Lower-tier PFICs, in each case as if the U.S. Holders held such shares directly, even though the U.S. Holders will not receive the proceeds of those distributions or dispositions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In general, if we are a PFIC for any taxable year during which a U.S. Holder holds our ADSs or Ordinary Shares, gain recognized by such U.S. Holder on a sale or other disposition (including certain pledges) of its ADSs or Ordinary Shares will be allocated ratably over that U.S. Holder&#8217;s holding period. The amounts allocated to the taxable year of the sale or disposition and to any year before we became a PFIC will be taxed as ordinary income. The amount allocated to each other taxable year will be subject to tax at the highest rate in effect for individuals or corporations, as appropriate, for that taxable year, and an interest charge will be imposed on the resulting tax liability for each such year. Furthermore, to the extent that distributions received by a U.S. Holder in any taxable year on its ADSs or Ordinary Shares exceed 125% of the average of the annual distributions on the ADSs or Ordinary Shares received during the preceding three taxable&#160;years or the U.S. Holder&#8217;s holding period, whichever is shorter, the excess distributions will be subject to taxation in the same manner. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under a rule commonly referred to as the &#8220;once a PFIC, always a PFIC&#8221; rule, if we are a PFIC for any taxable year during which a U.S. Holder owns ADSs or Ordinary Shares, we will generally continue to be </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-21</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">treated as a PFIC with respect to the U.S. Holder for all succeeding taxable&#160;years during which the U.S. Holder owns the ADSs or Ordinary Shares, even if we cease to meet the threshold requirements for PFIC status. If we are a PFIC for any taxable year but cease to be PFIC for subsequent&#160;years, U.S. Holders should consult their tax advisors regarding the advisability of making a &#8220;deemed sale&#8221; election that will allow them to eliminate the continuing PFIC status under certain circumstances, but may require them to recognize gain taxed under the general PFIC rules described in the preceding paragraph. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Alternatively, if we are a PFIC and if the ADSs are &#8220;regularly traded&#8221; on a &#8220;qualified exchange,&#8221; a U.S. Holder of ADSs may make a mark-to-market election that will result in tax treatment different from the general tax treatment for PFICs described above. The ADSs will be treated as &#8220;regularly traded&#8221; for any calendar year in which more than a de minimis quantity of the ADSs are traded on a qualified exchange on at least 15&#160;days during each calendar quarter. The Nasdaq Global Market, where the ADSs are listed, is a qualified exchange for this purpose, but there is no assurance that our ADSs will be treated as regularly traded for any relevant period. If a U.S. Holder makes the mark-to-market election, the U.S. Holder generally will recognize as ordinary income any excess of the fair market value of the ADSs at the end of each taxable year over their adjusted tax basis, and will recognize an ordinary loss in respect of any excess of the adjusted tax basis of the ADSs over their fair market value at the end of the taxable year (but only to the extent of the net amount of income previously included as a result of the mark-to-market election). If a U.S. Holder makes the election, the U.S. Holder&#8217;s tax basis in the ADSs will be adjusted to reflect the income or loss amounts recognized. Any gain recognized on the sale or other disposition of ADSs in a taxable year in which we are a PFIC will be treated as ordinary income, and any loss will be treated as an ordinary loss (but only to the extent of the net amount of income previously included as a result of the mark-to-market election, with any excess treated as capital loss). If a U.S. Holder makes the mark-to-market election, distributions paid on ADSs will be treated as discussed under &#8220;&#8212; Taxation of Distributions&#8221; below (but subject to the discussion in the immediately subsequent paragraph). U.S. Holders should consult their tax advisors regarding the availability and advisability of making a mark-to-market election in their particular circumstances. In particular, U.S. Holders should consider carefully the impact of a mark-to-market election with respect to their ADSs because we may have Lower-tier PFICs for which a mark-to-market election likely cannot be made. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The favorable tax rates for dividends paid to certain non-corporate U.S. Holders of ADSs, which are discussed below, do not apply to dividends from a corporation that is a PFIC (or is treated as a PFIC with respect to a U.S. Holder) in the year the dividend is paid or the preceding year. We do not intend to provide information necessary for U.S. Holders to make a &#8220;qualified electing fund election,&#8221; which, if available, would result in tax treatment different from the tax treatment for PFICs described above. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If we are a PFIC for any taxable year during which a U.S. Holder owns any ADSs or Ordinary Shares, the U.S. Holder will generally be required to file annual reports with the Internal Revenue Service (the &#8220;IRS&#8221;). U.S. Holders should consult their tax advisors regarding the PFIC rules and their application. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Taxation of Distributions</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following is subject to the discussion under &#8220;&#8212; </font><font style="font-style:italic;letter-spacing:0.2pt;">Passive Foreign Investment Company Rules</font><font style="letter-spacing:0.2pt;">&#8221; above. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Distributions paid on ADSs or Ordinary Shares, other than certain pro&#160;rata distributions of Ordinary Shares, will generally be treated as dividends to the extent paid out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles). Because we do not maintain calculations of our earnings and profits under U.S. federal income tax principles, we expect that any distributions will be reported to you as dividends. Dividends will not be eligible for the dividends-received deduction generally available to U.S. corporations under the Code. Subject to applicable limitations, dividends paid by &#8220;qualified foreign corporations&#8221; to certain non-corporate U.S. Holders are taxable at the favorable rates applicable to long-term capital gains. A non-U.S. corporation is generally treated as a qualified foreign corporation with respect to dividends paid on stock that is readily tradable on a securities market in the United States, such as the Nasdaq Global Market, where the ADSs are listed, or where the non-U.S. corporation is eligible for benefits of a comprehensive income tax treaty with the United States. Therefore such favorable rates may apply to dividends (if any) paid on our ADSs for so long as our ADSs are listed on the Nasdaq Global Market or if in the future we are eligible for benefits under the Treaty. However, as discussed above, the favorable rates do not apply if we are (or are treated with respect to a U.S. Holder as) a PFIC for the taxable </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-22</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">year in which the dividend is paid or the preceding taxable year. Non-corporate U.S. Holders should consult their tax advisors to determine whether the favorable rate will apply to dividends they receive and whether they are subject to any special rules that limit their ability to be taxed at this favorable rate. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Dividends will be treated as foreign-source income for foreign tax credit purposes. As described in &#8220;Taxation&#8201;&#8212;&#8201;&#160;Material PRC Income Tax Considerations,&#8221; dividends paid by us may be subject to PRC withholding tax. For U.S. federal income tax purposes, the amount of the dividend income will include any amounts withheld in respect of PRC withholding tax. Subject to applicable limitations, which vary depending upon your circumstances, PRC taxes withheld from dividend payments (at a rate not exceeding any applicable rate provided by the Treaty) generally will be creditable against your U.S. federal income tax liability. The rules governing foreign tax credits are complex. For example, certain Treasury regulations (the &#8220;Foreign Tax Credit Regulations&#8221;) provide that, in the absence of an election to apply the benefits of an applicable income tax treaty, in order for non-U.S. income taxes to be creditable, the relevant non-U.S. income tax rules must be consistent with certain U.S. federal income tax principles, and we have not determined whether the PRC income tax system meets these requirements. The IRS has released notices that provide relief from certain of the provisions of the Treasury regulations described above for taxable&#160;years ending before the date that a notice or other guidance withdrawing or modifying the temporary relief is issued (or any later date specified in such notice or other guidance). In lieu of claiming a credit, you may elect to deduct creditable PRC taxes in computing your taxable income, subject to applicable limitations. An election to deduct foreign taxes instead of claiming foreign tax credits applies to all creditable foreign taxes paid or accrued in the taxable year. You should consult your tax advisors regarding the creditability or deductibility of foreign taxes in your particular circumstances. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Sale or Other Disposition of ADSs or Ordinary Shares</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following is subject to the discussion under &#8220;&#8212; </font><font style="font-style:italic;letter-spacing:0.2pt;">Passive Foreign Investment Company Rules</font><font style="letter-spacing:0.2pt;">&#8221; above. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Gain or loss realized on the sale or other taxable disposition of ADSs or Ordinary Shares will be capital gain or loss, and will be long-term capital gain or loss if you held the ADSs or Ordinary Shares for more than one year. The amount of the gain or loss will equal the difference between your tax basis in the ADSs or Ordinary Shares disposed of and the amount realized on the disposition, in each case as determined in U.S. dollars. This gain or loss will generally be U.S.-source gain or loss for foreign tax credit purposes. The deductibility of capital losses is subject to limitations. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As described in &#8220;Taxation&#8201;&#8212;&#8201;</font><font style="font-style:italic;letter-spacing:0.2pt;">Material PRC Income Tax Considerations</font><font style="letter-spacing:0.2pt;">&#8221; above, gains on the sale of ADSs or Ordinary Shares may be subject to PRC taxes. Under the Code, capital gains of U.S. persons are generally treated as U.S.-source income. However, you may be able to elect to treat the gain as foreign-source income under the Treaty and claim foreign tax credit in respect of any PRC tax on dispositions. The Foreign Tax Credit Regulations generally preclude you from claiming a foreign tax credit with respect to PRC income taxes on gains from dispositions of ADSs or Ordinary Shares if you do not elect to apply the benefits of the Treaty. However, as described above, recent notices from the IRS indicate that the Treasury and the IRS are considering proposing amendments to such regulations and allow taxpayers, subject to certain conditions, to defer the application of many aspects of such regulations until the date when a notice or other guidance withdrawing or modifying this temporary relief is issued (or any later date specified in such notice or other guidance). However, even if the Foreign Tax Credit Regulations do not prohibit you from claiming a foreign tax credit with respect to PRC taxes on disposition gains, other limitations under the foreign tax credit rules may preclude you from claiming a foreign tax credit. In lieu of claiming a credit, it is possible that any PRC taxes on disposition gains may either be deductible or reduce the amount realized on the disposition. The rules governing foreign tax credits and deductibility of foreign taxes are complex. You should consult your tax advisor regarding the consequences of the imposition of any PRC tax on disposition gains, including the Treaty&#8217;s resourcing rule, any reporting requirements with respect to a Treaty-based return position and the creditability or deductibility of the PRC tax on disposition gains in your particular circumstances (including any applicable limitations). </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Information Reporting and Backup Withholding</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Payments of dividends and sales proceeds from the sale or exchange of our ADSs or Ordinary Shares that are made within the United States or through certain U.S.-related financial intermediaries generally are </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-23</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:500pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">subject to information reporting, and may be subject to backup withholding, unless (i)&#160;you are a corporation or other exempt recipient or (ii)&#160;in the case of backup withholding, you provide a correct taxpayer identification number and certify that you are not subject to backup withholding. Backup withholding is not an additional tax. The amount of any backup withholding from a payment to you will be allowed as a credit against your U.S. federal income tax liability and may entitle you to a refund, provided that the required information is timely furnished to the IRS. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Certain U.S. Holders who are individuals (and certain specified entities) may be required to report information relating to their ownership of ADSs or Ordinary Shares, or non-U.S. accounts through which ADSs or Ordinary Shares are held. You should consult your tax advisor regarding your reporting obligations with respect to the ADSs or Ordinary Shares.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-24</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="bPODF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PLAN OF DISTRIBUTION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have entered into a sales agreement, or Sales Agreement, with Leerink Partners LLC, or Leerink Partners, under which we may issue and sell up to US$100.0&#160;million of our American depositary shares, or ADSs, each representing one and one quarter (1.25) of our ordinary shares, par value US$0.0001 per share, from time to time through Leerink Partners as our sales agent. Sales of the ADSs, if any, will be made by any method that is deemed to be an &#8220;at the market offering&#8221; as defined in Rule&#160;415 under the Securities Act, including sales made directly on or through the Nasdaq Global Market, on or through any other existing trading market for our ADSs or to or through a market maker or otherwise, through block transactions and/or any other method permitted by law, in each case at market prices. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Leerink Partners will offer the ADSs subject to the terms and conditions of the Sales Agreement on a daily basis or as otherwise agreed upon by us and Leerink Partners. We will designate the maximum number or amount of ADSs to be sold through Leerink Partners on a daily basis or otherwise determine such maximum number or amount together with Leerink Partners. Subject to the terms and conditions of the Sales Agreement, Leerink Partners will use commercially reasonable efforts consistent with their normal trading and sales practices to sell on our behalf all of the ADSs requested to be sold by us. We may instruct Leerink Partners not to sell ADSs if the sales cannot be effected at or above a minimum price designated by us in any such instruction. Leerink Partners or we may suspend the offering of the ADSs being made through Leerink Partners under the Sales Agreement upon proper notice to the other parties. Leerink Partners and we each have the right, by giving written notice as specified in the Sales Agreement, to terminate the Sales Agreement at each party&#8217;s sole discretion at any time. The offering of the ADSs pursuant to the Sales Agreement will otherwise terminate upon the termination of the Sales Agreement as provided therein. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The compensation payable to Leerink Partners will be an amount of up to 3.0% of the gross proceeds of any ADSs sold through it pursuant to the Sales Agreement. We have also agreed to reimburse Leerink Partners for certain of their expenses in an amount up to $135,000, in addition to certain ongoing disbursements of its legal counsel in the amount up to $25,000 in connection with certain events described in the Sales Agreement. We estimate that the total expenses of the offering payable by us at the time of the establishment and on an annual basis, excluding compensation payable to Leerink Partners under the Sales Agreement, will be approximately $630,000 and $295,000, respectively. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The remaining sales proceeds, after deducting any expenses payable by us and any transaction fees imposed by any governmental, regulatory or self-regulatory organization in connection with the sales of the ADSs, will equal our net proceeds for the sale of such ADSs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Leerink Partners will provide written confirmation to us no later than the next succeeding trading day on the Nasdaq Global Market after each such day on which ADSs are sold through Leerink Partners under the Sales Agreement. Each confirmation will include the amount or number of ADSs sold through such Sales Agent on that day, the volume-weighted average price of the ADSs sold and the net proceeds to us from such sales. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Settlement for sales of ADSs will occur, unless the parties agree otherwise, on the second trading day (or such earlier day as is industry practice or as is required for regular-way trading) following the date on which any sales were made in return for payment of the net proceeds to us. There is no arrangement for funds to be received in an escrow, trust or similar arrangement. We will report at least biannually the number of ADSs sold through the Sales Agents under the Sales Agreement, the net proceeds to us and the compensation paid by us to the Sales Agents in connection with the sales of shares of ADSs during the relevant period. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In connection with the sale of the ADSs on our behalf pursuant to the Sales Agreement, Leerink Partners will be deemed to be an &#8220;underwriter&#8221; within the meaning of the Securities Act and the compensation paid to Leerink Partners will be deemed to be underwriting commissions or discounts. We have agreed in the Sales Agreement to provide indemnification and contribution to Leerink Partners with respect to certain liabilities, including liabilities under the Securities Act of 1933, as amended, or the Exchange Act of 1934, as amended. As sales agent, Leerink Partners will not engage in any transactions that stabilize the ADSs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Sales Agent and/or its affiliates have provided, and may in the future provide, various investment banking and other financial services for us for which services they have received, and may in the future receive, customary fees. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-25</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:572pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">This prospectus supplement and the accompanying base prospectus in electronic format may be made available on a website maintained by us and Leerink Partners may distribute this prospectus supplement and the accompanying base prospectus electronically. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">The address of Leerink Partners is 1301 Avenue of the Americas, 12th Floor, New York, NY 10019. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">S-26</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="bLEMA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:500pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">LEGAL MATTERS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are being represented by Davis Polk &amp; Wardwell LLP with respect to certain legal matters of U.S. federal securities and New York state law. Certain legal matters with respect to U.S. federal and New York State law in connection with this offering will be passed upon for the sales agent by Latham &amp; Watkins LLP. The validity of the Ordinary Shares represented by the ADSs offered in this offering and other certain legal matters as to Cayman Islands law will be passed upon for us by Walkers (Hong Kong). Legal matters as to PRC law will be passed upon for us by Jingtian &amp; Gongcheng and for the sales agent by Zhong Lun Law Firm. Davis Polk &amp; Wardwell LLP may rely upon Walkers (Hong Kong) with respect to matters governed by Cayman Islands law and Jingtian &amp; Gongcheng with respect to matters governed by PRC law. Latham &amp; Watkins LLP may rely upon Zhong Lun Law Firm with respect to matters governed by PRC law. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-27</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="bEXP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:528pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">EXPERTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">The financial statements incorporated in this Prospectus by reference to the Annual Report on Form&#160;20-F for the year ended December&#160;31, 2023 have been so incorporated in reliance on the report of PricewaterhouseCoopers Zhong Tian LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">The office of PricewaterhouseCoopers Zhong Tian LLP is located at 42/F New Bund Center, 588&#160;Dongyu Road, Pudong New Area, Shanghai 200126, the People&#8217;s Republic of China. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">S-28</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="bWYCF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:420pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">WHERE YOU CAN FIND MORE INFORMATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have filed with the U.S. Securities and Exchange Commission a registration statement (including amendments and exhibits to the registration statement) on Form F-3 under the Securities Act. Our SEC filings are available to the public over the Internet at the SEC&#8217;s website at </font><font style="font-style:italic;letter-spacing:0.2pt;">http://www.sec.gov</font><font style="letter-spacing:0.2pt;">. Copies of certain information filed by us with the SEC are also available on our website at </font><font style="font-style:italic;letter-spacing:0.2pt;">www.adagene.com</font><font style="letter-spacing:0.2pt;">. Our website is not a part of this prospectus supplement and is not incorporated by reference in this prospectus supplement. We furnish reports and other information to the SEC. You may also read and copy any document we file at the SEC&#8217;s public reference facilities and the website of the SEC referred to above. Our file number with the SEC is 001-39997. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus supplement is part of a registration statement we filed with the SEC. This prospectus supplement omits some information contained in the registration statement in accordance with SEC rules and regulations. You should review the information and exhibits in the registration statement for further information on us and our consolidated subsidiaries and the securities we are offering. Statements in this prospectus supplement concerning any document we filed as an exhibit to the registration statement or that we otherwise filed with the SEC are not intended to be comprehensive and are qualified by reference to these filings. You should review the complete document to evaluate these statements. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-29</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="bIBR">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:204pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">INCORPORATION BY REFERENCE</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The SEC allows us to incorporate by reference information into this document. This means that we can disclose important information to you by referring you to another document filed separately with the SEC. The information incorporated by reference is considered to be a part of this document, except for any information superseded by information that is included directly in this prospectus supplement incorporated by reference subsequent to the date of this prospectus supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We incorporate by reference the following documents or information that we have filed with the SEC: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;letter-spacing:0.2pt;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;letter-spacing:0.2pt;">
          <!--blacklining:none;-->
          <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001818838/000110465924041109/adag-20231231x20f.htm">our annual report on Form 20-F for the fiscal year ended December&#160;31, 2023, filed with the SEC on March&#160;29, 2024;</a><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;"><a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1818838/000110465921011303/a20-29876_128a12b.htm">the description of our Ordinary Shares contained in the registration statement on Form 8-A filed with the SEC on February&#160;3, 2021,</a> and any other amendment or report filed for the purpose of updating such description; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any future annual reports on Form 20-F filed with the SEC after the date of this prospectus and prior to the termination of the offering of the securities offered by this prospectus; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any future reports on Form 6-K that we furnished to the SEC after the date of this prospectus that are identified in such reports as being incorporated by reference in this prospectus. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Potential investors, including any beneficial owner, may obtain a copy of any of the documents summarized herein (subject to certain restrictions because of the confidential nature of the subject matter) or any of our SEC filings incorporated by reference herein without charge by written request directed to 4F,&#160;Building C14, No. 218, Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu Province, 215123, People&#8217;s Republic of China. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You should rely only on the information incorporated by reference or provided herein. We have not authorized anyone else to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus supplement is accurate as of any date other than the date on the front of those documents. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Any statement contained in a document incorporated by reference herein shall be deemed to be modified or superseded for purposes of this prospectus supplement to the extent that a statement contained herein, or in a subsequently filed document incorporated by reference herein, modifies or supersedes that statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute part of this prospectus supplement.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-30</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;margin-bottom:21.86pt;margin-left:27pt;width:541.31pt;">
        <div style="width:541.31pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PROSPECTUS</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:541.31pt; line-height:16pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">US$200,000,000</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="position:relative;margin-top:9.8pt; text-align:center; width:541.31pt;">
          <img src="lg_adagene-4clr.jpg" alt="[MISSING IMAGE: lg_adagene-4clr.jpg]" height="29" width="136" >
        </div>
        <div style="margin-top:8.6pt; text-align:center; width:541.31pt; line-height:19.5pt;font-weight:bold;font-size:18pt;">
          <font style="letter-spacing:-0.36pt;">Adagene Inc.</font><font style="font-weight:normal;letter-spacing:0.36pt;"> </font>
        </div>
        <div style="margin-top:4pt; text-align:center; width:541.31pt; line-height:15.5pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">Ordinary Shares </font>
          <br >
          <font style="letter-spacing:-0.28pt;">Warrants </font>
          <br >
          <font style="letter-spacing:-0.28pt;">Units</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:541.31pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Adagene Inc. (&#8220;Adagene&#8221; or &#8220;the Company&#8221;) or selling shareholders may offer from time to time up to a total amount of US$200,000,000, consisting of (i)&#160;ordinary shares of the Company, par value US$0.0001 per share (&#8220;Ordinary Shares&#8221;), including ordinary shares represented by American depositary shares, or ADSs, (ii)&#160;warrants to purchase ordinary shares or other securities of the Company (&#8220;Warrants&#8221;), (iii)&#160;units (&#8220;Units&#8221; and, collectively with the Ordinary Shares and Warrants, the &#8220;Securities&#8221;), or any combination thereof, in one or more offerings under this prospectus. Each ADS represents one and one quarter (1.25) ordinary shares. When we or selling shareholders decide to sell Securities, we or the selling shareholders will provide specific terms of the offered Securities in a prospectus supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:541.31pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This prospectus describes some of the general terms that may apply to these Securities and the general manner in which they may be offered. The specific terms of any Securities to be offered, and the specific manner in which they may be offered, will be described in one or more supplements to this prospectus. A prospectus supplement may also add, update or change information contained in this prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:541.31pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Securities covered by this prospectus may be offered and sold from time to time in the same offering or in separate offerings; to or through underwriters, dealers, and agents; or directly to purchasers. The names of any underwriters, dealers, or agents, if any, involved in the sale of our Securities, their compensation and any over-allotment options held by them will be described in the applicable prospectus supplement. For a more complete description of the plan of distribution of these Securities, see the section entitled &#8220;Plan of Distribution&#8221; beginning on page <a href="#tPOD">74</a> of this prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:541.31pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The ADSs are traded on the Nasdaq Global Market, or the Nasdaq, under the symbol &#8220;ADAG.&#8221; As of May&#160;19, 2022, the last reported sale price for the ADSs was US$2.86 per ADS. Pursuant to General Instruction I.B.5 of Form&#160;F-3, in no event will we sell the Securities covered hereby in a public primary offering with a value exceeding more than one-third of the aggregate market value of our voting and non-voting common equity held by non-affiliates in any 12-month period so long as the aggregate market value of our outstanding voting and non-voting common equity held by non-affiliates remains below US$75,000,000. During the 12 calendar&#160;months prior to and including the date of this prospectus, we have not offered or sold any securities pursuant to General Instruction I.B.5 of Form F-3. This limitation does not apply to offerings of ordinary shares on a secondary basis that may be sold by selling shareholders pursuant to this prospectus (as described in &#8220;Selling Shareholders&#8221;) in accordance with General Instruction I.B.3 of Form&#160;F-3. For the avoidance of doubt, any potential offerings of ordinary shares on a secondary basis by selling shareholders made pursuant to this registration statement on Form F-3 are limited to the then currently outstanding ordinary shares. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:541.31pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Investors are purchasing securities of a Cayman Islands holding company rather than securities of our subsidiaries that have substantive business operations in China or in the United States. Adagene Inc. is a Cayman Islands holding company that conducts its operations and operate its business in China through its PRC subsidiary, Adagene (Suzhou) Limited (&#8220;Adagene Suzhou&#8221;). In addition, Adagene Inc. conducts a substantial portion of its operations in the U.S. through its U.S. subsidiary, Adagene Incorporated. Such structure involves unique risks to investors in the ADSs and ordinary shares. In particular, as we are a holding company with substantive business operations in China, you should pay special attention to disclosures included in our most recent annual report on Form 20-F incorporated by reference in this prospectus and risk factors included herein, including but not limited to risk factor such as &#8220;uncertainties with respect to the PRC legal system, including uncertainties regarding the enforcement of laws, and sudden or unexpected changes in policies, laws and regulations in China could adversely affect us.&#8221; The PRC government has significant authority to exert influence on the ability of a company with substantive operations in China, such as us, to conduct its business, accept foreign investments or list on a U.S. or other foreign exchanges. For example, we face risks associated with regulatory approvals of offshore offerings, anti-monopoly regulatory actions, oversight on cybersecurity and data privacy, as well as the lack of The Public Company Accounting Oversight Board (&#8220;PCAOB&#8221;) inspection on our auditor. Trading in our ADSs on the Nasdaq or over-the-counter will be prohibited, and as a result, our ADSs will be delisted under the Holding Foreign Companies Accountable Act (&#8220;HFCA Act&#8221;), if the PCAOB has determined that it has been unable to inspect our auditor located in China for three consecutive years, starting from 2022. The potential enactment of the Accelerating Holding Foreign Companies Accountable Act would decrease the number of non-inspection years </font>
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;margin-bottom:21.86pt;margin-left:27pt;width:541.31pt;">
        <div style="width:541.31pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">from three years to two, thus reducing the time period before our ADSs will be prohibited from trading on the Nasdaq Stock Market or OTC or delisted. On December 16, 2021, PCAOB issued the HFCA Act Determination Report, according to which our auditor is subject to the determinations that the PCAOB is unable to inspect or investigate completely. In March 2022, the SEC issued its first &#8220;Conclusive list of issuers identified under the HFCAA&#8221; indicating that those companies are now formally subject to the delisting provisions if they remain on the list for three consecutive years. We were provisionally identified by the SEC on May 4, 2022 under the HFCA Act and anticipate being conclusively identified 15 business days after May 4, 2022. See https://&#160;www.sec.gov/hfcaa. Such risks could result in a material change in our operations and/or the value of our ADSs or could significantly limit or completely hinder our ability to offer or continue to offer ADSs and/or other securities to investors and cause the value of such securities to significantly decline or be worthless. The PRC government also has significant oversight and discretion over the conduct of our business and as such may influence our operations at any time, which could result in a material adverse effect on our operations. The PRC government has recently published new policies that significantly affected certain industries, and we cannot rule out the possibility that it will in the future release regulations or policies regarding the industry where we operate, which could adversely affect our business, financial condition and results of operations. Furthermore, the PRC government has recently indicated an intent to exert more oversight and control over overseas securities offerings and other capital markets activities and foreign investment in China-based companies like us. These risks could result in a material change in our operations and the value of our ordinary shares or the ADSs, or could significantly limit or completely hinder our ability to offer or continue to offer securities to investors and cause the value of such securities to significantly decline or become worthless. For a detailed description of risks related to doing business in China, see &#8220;Risk Factors&#8201;&#8212;&#8201;Risks Related to Doing Business in the PRC.&#8221; As used in this prospectus, &#8220;Adagene&#8221; refers to Adagene Inc., a Cayman Islands exempted company with limited liability, &#8220;Adagene Suzhou&#8221; refers to Adagene (Suzhou) Limited, a PRC incorporated company with limited liability, &#8220;Adagene Hong Kong&#8221; refers to Adagene (Hong Kong) Limited, our Hong Kong intermediary holding company, &#8220;Adagene Incorporated&#8221; refers to Adagene Incorporated, our U.S.&#160;subsidiary, and &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our company,&#8221; or &#8220;our&#8221; refers to Adagene Inc. and its subsidiaries. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:541.31pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">With a holding company structure, we currently rely principally on equity financing for our cash requirements, including the funds necessary to pay cash considerations for services we may incur. In the future, when and after we become profitable and generate cash flows from operating activities, we may rely principally on dividends and other distributions on equity from our PRC and U.S. subsidiaries for our cash requirements, including the funds necessary to pay dividends and other cash distributions to our shareholders or for services of any debt we may incur. If any of our subsidiaries or any newly formed subsidiaries incur debt on their own behalf in the future, the instruments governing their debt may restrict their ability to pay dividends or make other distributions to us. In 2019, 2020 and 2021, Adagene Inc. made payments of US$13.1&#160;million, US$15.5&#160;million and US$30.0&#160;million, respectively, in cash to Adagene Suzhou as consideration for providing services associated with research and development activities related to those intellectual properties owned by Adagene Inc. There were no intercompany loans provided by Adagene Inc. to Adagene Suzhou during the&#160;years ended and as of December&#160;31, 2019, 2020 and 2021. As advised by our PRC legal counsel, Tian Yuan Law Firm, Adagene Suzhou is able to mark up and charge to Adagene Inc., its ultimate parent, for providing services associated with research and development activities related to those intellectual properties owned by Adagene Inc. and Adagene Inc. is able to make cash payments to Adagene Suzhou for considerations of such services. In the future, cash proceeds raised from overseas financing activities, including this offering, may be transferred by Adagene Inc., the Cayman holding company, (i)&#160;through Adagene (Hong Kong) Limited, our Hong Kong subsidiary, to Adagene Suzhou, our PRC subsidiary, and (ii)&#160;to Adagene Incorporated, our U.S. subsidiary, via capital contribution, shareholder loans or consideration for the services rendered, as the case may be. Other than the above disclosed transfer of funds, we did not transfer any type of assets between Adagene Suzhou and other Adagene subsidiaries in 2019, 2020 and 2021. For risks associated with this structure, see &#8220;Risk Factors&#8201;&#8212;&#8201;We may rely on dividends and other distributions on equity paid by our PRC subsidiary to fund any cash and financing requirements that we may have, and any limitation on the ability of our PRC subsidiary to make payments to us could have material and adverse effect on our ability to conduct our business&#8221; and &#8220;&#8212; PRC regulation of loans to and direct investment in PRC entities by offshore holding companies and governmental control of currency conversion may delay or prevent us from using the proceeds of our public offering to make loans or additional capital contributions to our PRC subsidiary, which could materially and adversely affect our liquidity and our ability to fund and expand our business.&#8221; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:541.31pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Investing in these Securities involves certain risks. Please carefully consider the &#8220;Risk Factors&#8221; in Item&#160;3.D of our most recent annual report on Form 20-F incorporated by reference in this prospectus, the &#8220;Risk Factors&#8221; beginning on page <a href="#tRIFA">17</a> of this prospectus, and in any applicable prospectus supplement, for a discussion of the factors you should consider carefully before deciding to purchase these Securities.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:521.31pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus may not be used to offer or sell any Securities unless accompanied by a prospectus supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:541.31pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Neither the Securities and Exchange Commission nor any state or other securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:541.31pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The date of this prospectus is May 26, 2022.</font>
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="TOC3">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:202.5pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">TABLE OF CONTENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:308.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:427.33pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Page </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tATP"><font style="letter-spacing:0.2pt;">About This Prospectus </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tATP">1</a></font> <a href="#tATP"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tOUCO"><font style="letter-spacing:0.2pt;">Our Company </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tOUCO">3</a></font> <a href="#tOUCO"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tRIFA"><font style="letter-spacing:0.2pt;">Risk Factors </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tRIFA">17</a></font> <a href="#tRIFA"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tCNRF"><font style="letter-spacing:0.2pt;">Cautionary Note Regarding Forward-Looking Statements </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tCNRF">37</a></font> <a href="#tCNRF"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tUOP"><font style="letter-spacing:0.2pt;">Use of Proceeds </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tUOP">39</a></font> <a href="#tUOP"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tCAI"><font style="letter-spacing:0.2pt;">Capitalization and Indebtedness </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tCAI">40</a></font> <a href="#tCAI"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDOSC"><font style="letter-spacing:0.2pt;">Description of Share Capital and Memorandum and Articles of Association </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDOSC">41</a></font> <a href="#tDOSC"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDOW"><font style="letter-spacing:0.2pt;">Description of Warrants </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDOW">51</a></font> <a href="#tDOW"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDOU"><font style="letter-spacing:0.2pt;">Description of Units </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDOU">52</a></font> <a href="#tDOU"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tFOS"><font style="letter-spacing:0.2pt;">Forms of Securities </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tFOS">53</a></font> <a href="#tFOS"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDOAD"><font style="letter-spacing:0.2pt;">Description of American Depositary Shares </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDOAD">55</a></font> <a href="#tDOAD"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tEOC"><font style="letter-spacing:0.2pt;">Enforceability of Civil Liabilities </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tEOC">70</a></font> <a href="#tEOC"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tTAX"><font style="letter-spacing:0.2pt;">Taxation </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tTAX">72</a></font> <a href="#tTAX"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tSESH"><font style="letter-spacing:0.2pt;">Selling Shareholders </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tSESH">73</a></font> <a href="#tSESH"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tPOD"><font style="letter-spacing:0.2pt;">Plan of Distribution </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tPOD">74</a></font> <a href="#tPOD"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tEXP"><font style="letter-spacing:0.2pt;">Expenses </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tEXP">78</a></font> <a href="#tEXP"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tIOCD"><font style="letter-spacing:0.2pt;">Incorporation of Certain Documents by Reference </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tIOCD">79</a></font> <a href="#tIOCD"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tLEMA"><font style="letter-spacing:0.2pt;">Legal Matters </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tLEMA">80</a></font> <a href="#tLEMA"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tEPTR"><font style="letter-spacing:0.2pt;">Experts </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tEPTR">81</a></font> <a href="#tEPTR"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tWYCF"><font style="letter-spacing:0.2pt;">Where You Can Find More Information </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tWYCF">82</a></font>
            </td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">You should rely only on the information contained or incorporated by reference into this prospectus, in the applicable prospectus supplement or in any free writing prospectus filed by us with the SEC. We have not authorized any other person to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. You should not assume that the information contained or incorporated by reference into this prospectus and any prospectus supplement or in any free writing prospectus is accurate as of any date other than the respective dates thereof. Our business, financial condition, results of operations and prospects may have changed since those dates.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">i</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tATP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ABOUT THIS PROSPECTUS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus is part of a registration statement that we filed with the U.S. Securities and Exchange Commission, or the SEC, using a &#8220;shelf&#8221; registration process. Under this shelf registration process, we and the selling shareholders may, from time to time, sell up to US$200,000,000 of any combination of the Securities described in this prospectus. This prospectus provides you with a general description of the Securities we may offer. Each time we or any selling shareholders use this prospectus to offer Securities, we will provide one or more prospectus supplements that will contain specific information about the offering and the terms of those Securities. We may also add, update or change other information contained in this prospectus by means of a prospectus supplement or by incorporating by reference information we file with the SEC. The registration statement on file with the SEC includes exhibits that provide more detail on the matters discussed in this prospectus. If there is any inconsistency between the information in this prospectus and any related prospectus supplement, you should rely on the information in the applicable prospectus supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Before buying any of the Securities that we are offering, you should carefully read both this prospectus and any prospectus supplement with all of the information incorporated by reference in this prospectus, as well as the additional information described under the heading &#8220;Where You Can Find More Information&#8221; and &#8220;Incorporation of Certain Documents by Reference.&#8221; These documents contain important information that you should consider when making your investment decision. We have filed or incorporated by reference exhibits to the registration statement of which this prospectus forms a part. You should read the exhibits carefully for provisions that may be important to you. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The information contained in this prospectus, any applicable prospectus supplement or any document incorporated by reference in this prospectus is accurate only as of their respective dates, regardless of the time of delivery of this prospectus, any applicable prospectus supplement or the documents incorporated by reference in this prospectus or the sale of any Securities. Our business, financial condition, results of operations and prospects may have changed materially since those dates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Neither we nor any underwriters, dealers or agents have authorized anyone to provide you with information that is different from that contained in this prospectus, any amendment or supplement to this prospectus, or any free writing prospectus we may authorize to be delivered or made available to you. Neither we nor any underwriters, dealers or agents take responsibility for, or provide assurance as to the reliability of, any other information that others may give you. This prospectus does not constitute an offer to sell or the solicitation of an offer to buy any securities other than the Securities described in this prospectus or an offer to sell or the solicitation of an offer to buy such Securities in any circumstances in which such offer or solicitation is unlawful. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Neither we nor any underwriters, dealers or agents have taken any action that would permit the offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the Securities described herein and the distribution of this prospectus outside the United States. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In this prospectus, unless otherwise indicated or unless the context otherwise requires, </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">&#8220;Adagene Suzhou&#8221; refers to Adagene (Suzhou) Limited, our subsidiary in the PRC; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">&#8220;Adagene Incorporated&#8221; refers to Adagene Incorporated, our subsidiary in the U.S.; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">&#8220;ADSs&#8221; refers to the American depositary shares, each representing one and one quarter (1.25) of our ordinary shares; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.09pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.09pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">&#8220;Antibody binding interface&#8221; or &#8220;antibody binding sites&#8221; refers to the antibody binding surface spots in contact with its recognition antigen; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">&#8220;China&#8221; or &#8220;PRC&#8221; refers to the People&#8217;s Republic of China; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">&#8220;conformational diversity&#8221; or &#8220;dynamic diversity&#8221; refers to the existence of more than one conformation or structure due to dynamic fluctuation of the structures for a given protein sequence, independent of any conformational changes caused by external binding; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:236pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">&#8220;epitopes&#8221; or &#8220;epitope of an antigen&#8221; refers to the specific binding spots of an antigen in contact with its antibody binding surface; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">&#8220;Exchange Act&#8221; refers to the Exchange Act of 1934, as amended; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">&#8220;Greater China&#8221;, for the purpose of this prospectus/registration statement, refers to the People&#8217;s Republic of China, Hong Kong, Macau and Taiwan; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">&#8220;multi-specificity&#8221; refers to a protein exerting a similar function (such as binding) on distinctly different ligands, perhaps while using different active site residues; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">&#8220;NEObody(ies)&#8221; refers to antibody(ies) designed with dynamic binding sites that adapt kinetically to unique epitopes through novel MOA(s), using our NEObody technology; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">&#8220;ordinary shares&#8221; or &#8220;shares&#8221; refers to our ordinary shares of par value US$0.0001 per share; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">&#8220;POWERbody(ies)&#8221; refers to antibody(ies) that utilize(s) our SAFEbody technology to create new bispecific T-cell engagers, antibody-drug conjugates, or antibody(ies), which is(are) designed to reach beyond the therapeutic potency of traditional monospecific antibody(ies); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">&#8220;RMB&#8221; or &#8220;Renminbi&#8221; refers to the legal currency of the People&#8217;s Republic of China; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">&#8220;SAFEbody(ies)&#8221; refers to antibody(ies) engineered with its(their) binding sites masked, which is(are) designed to be selectively activated in the tumor microenvironment (TME), potentially limiting on-target off-tumor toxicity in normal tissues; SAFEbody&#174; is a registered trademark in the United States, China, Australia, Japan, Singapore, and the European Union; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">&#8220;Securities Act&#8221; refers to the Securities Act of 1933, as amended; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">&#8220;species cross-reactivity&#8221; refers to reactivity of the same protein that recognizes and binds to similar epitopes of a given class of targets in different species; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">&#8220;US$,&#8221; &#8220;dollars&#8221; or &#8220;U.S. dollars&#8221; refers to the legal currency of the United States; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">&#8220;we,&#8221; &#8220;us,&#8221; &#8220;our company,&#8221; and &#8220;our&#8221; refer to Adagene Inc., a Cayman Islands exempted company and its subsidiaries. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">References in any prospectus supplement to &#8220;the accompanying prospectus&#8221; are to this prospectus and to &#8220;the prospectus&#8221; are to this prospectus and the applicable prospectus supplement taken together. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tOUCO">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">OUR COMPANY</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Overview</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are a platform-driven, clinical-stage biopharmaceutical company transforming the discovery and development of novel antibody-based cancer immunotherapies. We are combining computational biology and artificial intelligence to design novel antibodies that address unmet patient needs. Powered by our proprietary Dynamic Precision Library (DPL) platform, which fuels our NEObody&#8482;, SAFEbody</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, and POWERbody&#8482; technologies, we are developing a highly differentiated pipeline of novel immunotherapies. We have forged strategic collaborations with reputable global partners that leverage our technology in multiple approaches at the vanguard of science. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We aim to push the boundaries of antibody discovery and engineering through the precise design, construction, and selection of antibody product candidates intractable to traditional antibody technology. We have pioneered a dynamic antibody technology interface to harness the conformational diversity of antibodies, which enlarges epitope sampling of a given drug target for differentiated therapeutic antibody development. Additionally, we have a proprietary precision masking technology and specialized antibody engineering capabilities which enable us to design therapeutics with unique features. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our Dynamic Precision Library (DPL) fuels our three antibody technology platforms, which can be used alone or together to create novel, differentiated antibody-based therapeutic candidates: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The NEObody technology platform is a fully synthetic phage display and yeast display-based antibody discovery technology, which we believe is differentiated from other synthetic antibody technologies through its innovative designs and precise constructions. NEObody technology enables the generation of antibodies designed with dynamic binding sites that adapt kinetically to unique epitopes, triggering a novel MOA. The species cross-reactive antibodies generated by NEObody technology not only have the potential to reveal new biological functions of the targets, but also facilitate preclinical studies using various immune system intact animal models, resulting in high fidelity translation from preclinical to clinical studies. We refer to antibodies generated by our NEObody technology as NEObodies. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The SAFEbody technology platform is designed to mask an antibody binding interface with a masking motif, which then prevents an antibody from binding to its target in healthy tissues, minimizing on target, off tumor toxicities. The masking motif is designed to activate, or unmask, the antibody to allow binding in the tumor microenvironment, or TME, where certain activation conditions such as a protease is upregulated as compared to healthy tissues, allowing the antibody to bind to its target for tumor killing. Our SAFEbody enabled therapeutic candidates are therefore designed to be activated predominantly in the TME while remaining largely in an inactive state in healthy tissues. Our SAFEbody technology can be applied to mask the binding sites of any antibodies including but not limited to NEObodies. We refer to such masked antibodies as SAFEbodies. Notably, SAFEbody technology can be applied to our NEObodies, such as what we did with ADG116 to potentially achieve an increased therapeutic index with ADG126. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The POWERbody technology platform enables the creation of new versions of antibodies, which may be bispecific T-cell engagers, or TCEs, or Fc-engineered antibodies, antibody-drug conjugates, or ADCs, or antibodies that are designed to reach beyond the therapeutic potency of traditional monospecific antibodies. Our POWERbody candidates incorporate SAFEbody precision masking technology and are designed to improve antitumor activity while maintaining the enhanced safety profile. As an example, we have developed bispecific TCEs with either a CD3 or a CD28 arm and demonstrated the ability to combine them together for potentially safe and durable immunotherapies. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our AI-powered technology allows us to engineer and select species cross-reactive antibodies designed to dynamically adapt to unique and evolutionally conserved epitopes. We believe that comprehensive </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> preclinical evaluations using these species cross-reactive antibodies are the key to assess the efficacy and safety potential of tailor-made antibody candidates before progressing them into lengthy and costly clinical trials. Our NEObody, SAFEbody and POWERbody technology platforms are all designed to facilitate favorable druggability, manageable CMC attributes, and reduced immunogenicity. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The figure below shows how our NEObody, SAFEbody, and POWERbody technologies are inter-connected with our DPL and utilized for the building of our product pipeline of mono- and combination immunotherapies. </font>
        </div>
        <div style="position:relative;margin-top:11.2pt; text-align:center; width:456pt;">
          <img src="tm2213007d1-pc_neobody4c.jpg" alt="[MISSING IMAGE: tm2213007d1-pc_neobody4c.jpg]" height="335" width="330" >
        </div>
        <div style="text-indent:20pt; margin-top:14.69pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Our DPL Platform fuels three antibody technology platforms, which can be used alone or together to create novel, differentiated antibody-based therapeutic candidates. Antibodies generated by NEObody technology are designed with dynamic binding sites that adapt kinetically to unique epitopes, thereby triggering a novel MOA. SAFEbody technology is designed to address safety and tolerability challenges associated with many antibody therapeutics by using precision masking technology to shield the binding domain of the biologic therapy. Through activation in the TME, this allows for tumor-specific targeting of antibodies, while minimizing on-target off-tumor toxicity in healthy tissues. POWERbody candidates are designed to unleash the efficacy of a therapeutic through Fc-engineering, drug conjugation, or T-cell engagement, while securing safety by precision masking with SAFEbody technology. Thus, POWERbody candidates also incorporate SAFEbody precision masking technology. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Robust, Transformative Pipeline</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">By leveraging our proprietary DPL platform and three platform technologies, we have developed a robust pipeline of innovative product candidates in various stages of development, ranging from research and discovery to preclinical and clinical development. Our highly differentiated and wholly-owned clinical-stage pipeline consists of two anti-CTLA-4 antibodies ADG116 (NEObody) and ADG126 (SAFEbody), and an anti-CD137 antibody, ADG106 (NEObody). All three candidates are in Phase&#160;1b/2 clinical evaluation in single agent and/or combination clinical trials designed to evaluate safety and preliminary efficacy. We also have a robust preclinical pipeline of five programs in IND-enabling studies, including a masked, Fc engineered anti-CD137 POWERbody and a masked anti-CD47 SAFEbody, which are both on track for clinical development, as well as over 50 programs in various stages of discovery. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, we have out-licensed the Greater China rights of ADG104, an anti-PD-L1 mAb currently in Phase&#160;2 clinical development, to Sanjin, and the Greater China rights of ADG125, a novel anti-CSF-1R mAB in Phase&#160;1 development to Dragon Boat Biopharmaceuticals. We have the right to apply for the patents derived from our core and key technologies pertaining to ADG104 and ADG125 in the rest of the world, where we retain a majority of the economic benefits. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following chart provides an overview of the status of each of our wholly-owned clinical and pre-clinical programs for which we have global rights: </font>
        </div>
        <div style="position:relative;margin-top:10.1pt; text-align:center; width:456pt;">
          <img src="tm2213007d1-tbl_program4c.jpg" alt="[MISSING IMAGE: tm2213007d1-tbl_program4c.jpg]" height="274" width="579" >
        </div>
        <div style="text-indent:20pt; margin-top:13.2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have deployed our NEObody and SAFEbody technology platforms to develop our three wholly-owned clinical candidates, ADG116, ADG126, ADG106, which are in ongoing Phase&#160;1b/2 clinical evaluation as monotherapy and in combination with other targeted therapies: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.09pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.09pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">ADG116 is a fully human anti-CTLA-4 NEObody, which binds to a novel epitope of CTLA-4 different from ipilimumab, the only CTLA-4 mAb approved globally. The dynamic interface of ADG116 enables not only its species cross-reactivity with human, cynomolgus monkey, and mouse CTLA-4 for preclinical studies, but also its dynamic engagement on a unique epitope of CTLA-4 to trigger a novel MOA distinct from ipilimumab by softer ligand blocking and stronger regulatory T-cell depletion via strong antibody-dependent cellular cytotoxicity (ADCC). ADG116 is designed to overcome the safety challenges of existing CTLA-4 therapeutics, and it has shown in robust preclinical studies and clinical evaluation to have an improved safety profile and early efficacy activity, including dose-dependent T-cell activation and tumor suppression in treatment-resistant &#8220;cold&#8221; and &#8220;warm&#8221; tumors such as pancreatic, ovarian and renal cell cancers. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">ADG126 is a fully human anti-CTLA-4 SAFEbody, which applies SAFEbody precision masking technology to ADG116 to further enhance safety and efficacy profiles by masking the antibody binding site which is then conditionally activated in the TME to limit on target, off tumor toxicity. With the SAFEbody precision masking technology, ADG126 is designed to overcome the safety challenges of existing CTLA-4 therapeutics, and optimize efficacy by achieving doses that may unlock the full potential of CTLA-4 as a proven target for strong ADCC-mediated Treg depletion in the TME. ADG126 has consistently shown a potential best-in-class profile, which is supported by preclinical evaluation, including GLP toxicology data, and enabled by the broad species cross-reactivity of ADG126. In clinic, no dose-limiting toxicities have been observed as of March&#160;31, 2022. Patients have received multiple cycles with continuous dosing, and favorable pharmacokinetic and pharmacodynamic activity compared to ADG116 has been observed. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">ADG106 is a fully human ligand-blocking agonistic anti-CD137 NEObody, which targets a unique epitope of CD137 that is different from other anti-CD137 antibodies currently under clinical development. Preclinical and clinical studies show that ADG106 is capable of binding to CD137 in a fashion similar to its natural ligand, CD137L. ADG106 is designed to balance safety and efficacy to overcome the known safety challenges of anti-CD137 targeted therapy, particularly when used in combination with anti-PD-1 or anti-CTLA-4 therapies. In clinic, ADG106 has shown a well-tolerated safety profile and evidence of single-agent efficacy, while combination therapy development is supported by the combined findings of our phase 1 monotherapy trials, data from extensive preclinical studies, as well as PD marker-based modelling from prior and ongoing trials. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Additionally, we have identified two of our five preclinical programs that are currently in IND-enabling studies, as candidates for the company&#8217;s next two IND or equivalent submissions and for subsequent advancement into clinical trials: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">ADG206 is a masked, Fc engineered anti-CD137 agonistic POWERbody. ADG206 incorporates SAFEbody</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> precision masking technology and is designed to achieve improved safety and efficacy. We have conducted preclinical studies demonstrating that the FcgR-mediated crosslinking of ADG206 enhances T cell responses and antitumor activity, while the SAFEbody masking technology secures its activation only in the TME to limit on-target off-tumor toxicities. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">ADG153 is a masked anti-CD47 IgG1 SAFEbody. ADG153 is differentiated by its strong ADCC and antibody-dependent cellular phagocytosis (ADCP) activity designed to realize the full potential of anti-CD47 therapy for both hematologic and solid tumor indications. ADG153 incorporates SAFEbody masking technology to limit on-target off-tumor toxicities and overcome the known safety liabilities of anti-CD47 therapies. We have conducted preclinical studies showing that ADG153 has potent anti-tumor activity, without inducing human hemagglutination, while minimizing anemia-related and antigen sink liabilities. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Global Partnerships and Collaborations</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have a successful track record of collaborations and partnerships with global biopharmaceutical companies and academic institutions. So far, we have established multiple collaborations and we continue to seek partnership opportunities where we can leverage our proprietary technology platform to develop novel antibodies to address unmet medical needs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We enter into collaborations with biotechnology and pharmaceutical companies to leverage the power of our technology platforms, creating a network of potential future revenue streams that complement future long-term value from our wholly-owned pipeline. These collaborations include both technology licensing agreements and outlicensing of product candidates, both of which allow us to retain significant future participation in product sales through royalties paid on net sales. In the future, we may also enter into strategic collaborations which may involve joint development for our preclinical and/or clinical assets to both accelerate the path to clinic and drive global commercialization. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have entered into technology licensing agreements with Sanofi, Exelixis and ADC Therapeutics to develop antibody-based therapeutics against tumor targets using our SAFEbody technology. We have also out&#8209;licensed the Greater China rights for two antibody candidates to Sanjin and its affiliates. Additionally, we have leveraged our DPL technology platform and antibody discovery and engineering capabilities in discovery collaborations with the U.S. National Institutes of Health (NIH), Mitsubishi Tanabe, Celgene (now BMS), GSK and Hengrui. To further advance our pipeline, we have also put in place various clinical collaborations, including clinical collaborations and supply agreements with Merck who will provide pembrolizumab for certain of our combination clinical trials, and an agreement with research organizations in Singapore for an investigator-initiated trial of our ADG106 clinical candidate in connection with nivolumab. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our collaborations empower our growth by generating cash flow and revenues that partially offset expenditures on our internal research and development programs, expand our knowledge base regarding antibody technology across multiple targets and antibodies provided by our partners, and provide us with future joint development opportunities. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Corporate History and Structure</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In February&#160;2011, Adagene Inc. was incorporated under the laws of the Cayman Islands as our offshore holding company. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In December&#160;2011, we established Adagene (Hong Kong) Limited, or Adagene Hong Kong, a wholly-owned subsidiary incorporated under the laws of Hong Kong, as our intermediary holding company. In February&#160;2012, Adagene Hong Kong incorporated Adagene (Suzhou) Limited, or Adagene Suzhou, in China, through which we commenced our research and development activities in China. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In September&#160;2017, we established a wholly-owned subsidiary in the state of Delaware, the United States, Adagene Incorporated, to conduct our research and development activities in the United States to facilitate the discovery and development of product candidates and expand our global presence, we have further incorporated several subsidiaries overseas, such as Australia, Singapore and Switzerland. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are a holding company and do not directly conduct any substantive business operations in the PRC. In addition to our R&amp;D activities in the United States, Australia and Singapore, we currently focus our business operations within the PRC through Adagene Suzhou. We (Adagene Inc.), however, hold certain intellectual properties and outsource certain research and development activities related to these intellectual properties to our subsidiaries. See &#8220;Risk Factors&#8201;&#8212;&#8201;Risks Related to Doing Business in the PRC.&#8221; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In February&#160;2021, we completed an initial public offering in which we offered and sold an aggregate of 10,571,375 ordinary shares in the form of ADSs. Upon the initial public offering, all of our then issued and outstanding preferred shares were automatically converted into ordinary shares on a one-for-one basis. On February&#160;5, 2021, the ADSs began trading on the Nasdaq under the symbol &#8220;ADAG.&#8221;</font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We were provisionally identified by the SEC on May 4, 2022 under the Holding Foreign Companies Accountable Act and anticipate being conclusively identified 15 business days after May 4, 2022. See https://www.sec.gov/hfcaa. See &#8220;Risk Factors&#8201;&#8212;&#8201;Risks Related to Doing Business in the PRC&#8201;&#8212;&#8201;Trading in our ADSs on the Nasdaq Stock Market or OTC will be prohibited, and as a result, our ADSs will be delisted under the HFCA Act, if the PCAOB is unable to inspect or fully investigate auditors located in China. On December 16, 2021, the PCAOB issued the HFCA Act Determination Report, according to which our auditor is subject to the determinations that the PCAOB is unable to inspect or investigate completely. The delisting of our ADSs, or the threat of their being delisted, may materially and adversely affect the value of your investment. If this happens there is no certainty that we will be able to list our ordinary shares on a non-U.S. exchange or that a market for our ordinary shares will develop outside of the United States.&#8221;</font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following diagram illustrates our corporate structure as of the date of this prospectus, including our material subsidiaries directly or indirectly owned by us through equity ownership (our group structure does not include any variable interest entities): </font>
        </div>
        <div style="position:relative;margin-top:9.8pt; text-align:center; width:456pt;">
          <img src="tm2213007d1-fc_corpobw.jpg" alt="[MISSING IMAGE: tm2213007d1-fc_corpobw.jpg]" height="283" width="591" >
        </div>
        <div style="margin-top:16.6pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Summary of Risk Factors</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Investors are purchasing Securities of a Cayman Islands holding company rather than securities of our subsidiary that have substantive business operations in China or United States. Adagene Inc. is a Cayman Islands holding company that conducts its operations and operate its business in China through its PRC subsidiary, Adagene (Suzhou) Limited. In addition, Adagene Inc. conducts a substantial portion of its operations in the U.S. through its U.S. subsidiary, Adagene Incorporated. Our corporate group does not include any variable interest entities. Such structure involves unique risks to investors in the ADSs and </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">7</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">ordinary shares. You should carefully consider all of the information in this prospectus, including disclosures included in our most recent annual report on Form 20-F incorporated by reference in this prospectus, before making an investment in our ADSs. In particular, as we are a holding company with substantial business operations in China, you should pay special attention to subsections headed &#8220;Recent Regulatory Developments,&#8221; &#8220;Holding Company Structure&#8221;, and &#8220;Risks Related to Doing Business in the PRC,&#8221; including but not limited to risk factor such as &#8220;uncertainties with respect to the PRC legal system, including uncertainties regarding the enforcement of laws, and sudden or unexpected changes in policies, laws and regulations in China could adversely affect us.&#8221; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The PRC government has significant authority to exert influence on the ability of a company with substantive operations in China, such as us, to conduct its business, accept foreign investments or list on a U.S. or other foreign exchanges. For example, we face risks associated with regulatory approvals of offshore offerings, anti-monopoly regulatory actions, oversight on cybersecurity and data privacy, as well as the lack of PCAOB inspection on our auditor. Such risks could result in a material change in our operations and/or the value of our ADSs or could significantly limit or completely hinder our ability to offer or continue to offer ADSs and/or other securities to investors and cause the value of such securities to significantly decline or be worthless. The PRC government also has significant oversight and discretion over the conduct of our business and as such may influence our operations at any time, which could result in a material adverse effect on our operations. The PRC government has recently published new policies that significantly affected certain industries, and we cannot rule out the possibility that it will in the future release regulations or policies regarding the industry where we operate, which could adversely affect our business, financial condition and results of operations. Furthermore, the PRC government has recently indicated an intent to exert more oversight and control over overseas securities offerings and other capital markets activities and foreign investment in China-based companies like us. These risks could result in a material change in our operations and the value of our ordinary shares or the ADSs, or could significantly limit or completely hinder our ability to offer or continue to offer securities to investors and cause the value of such securities to significantly decline or become worthless. Below please find a summary of the principal risks we face, organized under relevant headings. These risks are discussed more fully in the section titled &#8220;Risk Factors.&#8221; </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to Doing Business in the PRC</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Risks and uncertainties related to doing business in China include, but are not limited to, the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">uncertainties with respect to the PRC legal system, including uncertainties regarding the enforcement of laws, and sudden or unexpected changes in policies, laws and regulations in China could adversely affect us; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">PRC government has significant oversight over the conduct of our business and as such may influence our operations at any time, which may potentially result in a material adverse effect on our operations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the PCAOB is currently unable to inspect our auditor in relation to their audit work performed for our financial statements and the inability of the PCAOB to conduct inspections over our auditor deprives our investors with the benefits of such inspections; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">trading in our ADSs on the Nasdaq Stock Market or OTC will be prohibited, and as a result, our ADSs will be delisted under the HFCA Act, if the PCAOB is unable to inspect or fully investigate auditors located in China. On December&#160;16, 2021, the PCAOB issued the HFCA Act Determination Report, according to which our auditor is subject to the determinations that the PCAOB is unable to inspect or investigate completely. The delisting of our ADSs, or the threat of their being delisted, may materially and adversely affect the value of your investment. If this happens there is no certainty that we will be able to list our ordinary shares on a non-U.S. exchange or that a market for our ordinary shares will develop outside of the United States; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the potential enactment of the Accelerating Holding Foreign Companies Accountable Act would decrease the number of non-inspection&#160;years from three&#160;years to two, thus reducing the time period before our ADSs will be prohibited from trading on the Nasdaq Stock Market or OTC or delisted; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">proceedings instituted by the SEC against certain PRC-based accounting firms, including the affiliate of our independent registered public accounting firm, or any related adverse regulatory </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">8</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:30pt; width:426pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">development in the PRC, could result in our financial statements being determined to not be in compliance with the requirements of the Exchange Act; and </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the approval of or report and filing with the China Securities Regulatory Commission or other governmental authorities may be required in connection with our future offerings, and, if required, we cannot predict if we will be able to obtain such approval or complete such report and filing process. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to Our Financial Prospects and Need for Additional Capital</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Risks and uncertainties related to our financial prospectus and need for additional capital include, but are not limited to, the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">we have a limited operating history, which may make it difficult to evaluate our current business and predict our future performance; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">we have incurred net losses historically and we may continue to incur net losses in the near future; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">we may need to obtain substantial additional financing to fund our growth and operations, which may not be available on acceptable terms, if at all; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">raising additional capital may lead to dilution of shareholdings by our existing shareholders and restrict our operations or require us to relinquish rights to our technologies or product candidates; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">we have certain shareholders who have board representation rights and their individual interests may differ from yours. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to Clinical Development of Our Product Candidates</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Risks and uncertainties related to clinical development of our product candidates include, but are not limited to, the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">we may not be able to identify or discover new product candidates, and may allocate our limited resources to pursue a particular product candidate and fail to capitalize on product candidates that may later prove to be more profitable, or for which there is a greater likelihood of success; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">we may not be successful in our efforts to use and expand our proprietary platforms to build a pipeline of product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any failures or setbacks in our platforms or our other proprietary technologies could negatively affect our business and financial condition; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our product candidates, for which we intend to seek approval as biologics products, may face competition sooner than anticipated; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">we depend substantially on the success of our product candidates, particularly ADG106, ADG126, ADG116 and ADG104, which are in clinical development, and our ability to identify additional product candidates. Clinical trials of our product candidates may not be successful. If we are unable to successfully identify new product candidates, complete clinical development, obtain regulatory approval and commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to Obtaining Regulatory Approval of Our Drug Candidates</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Risks and uncertainties related to obtaining regulatory approval of our drug candidates include, but are not limited to, the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the regulatory approval processes of the FDA, NMPA and other comparable regulatory authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approvals for our product candidates, our business will be substantially harmed; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">9</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:30pt; width:426pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business; </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">even if we obtain FDA approval of any of our product candidates, we may never obtain approval or commercialize such products outside of the United States, which would limit our ability to realize their full market potential; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">we are conducting clinical trials and may in the future conduct additional clinical trials for our product candidates outside the United States and/or China, and FDA, NMPA and similar foreign regulatory authorities may not accept data from such trials; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our product candidates may cause undesirable adverse events, side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following any regulatory approval. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:5pt; width:436pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to Our Intellectual Property</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Risks and uncertainties related to our intellectual property include, but are not limited to, the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">it is difficult and costly to protect our proprietary rights and technology, and we may not be able to protect our intellectual property rights throughout the world; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">we may not be successful in obtaining or maintaining necessary rights for our development pipeline through acquisitions and licensing deals; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">we may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful, and any unfavorable outcome from such litigation could limit our research and development activities and/or our ability to commercialize our product candidates; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our commercial success depends significantly on our ability to operate without infringing upon, misappropriating or otherwise violating the intellectual property rights of third parties. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:5pt; width:436pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to the ADSs</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:5pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Risks and uncertainties related to the ADSs include, but are not limited to, the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our business and financial results, including our ability to raise capital or raise capital on favorable terms and the market price of our ADSs, may be adversely affected by the geopolitical factors arising in connection with Russia&#8217;s invasion of Ukraine, including particularly how countries like the United States and China choose to respond to this war. As a result, the value of our ADSs may significantly decline; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">you may be subject to limitations on transfer of your ADSs; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the trading price of the ADSs is likely to be volatile, which could result in substantial losses to investors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">we are an emerging growth company within the meaning of the Securities Act and may take advantage of certain reduced reporting requirements; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if securities or industry analysts cease to publish research or reports about our business, or if they adversely change their recommendations regarding the ADSs, the market price for the ADSs and trading volume could decline; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the sale or availability for sale, or perceived sale or availability for sale, of substantial amounts of the ADSs could adversely affect their market price; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">due to our ADSs&#8217; price fluctuations there is a significant risk that we will be a passive foreign investment company for 2022 or any future taxable year, which could subject U.S. investors in our ADSs or ordinary shares to significant adverse U.S. federal income tax consequences; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if a person is treated as owning 10% or more of our stock by vote or value, such person may be subject to adverse U.S. federal income tax consequences. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">10</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Recent Regulatory Developments</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Cybersecurity Review Measures</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On December&#160;28, 2021, the Cyberspace Administration of China, or the CAC, and 12 other relevant PRC government authorities published the amended Cybersecurity Review Measures, or the Cybersecurity Review Measures, which went on February&#160;15, 2022 and supersede and replace the current Cybersecurity Review Measures previously promulgated on April&#160;13, 2020. The Cybersecurity Review Measures provide that the purchase of network products and services by a &#8220;critical information infrastructure operator&#8221; and the data processing activities of a &#8220;network platform operator&#8221; that affect or may affect national security shall be subject to the cybersecurity review. Furthermore, if a &#8220;network platform operator&#8221; that possesses personal information of more than one million users intends to go public in a foreign country, it must apply for a cybersecurity review with the Cybersecurity Review Office. In addition, the relevant PRC governmental authorities may initiate cybersecurity review if they determine certain network products, services, or data processing activities affect or may affect national security. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, on November&#160;14, 2021, the CAC released the Regulations for the Administration of Network Data Security (Draft for Comment), or the Draft Data Security Regulations, for public comments. The Draft Data Security Regulations provide that (i)&#160;a data processor who processes personal information of more than one million individuals must complete a cybersecurity review if it intends to be listed in a foreign country, and (ii)&#160;a data processor who carries out other data processing activities which affect or may affect national security should also complete the cybersecurity review. The Draft Data Security Regulations provide a broad definition of &#8220;data processing activities&#8221;, including collection, storage, usage, processing, transfer, provision, publication, deletion and other activities, which covers the entire life cycle of data processing. The Draft Data Security Regulations also provide a broad definition of &#8220;data processors&#8221; as individuals and entities that may autonomously determine the purpose and method of data processing activities. In addition, the Draft Data Security Regulations require data processors who process important data or whose securities are listed outside of China to carry out annual data security assessment either by itself or through a third party data security service provider and submit the assessment report to a local agency of the CAC. See &#8220;Item&#160;4. Information of the Company&#8201;&#8212;&#8201;4.B. Business Overview&#8201;&#8212;&#8201;Regulation&#8201;&#8212;&#8201;Other PRC Government Regulations&#8201;&#8212;&#8201;Regulations on Information Security and Data Protection&#8221; in our annual report on Form 20-F for the year ended December&#160;31, 2021, which is incorporated in this prospectus by reference, for detailed discussion. As advised by our PRC legal counsel, the Draft Data Security Regulations were released for public comment only with the deadline of submitting public comments or opinions by December&#160;13, 2021, and its provisions and anticipated adoption or effective date are subject to changes and thus its interpretation and implementation remain substantially uncertain. We cannot predict the impact of the Draft Data Security Regulations, if any, at this stage, and we will closely monitor and assess any development in the rule-making process. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As advised by our PRC legal counsel, Tian Yuan Law Firm, given the nature of our business, since we do not possess or process personal information of more than one million users/individuals, and we do not believe we are a &#8220;critical information infrastructure operator&#8221;, &#8220;network platform operator&#8221; or a data processor whose purchase of network products and services or data processing activities affect or may affect national security, the offering of our ADSs will not be subject to the cybersecurity review process under the Cybersecurity Review Measures, although we cannot guarantee that the relevant PRC regulatory authority will agree with our interpretation. In addition, we believe, to the best of our knowledge, our business operations do not violate the regulations or policies that have been issued by the CAC to the date of this prospectus in all material aspects. As of the date of this prospectus, the Cybersecurity Review Measures and the Draft Data Security Regulations have not materially affected our business and operations, but in anticipation of the strengthened implementation of cybersecurity laws and regulations and the continued expansion of our business, we face potential risks if we are deemed as a critical information infrastructure operator, a network platform operator or data processing operator under the PRC cybersecurity laws and regulations. In such case, we must fulfill certain obligations as required under the PRC cybersecurity laws and regulations, including, among others, storing personal information and other important data collected and produced within the PRC territory as we advance our drug discovery pipelines as part of our future operations in China, and we may be subject to lengthy cybersecurity review, annual data security assessment and other enhanced regulatory requirements when purchasing network products and services or conducting </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">11</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">other data processing activities. We may face challenges in addressing such enhanced regulatory requirements and be required to make necessary changes to our internal policies and practices in data privacy and cybersecurity matters. As advised by our PRC legal counsel, Tian Yuan Law Firm, as of the date of this prospectus, no detailed rules or implementation of the Cybersecurity Review Measures have been issued by the CAC and the Draft Data Security Regulations were only released for public comments, and the PRC governmental authorities have broad discretion in the interpretation and enforcement of these laws and regulations. It also remains uncertain whether the future regulatory changes will impose additional restrictions on companies like us. We cannot predict the impact of the Cybersecurity Review Measures and/or the Draft Data Security Regulations, if any, at this stage, and we will closely monitor and assess any development in the rule-making process. If the future enacted laws and regulations, including the enacted version of the data security regulations mandate clearance of cybersecurity review and other specific actions to be completed by companies like us before we are able to complete this offering, we will face uncertainties as to whether such clearance and/or other specific actions can be timely obtained or completed, or at all. If we are not able to comply with the cybersecurity and data privacy requirements in a timely manner, or at all, we may be subject to government enforcement actions and investigations, fines, penalties, or suspension of our non-compliant operations, among other sanctions, which could materially and adversely affect our business and results of operations. As of the date of this prospectus, we have not been involved in any investigation on cybersecurity review made by the CAC on such basis, and we have not received any inquiry, notice, warning, or sanction in such respect. We have been making continuous efforts to comply with the relevant cybersecurity and data protection laws and regulations of the PRC, and will endeavor to comply with any updated applicable laws, regulations or guidelines as issued by any relevant regulatory authority in the PRC. See &#8220;Risk Factors&#8201;&#8212;&#8201;Risks Related to Doing Business in the PRC&#8201;&#8212;&#8201;Failure to comply with existing or future laws and regulations related to privacy or data security could lead to government enforcement actions, which could include civil or criminal fines or penalties, investigation or sanction by regulatory authorities, private litigation, other liabilities, and/or adverse publicity.&#8221; </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Potential CSRC Approval Required for the Offering and Listing of Our ADSs</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On December&#160;24, 2021, the CSRC published the Provisions of the State Council on the Administration of Overseas Securities Offering and Listing by Domestic Companies (Draft for Comments), and Administrative Measures for the Filing of Overseas Securities Offering and Listing by Domestic Companies (Draft for Comments), or collectively, the Draft Overseas Listing Regulations, which set out the new regulatory requirements and filing procedures for Chinese companies seeking direct or indirect listing in overseas markets. The Draft Overseas Listing Regulations, among others, stipulate that (i)&#160;Chinese companies that seek to offer and list securities in overseas markets directly or indirectly shall fulfill the filing procedures with and report relevant information to the CSRC, (ii)&#160;in the context of an initial public offering, an initial filing shall be submitted within three (3)&#160;working days after the application for an initial public offering is submitted, and a second filing shall be submitted after the listing is completed, (iii)&#160;in the context of follow-on offering after the completion of the initial public offering, an filing shall be submitted within three (3)&#160;working days after the completion of the offering or within three (3)&#160;working days from the date of the first announcement of the transaction depending on the purpose for which the follow-on offering are conducted, and (iv)&#160;if an issuer issuing securities in batches after listing abroad (such as &#8220;shelf takedowns&#8221; or at-the-marketing offerings), it shall, after the completion of the initial batch offering, submit the fillings to the CSRC within three (3)&#160;working days, stating the total number of securities to be issued in connection with such batch issuance. Upon completion of each of the remaining batches, the issuer shall file a record of the issuance with CSRC within three (3)&#160;working days. Moreover, an overseas offering and listing is prohibited under circumstances if (i)&#160;it is prohibited by PRC laws, (ii)&#160;it may constitute a threat to or endanger national security as reviewed and determined by competent PRC authorities, (iii)&#160;it has material ownership disputes over equity, major assets, and core technology, (iv)&#160;in recent three&#160;years, the Chinese operating entities, and their controlling shareholders and actual controllers have committed relevant prescribed criminal offenses or are currently under investigations for suspicion of criminal offenses or major violations, (v)&#160;the directors, supervisors, or senior executives have been subject to administrative punishment for severe violations, or are currently under investigations for suspicion of criminal offenses or major violations, or (vi)&#160;it has other circumstances as prescribed by the State Council. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Draft Overseas Listing Regulations, among others, stipulate that if the issuer meets the following conditions, its offering and listing shall be determined as an &#8220;indirect overseas offering and listing by a </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">12</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Chinese company&#8221; and is therefore subject to the filing requirement: (1)&#160;the revenues, profits, total assets or net assets of the Chinese operating entities in the most recent financial year accounts for more than 50% of the corresponding data in the issuer&#8217;s audited consolidated financial statements for the same period; (2)&#160;the majority of senior management in charge of business operation are Chinese citizens or have domicile in PRC, and its principal place of business is located in PRC or main business activities are conducted in PRC. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">According to the Draft Overseas Listing Regulations, if we failed to complete the filing procedures with the CSRC for our future offering as contemplated in applicable prospectus supplement or fell within any of the circumstances where any of our future follow-on offerings is prohibited by the State Council, we may be subject to penalties, sanctions and fines imposed by the CSRC and relevant departments of the State Council. In severe circumstances, the business of our PRC subsidiary may be ordered to suspend and their business qualifications and licenses may be revoked. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As advised by our PRC legal counsel, Tian Yuan Law Firm, the Draft Overseas Listing Regulations were released only for soliciting public comment as of the date of this prospectus and their provisions and anticipated adoption or effective date are subject to changes and thus their interpretation and implementation remain substantially uncertain, we cannot predict the impact of the Draft Overseas Listing Regulations on this Offering, if any, at this stage, or guarantee that we will be able to satisfy the scrutinized and new regulatory requirements in case they were adopted in the current form. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, On July&#160;6, 2021, certain PRC regulatory authorities issued Opinions on Strictly Cracking Down on Illegal Securities Activities, which emphasized the need to strengthen regulation over illegal securities activities and supervision on overseas listings by China-based companies and propose to take effective measures, such as promoting the development of relevant regulatory systems to deal with the risks and incidents faced by China-based overseas-listed companies. There are still uncertainties regarding the interpretation and implementation of these opinions, Draft Overseas Listing Regulations and further explanations or detailed rules and regulations with respect to these opinions may be issued in the future, which may impose additional requirements on us. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of the date of this prospectus, no official guidance and related implementation rules have been issued in relation to these recently issued opinions and the interpretation and implementation of these opinions remain unclear at this stage. We cannot assure you that we will not be required to obtain the approval of the CSRC or of potentially other regulatory authorities to maintain the listing status of our ADSs on the Nasdaq or to conduct follow-on offerings of securities in the future. We intend to comply with applicable effective PRC laws and regulations governing our future potential follow-on offerings and complete relevant applicable fillings with CSRC, if required. We have been closely monitoring regulatory developments in China regarding any necessary approvals from the CSRC, the CAC, or other PRC regulatory authorities required for overseas Listings. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of the date of this prospectus, we have not received any inquiry, notice, warning, sanctions or regulatory objection from the CSRC. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Material Licenses and Approvals</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our PRC subsidary&#8217;s operations in China are covered by permissions requirements from the State Administration for Market Regulation, or the SAMR, and the National Medical Products Administration, or the NMPA. Our PRC subsidiary has obtained all material licenses and approvals required for our operations in China. We believe, to the best of our knowledge, as of the date of this prospectus, our PRC subsidary&#8217;s operations in China are not subject to the approvals or filing requirements from the CSRC or cyber security review process from the CAC. However, in connection with the potential offering of securities under this registration statement on Form F-3, filings or permissions from the CSRC or CAC may be required. See detailed discussions &#8220;Our Company&#8201;&#8212;&#8201;Recent Regulatory Developments.&#8217;&#8217; If we or our PRC subsidiary (i)&#160;do not receive or maintain such permissions or approvals, (ii) inadvertently conclude that such permissions or approvals are not required or (iii) applicable laws, regulations, or interpretations change and we are required to obtain such permissions or approvals in the future, we may be subject to government enforcement actions, investigations, penalties, sanctions and fines imposed by the CSRC, the CAC and relevant departments of the State Council. In severe circumstances, the&#160;business of our PRC subsidiary may be ordered to suspend and its business qualifications and licenses may be revoked. For details of our material </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">13</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">licenses and approvals, see &#8220;Item&#160;4. Information of the Company&#8201;&#8212;&#8201;4.B.&#160;Business Overview&#8201;&#8212;&#8201;Material Licenses and Approvals.&#8221; For risks relating to licenses and approvals required for our operations in China, see &#8220;Item&#160;3. Key Information&#8201;&#8212;&#8201;3.D. Risk Factors&#8201;&#8212;&#8201;Risks Related to Doing Business in the PRC,&#8221; &#8220;&#8212;&#160;Risks Related to Clinical Development of Our Product Candidates,&#8221; and &#8220;&#8212; Risks Related to Obtaining Regulatory Approval of Our Drug Candidates.&#8221; in our annual report on Form 20-F for the year ended December&#160;31, 2021, which is incorporated in this prospectus by reference. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Transfer of Funds and Other Assets</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of the date of this prospectus, we do not have cash management policies and procedures in place that dictate how funds are transferred through our organization. Rather, the funds can be&#160;transferred in accordance with the applicable PRC laws and regulations discussed in this section. See also &#8220;Item&#160;8.&#8201;&#8212;&#8201;Financial Information&#8201;&#8212;&#8201;8.A. Consolidated Statements and Other Financial Information&#8201;&#8212; Dividend Policy&#8221; in our annual report on Form 20-F for the year ended December 31, 2021, which is incorporated in this prospectus by reference. Under relevant PRC laws and regulations, we are permitted to remit funds to Adagene Suzhou through loans, capital contributions or as payment of considerations for the services rendered. In 2019, 2020 and 2021, Adagene Inc. made payments of US$13.1&#160;million, US$15.5&#160;million and US$30.0&#160;million, respectively, in cash to Adagene Suzhou as consideration for providing services associated with research and development activities related to those intellectual properties owned by Adagene Inc. There were no intercompany loans provided by Adagene Inc. to Adagene Suzhou during the&#160;years ended and as of December&#160;31, 2019, 2020 and 2021. In addition, as advised by our PRC legal counsel, Tian Yuan Law Firm, Adagene Suzhou is able to mark up and charge to Adagene Inc., its ultimate parent, for providing services associated with research and development activities related to those intellectual properties owned by Adagene Inc. and Adagene Inc. is able to make cash payments to Adagene Suzhou for considerations of such services. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Other than the above disclosed transfer of funds, we did not transfer any type of assets between Adagene Suzhou and other Adagene subsidiaries in 2019, 2020 and 2021. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Holding Company Structure</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Adagene Inc. is a holding company with no material operations of its own. Adagene Inc. holds certain intellectual properties and outsources certain research and development activities related to these intellectual properties to its subsidiaries. We conduct our operations primarily through our subsidiaries. As a result, our ability to pay dividends depends upon dividends paid by our subsidiaries. If our subsidiaries or any newly formed subsidiaries incur debt on their own behalf in the future, the instruments governing their debt may restrict their ability to pay dividends to us. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, our subsidiary in China is permitted to pay dividends to us only out of their retained earnings, if any, as determined in accordance with the Accounting Standards for Business Enterprise as promulgated by the Ministry of Finance of the PRC, or PRC GAAP. Pursuant to the law applicable to China&#8217;s foreign investment enterprise, our subsidiary that is foreign investment enterprise in the PRC has to make appropriation from its after-tax profit, as determined under PRC GAAP, to reserve funds including (i)&#160;general reserve fund, (ii)&#160;enterprise expansion fund and (iii)&#160;staff bonus and welfare fund. The appropriation to the general reserve fund must be at least 10% of the after-tax profits calculated in accordance with PRC GAAP. Appropriation is not required if the reserve fund has reached 50% of the registered capital of our subsidiary. Appropriation to the other two reserve funds are at our subsidiary&#8217;s discretion. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As an offshore holding company, we are permitted under PRC laws and regulations to provide funding from the proceeds of our offshore fund-raising activities to our PRC subsidiary through loans or capital contributions, subject to the satisfaction of the applicable government registration and approval requirements. See &#8220;Risk Factors&#8201;&#8212;&#8201;Risks Related to Doing Business in the PRC&#8201;&#8212;&#8201;PRC regulation of loans to and direct investment in PRC entities by offshore holding companies and governmental control of currency conversion may delay or prevent us from using the proceeds of our public offering to make loans or additional capital contributions to our PRC subsidiary, which could materially and adversely affect our liquidity and our ability to fund and expand our business.&#8221; As a result, there is uncertainty with respect to our ability to provide prompt financial support to our PRC subsidiary when needed. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">14</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Corporate Information</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Adagene was incorporated in the Cayman Islands in February&#160;2011. We conduct our operations in China primarily through our subsidiary in China, Adagene Suzhou, which was incorporated in February&#160;2012. In September&#160;2017, we established a wholly-owned subsidiary in the state of Delaware, the United States, Adagene Incorporated, to conduct our research and development activities in the United States to facilitate the discovery and development of product candidates and expand our global presence, we have further incorporated several subsidiaries overseas, such as Australia, Singapore and Switzerland. The ADSs, each representing one and one quarter (1.25) of our ordinary shares, par value US$0.0001 per share, are currently traded on the Nasdaq under the symbol &#8220;ADAG&#8221;. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our principal executive office of our main operations is located at 4F, Building C14, No. 218, Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu Province, 215123, People&#8217;s Republic of China. Our registered office is located at Vistra (Cayman) Limited, P. O. Box 31119 Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman, KY1&#8201;&#8212;&#8201;1205 Cayman Islands. Our telephone number is +86-512-8777-3632. Our business address of our San Diego office is 10179 Huennekens Street Suite 103, San Diego, CA 92121. We have appointed Cogency Global Inc., which is located at 122 East 42nd Street, 18th Floor, New York, NY 10168, as our agent upon whom process may be served in any action brought against us under the securities laws of the United States with an offering of Securities registered by the registration statement of which this prospectus is a part. Our corporate website is </font><font style="font-style:italic;letter-spacing:0.2pt;">www.adagene.com</font><font style="letter-spacing:0.2pt;">. The reference to our website is an inactive textual reference only, and information contained therein or connected thereto is not incorporated into this prospectus or the registration statement of which it forms a part. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Implications of Being an Emerging Growth Company</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We qualify as an &#8220;emerging growth company&#8221; as defined in the Jumpstart our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). As an emerging growth company, we may take advantage of specified reduced reporting and other burdens that are otherwise applicable generally to public companies. These provisions include: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.69pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.69pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a requirement to have only two&#160;years of audited financial statements in addition to any required interim financial statements and correspondingly reduced Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations disclosure; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">an exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting pursuant to Section&#160;404 of the Sarbanes-Oxley Act of 2002 (the &#8220;Sarbanes-Oxley Act&#8221;); and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to the extent that we no longer qualify as a foreign private issuer, (i)&#160;reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and (ii)&#160;exemptions from the requirements of holding a non-binding advisory vote on executive compensation, including golden parachute compensation. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may take advantage of these provisions for up to five&#160;years or such earlier time that we are no longer an emerging growth company. We will remain an emerging growth company until the earliest of (i)&#160;the last day of the fiscal year in which we have total annual gross revenues of at least US$1.07&#160;billion; (ii)&#160;the last day of our fiscal year following the fifth anniversary of the completion of this offering; (iii)&#160;the date on which we have issued more than US$1.0&#160;billion in non-convertible debt during the previous three&#160;years; or (iv)&#160;the date on which we are deemed to be a large accelerated filer under the rules of the SEC, which means the market value of our ordinary shares that are held by non-affiliates equals or exceeds US$700.0&#160;million as of the last business day of our most recently completed second fiscal quarter. We may choose to take advantage of some but not all of these reduced burdens. For example, Section&#160;107 of the JOBS Act also provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards applicable to public companies. This provision allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We do not plan to &#8220;opt out&#8221; of such exemptions afforded to an emerging growth company. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">15</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:298pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Implications of Being a Foreign Private Issuer</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are also considered as a &#8220;foreign private issuer.&#8221; Accordingly, we report under the Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), as a non-U.S. company with foreign private issuer status. This means that, even after we no longer qualify as an emerging growth company, as long as we qualify as a foreign private issuer under the Exchange Act, we will be exempt from certain provisions of the Exchange Act that are applicable to U.S. domestic public companies, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of a security registered under the Exchange Act; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the sections of the Exchange Act requiring insiders to file public reports of their stock ownership and trading activities and liability for insiders who profit from trades made in a short period of time; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the rules under the Exchange Act requiring the filing with the Securities and Exchange Commission, or SEC, of quarterly reports on Form 10-Q containing unaudited financial and other specified information, or current reports on Form 8-K, upon the occurrence of specified significant events. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may take advantage of these exemptions until such time as we are no longer a foreign private issuer. We would cease to be a foreign private issuer at such time as more than 50% of our outstanding voting securities are held by U.S. residents and any of the following three circumstances applies: (i)&#160;the majority of our executive officers or directors are U.S. citizens or residents, (ii)&#160;more than 50% of our assets are located in the United States or (iii)&#160;our business is administered principally in the United States. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In this prospectus and in the documents incorporated by reference in this prospectus, we have taken advantage of certain of the reduced reporting requirements as a result of being an emerging growth company and a foreign private issuer. Accordingly, the information contained in this prospectus and in the documents incorporated by reference in this prospectus may be different than the information you receive from other public companies in which you hold equity securities.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">16</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tRIFA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">RISK FACTORS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Investors in the Securities are purchasing securities of a Cayman Islands holding company rather than securities of its subsidiaries that have substantive business operations in China or in the U.S. Adagene is a Cayman Islands holding company that conducts its operations and operates its business in China through its PRC subsidiary, Adagene Suzhou. In addition, Adagene Inc. conducts a substantial portion of its operations in the U.S. through its U.S. subsidiary, Adagene Incorporated. Such structure involves unique risks to investors in the Securities. You should carefully consider all of the information in this prospectus before making an investment in the Securities. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Accordingly, you should carefully consider: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the information contained in or incorporated by reference into this prospectus; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the information contained in or incorporated by reference into any prospectus supplement relating to specific offerings of Securities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the risks described in our annual report on Form 20-F for our fiscal year ended December&#160;31, 2021, on file with the SEC, which is incorporated by reference into this prospectus; and any updates to those risk factors in our reports on Form 6-K incorporated by reference in this prospectus; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">other risks and other information that may be contained in, or incorporated by reference from, other filings we make with the SEC, including in any prospectus supplement relating to specific offerings of Securities. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The discussion of risks contained in or incorporated by reference into this prospectus or into any prospectus supplement comprises material risks of which we are aware. You should pay special attention to subsections headed &#8220;Recent Regulatory Developments,&#8221; &#8220;Holding Company Structure,&#8221; and &#8220;Risks Related to Doing Business in the PRC.&#8221; Our actual results could differ materially and adversely from those anticipated in this prospectus. If any of the events or developments described actually occurs, our business, financial condition or results of operations would likely suffer, and you may lose all or part of your investment. Although we discuss key risks in our discussion of risk factors, new risks may emerge in the future, which may prove to be significant. We cannot predict future risks or estimate the extent to which they may affect our business, results of operations, financial condition and prospects. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Please see &#8220;Where You Can Find More Information&#8221; and &#8220;Incorporation of Certain Documents by Reference&#8221; for information on where you can find the documents we have filed with or furnished to the SEC and which are incorporated into this prospectus by reference. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to Doing Business in the PRC</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Uncertainties with respect to the PRC legal system, including uncertainties regarding the enforcement of laws, and sudden or unexpected changes in policies, laws and regulations in China could adversely affect us.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our operations in China are governed by the PRC laws and regulations. The PRC legal system is a civil law system based on written statutes. Unlike the common law system, prior court decisions under the civil law system may be cited for reference but have limited precedential value. In addition, any new PRC laws or changes in PRC laws and regulations related to, among other things, foreign investment and manufacturing in China could have a material adverse effect on our business and our ability to operate our business in China. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For example, two draft regulations relating to overseas offerings by domestic companies of equity shares, depository receipts, convertible corporate bonds, or other equity-like securities, and overseas listing of the securities for trading&#8201;&#8212;&#8201;namely the Provisions of the State Council on the Administration of Overseas Securities Offering and Listing by Domestic Companies (Draft for Comments) and the Administrative Measures for the Filing of Overseas Securities Offering and Listing by Domestic Companies (Draft for Comments)&#8201;&#8212;&#8201;were recently released in December&#160;2021 for public comments. Pursuant to such draft regulations, a filing-based regulatory system would be implemented covering both direct and indirect overseas offering and listing, among which, (i)&#160;if an issuer listed in other overseas markets after overseas offerings, the issuer shall submit to the CSRC filing documents within three working days after such application is submitted; (ii)&#160;if an issuer issues overseas listed securities after listing abroad and issues such securities aiming </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">17</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">at purchasing assets, the issuer shall submit to the CSRC filing documents within three working days after the issue is completed, however, if the assets purchased are domestic assets, the filing procedure shall be performed within three working days from the date of the first announcement of the transaction; and (iii)&#160;if the significant events, such as change of control and termination of the listing, occur after the issuer&#8217;s overseas listing, it should report the details to CSRC within three working days from the date of occurrence. Uncertainties exist regarding the final form of these regulations as well as the interpretation and implementation thereof after promulgation. If those two rules were adopted in the current form, we may be required to file documents regarding the events listed in the regulations with the CRSC before or after the events occurred. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">From time to time, we may have to resort to administrative and court proceedings to enforce our legal rights. Any administrative and court proceedings in China may be protracted, resulting in substantial costs and diversion of resources and management attention. Since PRC administrative and court authorities have significant discretion in interpreting and implementing statutory provisions and contractual terms, it may be more difficult to evaluate the outcome of administrative and court proceedings and the level of legal protection we enjoy, than in more developed legal systems. These uncertainties may impede our ability to enforce contracts in China and could materially and adversely affect our business and results of operations. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Furthermore, the PRC legal system is based in part on government policies and internal rules, some of which are not published on a timely basis, or at all, and may have retroactive effect. As a result, we may not be aware of our violation of any of these policies and rules until sometime after the violation. Such unpredictability towards our contractual, property and procedural rights could adversely affect our business, and impede our ability to continue our operations and proceed with our future business plans. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PRC government has significant oversight over the conduct of our business and as such may influence our operations at any time, which may potentially result in a material adverse effect on our operations.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">PRC government has significant oversight over the conduct of our business and may intervene or influence our operations at any time, which may potentially result in a material adverse effect on our operations. PRC government has also recently indicated an intent to exert more oversight over offerings that are conducted overseas and foreign investment in China-based issuers, which could impact our ability to raise additional capital in international capital markets. In addition, the PRC government has recently published new policies that significantly affected certain industries, and we cannot rule out the possibility that it will in the future release regulations or policies regarding our industry that could adversely affect our business, financial condition and results of operations. Any such action could significantly limit or completely hinder our ability to offer or continue to offer Securities to investors and cause the value of such Securities to significantly decline or be worthless. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">However, as there are still regulatory uncertainties in this regard, we cannot assure you that we will be able to comply with new laws and regulations in all respects, and we may be ordered to rectify, suspend or terminate any actions or services that are deemed illegal by the regulatory authorities and become subject to material penalties, which may materially harm our business, financial condition, results of operations and prospects. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The PCAOB is currently unable to inspect our auditor in relation to their audit work performed for our financial statements and the inability of the PCAOB to conduct inspections over our auditor deprives our investors with the benefits of such inspections.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our auditor, the independent registered public accounting firm that issues the audit report included elsewhere in our most recent annual report on Form 20-F incorporated by reference in this prospectus, as an auditor of companies that are traded publicly in the United States and a firm registered with the Public Company Accounting Oversight Board (United States), or the PCAOB, is subject to laws in the United States pursuant to which the PCAOB conducts regular inspections to assess its compliance with the applicable professional standards. Since our auditor is located in China, a jurisdiction where the PCAOB has been unable to conduct inspections without the approval of the Chinese authorities, our auditor is not currently inspected by the PCAOB. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">18</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This lack of the PCAOB inspections in China prevents the PCAOB from fully evaluating audits and quality control procedures of our independent registered public accounting firm. As a result, we and investors in our ordinary shares and/or ADS are deprived of the benefits of such PCAOB inspections. The inability of the PCAOB to conduct inspections of auditors in China makes it more difficult to evaluate the effectiveness of our independent registered public accounting firm&#8217;s audit procedures or quality control procedures as compared to auditors outside of China that are subject to the PCAOB inspections, which could cause investors and potential investors in our ordinary shares and/or ADSs to lose confidence in our audit procedures and reported financial information and the quality of our financial statements. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Trading in our ADSs on the Nasdaq Stock Market or OTC will be prohibited, and as a result, our ADSs will be delisted under the HFCA Act, if the PCAOB is unable to inspect or fully investigate auditors located in China. On December&#160;16, 2021, the PCAOB issued the HFCA Act Determination Report, according to which our auditor is subject to the determinations that the PCAOB is unable to inspect or investigate completely. The delisting of our ADSs, or the threat of their being delisted, may materially and adversely affect the value of your investment. If this happens there is no certainty that we will be able to list our ordinary shares on a non-U.S. exchange or that a market for our ordinary shares will develop outside of the United States.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As part of a continued regulatory focus in the United States on access to audit and other information currently protected by national law, in particular China&#8217;s, the Holding Foreign Companies Accountable Act, or the HFCA Act, has been signed into law on December&#160;18, 2020. The HFCA Act requires the SEC to prohibit the trading of securities of a Chinese or a non-U.S. company on U.S. securities exchanges or the over-the-counter market if the PCAOB has determined that it has been unable to inspect the company&#8217;s accounting firm for three consecutive&#160;years because of a position taken by an authority in the company&#8217;s jurisdiction. The HFCA Act also requires such companies to make certain disclosures about their ownership by governmental entities and their relationships with the Chinese Communist Party. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On December&#160;2, 2021, the SEC adopted final amendments to its rules implementing the HFCA Act (the &#8220;Final Amendments&#8221;). The Final Amendments finalize the interim final rules adopted in March with two major modifications. First, the Final Amendments clarify how the requirements apply to variable interest entities. Second, the Final Amendments include requirements to disclose information, including the auditor name and location, the&#160;percentage of shares of the issuer owned by governmental entities, whether governmental entities in the applicable foreign jurisdiction with respect to the auditor has a controlling financial interest with respect to the issuer, the name of each official of the Chinese Communist Party who is a member of the board of the issuer, and whether the articles of incorporation of the issuer contains any charter of the Chinese Communist Party. The Final Amendments also establish procedures the SEC will follow in identifying issuers and prohibiting trading by certain issuers under the HFCA Act. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On December&#160;16, 2021, PCAOB issued the HFCA Act Determination Report, according to which our auditor is subject to the determinations that the PCAOB is unable to inspect or investigate completely. In March&#160;2022, the SEC issued its first &#8220;Conclusive list of issuers identified under the HFCAA&#8221; indicating that those companies are now formally subject to the delisting provisions if they remain on the list for three consecutive&#160;years. We were provisionally identified by the SEC on May 4, 2022 under the HFCA Act and anticipate being conclusively identified 15 business days after May 4, 2022. See https://www.sec.gov/hfcaa. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The HFCA Act or other efforts to increase U.S. regulatory access to audit information could cause investor uncertainty for affected issuers, including us, and the market price of the ADSs could be adversely affected. Additionally, whether the PCAOB will be able to conduct inspections of our auditor in the three consecutive&#160;years or at all, is subject to substantial uncertainty and depends on factors out of our or our auditor&#8217;s control. If our auditor is unable to meet the PCAOB inspection requirement in time, we will be delisted from the Nasdaq and our ADSs will not be permitted for trading over-the-counter either. Such a delisting would substantially impair your ability to sell or purchase our ADSs when you wish to do so, and the risk and uncertainty associated with delisting would have a negative impact on the price of our ADSs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If our ADS are delisted from the U.S. securities exchange and are prohibited from trading in the over-the-counter market in the United States, there is no certainly that we will be able to list our ordinary shares on a non U.S. securities exchange or that a market for our ordinary shares will develop outside of the United States. Such a delisting would significantly affect our ability to raise capital on terms acceptable to us, or at all, which would have a material adverse impact on our business, financial condition and prospects. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">19</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The potential enactment of the Accelerating Holding Foreign Companies Accountable Act would decrease the number of non-inspection&#160;years from three&#160;years to two, thus reducing the time period before our ADSs will be prohibited from trading on the Nasdaq Stock Market or OTC or delisted.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On June&#160;22, 2021, the U.S. Senate passed a bill, also known as the Accelerating Holding Foreign Companies Accountable Act, to amend Section&#160;104(i) of the Sarbanes-Oxley Act of 2002 (15 U.S.C.&#160;7214(i)) to prohibit securities of any registrant from being listed on any of the U.S. securities exchanges or traded over-the-counter if the auditor of the registrant&#8217;s financial statements is not subject to PCAOB inspection for two consecutive&#160;years, instead of three consecutive&#160;years as currently required under the HFCA Act, after the law becomes effective. On February&#160;4, 2022, the U.S. House of Representatives passed the America COMPETES Act of 2022, which includes the exact same amendments as the bill passed by the Senate. The America COMPETES Act of 2022 however includes a broader range of legislation not related to the HFCA Act in response to the U.S. Innovation and Competition Act passed by the Senate in 2021. The U.S. House of Representatives and U.S. Senate will need to agree on amendments to these respective bills to align the legislation and pass their amended bills before the President can sign into law. It is unclear when the U.S. Senate and U.S. House of Representatives will resolve the differences in the U.S. Innovation and Competition Act and the America COMPETES Act of 2022 bills currently passed, or when the U.S. President will sign on the bill to make the amendment into law, or at all. In the case that the bill becomes the law, it will reduce the time period before our ADSs will be prohibited from trading on the Nasdaq or over-the-counter or be delisted. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Proceedings instituted by the SEC against certain PRC-based accounting firms, including the affiliate of our independent registered public accounting firm, or any related adverse regulatory development in the PRC, could result in our financial statements being determined to not be in compliance with the requirements of the Exchange Act.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In December&#160;2012, the SEC instituted administrative proceedings against the Big Four PRC-based accounting firms, including our independent registered public accounting firm, alleging that these firms had violated U.S. securities laws and the SEC&#8217;s rules and regulations thereunder by failing to provide to the SEC the firms&#8217; audit work papers with respect to certain PRC-based companies that are publicly traded in the United States. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On January&#160;22, 2014, the administrative law judge presiding over the matter rendered an initial decision that each of the firms had violated the SEC&#8217;s rules of practice by failing to produce audit papers and other documents to the SEC. The initial decision censured each of the firms and barred them from practicing before the SEC for a period of six&#160;months. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On February&#160;6, 2015, the four China-based accounting firms each agreed to a censure and to pay a fine to the SEC to settle the dispute and avoid suspension of their ability to practice before the SEC and audit U.S.-listed companies. The settlement required the firms to follow detailed procedures and to seek to provide the SEC with access to Chinese firms&#8217; audit documents via the CSRC. Under the terms of the settlement, the underlying proceeding against the four China-based accounting firms was deemed dismissed with prejudice four&#160;years after entry of the settlement. The four-year mark occurred on February&#160;6, 2019. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">While we cannot predict if the SEC will further challenge the four China-based accounting firms&#8217; compliance with U.S. law in connection with U.S. regulatory requests for audit work papers or if the results of such a challenge would result in the SEC imposing penalties such as suspensions, if the accounting firms are subject to additional remedial measures, our ability to file our financial statements in compliance with SEC requirements could be impacted. A determination that we have not timely filed financial statements in compliance with SEC requirements could ultimately lead to the delisting of our ordinary shares or ADSs or the termination of the registration of our ordinary shares or ADSs under the Exchange Act, or both, which would substantially reduce or effectively terminate the trading of our ordinary shares or ADSs in the United States. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the event that the SEC restarts the administrative proceedings, depending upon the final outcome, listed companies in the United States with major PRC operations, such as us, may find it difficult or impossible to retain auditor in respect of their operations in the PRC, which could result in financial statements being determined to not be in compliance with the requirements of the Exchange Act, including </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">20</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">possible delisting. Moreover, any negative news about any such future proceedings against these audit firms may cause investor uncertainty regarding China-based, U.S.-listed companies and the market price of our ADSs may be adversely affected. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If our independent registered public accounting firm was denied, even temporarily, the ability to practice before the SEC and we were unable to timely find another registered public accounting firm to audit and issue an opinion on our financial statements, our financial statements could be determined not to be in compliance with the requirements of the Exchange Act. Such a determination could ultimately lead to the delisting of our ADSs from the Nasdaq Stock Market or deregistration from the SEC, or both, which would substantially reduce or effectively terminate the trading of our ADSs in the United States. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We may be restricted from transferring our scientific data abroad.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On March&#160;17, 2018, the General Office of the PRC State Council promulgated the Measures for the Management of Scientific Data, or the Scientific Data Measures, which provide a broad definition of scientific data and relevant rules for the management of scientific data. According to the Scientific Data Measures, enterprises in China must seek governmental approval before any scientific data involving a state secret may be transferred abroad or to foreign parties. Further, any researcher conducting research funded, at least in part, by the PRC government is required to submit relevant scientific data for management by the entity to which such researcher is affiliated before such data may be published in any foreign academic journal. Currently, as the term &#8220;state secret&#8221; is not clearly defined, there is no assurance that we can always obtain relevant approvals for sending scientific data (such as the results of our preclinical studies or clinical trials conducted within China) abroad, or to our foreign partners in China. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Moreover, the Cyberspace Administration of China, or the CAC, issued the Measures on Security Assessment of the Cross-border Transfer of Personal Information (Draft for Comment) in June&#160;2019, pursuant to which, any cross-border transfer of information that may endanger national security, damage public interest, or fail to offer effective protection of personal information security, as assessed by relevant regulatory bodies, will be prohibited. In October&#160;2021, CAC issued the Measures on Security Assessment of the Cross-border Data Transfer (Draft for Comment), which adjusts the thresholds for triggering mandatory security assessments not only in the cross-border transfers of personal information, but also in the cross-border transfers of &#8220;important data&#8221; collected and generated in China under certain circumstance. Given that the government body will have full discretion in the assessment, it is unclear if and the extent to which our clinical data will be considered as an endangerment to national or personal information security, if the regulation becomes effective. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Cross-border data transfer from other jurisdictions may also be limited if we fail to comply with relevant requirements, such as obtaining authorization from patients regarding the use, transfer and retrieval of their personal information or data and adopting measures to ensure the safety of personal information or data in the transfer. Also, cross-border transfer of personal data by its nature is subject to general data privacy regulations in various jurisdictions, and thus any failure to comply with data privacy protection may lead to a restriction of transferring our data across different jurisdictions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If we are unable to obtain the necessary approvals in a timely manner, or at all, our research and development of product candidates may be hindered, which may materially and adversely affect our business, results of operations, financial conditions and prospects. If relevant government authorities consider the transmission of our scientific data to be in violation of the requirements under the Scientific Data Measures, we may be subject to specific administrative penalties imposed by those government authorities </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Failure to comply with existing or future laws and regulations related to privacy or data security could lead to government enforcement actions, which could include civil or criminal fines or penalties, private litigation, other liabilities, and/or adverse publicity. Compliance or the failure to comply with such laws could increase the costs of our products and services, limit their use or adoption, and otherwise negatively affect our operating results and business.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The regulatory framework for the collection, use, safeguarding, sharing, transfer and other processing of personal information and important data worldwide is rapidly evolving and is likely to remain uncertain </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">21</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">for the foreseeable future. Regulatory authorities in virtually every jurisdiction in which we operate have implemented and are considering a number of legislative and regulatory proposals concerning data protection. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Regulatory authorities in China have implemented and are considering a number of legislative and regulatory proposals concerning data protection. For example, China&#8217;s Cybersecurity Law, which became effective in June&#160;2017, established China&#8217;s first national-level data protection for &#8220;network operators,&#8221; which may include all organizations in China that connect to or provide services over the internet or other information network. The Cybersecurity Law requires network operators to perform certain functions related to cybersecurity protection. In addition, the Cybersecurity Law imposes certain requirements on network operators of critical information infrastructure, or the CIIOs. For example, the CIIOs generally shall, during their operations in the PRC, store the personal information and important data collected and produced within the territory of PRC, and shall perform certain security obligations as required under the Cybersecurity Law, including that the CIIOs shall pass the national security review when purchasing network product or service which may affect national security. In addition, China&#8217;s Data Security Law, which was promulgated by the Standing Committee of PRC National People&#8217;s Congress, or the SCNPC, on June&#160;10, 2021 and came into effect on September&#160;1, 2021, outlines the main system framework of data security protection. For example, the Data Security Law introduces a data classification and hierarchical protection system based on the importance of data in economic and social development, as well as the degree of harm it will cause to national security, public interests, or legitimate rights and interests of individuals or organizations when such data is tampered with, destroyed, leaked, or illegally acquired or used. Processors of &#8220;important data&#8221; are further required to conduct periodic risk assessment and submit assessment report to relevant regulatory authorities. In addition, the Data Security Law provides a national security review procedure for those data activities which may affect national security. Furthermore, Regulations on the Security Protection of Critical Information Infrastructure, which was promulgated by the State Council of PRC on July&#160;30, 2021 and came into effect on September&#160;1, 2021, or the CII Protection Regulations, stipulates the obligations and liabilities of the regulators, society and CIIOs in protecting the security of critical information infrastructure, or the CII. According to the CII Protection Regulations, regulators supervising specific industries shall formulate detailed guidance to recognize the CII in the respective sectors, and CIIOs shall take the responsibility to protect the CII&#8217;s security by performing certain prescribed obligations. For example, CIIOs are required to conduct network security test and risk assessment, report the assessment results to relevant regulatory authorities, and timely rectify the issues identified at least once a year. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Opinions on Strictly Cracking Down Illegal Securities Activities in Accordance with the Law, which were issued by the General Committee and State Council on July&#160;6, 2021, require the speed-up of the revision of the provisions on strengthening the confidentiality and archives coordination between regulators related to overseas issuance and listing of securities, and improvement to the laws and regulations related to data security, cross-border data flow, and management of confidential information. Numerous regulations, guidelines and other measures have been or are expected to be adopted under the umbrella of, or in addition to the Cybersecurity Law and Data Security Law , including the Cybersecurity Review Measures published by Cyberspace Administration of China, or the CAC, and other 12 relevant PRC government authorities in December&#160;2021, which provides that, among others, if a &#8220;network platform operator&#8221; that possesses personal information of more than one million users intends to go public in a foreign country, it must apply for a cybersecurity review with the Cybersecurity Review Office, and that the relevant PRC governmental authorities may initiate cybersecurity review if they determine certain network products, services, or data processing activities affect or may affect national security. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On October&#160;29, 2021, the CAC published the Measures on Security Assessment of Cross-border Transfer of Data (Draft for Comments), or the draft security assessment measures, which provide that data processors shall make self-assessment of the risks before transferring data cross-border, and shall apply for security assessment for cross-border data transfer in any of the following circumstances: (i)&#160;transferring personal information and important data collected and produced by CIIO operators; (ii)&#160;important data is included in the data transferred cross-border; (iii)&#160;transferring personal information cross-border by personal information processors which process more than one million individuals&#8217; personal information; (iv)&#160;transferring more than one hundred thousand individuals&#8217; personal information or more than ten thousand individuals&#8217; sensitive personal information cumulatively; or (v)&#160;other circumstances which require the application for cross-border data transfer security assessment as determined by the CAC. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">22</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, the CAC published the Regulations for the Administration of Cyber Data Security (Draft for Comment), or the Draft Data Security Regulations, for public comments in November&#160;2021, which reiterate that a data processor who processes personal information of more than one million individuals must complete the cybersecurity review if it intends to be listed in a foreign country, and if a data processor conducts any data processing activities that affect or may affect national security, an application for cybersecurity review shall also be made by such a processor. The Draft Data Security Regulations also require that data processors who process important data or whose securities are listed outside of China shall carry out annual data security assessment by itself or through a third party data security service provider and submit the assessment report to local agency of the CAC. Also see &#8220;Item&#160;4. Information on the Company&#8201;&#8212;&#8201;4.B. Business Overview&#8201;&#8212;&#8201;Regulation&#8201;&#8212;&#8201;Other PRC Government Regulations&#8201;&#8212;&#8201;Regulations on Information Security and Data Protection&#8221; for detailed discussion. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of the date of this prospectus, the exact scope of CIIOs and important data under the current laws, regulations and regulatory regime remains unclear, and the authorities may have wide discretion in the interpretation and enforcement of the related laws and regulations. If we are deemed as a CIIO, or as an operator who collects, uses and processes important data according to the Cybersecurity Law, Data Security Law and other relevant laws and regulations, we may need to perform or be subject to certain prescribed obligations, and if we were found to be in violation of these applicable laws and regulations, we may be subject to administrative penalties, including fines and service suspension. We also cannot rule out the possibility that certain of our customers may be deemed as CIIOs, or as operators processing important data, in which case our products or services or data processing activities, if being deemed as related to national security, will need to be submitted for cybersecurity review before we can enter into agreements with such customers, and before the conclusion of such procedure, the customers will not be allowed to use our products or services. If the reviewing authority considers that the use of our services by certain of our customers involves risk of disruption, is vulnerable to external attacks, or may negatively affect, compromise, or weaken the protection of national security, we may not be able to provide our products or services to such customers, which could have a material adverse effect on our results of operations and business prospects. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of the date of this prospectus, we have not been involved in any investigations on cybersecurity review initiated by the Cyberspace Administration of China, and we have not received any inquiry, notice, warning, sanctions in such respect or any regulatory objections to our listing status on the Nasdaq. In addition, as advised by our PRC legal counsel, Tian Yuan Law Firm, given the nature of our business, the facts that we do not possess or process personal information of more than one million users/individuals, and our self-assessments that we are not a &#8220;critical information infrastructure operator&#8221;, &#8220;network platform operator&#8221; or a data processor whose purchase of network products and services or data processing activities affect or may affect national security, we believe, to the best of our knowledge, our business operations do not violate the regulations or policies that have been issued by the CAC to the date of this prospectus in all material aspects. As there are still uncertainties regarding the further enaction of new laws and regulations as well as the revision, interpretation and implementation of those existing laws and regulations, however, we cannot assure you that we will be able to comply with such regulations in all respects, and we may be ordered to rectify, suspend or terminate any actions or services that are deemed illegal or incompliance by the regulatory authorities and become subject to fines and/or other penalties. If we are unable to address such issue in a timely manner or at all, we may be required to suspend or terminate our related businesses or face other penalties, our business, financial condition, results of operations, and prospects could be materially harmed. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Furthermore, certain PRC regulatory authorities recently issued the Opinions on Strictly Cracking Down on Illegal Securities Activities. These opinions call for strengthened regulation over illegal securities activities and supervision of overseas listings by China-based companies and propose to take effective measures. As of the date of this prospectus, no official guidance or related implementation rules have been issued and taken into effect in relation to such opinions and as a result, the interpretation and implementation of these opinions remain unclear at this stage. We cannot assure you that we will not be required to obtain the pre-approval of the CSRC and potentially other regulatory authorities to pursue an offering of securities overseas or to maintain the listing status of our ADSs on the Nasdaq. See also &#8220;&#8212; The approval of or report and filing with the China Securities Regulatory Commission or other governmental authorities may be required in connection with this offering, and, if required, we cannot predict if we will be able to obtain such approval or complete such report and filing process.&#8221; </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">23</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, certain industry-specific laws and regulations affect the collection and transfer of personal data in China. For example, the PRC State Council promulgated Regulations on the Administration of Human Genetic Resources (effective in July&#160;2019), which require approval from or filings with the Science and Technology Administration Department of the State Council where human genetic resources, or HGR, are involved in any international collaborative project and additional approval for any export or cross-border transfer of the HGR samples or human genetic resource information. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our practices, potentially resulting in confiscation of HGR samples and human genetic resource information and administrative fines or in worst cases, criminal penalties. In addition, the interpretation and application of data and personal information protection laws in China and elsewhere are often uncertain and in flux. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Dividends we receive from our subsidiary located in the PRC may be taxed at a higher rate, which could materially and adversely affect the amount of dividends, if any, we may pay our shareholders.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to the Double Tax Avoidance Arrangement between Hong Kong and China, or the Double Tax Avoidance Treaty, and the Notice on Certain Issues with Respect to the Enforcement of Dividend Provisions in Tax Treaties, or the Notice on Tax Treaties, issued on February&#160;20, 2009 by the State Administration of Taxation of the PRC, or the SAT, if a Hong Kong resident enterprise owns more than 25% of the equity interest of a PRC company at all times during the twelve-month period immediately prior to obtaining a dividend from such company, the 10% withholding tax on such dividend is reduced to 5%, provided that certain other conditions and requirements under the Double Tax Avoidance Treaty and other applicable PRC laws are satisfied at the discretion of the relevant PRC tax authority. However, based on the Notice on Tax Treaties, if the relevant PRC tax authorities determine, in their discretion, that a company benefits from such reduced income tax rate due to a structure or arrangement that is primarily tax-driven, the PRC tax authorities may adjust the preferential tax treatment. Based on the Notice on Issues concerning Beneficial Owner in Tax Treaties, or Circular 9, issued on February&#160;3, 2018 by the SAT and effective on April&#160;1, 2018, when determining the applicant&#8217;s status as a &#8220;beneficial owner&#8221; for purpose of tax treatments in connection with dividends, interests or royalties in the tax treaties, several factors will be taken into account, and it will be analyzed according to the actual circumstances of the specific cases. If our Hong Kong subsidiary is determined by PRC government authorities as receiving benefits from reduced income tax rates due to a structure or arrangement that is primarily tax-driven, the dividends paid by our PRC subsidiary to our Hong Kong subsidiary will be taxed at a higher rate, which will have an adverse effect on our financial and operational conditions. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Your investments in our ADSs, Ordinary Shares and/or other Securities are investments in securities of a Cayman Islands holding company rather than securities of our subsidiaries that have substantive business operations in China. As a result, you may experience difficulties in effecting service of legal process, enforcing foreign judgments or bringing actions in China against us or our management based on foreign laws.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Adagene Inc. is a holding company incorporated under the laws of the Cayman Islands with no operations of its own. It conducts a substantial portion of its operations in China primarily through its subsidiary in China, in particular Adagene (Suzhou) Limited. In addition, Adagene Inc. conducts its substantial portion of operations in the U.S. through its U.S. subsidiary, Adagene Incorporated. As such, investors in the ADSs, Ordinary Shares or other Securities are not purchasing equity securities or other securities of our subsidiaries that have substantive business operations in China or in the U.S. but instead are purchasing equity securities or other securities of a Cayman Islands holding company. In addition, some of our senior executive officers and directors reside within China for a significant portion of the time and some are PRC nationals. As a result, it may be difficult for our shareholders or investors to effect service of process upon us or those persons inside China. In addition, China does not have treaties providing for the reciprocal recognition and enforcement of judgments of courts with the Cayman Islands and many other countries and regions. Therefore, recognition and enforcement in China of judgments of a court in any of these non-PRC jurisdictions in relation to any matter not subject to a binding arbitration provision may be difficult or impossible. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Shareholder claims that are common in the United States, including securities law class actions and fraud claims, generally are difficult to pursue as a matter of law or practicality in China. For example, in </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">24</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">China, there are significant legal and other obstacles to obtaining information needed for shareholder investigations or litigation outside China or otherwise with respect to foreign entities. Although the local authorities in China may establish a regulatory cooperation mechanism with the securities regulatory authorities of another country or region to implement cross-border supervision and administration, such regulatory cooperation with the securities regulatory authorities in the Unities States have not been efficient in the absence of mutual and practical cooperation mechanism. According to Article&#160;177 of the PRC Securities Law which became effective in March&#160;2020, no overseas securities regulator is allowed to directly conduct investigation or evidence collection activities within the territory of the PRC. Accordingly, without the consent of the competent PRC securities regulators and relevant authorities, no organization or individual may provide the documents and materials relating to securities business activities to overseas parties. See also &#8220;Item&#160;3 Key Information&#8201;&#8212;&#8201;Risk Factors&#8201;&#8212;&#8201;Risks Related to the ADSs&#8201;&#8212;&#8201;You may face difficulties in protecting your interests, and your ability to protect your rights through U.S. courts may be limited, because we are incorporated under Cayman Islands law&#8221; in our annual report on Form 20-F for the year ended December&#160;31, 2021, which is incorporated in this prospectus by reference. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Recent litigation and negative publicity surrounding China-based companies listed in the United States may result in increased regulatory scrutiny of us and negatively impact the trading price of the ADSs and could have a material adverse effect upon our business, including our results of operations, financial condition, cash flows and prospects.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We believe that litigation and negative publicity surrounding companies with operations in China that are listed in the United States have negatively impacted stock prices for these companies. Various equity-based research organizations have published reports on China-based companies after examining their corporate governance practices, related party transactions, sales practices and financial statements, and these reports have led to special investigations and listing suspensions on U.S. national exchanges. Any similar scrutiny of us, regardless of its lack of merit, could result in a diversion of management resources and energy, potential costs to defend ourselves against rumors, decreases and volatility in the ADS trading price, and increased directors and officers insurance premiums and could have an adverse effect upon our business, including our results of operations, financial condition, cash flows and prospects. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Changes in U.S. and international trade policies, particularly with regard to China, may adversely impact our business and operating results.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Although cross-border business may not be an area of our focus, if we plan to expand our business internationally in the future, any unfavorable government policies on international trade, such as capital controls or tariffs, may affect the demand for our products and services, impact our competitive position, or prevent us from being able to conduct business in certain countries. If any new tariffs, legislation, or regulations are implemented, or if existing trade agreements are renegotiated, such changes could adversely affect our business, financial condition, and results of operations. Recently, there have been heightened tensions in international economic relations, such as the one between the United States and China. The U.S. government has recently imposed, and has recently proposed to impose additional, new, or higher tariffs on certain products imported from China to penalize China for what it characterizes as unfair trade practices. China has responded by imposing, and proposing to impose additional, new, or higher tariffs on certain products imported from the United States. Following mutual retaliatory actions for&#160;months, on January&#160;15, 2020, the United States and China entered into the Economic and Trade Agreement between the United States of America and the People&#8217;s Republic of China as a phase one trade deal, effective on February&#160;14, 2020. It remains unclear what additional actions, if any, will be taken by the U.S. or other governments with respect to international trade, tax policy related to international commerce, or other trade matters. The situation is further complicated by the political tensions between the United States and China that escalated during the COVID-19 pandemic and in the wake of the PRC National People&#8217;s Congress&#8217; decision on Hong Kong national security legislation, sanctions imposed by the U.S. Department of Treasury on certain officials of the Hong Kong Special Administrative Region and the central government of the PRC and the executive orders issued by U.S. President in August&#160;2020 that prohibit certain transactions with certain China-based companies and their respective subsidiaries. Rising trade and political tensions could reduce levels of trade, investments, technological exchanges and other economic activities between China and other countries, which would have an adverse effect on global economic conditions, the stability of global financial markets, and international trade policies. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">25</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Although the direct impact of the current international trade and political tension, and any escalation of such tension, on the biopharmaceutical companies in China is uncertain, the negative impact on general, economic, political and social conditions may adversely impact our business, financial condition and results of operations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The approval of or report and filing with the China Securities Regulatory Commission or other governmental authorities may be required in connection with this offering, and, if required, we cannot predict if we will be able to obtain such approval or complete such report and filing process.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Regulations on Mergers and Acquisitions of Domestic Enterprises by Foreign Investors, or the M&amp;A Rules, requires an overseas special purpose vehicle formed for listing purposes through acquisitions of PRC domestic companies and controlled by PRC companies or individuals to obtain the approval of the CSRC prior to the listing and trading of such special purpose vehicle&#8217;s securities on an overseas stock exchange. However, the application of the M&amp;A Rules remains unclear. If CSRC approval is required, it is uncertain whether it would be possible for us to obtain the approval, and any failure to obtain or delay in obtaining CSRC approval for this offering would subject us to sanctions imposed by the CSRC and other PRC regulatory agencies. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our PRC legal counsel has advised us based on their understanding of the current PRC laws, rules and regulations that no permission is required from CSRC for us to maintain our listing of the ADSs on the Nasdaq, given that (i)&#160;the CSRC currently has not issued any definitive rule or interpretation concerning whether offering such as this offering contemplated by our Company are subject to the M&amp;A Rules; and (ii)&#160;our PRC subsidiary was incorporated as wholly foreign-owned enterprises by means of direct investment not subject to the M&amp;A Rules. There can be no assurance that the relevant PRC government agencies, including the CSRC, would reach the same conclusion as our PRC legal counsel. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, the recently issued Opinions on Strictly Cracking Down on Illegal Securities Activities emphasized the need to strengthen regulation over illegal securities activities and supervision on overseas listings by China-based companies and propose to take effective measures, such as promoting the development of relevant regulatory systems to deal with the risks and incidents faced by China-based overseas-listed companies. There are still uncertainties regarding the interpretation and implementation of these opinions, Draft Overseas Listing Regulations and further explanations or detailed rules and regulations with respect to these opinions may be issued in the future, which may impose additional requirements on us. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Furthermore, on December&#160;24, 2021, the CSRC published the Provisions of the State Council on the Administration of Overseas Securities Offering and Listing by Domestic Companies (Draft for Comments), and Administrative Measures for the Filing of Overseas Securities Offering and Listing by Domestic Companies (Draft for Comments), or collectively, the Draft Overseas Listing Regulations, which set out the new regulatory requirements and filing procedures for Chinese companies seeking direct or indirect listing in overseas markets. The Draft Overseas Listing Regulations, among others, stipulate that (i)&#160;Chinese companies that seek to offer and list securities in overseas markets directly or indirectly shall fulfill the filing procedures with and report relevant information to the CSRC, (ii)&#160;in the context of an initial public offering, an initial filing shall be submitted within three (3)&#160;working days after the application for an initial public offering is submitted, and (iii)&#160;in the context of follow-on offering after the completion of the initial public offering, an filing shall be submitted within three (3)&#160;working days after the completion of the offering or within three (3)&#160;working days from the date of the first announcement of the transaction depending on the purpose for which the follow-on offering are conducted. Moreover, an overseas offering and listing is prohibited under circumstances if (i)&#160;it is prohibited by PRC laws, (ii)&#160;it may constitute a threat to or endanger national security as reviewed and determined by competent PRC authorities, (iii)&#160;it has material ownership disputes over equity, major assets, and core technology, (iv)&#160;in recent three&#160;years, the Chinese operating entities, and their controlling shareholders and actual controllers have committed relevant prescribed criminal offenses or are currently under investigations for suspicion of criminal offenses or major violations, (v)&#160;the directors, supervisors, or senior executives have been subject to administrative punishment for severe violations, or are currently under investigations for suspicion of criminal offenses or major violations, or (vi)&#160;it has other circumstances as prescribed by the State Council. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Draft Overseas Listing Regulations, among others, stipulate that if the issuer meets the following conditions, its offering and listing shall be determined as an &#8220;indirect overseas offering and listing by a </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">26</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Chinese company&#8221; and is therefore subject to the filing requirement: (1)&#160;the revenues, profits, total assets or net assets of the Chinese operating entities in the most recent financial year accounts for more than 50% of the corresponding data in the issuer&#8217;s audited consolidated financial statements for the same period; (2)&#160;the majority of senior management in charge of business operation are Chinese citizens or have domicile in PRC, and its principal place of business is located in PRC or main business activities are conducted in PRC. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">According to the Draft Overseas Listing Regulations, if we failed to complete the filing procedures with the CSRC for our future offering or fell within any of the circumstances where our proposed listing overseas is prohibited by the State Council, we may be subject to penalties, sanctions and fines imposed by the CSRC and relevant departments of the State Council. In severe circumstances, the business of our PRC subsidiary may be ordered to suspend and their business qualifications and licenses may be revoked. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As advised by our PRC legal counsel, the Draft Overseas Listing Regulations were released only for soliciting public comment as of the date of this prospectus and their provisions and anticipated adoption or effective date are subject to changes and thus their interpretation and implementation remain substantially uncertain, we cannot predict the impact of the Draft Overseas Listing Regulations on this Offering, if any, at this stage, or guarantee that we will be able to satisfy the scrutinized and new regulatory requirements in case they were adopted in the current form. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If we are classified as a PRC resident enterprise for PRC income tax purposes, such classification could result in unfavorable tax consequences to us and our non-PRC shareholders or ADS holders.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under the PRC Enterprise Income Tax Law and its implementation rules, an enterprise established outside of the PRC with a &#8220;de facto management body&#8221; within the PRC is considered a &#8220;resident enterprise&#8221; and will be subject to the enterprise income tax on its global income at the rate of 25%. The implementation rules define the term &#8220;de facto management body&#8221; as the body that exercises full and substantial control over and overall management of the business, productions, personnel, accounts and properties of an enterprise. In 2009, SAT issued a circular, known as SAT Circular 82, which provides certain specific criteria for determining whether the &#8220;de facto management body&#8221; of a PRC-controlled enterprise that is incorporated offshore is located in China. Although this circular only applies to offshore enterprises controlled by PRC enterprises or PRC enterprise groups, not those controlled by PRC individuals or foreigners, the criteria set forth in the circular may reflect the SAT&#8217;s general position on how the &#8220;de facto management body&#8221; test should be applied in determining the tax resident status of all offshore enterprises. According to SAT Circular 82, an offshore incorporated enterprise controlled by a PRC enterprise or a PRC enterprise group will be regarded as a PRC tax resident by virtue of having its &#8220;de facto management body&#8221; in China and will be subject to PRC enterprise income tax on its global income only if all of the following conditions are met: (i)&#160;the primary location of the day-to-day operational management and the places where they perform their duties are in the PRC; (ii)&#160;decisions relating to the enterprise&#8217;s financial and human resource matters are made or are subject to approval by organizations or personnel in the PRC; (iii)&#160;the enterprise&#8217;s primary assets, accounting books and records, company seals, and board and shareholder resolutions, are located or maintained in the PRC; and (iv)&#160;at least 50% of voting board members or senior executives habitually reside in the PRC. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We believe that we are not a PRC resident enterprise for PRC tax purposes. However, the tax resident status of an enterprise is subject to determination by the PRC tax authorities and uncertainties remain with respect to the interpretation of the term &#8220;de facto management body.&#8221; If the PRC tax authorities determine that we or any of our non-PRC subsidiaries are a PRC resident enterprise for enterprise income tax purposes, we or the subsidiary will be subject to PRC tax at a rate of 25%. In addition, we may be required to withhold taxes from dividends, and non-PRC shareholders (including ADS holders) may be subject to PRC tax on gains realized on the sale or other disposition of ADSs or ordinary shares, if such income is treated as sourced from within the PRC, as described below under &#8220;Risk Factors&#8201;&#8212;&#8201;Risks Related to the ADS&#8201;&#8212;&#8201;You may be subject to PRC income tax on dividends from us or any gain realized on the transfer of our ADSs.&#8221; </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">You may be subject to PRC income tax on dividends from us or on any gain realized on the transfer of our ADSs.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under the Enterprise Income Tax Law of the PRC, or the EIT Law, and its implementation rules, PRC withholding tax at the rate of 10% is generally applicable to dividends from PRC sources paid to investors </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">27</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">that are resident enterprises outside of China and that do not have an establishment or place of business in China, or that have an establishment or place of business in China but the relevant income is not effectively connected with the establishment or place of business. Any gain realized on the transfer of shares by such investors is subject to 10% PRC income tax if this gain is regarded as income derived from sources within China. Under the PRC Individual Income Tax Law and its implementation rules, dividends from sources within China paid to foreign individual investors who are not PRC residents are generally subject to a PRC withholding tax at a rate of 20% and gains from PRC sources realized by these investors on the transfer of shares are generally subject to 20% PRC income tax. Any such PRC tax liability may be reduced by the provisions of an applicable tax treaty. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Although substantially all of our business operations are in China, it is unclear whether the dividends we pay with respect to our shares or ADSs, or the gains realized from the transfer of our shares or ADSs, would be treated as income derived from sources within China and as a result be subject to PRC income tax if we are considered a PRC resident enterprise. If PRC income tax is imposed on gains realized through the transfer of our ADSs or on dividends paid to our non-resident investors, the value of your investment in our ADSs may be adversely affected. Furthermore, our shareholders whose jurisdictions of residence have tax treaties or arrangements with China may not qualify for, or able to obtain in practice, the benefits under these tax treaties or arrangements. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The biopharmaceutical industry in China is highly regulated and such regulations are subject to changes which may affect approval and commercialization of our product candidates.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Part of our research and development operations are in China, which we believe confers clinical, commercial and regulatory advantages. The biopharmaceutical industry in China is subject to comprehensive government regulation and supervision, encompassing the approval, registration, manufacturing, packaging, licensing and marketing of new product candidates. See &#8220;Item&#160;4 Information on the Company&#8201;&#8212;&#8201; Regulation&#8221; in our annual report on Form 20-F for the year ended December&#160;31, 2021, which is incorporated in this prospectus by reference, for a discussion of the regulatory requirements that are applicable to our current and planned business activities in China. In recent&#160;years, the regulatory framework in China regarding the biopharmaceutical industry has undergone significant changes, and we expect that it will continue to undergo significant changes. Any such changes or amendments may result in increased compliance costs on our business or cause delays in or prevent the successful development or commercialization of our product candidates in China and reduce the current benefits we believe are available to us from developing and manufacturing drugs in China. PRC authorities have become increasingly vigilant in enforcing laws in the biopharmaceutical industry and any failure by us or our partners to maintain compliance with applicable laws and regulations or obtain and maintain required licenses and permits may result in the suspension or termination of our business activities fines, warnings, administrative or criminal penalties in China. We believe our strategy and approach are aligned with the PRC government&#8217;s regulatory policies, but we cannot ensure that our strategy and approach will continue to be aligned. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Substantial uncertainties exist with respect to the interpretation and implementation of the newly enacted Foreign Investment Law and how it may impact the viability of our current corporate structure, corporate governance and business operations.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On March&#160;15, 2019, the PRC National People&#8217;s Congress approved the Foreign Investment Law, which came into effect on January&#160;1, 2020 and replaces the trio of existing laws regulating foreign investment in the PRC, namely, the Sino-Foreign Equity Joint Venture Enterprise Law, the Sino-Foreign Cooperative Joint Venture Enterprise Law and the Wholly Foreign-Invested Enterprise Law, together with their implementation rules and ancillary regulations and become the legal foundation for foreign investment in the PRC. Meanwhile, the </font><font style="font-style:italic;letter-spacing:0.2pt;">Implementation Regulation of the Foreign Investment Law and the Measures for Reporting of Information on Foreign Investment</font><font style="letter-spacing:0.2pt;"> came into effect as of January&#160;1, 2020, which clarified and elaborated the relevant provisions of the </font><font style="font-style:italic;letter-spacing:0.2pt;">Foreign Investment Law</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Foreign Investment Law sets out the basic regulatory framework for foreign investments and proposes to implement a system of pre-entry national treatment with a negative list for foreign investments, pursuant to which (i)&#160;foreign entities and individuals are prohibited from investing in the areas that are not open to foreign investments, (ii)&#160;foreign investments in the restricted industries must satisfy certain </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">28</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">requirements under the law, and (iii)&#160;foreign investments in business sectors outside of the negative list will be treated equally with domestic investments. The Foreign Investment Law also sets forth necessary mechanisms to facilitate, protect and manage foreign investments and proposes to establish a foreign investment information reporting system, through which foreign investors or foreign-invested enterprises are required to submit initial report, report of changes, report of deregistration and annual report relating to their investments to the Ministry of Commerce, or MOFCOM, or its local branches. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our business may be negatively affected by the potential obligations to make additional social insurance and housing fund contributions.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are required by PRC labor laws and regulations, such as the Social Insurance Law, Administrative Regulations on the Housing Provident Fund and other related rules, to pay various statutory employee benefits, including pensions insurance, medical insurance, work-related injury insurance, unemployment insurance, maternity insurance and housing fund, to designated government agencies for the benefit of our employees. The relevant government agencies may examine whether an employer has made adequate and timely payments of the requisite statutory employee benefits, and employers who fail to make adequate and timely payments may be subject to supplemental contributions, late payment fees, fines compulsory enforcement and/or other penalties. If the relevant PRC authorities determine that we shall make supplemental social insurance and housing fund contributions or that we are subject to fines and legal sanctions in relation to our failure to make social insurance and housing fund contributions in full for our employees, our business, financial condition and results of operations may be adversely affected. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The lease agreements of our leased properties have not been registered with the relevant PRC government authorities as required by PRC law, which may expose us to potential fines.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under PRC law, lease agreements of commodity housing tenancy are required to be registered with the local construction (real estate) departments. Although failure to do so does not in itself invalidate the leases, the parties of the lease agreements may be exposed to potential fines if they fail to rectify such non-compliance within the prescribed time frame after receiving notice from the relevant PRC government authorities. The penalty ranges from RMB1,000 to RMB10,000 for each unregistered lease, at the discretion of the relevant authority. As of the date of this prospectus, the lease agreements for our leased properties in China have not been registered with the relevant PRC government authorities. As of the date of this prospectus, we are not aware of any regulatory or governmental actions, claims or investigations being contemplated or any challenges by third parties to our use of our leased properties that the lease agreements of which have not been registered with the government authorities. However, we cannot assure you that the government authorities will not impose fines on us due to our failure to register any of our lease agreements, which may negatively impact our financial condition. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Any failure to comply with PRC regulations regarding the registration requirements for employee stock incentive plans may subject the PRC plan participants or us to fines and other legal or administrative sanctions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In February&#160;2012, SAFE promulgated the Notices on Issues Concerning the Foreign Exchange Administration for Domestic Individuals Participating in Stock Incentive Plan of Overseas Publicly Listed Company, replacing earlier rules promulgated in 2007. Pursuant to these rules, PRC citizens and non-PRC citizens who reside in China for a continuous period of not less than one year who participate in any stock incentive plan of an overseas publicly listed company, subject to a few exceptions, are required to register with SAFE through a domestic qualified agent, which could be the PRC subsidiary of such overseas-listed company, and complete certain other procedures. In addition, an overseas-entrusted institution must be retained to handle matters in connection with the exercise or sale of stock options and the purchase or sale of shares and interests. We and our executive officers and other employees who are PRC citizens or who reside in the PRC for a continuous period of not less than one year and who have been granted options will be subject to these regulations. Failure to complete the SAFE registrations may subject them to fines and legal sanctions, there may be additional restrictions on the ability of them to exercise their stock options or remit proceeds gained from the sale of their stock into the PRC. We also face regulatory uncertainties that could restrict our ability to adopt incentive plans for our directors, executive officers and employees under PRC law. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">29</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We face uncertainty with respect to indirect transfers of equity interests in PRC resident enterprises by their non-PRC holding companies.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to the Notice on Strengthening Administration of Enterprise Income Tax for Share Transfers by Non-PRC Resident Enterprises, or SAT Circular 698, issued by the SAT in 2009 with retroactive effect from January&#160;1, 2008, where a non-resident enterprise transfers the equity interests of a PRC resident enterprise indirectly by disposition of the equity interests of an overseas holding company, or an Indirect Transfer, and such overseas holding company is located in a tax jurisdiction that: (i)&#160;has an effective tax rate less than 12.5% or (ii)&#160;does not tax foreign income of its residents, the non-resident enterprise, being the transferor, shall report to the competent tax authority of the PRC resident enterprise this Indirect Transfer. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On February&#160;3, 2015, the SAT issued the Announcement of the State Administration of Taxation on Several Issues Concerning the Enterprise Income Tax on Indirect Property Transfer by Non-Resident Enterprises, or SAT Bulletin 7. SAT Bulletin 7 supersedes the rules with respect to the Indirect Transfer under SAT Circular 698. SAT Bulletin 7 has introduced a new tax regime that is significantly different from the previous one under SAT Circular 698. SAT Bulletin 7 extends the PRC&#8217;s tax jurisdiction to not only Indirect Transfers set forth under SAT Circular 698 but also transactions involving a transfer of other taxable assets through an offshore transfer of a foreign intermediate holding company. In addition, SAT Bulletin 7 provides clearer criteria than SAT Circular 698 for assessment of reasonable commercial purposes and has introduced safe harbors for internal group restructurings and the purchase and sale of equity through a public securities market. SAT Bulletin 7 also brings challenges to both foreign transferor and transferee (or another person who is obligated to pay for the transfer) of taxable assets. Where a non-resident enterprise transfers taxable assets indirectly by disposing of the equity interests of an overseas holding company, which is an Indirect Transfer, the non-resident enterprise, being the transferor, or the transferee, or the PRC entity that directly owns the taxable assets, may report such Indirect Transfer to the relevant tax authority. Using a &#8220;substance over form&#8221; principle, the PRC tax authority may disregard the existence of the overseas holding company if it lacks a reasonable commercial purpose and was established for the purpose of reducing, avoiding or deferring PRC tax. As a result, gains derived from such Indirect Transfer may be subject to PRC enterprise income tax, and the transferee or another person who is obligated to pay for the transfer is obligated to withhold the applicable taxes, currently at a rate of 10% for the transfer of equity interests in a PRC resident enterprise. Both the transferor and the transferee may be subject to penalties under PRC tax laws if the transferee fails to withhold the taxes and the transferor fails to pay the taxes. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On October&#160;17, 2017, the SAT issued the Announcement of the State Administration of Taxation on Matters Concerning Withholding of Income Tax of Non-resident Enterprises at Source, or SAT Bulletin&#160;37, which, among others, repealed the SAT Circular 698 on December&#160;1, 2017. SAT Bulletin 37 further details and clarifies the tax withholding methods in respect of income of non-resident enterprises under SAT Circular&#160;698. In addition, certain rules stipulated in SAT Bulletin 7 are replaced by SAT Bulletin 37. Where the non-resident enterprise fails to declare the tax payable pursuant to Article&#160;39 of the PRC Enterprise Income Tax Law, the tax authority may order it to pay the tax due within required time limits, and the non-resident enterprise shall declare and pay the tax payable within such time limits specified by the tax authority; however, if the non-resident enterprise voluntarily declares and pays the tax payable before the tax authority orders it to do so within required time limits, it shall be deemed that such enterprise has paid the tax in time. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We face uncertainties as to the reporting and other implications of certain past and future transactions where PRC taxable assets are involved, such as offshore restructuring, sale of the shares in our offshore subsidiaries and investments. Our company may be subject to filing obligations or taxed if our company is a transferor in such transactions, and may be subject to withholding obligations if our company is a transferee in such transactions, under SAT Bulletin 7 and SAT Bulletin 37. For transfer of shares in our company by investors who are non-PRC resident enterprises, our PRC subsidiary may be requested to assist in the filing under SAT Bulletin 7 and SAT Bulletin 37. As a result, we may be required to expend valuable resources to comply with SAT Bulletin 7 and SAT Bulletin 37 or to request the relevant transferors from whom we purchase taxable assets to comply with these circulars, or to establish that our company should not be taxed under these circulars, which may have a material adverse effect on our financial condition and results of operations. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">30</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If our preferential tax treatments are revoked, become unavailable or if the calculation of our tax liability is challenged by the PRC tax authorities, we may be required to pay tax, interest and penalties in excess of our tax provisions, and our results of operations could be materially and adversely affected.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Chinese government has provided various tax incentives to our subsidiary in China. These incentives include reduced enterprise income tax rates. For example, under the Enterprise Income Tax Law and its implementation rules, the statutory enterprise income tax rate is 25%. However, the income tax of an enterprise that has been determined to be a technologically advanced service enterprise can be reduced to a preferential rate of 15%. Any increase in the enterprise income tax rate applicable to our PRC subsidiary, or any discontinuation or retroactive or future reduction of any of the preferential tax treatments currently enjoyed by our PRC subsidiary, could adversely affect our business, financial condition and results of operations. In addition, in the ordinary course of our business, we are subject to complex income tax and other tax regulations and significant judgment is required in the determination of a provision for income taxes. Although we believe our tax provisions are reasonable, if the PRC tax authorities successfully challenge our position and we are required to pay tax, interest and penalties in excess of our tax provisions, our financial condition and results of operations would be materially and adversely affected. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Certain PRC regulations may make it more difficult for us to pursue growth through acquisitions.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Among other things, the Regulations on Mergers and Acquisitions of Domestic Enterprises by Foreign Investors, or the M&amp;A Rules, adopted by six PRC regulatory agencies in 2006 and amended in 2009, established additional procedures and requirements that could make merger and acquisition activities by foreign investors more time-consuming and complex. Such regulation requires, among other things, the MOFCOM be notified in advance or its approval be obtained in certain situations, such as any change-of-control transaction in which a foreign investor acquires control of a PRC domestic enterprise of Undertakings, issued by the State Council in 2008 and amended in 2018, were triggered. Moreover, the Anti-Monopoly Law promulgated by the Standing Committee of the PRC National People&#8217;s Congress, or NPC, which became effective in 2008 requires that transactions which are deemed concentrations and involve parties with specified turnover thresholds must be cleared by the MOFCOM before they can be completed. In addition, PRC national security review rules which became effective in September&#160;2011 require acquisitions by foreign investors of PRC companies engaged in military-related or certain other industries that are crucial to national security be subject to security review before consummation of any such acquisition. We may pursue potential strategic acquisitions that are complementary to our business and operations. Complying with the requirements of these regulations to complete such transactions could be time-consuming, and any required approval processes, including obtaining approval or clearance from the MOFCOM, may delay or inhibit our ability to complete such transactions, which could affect our ability to expand our business or maintain our market share. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PRC regulations relating to offshore investment activities by PRC residents may limit our PRC subsidiary&#8217; ability to change their registered capital or distribute profits to us or otherwise expose us or our PRC resident beneficial owners to liability and penalties under PRC laws.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In July&#160;2014, SAFE promulgated the Circular on Relevant Issues Concerning Foreign Exchange Control on Domestic Residents&#8217; Offshore Investment and Financing and Roundtrip Investment Through Special Purpose Vehicles, or SAFE Circular 37. SAFE Circular 37 requires PRC residents (including PRC individuals and PRC corporate entities as well as foreign individuals that are deemed as PRC residents for foreign exchange administration purpose) to register with SAFE or its local branches in connection with their direct or indirect offshore investment activities. SAFE Circular 37 is applicable to our shareholders who are PRC residents and may be applicable to any offshore acquisitions that we make in the future. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under SAFE Circular 37, PRC residents who make, or have prior to the implementation of SAFE Circular 37 made, direct or indirect investments in offshore special purpose vehicles, or SPVs, will be required to register such investments with SAFE or its local branches. In addition, any PRC resident who is a direct or indirect shareholder of an SPV, is required to update its filed registration with the local branch of SAFE with respect to that SPV, to reflect any material change, including, among other things, any major change of a PRC resident shareholder, name or term of operation of the SPVs, or any increase or reduction of the SPVs&#8217; registered capital, share transfer or swap, merger or division. Moreover, any subsidiary of such </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">31</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">SPV in China is required to urge the PRC resident shareholders to update their registration with the local branch of SAFE. If any PRC shareholder of such SPV fails to make the required registration or to update the previously filed registration, the subsidiary of such SPV in China may be prohibited from distributing its profits or the proceeds from any capital reduction, share transfer or liquidation to the SPV, and the SPV may also be prohibited from making additional capital contributions into its subsidiary in China. On February&#160;13, 2015, SAFE promulgated a Notice on Further Simplifying and Improving Foreign Exchange Administration Policy on Direct Investment, or SAFE Notice 13, which became effective on June&#160;1, 2015. Under SAFE Notice 13, applications for foreign exchange registration of inbound foreign direct investments and outbound overseas direct investments, including those required under SAFE Circular 37, will be filed with qualified banks instead of SAFE or its branches. The qualified banks will directly examine the applications and accept registrations under the supervision of SAFE. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Some of our existing shareholders, each of whom owns our ordinary shares, including but not limited to as a result of exercising share options, are PRC residents under SAFE Circular 37. However, we cannot provide any assurance that these PRC residents comply with our request to make or obtain any applicable registrations or change registration or comply with all of the requirements under SAFE Circular 37 or other related rules. Furthermore, we may not be informed of the identities of all the PRC residents holding direct or indirect interest in our company. The failure or inability of our PRC resident shareholders to comply with the registration procedures set forth in these regulations may subject us to fines and legal sanctions, restrict our cross-border investment activities, limit the ability of our wholly foreign-owned subsidiary in China to distribute dividends and the proceeds from any reduction in capital, share transfer or liquidation to us, and we may also be prohibited from injecting additional capital into the subsidiary. Moreover, failure to comply with the various foreign exchange registration requirements described above could result in liability under PRC law for circumventing applicable foreign exchange restrictions. As a result, our business operations and our ability to distribute profits to you could be materially and adversely affected. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Furthermore, as these foreign exchange regulations are still relatively new and their interpretation and implementation has been constantly evolving, it is unclear how these regulations, and any future regulation concerning offshore or cross-border transactions, will be interpreted, amended and implemented by the relevant government authorities. For example, we may be subject to a more stringent review and approval process with respect to our foreign exchange activities, such as remittance of dividends and foreign-currency-denominated borrowings, which may adversely affect our financial condition and results of operations. In addition, if we decide to acquire a PRC domestic company, we cannot assure you that we or the owners of such company, as the case may be, will be able to obtain the necessary approvals or complete the necessary filings and registrations required by the foreign exchange regulations. This may restrict our ability to implement our acquisition strategy and could adversely affect our business and prospects. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We may be materially adversely affected if our shareholders and beneficial owners who are PRC entities fail to comply with the relevant PRC overseas investment regulations.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On December&#160;26, 2017, the NDRC promulgated the Administrative Measures on Overseas Investments, or NDRC Order No. 11, which took effect as of March&#160;1, 2018. According to NDRC Order No. 11, non-sensitive overseas investment projects are subject to record-filing requirements with the local branch of the NDRC. On September&#160;6, 2014, MOFCOM promulgated the </font><font style="font-style:italic;letter-spacing:0.2pt;">Administrative Measures on Overseas Investments</font><font style="letter-spacing:0.2pt;">, which took effect as of October&#160;6, 2014. According to this regulation, overseas investments of PRC enterprises that involve non-sensitive countries and regions and non-sensitive industries are subject to record-filing requirements with a local MOFCOM branch. According to the </font><font style="font-style:italic;letter-spacing:0.2pt;">Circular of the State Administration of Foreign Exchange on Issuing the Regulations on Foreign Exchange Administration of the Overseas Direct Investment of Domestic Institutions</font><font style="letter-spacing:0.2pt;">, which was promulgated by SAFE on July&#160;13, 2009 and took effect on August&#160;1, 2009, PRC enterprises must register for overseas direct investment with a local SAFE branch. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may not be fully informed of the identities of all our shareholders or beneficial owners who are PRC entities, and we cannot provide any assurance that all of our shareholders and beneficial owners who are PRC entities has or will comply with our request to complete the overseas direct investment procedures under the aforementioned regulations or other related rules in a timely manner, or at all. If they fail to complete the filings or registrations required by the overseas direct investment regulations, the relevant authorities may order them to suspend or cease the implementation of such investment impose warnings </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">32</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">and sanctions and make corrections within a specified time, or limit our ability to distribute dividends and proceeds to our PRC subsidiary, which may adversely affect our business, financial condition and results of operations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PRC regulation of loans to and direct investment in PRC entities by offshore holding companies and governmental control of currency conversion may delay or prevent us from using the proceeds of our public offering to make loans or additional capital contributions to our PRC subsidiary, which could materially and adversely affect our liquidity and our ability to fund and expand our business.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are an offshore holding company conducting our operations in China through our PRC subsidiary. We also hold certain intellectual properties and outsource certain research and development activities related to these intellectual properties to our subsidiaries. We may in the future make loans or provide guarantee to our PRC subsidiary subject to the approval or registration from governmental authorities and limitation of amount, or we may make additional capital contributions to our wholly foreign-owned subsidiary in China. Any loans to our wholly foreign-owned subsidiary in China, which are treated as foreign-invested enterprises under PRC law, are subject to foreign exchange loan registrations. In addition, a foreign-invested enterprise, or FIE, shall use its capital pursuant to the principle of authenticity and self-use within its business scope. The capital of an FIE shall not be used for the following purposes: (i)&#160;directly or indirectly used for payment beyond the business scope of the enterprises or the payment prohibited by relevant laws and regulations; (ii)&#160;directly or indirectly used for investment in securities or investments other than banks&#8217; principal-secured products unless otherwise provided by relevant laws and regulations; (iii)&#160;the granting of loans to non-affiliated enterprises, except where it is expressly permitted in the business license; and (iv)&#160;paying the expenses related to the purchase of real estate that is not for self-use (except for the foreign-invested real estate enterprises). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In light of the various requirements imposed by PRC regulations on loans to and direct investment in PRC entities by offshore holding companies, we cannot assure you that we will be able to complete the necessary government registrations or obtain the necessary government approvals on a timely basis, if at all, with respect to future loans by us to our PRC subsidiary or with respect to future capital contributions by us to our PRC subsidiary. If we fail to complete such registrations or obtain such approvals, our ability to use the proceeds from our public offering and to capitalize or otherwise fund our PRC operations may be negatively affected, which could materially and adversely affect our liquidity and our ability to fund and expand our business. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We may rely on dividends and other distributions on equity paid by our PRC subsidiary to fund any cash and financing requirements we may have, and any limitation on the ability of our PRC subsidiary to make payments to us could have a material and adverse effect on our ability to conduct our business.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are a Cayman Islands holding company and we rely principally on dividends and other distributions on equity from our PRC subsidiary for our cash requirements, including the funds necessary to pay dividends and other cash distributions to our shareholders for services of any debt we may incur. If our PRC subsidiary incurs debt on its own behalf in the future, the instruments governing the debt may restrict its ability to pay dividends or make other distributions to us. Under PRC laws and regulations, our PRC subsidiary, which is a wholly foreign-owned enterprise, may pay dividends only out of its respective accumulated profits as determined in accordance with PRC accounting standards and regulations. In addition, a wholly foreign-owned enterprise is required to set aside at least 10% of its accumulated after-tax profits each year, if any, to fund a certain statutory reserve fund, until the aggregate amount of such fund reaches 50% of its registered capital. Such reserve funds cannot be distributed to us as dividends. At its discretion, a wholly foreign-owned enterprise may allocate a portion of its after-tax profits based on PRC accounting standards to an enterprise expansion fund, or a staff welfare and bonus fund. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A portion of our revenue was generated by our PRC subsidiary in Renminbi, which is not freely convertible into other currencies. As a result, any restriction on currency exchange may limit the ability of our PRC subsidiary to use its Renminbi revenues to pay dividends to us. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The PRC government may continue to strengthen its capital controls, and more restrictions and substantial vetting process may be put forward by SAFE for cross-border transactions falling under both the current account and the capital account. Any limitation on the ability of our PRC subsidiary to pay </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">33</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">dividends or make other kinds of payments to us could materially and adversely limit our ability to grow, make investments or acquisitions that could be beneficial to our business, pay dividends, or otherwise fund and conduct our business. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, the Enterprise Income Tax Law and its implementation rules provide that a withholding tax rate of up to 10% will be applicable to dividends payable by Chinese companies to non-PRC-resident enterprises unless otherwise exempted or reduced according to treaties or arrangements between the PRC central government and governments of other countries or regions where the non-PRC-resident enterprises are incorporated. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Fluctuations in exchange rates could have a material adverse effect on our results of operations and the value of your investment.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The value of the Renminbi against the U.S. dollar and other currencies may fluctuate and is affected by, among other things, changes in political and economic conditions in China and by China&#8217;s foreign exchange policies. On July&#160;21, 2005, the PRC government changed its policy of pegging the value of the Renminbi to the U.S. dollar, and the Renminbi appreciated more than 20% against the U.S. dollar over the following three&#160;years. Between July&#160;2008 and June&#160;2010, this appreciation halted and the exchange rate between the Renminbi and the U.S. dollar remained within a narrow band. Since June&#160;2010, the Renminbi has fluctuated against the U.S. dollar, at times significantly and unpredictably. Since October&#160;1, 2016, Renminbi has joined the International Monetary Fund&#8217;s basket of currencies that make up the Special Drawing Right, or SDR, along with the U.S. dollar, the Euro, the Japanese yen and the British pound. In the fourth quarter of 2016, the Renminbi has depreciated significantly in the backdrop of a surging U.S. dollar and persistent capital outflows of China. With the development of the foreign exchange market and progress towards interest rate liberalization and Renminbi internationalization, the PRC government may in the future announce further changes to the exchange rate system, and we cannot assure you that the Renminbi will not appreciate or depreciate significantly in value against the U.S. dollar in the future. It is difficult to predict how market forces or PRC or U.S. government policy may impact the exchange rate between the Renminbi and the U.S. dollar in the future. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Significant revaluation of the Renminbi may have a material and adverse effect on your investment. For example, to the extent that we need to convert U.S. dollars we receive from our public offering into Renminbi for our operations, appreciation of the Renminbi against the U.S. dollar would have an adverse effect on the Renminbi amount we would receive from the conversion. Conversely, if we decide to convert our Renminbi into U.S. dollars for the purpose of making payments for dividends on our ordinary shares or the ADSs or for other business purposes, appreciation of the U.S. dollar against the Renminbi would have a negative effect on the U.S. dollar amount available to us. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Very limited hedging options are available in China to reduce our exposure to exchange rate fluctuations. To date, we have not entered into any hedging transactions in an effort to reduce our exposure to foreign currency exchange risk. While we may decide to enter into hedging transactions in the future, the availability and effectiveness of these hedges may be limited and we may not be able to adequately hedge our exposure or at all. In addition, our currency exchange losses may be magnified by PRC exchange control regulations that restrict our ability to convert Renminbi into foreign currency. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Governmental control of currency conversion may limit our ability to utilize our cash balance effectively and affect the value of your investment.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The PRC government imposes controls on the convertibility of the Renminbi into foreign currencies and, in certain cases, the remittance of currency out of China. In the&#160;years ended December&#160;31, 2021, we did not receive any of our revenues in Renminbi in cash. Under our current corporate structure, our Cayman Islands holding company primarily relies on previous rounds of private financing to fund any cash and financing requirements we may have. Under existing PRC foreign exchange regulations, payments of current account items, including profit distributions, interest payments and trade and service-related foreign exchange transactions, can be made in foreign currencies without prior approval of SAFE by complying with applicable laws and regulations, as well as certain procedural requirements. Specifically, under the existing exchange restrictions, without prior approval of SAFE, cash generated from the operations of our PRC subsidiary may be used to pay dividends to our company. However, approval from or registration with </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">34</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">appropriate government authorities is required where Renminbi is to be converted into foreign currency and remitted out of China to pay capital expenses such as the repayment of loans denominated in foreign currencies. As a result, we need to obtain SAFE approval to use the cash generated from the operations of our PRC subsidiary to pay off their respective debt in a currency other than Renminbi owed to entities outside China, or to make other capital expenditure payments outside China in a currency other than Renminbi. The PRC government may at its discretion restrict access to foreign currencies for current account transactions in the future. If the foreign exchange control system prevents us from obtaining sufficient foreign currencies to satisfy our foreign currency demands, we may not be able to pay dividends in foreign currencies to our shareholders, including holders of the ADSs. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to the ADSs</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Although we believe we were not a passive foreign investment company, or PFIC, for 2021, due to our ADSs&#8217; price fluctuations there is a significant risk that we will be a PFIC for 2022 or any future taxable year, which could subject U.S. investors in our ADSs or ordinary shares to significant adverse U.S. federal income tax consequences.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In general, a non-U.S. corporation will be a PFIC for any taxable year in which (i)&#160;75% or more of its gross income consists of passive income, or the income test, or (ii)&#160;50% or more of the average value of its assets (generally determined on a quarterly basis) consists of assets that produce, or are held for the production of, passive income, or the asset test. For purposes of the above calculations, a non-U.S. corporation that directly or indirectly owns at least 25% by value of the ordinary shares of another corporation is treated as if it held its proportionate share of the assets of the other corporation and received directly its proportionate share of the income of the other corporation. Passive income generally includes interest, dividends, gains from certain property transactions, rents and royalties (other than certain rents or royalties derived in the active conduct of a trade or business). Cash is generally a passive asset for PFIC purposes. Goodwill is an active asset under the PFIC rules to the extent attributable to activities that produce active income. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The assets shown on our balance sheet are expected to consist primarily of cash and cash equivalents for the foreseeable future. Therefore, whether we will satisfy the asset test for any taxable year will depend largely on the value of our goodwill and on how quickly we utilize the cash in our business. We cannot give any assurance as to whether we will be a PFIC for any taxable year because (i)&#160;the value of our goodwill may be determined by reference to our market capitalization, which has been, and may continue to be, volatile, (ii)&#160;we expect to hold a significant amount of cash, and (iii)&#160;a company&#8217;s PFIC status is an annual factual determination that can be made only after the end of each taxable year and depends on the composition of its income and assets and the value of its assets from time to time. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Based on the average price of our ADSs during 2021, we believe that we were not a PFIC for our taxable year ended December&#160;31, 2021. However, while we hold a substantial amount of cash and cash equivalents our PFIC status for any taxable year will depend primarily on the average value of our goodwill. Because our market capitalization has declined substantially since our initial public offering (including in recent&#160;months), if the value of our goodwill is determined by reference to our market capitalization there is a significant risk that we will be a PFIC for our taxable year 2022, and possibly future taxable&#160;years. In addition, prior to the commercialization of our product candidates, we could be a PFIC for any taxable year in which our interest and other investment income constitutes 75% or more of our total gross income. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If we are a PFIC for any taxable year during which a U.S. investor owns our ADSs or ordinary shares, the U.S. taxpayer generally will be subject to adverse U.S. federal income tax consequences, including increased tax liability on disposition gains and &#8220;excess distributions,&#8221; and additional reporting requirements. This will generally continue to be the case even if we ceased to be a PFIC in a later taxable year, unless certain elections are made. For further discussion of the PFIC rules, see &#8220;Item&#160;10 Additional Information&#8201;&#8212;&#8201; Taxation&#8201;&#8212;&#8201;Material U.S. Federal Income Tax Consequences&#8201;&#8212;&#8201;Passive Foreign Investment Company Rules&#8221; in our annual report on Form 20-F for the year ended December&#160;31, 2021, incorporated here by reference. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Whether or not we will be treated as a PFIC with respect to a particular U.S. investor will depend on whether the U.S. investors owns our ADSs or ordinary share&#160;years during a taxable year in which we are a </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">35</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:404pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">PFIC. The applicable prospectus supplement will describe any changes in fact relevant to the determination of our PFIC status between the date of this registration statement and the date of such prospectus supplement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If a U.S. person is treated as owning 10% or more of our stock by vote or value, such person may be subject to adverse U.S. federal income tax consequences.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If a U.S. person is treated as owning (directly, indirectly or constructively) 10% or more of our stock (including our ADSs and ordinary shares) by value or voting power, such person generally will be treated as a &#8220;United States shareholder&#8221; with respect to each &#8220;controlled foreign corporation&#8221;, or CFC, in our group. A CFC is a non-U.S. corporation more than 50% of the stock (by voting power or value) of which is owned (directly, indirectly or constructively) by &#8220;United States shareholders.&#8221; We have not determined whether we are a CFC. However, even if we are not a CFC, under certain ownership attribution rules our non-U.S. subsidiaries could be treated as owned by our U.S. subsidiary and thus may be treated as CFCs. A&#160;United States shareholder of a CFC may be subject to additional U.S. federal income tax liabilities and reporting requirements. We do not intend to furnish to any information that may be necessary for United States shareholders, if any, to comply with the CFC rules. Prospective U.S. investors that may be treated for purposes of the CFC rules as owning 10% of our stock by voting power or value should consult their tax advisers regarding the potential application of these rules in their particular circumstances.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">36</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tCNRF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus contains forward-looking statements that reflect our current expectations and views of future events. All statements other than statements of historical facts are forward-looking statements. These forward-looking statements are made under the &#8220;safe harbor&#8221; provision under Section&#160;21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and as defined in the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks, uncertainties and other factors, including but not limited to Adagene&#8217;s ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development or regulatory approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of Adagene&#8217;s drug candidates; Adagene&#8217;s ability to achieve commercial success for its drug candidates, if approved; Adagene&#8217;s ability to obtain and maintain protection of intellectual property for its technology and drugs; Adagene&#8217;s reliance on third parties to conduct drug development, manufacturing and other services; Adagene&#8217;s limited operating history and Adagene&#8217;s ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; Adagene&#8217;s ability to enter into additional collaboration agreements beyond its existing strategic partnerships or collaborations, and the impact of the COVID-19 pandemic on Adagene&#8217;s clinical development, commercial and other operations, as well as those risks more fully discussed in the &#8220;Risk Factors&#8221; section in Adagene&#8217;s filings with the SEC. Such known and unknown risks, uncertainties and other factors may cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. In some cases, you can identify these forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;aim,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;is/are likely to,&#8221; &#8220;potential,&#8221; &#8220;continue&#8221; or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements include, but are not limited to, statements about: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our goals and growth strategies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our future business development, results of operations and financial condition; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.09pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.09pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the timing of the initiation, progress and potential results of our preclinical studies, clinical trials and our discovery programs; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to utilize our proprietary Dynamic Precision Library platform, or DPL, to design, construct and develop next-generation antibodies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to advance product candidates into, and successfully complete, clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the timing or likelihood of regulatory filings and approvals; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our estimates of the number of patients who suffer from the diseases we are targeting and the number of patients that may enroll in our clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the commercializing of our product candidates, if approved; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability and the potential to successfully manufacture and supply our product candidates for clinical trials and for commercial use, if approved; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">future strategic arrangements and/or collaborations and the potential benefits of such arrangements; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our anticipated use of our existing resources and the proceeds from our initial public offering; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing and our ability to obtain additional capital; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure requirements; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to retain the continued service of our key personnel and to identify, hire and retain additional qualified professionals; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the implementation of our business model, strategic plans for our business and product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">37</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:144pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the scope of protection we are able to establish and maintain for intellectual property rights, such as our proprietary DPL, which includes NEObody platform, SAFEbody platform and POWERbody platform, product candidates and discovery programs; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our potential to enter into new collaborations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the pricing, coverage and reimbursement of our product candidates, if approved; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">developments relating to our competitors and our industry, including competing product candidates and therapies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the direct and indirect impact of the COVID-19 pandemic on our business and operations and on development of our clinical and preclinical programs, and the duration and impact of COVID-19 or any of its variants that may affect, precipitate or exacerbate one or more of any of the risks and uncertainties mentioned in this annual report; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">relevant government policies and regulations relating to our business and industry; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">general economic and business condition in the markets we have businesses; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">assumptions underlying or related to any of the foregoing. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We would like to caution you not to place undue reliance on these forward-looking statements and you should read these statements in conjunction with the risk factors disclosed in &#8220;Item&#160;3. Key Information&#8201;&#8212;&#8201;</font>
          <br >
          <font style="letter-spacing:0.2pt;">D. Risk Factors&#8221; in our annual report on Form 20-F for the year ended December&#160;31, 2021, which is incorporated in this prospectus by reference, and other risks outlined in our other filings with the Securities and Exchange Commission, or the SEC. Those risks are not exhaustive. We operate in an evolving environment. New risks emerge from time to time and it is impossible for our management to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. We qualify all of our forward-looking statements by these cautionary statements. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements contained in or incorporated into this prospectus and any applicable prospectus supplement speak only as of the date of hereof or thereof or of such documents incorporated by reference or, if obtained from third-party studies or reports, the date of the corresponding study or report, and are expressly qualified in their entirety by the cautionary statements in this prospectus, any applicable prospectus supplement and the documents incorporated by reference herein and therein. We do not undertake any obligation to update or revise the forward-looking statements except as required under applicable law. You should read this prospectus and the documents that we reference in this prospectus completely and with the understanding that our actual future results may be materially different from what we expect. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">38</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tUOP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:548pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">USE OF PROCEEDS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">Unless the applicable prospectus supplement states otherwise, the net proceeds from the sale of Securities offered by our company will be used to fund research and development activities and for general corporate purposes, which may include additions to working capital, capital expenditures, financing of acquisitions and other business combinations, investments in or extensions of credit to our subsidiaries and the repayment of indebtedness. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">39</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tCAI">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:584pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">CAPITALIZATION AND INDEBTEDNESS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">Our capitalization and indebtedness will be set forth in a prospectus supplement to this prospectus or in a report subsequently furnished to the SEC and specifically incorporated herein by reference.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">40</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tDOSC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DESCRIPTION OF SHARE CAPITAL AND MEMORANDUM AND ARTICLES OF ASSOCIATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following is a summary of our share capital and certain provisions of our amended and restated memorandum and articles of association. This summary does not purport to be complete and is qualified in its entirety by the provisions of our amended and restated memorandum and articles of association and applicable provisions of the laws of the Cayman Islands. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">See &#8220;Where You Can Find More Information&#8221; elsewhere in this prospectus for information on where you can obtain copies of our articles of incorporation and our bylaws, which have been filed with and are publicly available from the SEC. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of the date of this prospectus, our authorized share capital is US$80,000 divided into 800,000,000 shares comprising (i)&#160;640,000,000 ordinary shares of a par value of US$0.0001 each, and (ii)&#160;160,000,000 shares of a par value of US$0.0001 each of such class or classes (however designated) as our board of directors may determine in accordance with our amended and restated memorandum and articles of association. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Memorandum and Articles of Association</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">General.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Holders of ordinary shares have the same rights. All of our issued and outstanding ordinary shares are fully paid and non-assessable. Certificates representing the ordinary shares are issued in registered form. We may not issue share to bearer. Our shareholders who are nonresidents of the Cayman Islands may freely hold, transfer and vote their ordinary shares. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Dividends.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The holders of our ordinary shares are entitled to such dividends as may be declared by our board of directors subject to our amended and restated memorandum and articles of association and the Companies Act. In addition, our shareholders may, subject to the provisions of our articles of association, by ordinary resolution declare a dividend, but no dividend may exceed the amount recommended by our directors. Our amended and restated memorandum and articles of association provide that dividends may be declared and paid out of our profits, realized or unrealized, or from any reserve set aside from profits which our board of directors determine is no longer needed. Dividends may also be declared and paid out of the share premium account or any other fund or account which can be authorized for this purpose in accordance with the Companies Act. No dividend may be declared and paid unless our directors determine that, immediately after the payment, we will be able to pay our debts as they become due in the ordinary course of business and we have funds lawfully available for such purpose. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Voting Rights.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;In respect of all matters subject to a shareholders&#8217; vote, holder of an ordinary share is entitled to one vote for each ordinary share registered in his or her name on our register of members. Voting at any meeting of shareholders is by way of a poll unless a show of hands is permitted. A poll may be demanded by the chairman of such meeting or any one shareholder. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A quorum required for a meeting of shareholders consists of two or more shareholders holding not less than one-half of the votes attaching to the issued and outstanding shares entitled to vote at general meetings present in person or by proxy or, if a corporation or other non-natural person, by its duly authorized representative. As a Cayman Islands exempted company, we are not obliged by the Companies Act to call shareholders&#8217; annual general meetings. Our amended and restated memorandum and articles of association provide that we may (but are not obliged to) in each year hold a general meeting as our annual general meeting in which case we will specify the meeting as such in the notices calling it, and the annual general meeting will be held at such time and place as may be determined by our board of directors. We, however, will hold an annual shareholders&#8217; meeting during each fiscal year, as required by the Listing Rules of the Nasdaq Global Market. Each general meeting, other than an annual general meeting, shall be an extraordinary general meeting. Shareholders&#8217; annual general meetings and any other general meetings of our shareholders may be called by a majority of our board of directors or our chairman or upon a requisition of shareholders holding at the date of deposit of the requisition not less than 20% of the votes attaching to the issued and outstanding shares entitled to vote at general meetings, in which case the directors are obliged to call such meeting and to put the resolutions so requisitioned to a vote at such meeting; however, our post-offering memorandum and articles of association do not provide our shareholders with any right to put any proposals before annual general meetings or extraordinary general meetings not called by such </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">41</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">shareholders. Advance notice of at least seven (7)&#160;days is required for the convening of our annual general meeting and other general meetings in accordance with our amended and restated memorandum and articles of association. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">An ordinary resolution to be passed at a meeting by the shareholders requires the affirmative vote of a simple majority of the votes attaching to the ordinary shares cast by those shareholders entitled to vote who are present in person or by proxy at a general meeting, while a special resolution also requires the affirmative vote of no less than two-thirds of the votes attaching to the ordinary shares cast by those shareholders entitled to vote who are present in person or by proxy at a general meeting. A special resolution will be required for important matters such as a change of name or making changes to our amended and restated memorandum and articles of association. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Transfer of Ordinary Shares.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Subject to the restrictions in our amended and restated memorandum and articles of association as set out below, any of our shareholders may transfer all or any of his or her ordinary shares by an instrument of transfer in the usual or common form or any other form approved by our board of directors. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our board of directors may, in its absolute discretion, decline to register any transfer of any ordinary share. Our board of directors may also decline to register any transfer of any ordinary share unless: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the instrument of transfer is lodged with us, accompanied by the certificate for the ordinary shares to which it relates and such other evidence as our board of directors may reasonably require to show the right of the transferor to make the transfer; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the instrument of transfer is in respect of only one class of shares; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the instrument of transfer is properly stamped, if required; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">in the case of a transfer to joint holders, the number of joint holders to whom the ordinary share is to be transferred does not exceed four; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the shares are free from any lien in favor of us; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a fee of such maximum sum as the Nasdaq may determine to be payable or such lesser sum as our directors may from time to time require is paid to us in respect thereof. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If our directors refuse to register a transfer, they shall, within three&#160;months after the date on which the instrument of transfer was lodged, send to each of the transferor and the transferee notice of such refusal. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The registration of transfers may, after compliance with any notice requirement of the Nasdaq, be suspended and the register closed at such times and for such periods as our board of directors may from time to time determine, </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, </font><font style="font-style:italic;letter-spacing:0.2pt;">however</font><font style="letter-spacing:0.2pt;">, that the registration of transfers shall not be suspended nor the register closed for more than 30&#160;days in any year as our board may determine. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Liquidation.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;On a return of capital on winding up or otherwise (other than on conversion, redemption or purchase of ordinary shares), if the assets available for distribution amongst our shareholders shall be more than sufficient to repay the whole of the share capital at the commencement of the winding up, the surplus shall be distributed amongst our shareholders in proportion to the par value of the shares held by them at the commencement of the winding up, subject to a deduction from those shares in respect of which there are monies due, of all monies payable to our company for unpaid calls or otherwise. If our assets available for distribution are insufficient to repay all of the paid-up capital, the assets will be distributed so that the losses are borne by our shareholders in proportion to the par value of the shares held by them. Any distribution of assets or capital to a holder of ordinary shares will be the same in any liquidation event. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Calls on Ordinary Shares and Forfeiture of Ordinary Shares.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Our board of directors may from time to time make calls upon shareholders for any amounts unpaid on their ordinary shares in a notice served to such shareholders at least 14 clear days prior to the specified time of payment. The ordinary shares that have been called upon and remain unpaid are subject to forfeiture. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Redemption, Repurchase and Surrender of Ordinary Shares.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;We may issue shares on terms that such shares are subject to redemption, at our option or at the option of the holders thereof, on such terms and in such manner as may be determined, before the issue of such shares, by our board of directors or by an </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">42</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">ordinary resolution of our shareholders. Our company may also repurchase any of our shares provided that the manner and terms of such purchase have been approved by our board of directors or by an ordinary resolution of our shareholders, or are otherwise authorized by our post-offering memorandum and articles of association. Under the Companies Act, the redemption or repurchase of any share may be paid out of our company&#8217;s profits or out of the proceeds of a fresh issue of shares made for the purpose of such redemption or repurchase, or out of capital (including share premium account and capital redemption reserve) if the Company can, immediately following such payment, pay its debts as they fall due in the ordinary course of business. In addition, under the Companies Act no such share may be redeemed or repurchased (a)&#160;unless it is fully paid up, (b)&#160;if such redemption or repurchase would result in there being no shares outstanding, or (c)&#160;if the company has commenced liquidation. In addition, our company may accept the surrender of any fully paid share for no consideration. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Variations of Rights of Shares.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;If at any time our share capital is divided into different classes or series of shares, the rights attached to any class or series of shares (unless otherwise provided by the terms of issue of the shares of that class or series), whether or not our company is being wound-up, may be varied with the consent in writing of holders of not less than a majority of the issued shares of that class or series or with the sanction of a special resolution at a separate meeting of the holders of the shares of the class or series. The rights conferred upon the holders of the shares of any class issued shall not, unless otherwise expressly provided by the terms of issue of the shares of that class, be deemed to be varied by the creation or issue of further shares ranking </font><font style="font-style:italic;letter-spacing:0.2pt;">pari&#160;passu</font><font style="letter-spacing:0.2pt;"> with such existing class of shares. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Inspection of Books and Records.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Holders of our ordinary shares have no general right under Cayman Islands law to inspect or obtain copies of our list of shareholders or our corporate records. However, we will provide our shareholders with annual audited financial statements. See &#8220;Where You Can Find More Information.&#8221; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Issuance of Additional Shares.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Our amended and restated memorandum and articles of association authorizes our board of directors to issue additional ordinary shares from time to time as our board of directors shall determine, to the extent of available authorized but unissued shares. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our amended and restated memorandum and articles of association also authorizes our board of directors to establish from time to time one or more series of preferred shares and to determine, with respect to any series of preferred shares, the terms and rights of that series, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the designation of the series; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the number of shares of the series; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the dividend rights, dividend rates, conversion rights, voting rights; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the rights and terms of redemption and liquidation preferences. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our board of directors may issue preferred shares without action by our shareholders to the extent authorized but unissued. Issuance of these shares may dilute the voting power of holders of ordinary shares. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Anti-Takeover Provisions.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Some provisions of our amended and restated memorandum and articles of association may discourage, delay or prevent a change of control of our company or management that shareholders may consider favorable, including provisions that authorize our board of directors to issue preferred shares in one or more series and to designate the price, rights, preferences, privileges and restrictions of such preferred shares without any further vote or action by our shareholders. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Changes in Capital.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may from time to time by ordinary resolution: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">increase the share capital by such sum, to be divided into shares of such classes and amount, as the resolution shall prescribe; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">consolidate and divide all or any of our share capital into shares of a larger amount than our existing shares; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">43</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">sub-divide our existing shares, or any of them into shares of a smaller amount; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">cancel any shares which, at the date of the passing of the resolution, have not been taken or agreed to be taken by any person and diminish the amount of our share capital by the amount of the shares so canceled. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may by special resolution, subject to any confirmation or consent required by the Companies Act, reduce our share capital or any capital redemption reserve in any manner permitted by law. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Exempted Company.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;We are an exempted company with limited liability under the Companies Act. The Companies Act distinguishes between ordinary resident companies and exempted companies. Any company that is registered in the Cayman Islands but conducts business mainly outside of the Cayman Islands may apply to be registered as an exempted company. The requirements for an exempted company are essentially the same as for an ordinary company except that an exempted company: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">does not have to file an annual return of its shareholders with the Registrar of Companies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">is not required to open its register of members for inspection; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">does not have to hold an annual general meeting; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">may issue shares with no par value; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">may obtain an undertaking against the imposition of any future taxation (such undertakings are usually given for 30&#160;years in the first instance); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">may register by way of continuation in another jurisdiction and be deregistered in the Cayman Islands; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">may register as a limited duration company; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">may register as a segregated portfolio company. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;Limited liability&#8221; means that the liability of each shareholder is limited to the amount unpaid by the shareholder on that shareholder&#8217;s shares of the company. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Register of Members</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under the Companies Act, we must keep a register of members and there should be entered therein: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the names and addresses of our members, and a statement of the shares held by each member, which shall include: (i)&#160;the amount paid or agreed to be considered as paid on the shares of each member, (ii)&#160;the number and category of shares held by each member, and (iii)&#160;whether each relevant category of shares held by a member carries voting rights under the post-offering memorandum and articles of association, and if so, whether such voting rights are conditional; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the date on which the name of any person was entered on the register as a member; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.01pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the date on which any person ceased to be a member. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under the Companies Act, the register of members of our company is prima facie evidence of the matters set out therein (that is, the register of members will raise a presumption of fact on the matters referred to above unless rebutted) and a member registered in the register of members is deemed as a matter of the Companies Act to have legal title to the shares as set against its name in the register of members. Upon completion of this offering, we will perform the procedure necessary to immediately update the register of members to record and give effect to the issuance of shares by us to the Depositary (or its nominee) as the depositary. Once our register of members has been updated, the shareholders recorded in the register of members will be deemed to have legal title to the shares set against their name. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If the name of any person is incorrectly entered in or omitted from our register of members, or if there is any default or unnecessary delay in entering on the register the fact of any person having ceased to be a member of our company, the person or member aggrieved (or any member of our company or our company itself) may apply to the Grand Court of the Cayman Islands for an order that the register be rectified, and the Court may either refuse such application or it may, if satisfied of the justice of the case, make an order for the rectification of the register. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">44</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Differences in Corporate Law</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Companies Act is derived, to a large extent, from the older Companies Acts of England, but does not follow many recent English law statutory enactments. In addition, the Companies Act differs from laws applicable to United States corporations and their shareholders. Set forth below is a summary of the significant differences between the provisions of the Companies Law applicable to us and the laws applicable to companies incorporated in the State of Delaware. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Mergers and Similar Arrangements.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The Companies Act permits mergers and consolidations between Cayman Islands companies and between Cayman Islands companies and non-Cayman Islands companies. For these purposes, (a)&#160;&#8220;merger&#8221; means the merging of two or more constituent companies and the vesting of their undertaking, property and liabilities in one of such companies as the surviving company, and (b)&#160;a &#8220;consolidation&#8221; means the combination of two or more constituent companies into a consolidated company and the vesting of the undertaking, property and liabilities of such companies to the consolidated company. In order to effect such a merger or consolidation, the directors of each constituent company must approve a written plan of merger or consolidation, which must then be authorized by (a)&#160;a special resolution of the shareholders of each constituent company, and (b)&#160;such other authorization, if any, as may be specified in such constituent company&#8217;s articles of association. The written plan of merger or consolidation must be filed with the Registrar of Companies of the Cayman Islands together with a declaration as to the solvency of the consolidated or surviving company, a declaration as to the assets and liabilities of each constituent company and an undertaking that a copy of the certificate of merger or consolidation will be given to the members and creditors of each constituent company and that notification of the merger or consolidation will be published in the Cayman Islands Gazette. Court approval is not required for a merger or consolidation which is effected in compliance with these statutory procedures. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A merger between a Cayman parent company and its Cayman subsidiary or subsidiaries does not require authorization by a resolution of shareholders of that Cayman subsidiary if a copy of the plan of merger is given to every member of that Cayman subsidiary to be merged unless that member agrees otherwise. For this purpose, a company is a &#8220;parent&#8221; of a subsidiary if it holds issued shares that together represent at least ninety&#160;percent (90%) of the votes at a general meeting of the subsidiary. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The consent of each holder of a fixed or floating security interest over a constituent company is required unless this requirement is waived by a court in the Cayman Islands. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Save in certain limited circumstances, a shareholder of a Cayman constituent company who dissents from the merger or consolidation is entitled to payment of the fair value of his shares (which, if not agreed between the parties, will be determined by the Cayman Islands court) upon dissenting to the merger or consolidation, provided that the dissenting shareholder complies strictly with the procedures set out in the Companies Act. The exercise of dissenter rights will preclude the exercise by the dissenting shareholder of any other rights to which he or she might otherwise be entitled by virtue of holding shares, save for the right to seek relief on the grounds that the merger or consolidation is void or unlawful. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Separate from the statutory provisions relating to mergers and consolidations, the Companies Act also contains statutory provisions that facilitate the reconstruction and amalgamation of companies by way of schemes of arrangement, provided that the arrangement is approved by a majority in number of each class of shareholders and creditors with whom the arrangement is to be made, and who must in addition represent three- fourths in value of each such class of shareholders or creditors, as the case may be, that are present and voting either in person or by proxy at a meeting, or meetings, convened for that purpose. The convening of the meetings and subsequently the arrangement must be sanctioned by the Grand Court of the Cayman Islands. While a dissenting shareholder has the right to express to the court the view that the transaction ought not to be approved, the court can be expected to approve the arrangement if it determines that: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the statutory provisions as to the required majority vote have been met; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the shareholders have been fairly represented at the meeting in question and the statutory majority are acting bona fide without coercion of the minority to promote interests adverse to those of the class; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the arrangement is such that may be reasonably approved by an intelligent and honest man of that class acting in respect of his interest; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">45</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the arrangement is not one that would more properly be sanctioned under some other provision of the Companies Act. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Companies Act also contains a statutory power of compulsory acquisition which may facilitate the &#8220;squeeze out&#8221; of a dissenting minority shareholder upon a tender offer. When a tender offer is made and accepted by holders of 90.0% of the shares affected within four&#160;months, the offeror may, within a two-month period commencing on the expiration of such four-month period, require the holders of the remaining shares to transfer such shares to the offeror on the terms of the offer. An objection can be made to the Grand Court of the Cayman Islands but this is unlikely to succeed in the case of an offer which has been so approved unless there is evidence of fraud, bad faith or collusion. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If an arrangement and reconstruction is thus approved, or if a tender offer is made and accepted, a dissenting shareholder would have no rights comparable to appraisal rights, which would otherwise ordinarily be available to dissenting shareholders of Delaware corporations, providing rights to receive payment in cash for the judicially determined value of the shares. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Shareholders&#8217; Suits.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;In principle, we will normally be the proper plaintiff to sue for a wrong done to us as a company, and as a general rule a derivative action may not be brought by a minority shareholder. However, based on English authorities, which would in all likelihood be of persuasive authority in the Cayman Islands, the Cayman Islands court can be expected to follow and apply the common law principles (namely the rule in </font><font style="font-style:italic;letter-spacing:0.2pt;">Foss v. Harbottle</font><font style="letter-spacing:0.2pt;"> and the exceptions thereto) which permit a minority shareholder to commence a class action against or derivative actions in the name of the company to challenge actions where: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a company acts or proposes to act illegally or ultra vires; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the act complained of, although not ultra vires, could only be effected duly if authorized by more than a simple majority vote that has not been obtained; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">those who control the company are perpetrating a &#8220;fraud on the minority.&#8221; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Indemnification of Directors and Executive Officers and Limitation of Liability.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Cayman Islands law does not limit the extent to which a company&#8217;s memorandum and articles of association may provide for indemnification of officers and directors, except to the extent any such provision may be held by the Cayman Islands courts to be contrary to public policy, such as to provide indemnification against civil fraud or the consequences of committing a crime. Our post-offering memorandum and articles of association provide that that we shall indemnify our officers and directors against all actions, proceedings, costs, charges, expenses, losses, damages or liabilities incurred or sustained by such directors or officer, other than by reason of such person&#8217;s dishonesty, willful default or fraud, in or about the conduct of our company&#8217;s business or affairs (including as a result of any mistake of judgment) or in the execution or discharge of his duties, powers, authorities or discretions, including without prejudice to the generality of the foregoing, any costs, expenses, losses or liabilities incurred by such director or officer in defending (whether successfully or otherwise) any civil proceedings concerning our company or its affairs in any court whether in the Cayman Islands or elsewhere. This standard of conduct is generally the same as permitted under the Delaware General Corporation Law for a Delaware corporation. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, we have entered into indemnification agreements with our directors and executive officers that provide such persons with additional indemnification beyond that provided in our post-offering memorandum and articles of association. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers or persons controlling us under the foregoing provisions, we have been informed that in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Directors&#8217; Fiduciary Duties.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Under Delaware corporate law, a director of a Delaware corporation has a fiduciary duty to the corporation and its shareholders. This duty has two components: the duty of care and the duty of loyalty. The duty of care requires that a director act in good faith, with the care that an ordinarily prudent person would exercise under similar circumstances. Under this duty, a director must inform himself of, and disclose to shareholders, all material information reasonably available regarding a significant </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">46</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">transaction. The duty of loyalty requires that a director acts in a manner he reasonably believes to be in the best interests of the corporation. He must not use his corporate position for personal gain or advantage. This duty prohibits self-dealing by a director and mandates that the best interest of the corporation and its shareholders take precedence over any interest possessed by a director, officer or controlling shareholder and not shared by the shareholders generally. In general, actions of a director are presumed to have been made on an informed basis, in good faith and in the honest belief that the action taken was in the best interests of the corporation. However, this presumption may be rebutted by evidence of a breach of one of the fiduciary duties. Should such evidence be presented concerning a transaction by a director, the director must prove the procedural fairness of the transaction, and that the transaction was of fair value to the corporation. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">As a matter of Cayman Islands law, a director of a Cayman Islands company is in the position of a fiduciary with respect to the company and therefore it is considered that he owes the following duties to the company&#8201;&#8212;&#8201;a duty to act bona fide in the best interests of the company, a duty not to make a profit based on his position as director (unless the company permits him to do so), a duty not to put himself in a position where the interests of the company conflict with his personal interest or his duty to a third party, and a duty to exercise powers for the purpose for which such powers were intended. A director of a Cayman Islands company owes to the company a duty to act with skill and care. It was previously considered that a director need not exhibit in the performance of his duties a greater degree of skill than may reasonably be expected from a person of his knowledge and experience. However, English and Commonwealth courts have moved towards an objective standard with regard to the required skill and care and these authorities are likely to be followed in the Cayman Islands. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">Under our post-offering memorandum and articles of association, directors who are in any way, whether directly or indirectly, interested in a contract or proposed contract with our company must declare the nature of their interest at a meeting of the board of directors. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Shareholder Action by Written Consent.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Under the Delaware General Corporation Law, a corporation may eliminate the right of shareholders to act by written consent by amendment to its certificate of incorporation. The Companies Act and our post-offering memorandum and articles of association provide that our shareholders may approve corporate matters by way of a unanimous written resolution signed by or on behalf of each shareholder who would have been entitled to vote on such matter at a general meeting without a meeting being held. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Shareholder Proposals.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Under the Delaware General Corporation Law, a shareholder has the right to put any proposal before the annual meeting of shareholders, provided it complies with the notice provisions in the governing documents. A special meeting may be called by the board of directors or any other person authorized to do so in the governing documents, but shareholders may be precluded from calling special meetings. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">The Companies Act provides shareholders with only limited rights to requisition a general meeting, and does not provide shareholders with any right to put any proposal before a general meeting. However, these rights may be provided in a company&#8217;s articles of association. Our post-offering memorandum and articles of association allow our shareholders holding in aggregate not less than twenty&#160;percent of all votes attaching to the issued and outstanding shares of our company entitled to vote at general meetings to requisition an extraordinary general meeting of our shareholders, in which case our board is obliged to convene an extraordinary general meeting and to put the resolutions so requisitioned to a vote at such meeting. Other than this right to requisition a shareholders&#8217; meeting, our post-offering memorandum and articles of association do not provide our shareholders with any other right to put proposals before annual general meetings or extraordinary general meetings not called by such shareholders. As an exempted Cayman Islands company, we are not obliged by law to call shareholders&#8217; annual general meetings. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Cumulative Voting.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Under the Delaware General Corporation Law, cumulative voting for elections of directors is not permitted unless the corporation&#8217;s certificate of incorporation specifically provides for it. Cumulative voting potentially facilitates the representation of minority shareholders on a board of directors since it permits the minority shareholder to cast all the votes to which the shareholder is entitled on a single director, which increases the shareholder&#8217;s voting power with respect to electing such director. There are no prohibitions in relation to cumulative voting under the laws of the Cayman Islands but our post-offering memorandum and articles of association do not provide for cumulative voting. As a result, our shareholders are not afforded any less protections or rights on this issue than shareholders of a Delaware corporation. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">47</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Removal of Directors.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Under the Delaware General Corporation Law, a director of a corporation with a classified board may be removed only for cause with the approval of a majority of the outstanding shares entitled to vote, unless the certificate of incorporation provides otherwise. Under our post-offering memorandum and articles of association, directors not appointed by Peter Peizhi Luo, JSR Limited, Wuxi Pharmatech Healthcare Fund&#160;I L.P., and General Atlantic Singapore AI Pte. Ltd. may be removed with or without cause, by an ordinary resolution of our shareholders. A director shall hold office until the expiration of his or her term or his or her successor shall have been elected and qualified, or until his or her office is otherwise vacated. In addition, a director&#8217;s office shall be vacated if the director (i)&#160;becomes bankrupt or makes any arrangement or composition with his creditors; (ii)&#160;is found to be or becomes of unsound mind or dies; (iii)&#160;resigns his office by notice in writing to the company; (iv)&#160;without special leave of absence from our board of directors, is absent from three consecutive meetings of the board and the board resolves that his office be vacated; (v)&#160;is prohibited by law or the Listing Rules of the Nasdaq Global Market from being a director; or (vi)&#160;is removed from office pursuant to any other provisions of our post-offering memorandum and articles of association. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Transactions with Interested Shareholders.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The Delaware General Corporation Law contains a business combination statute applicable to Delaware corporations whereby, unless the corporation has specifically elected not to be governed by such statute by amendment to its certificate of incorporation, it is prohibited from engaging in certain business combinations with an &#8220;interested shareholder&#8221; for three&#160;years following the date that such person becomes an interested shareholder. An interested shareholder generally is a person or a group who or which owns or owned 15% or more of the target&#8217;s outstanding voting share within the past three&#160;years. This has the effect of limiting the ability of a potential acquirer to make a two-tiered bid for the target in which all shareholders would not be treated equally. The statute does not apply if, among other things, prior to the date on which such shareholder becomes an interested shareholder, the board of directors approves either the business combination or the transaction which resulted in the person becoming an interested shareholder. This encourages any potential acquirer of a Delaware corporation to negotiate the terms of any acquisition transaction with the target&#8217;s board of directors. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Cayman Islands law has no comparable statute. As a result, we cannot avail ourselves of the types of protections afforded by the Delaware business combination statute. However, although Cayman Islands law does not regulate transactions between a company and its significant shareholders, the directors of the Company are required to comply with fiduciary duties which they owe to the Company under Cayman Islands laws, including the duty to ensure that, in their opinion, any such transactions must be entered into bona fide in the best interests of the company, and are entered into for a proper corporate purpose and not with the effect of constituting a fraud on the minority shareholders. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Dissolution; Winding up.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Under the Delaware General Corporation Law, unless the board of directors approves the proposal to dissolve, dissolution must be approved by shareholders holding 100% of the total voting power of the corporation. Only if the dissolution is initiated by the board of directors may it be approved by a simple majority of the corporation&#8217;s outstanding shares. Delaware law allows a Delaware corporation to include in its certificate of incorporation a supermajority voting requirement in connection with dissolutions initiated by the board. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under Cayman Islands law, a company may be wound up by either an order of the courts of the Cayman Islands or by a special resolution of its members or, if the company is unable to pay its debts as they fall due, by an ordinary resolution of its members. The court has authority to order winding up in a number of specified circumstances including where it is, in the opinion of the court, just and equitable to do so. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Variation of Rights of Shares.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Under the Delaware General Corporation Law, a corporation may vary the rights of a class of shares with the approval of a majority of the outstanding shares of such class, unless the certificate of incorporation provides otherwise. Under Cayman Islands law and our post-offering memorandum and articles of association, if our share capital is divided into more than one class of shares, we may vary the rights attached to any class with the written consent of the holders of not less than a majority of the issued shares of that class or with the sanction of a special resolution passed at a general meeting of the holders of the shares of that class. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">48</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Amendment of Governing Documents.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Under the Delaware General Corporation Law, a corporation&#8217;s governing documents may be amended with the approval of a majority of the outstanding shares entitled to vote, unless the certificate of incorporation provides otherwise. Under the Companies Act and our post-offering memorandum and articles of association, our memorandum and articles of association may only be amended by a special resolution of our shareholders. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Rights of Nonresident or Foreign Shareholders.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;There are no limitations imposed by our post-offering memorandum and articles of association on the rights of nonresident or foreign shareholders to hold or exercise voting rights on our shares. In addition, there are no provisions in our post-offering amended and restated memorandum and articles of association governing the ownership threshold above which shareholder ownership must be disclosed. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">History of Securities Issuances</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following is a summary of securities issuances by Adagene Inc. in the&#160;years ended December&#160;31, 2019, 2020 and 2021. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Ordinary Shares</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the&#160;years ended December&#160;31, 2019, 2020 and 2021, we issued a total of 4,709,313 ordinary shares to employees for an aggregate consideration of US$8.0&#160;million upon the exercise of certain share incentive awards. For the purpose of this paragraph only, such number of shares includes the 1,585,000 ordinary shares, issued but deemed to be not then outstanding to Great Han Fortune LP. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In March&#160;2021, we issued a total of 23,734 ordinary shares to certain senior management for nominal consideration under the 2021 Plan as part of their compensation. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In February&#160;2021, at the closing of our initial public offering, we offered and sold an aggregate of 10,571,375 ordinary shares in the form of ADSs at a public offering price of US$19.00 per ADS. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Upon the completion of our initial public offering in February&#160;2021, all of our then issued and outstanding preferred shares were automatically converted into ordinary shares on a one-for-one basis. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Preferred Shares</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On June&#160;13, 2019, we issued a total of 1,567,260 Series&#160;C-2 Preferred Shares to Mega Prime Development Limited, Poly Platinum Enterprises Limited and Chief Strategic International Limited for an aggregate consideration of US$16.0&#160;million. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On November&#160;21, 2019, we issued 293,861 Series&#160;C-2 Preferred Shares to MODEST CHAMPION LIMITED for a consideration of US$3.0&#160;million. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On December&#160;19, 2019, we issued 4,452,441 Series&#160;C-3 Preferred Shares to General Atlantic Singapore AI Pte. Ltd. for a consideration of US$50.0&#160;million. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Award Grants</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have granted awards to purchase our ordinary shares to certain of our directors, executive officers and employees pursuant to the Second Amended and Restated Share Incentive Plan in December&#160;2019, or the 2019 Plan, and the 2021 Performance Incentive Plan, or the 2021 Plan. As of March&#160;31, 2022, the aggregate number of our ordinary shares underlying our outstanding awards under the 2019 Plan is 2,872,514, excluding awards that were forfeited, cancelled or exercised after the relevant grant dates. The term of the awards will expire not more than ten&#160;years after the date of grant. As of March&#160;31, 2022, we have granted 2,746,732 shares awards under the 2021 Plan. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Share Cancellation</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On January&#160;16, 2021, certain management members surrendered a total of 491,119 ordinary shares for cancellation to settle the balance due under their respective promissory notes issued in connection with the share purchase plans. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">49</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:536pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;font-style:italic;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">Share Repurchase</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">On July&#160;7, 2021, the Board of Directors approved a share repurchase program to repurchase up to US$20&#160;million of outstanding ADSs of the Company, from time to time over a 12-month period from the date on which a formal stock repurchase plan engagement agreement was signed with a qualified broker-dealer. As of December&#160;31, 2021, 236,139 outstanding ADSs representing 295,174 ordinary shares were repurchased with a total consideration of US$2.4&#160;million, among which, 160,880 ADSs representing 201,100 ordinary shares repurchased shares were cancelled. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">50</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tDOW">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:232pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DESCRIPTION OF WARRANTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may issue warrants to purchase ordinary shares or other securities. We may issue warrants independently or together with other securities. Warrants sold with other securities may be attached to or separate from the other securities. We will issue warrants under one or more warrant agreements between our company and a warrant agent that we will name in the applicable prospectus supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The prospectus supplement relating to any warrants we offer will include specific terms relating to the offering. These terms will include some or all of the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the title of the warrants; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the aggregate number of warrants offered; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the designation, number and terms of the ordinary shares or other securities purchasable upon exercise of the warrants and procedures by which those numbers may be adjusted; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the exercise price of the warrants; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the dates or periods during which the warrants are exercisable; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the designation and terms of any securities with which the warrants are issued; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if the warrants are issued as a unit with another security, the date on and after which the warrants and the other security will be separately transferable; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if the exercise price is not payable in U.S. dollars, the foreign currency, currency unit or composite currency in which the exercise price is denominated; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any minimum or maximum amount of warrants that may be exercised at any one time; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any terms relating to the modification of the warrants; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any terms, procedures and limitations relating to the transferability, exchange or exercise of the warrants; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any other specific terms of the warrants. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The terms of any warrants to be issued and a description of the material provisions of the applicable warrant agreement will be set forth in the applicable prospectus supplement. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">51</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tDOU">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:506pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DESCRIPTION OF UNITS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As specified in the applicable prospectus supplement, we may issue&#160;units consisting of one or more ordinary shares, warrants, or any combination of such securities. The applicable prospectus supplement will describe: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the terms of the&#160;units and of the ordinary shares, and/or warrants comprising the&#160;units, including whether and under what circumstances the securities comprising the&#160;units may be traded separately; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a description of the terms of any unit agreement governing the&#160;units; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a description of the provisions for the payment, settlement, transfer or exchange of the&#160;units.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">52</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tFOS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">FORMS OF SECURITIES</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Each warrant and unit will be represented either by a certificate issued in definitive form to a particular investor or by one or more global securities representing the entire issuance of securities. Certificated securities in definitive form and global securities will be issued in registered form. Definitive securities name you or your nominee as the owner of the security, and in order to transfer or exchange these securities or to receive payments other than interest or other interim payments, you or your nominee must physically deliver the securities to the trustee, registrar, paying agent or other agent, as applicable. Global securities name a depositary or its nominee as the owner of the warrants or&#160;units represented by these global securities. The depositary maintains a computerized system that will reflect each investor&#8217;s beneficial ownership of the securities through an account maintained by the investor with its broker/dealer, bank, trust company or other representative, as we explain more fully below. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Registered Global Securities</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may issue the registered warrants and&#160;units in the form of one or more fully registered global securities that will be deposited with a depositary or its nominee identified in the applicable prospectus supplement and registered in the name of that depositary or nominee. In those cases, one or more registered global securities will be issued in a denomination or aggregate denominations equal to the portion of the aggregate principal or face amount of the securities to be represented by registered global securities. Unless and until it is exchanged in whole for securities in definitive registered form, a registered global security may not be transferred except as a whole by and among the depositary for the registered global security, the nominees of the depositary or any successors of the depositary or those nominees. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If not described below, any specific terms of the depositary arrangement with respect to any securities to be represented by a registered global security will be described in the prospectus supplement relating to those securities. We anticipate that the following provisions will apply to all depositary arrangements. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Ownership of beneficial interests in a registered global security will be limited to persons, called participants, that have accounts with the depositary or persons that may hold interests through participants. Upon the issuance of a registered global security, the depositary will credit, on its book-entry registration and transfer system, the participants&#8217; accounts with the respective principal or face amounts of the securities beneficially owned by the participants. Any dealers, underwriters or agents participating in the distribution of the securities will designate the accounts to be credited. Ownership of beneficial interests in a registered global security will be shown on, and the transfer of ownership interests will be effected only through, records maintained by the depositary, with respect to interests of participants, and on the records of participants, with respect to interests of persons holding through participants. The laws of some states may require that some purchasers of securities take physical delivery of these securities in definitive form. These laws may impair your ability to own, transfer or pledge beneficial interests in registered global securities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">So long as the depositary, or its nominee, is the registered owner of a registered global security, that depositary or its nominee, as the case may be, will be considered the sole owner or holder of the securities represented by the registered global security for all purposes under the applicable warrant agreement or unit agreement. Except as described below, owners of beneficial interests in a registered global security will not be entitled to have the securities represented by the registered global security registered in their names, will not receive or be entitled to receive physical delivery of the securities in definitive form and will not be considered the owners or holders of the securities under the applicable warrant agreement or unit agreement. Accordingly, each person owning a beneficial interest in a registered global security must rely on the procedures of the depositary for that registered global security and, if that person is not a participant, on the procedures of the participant through which the person owns its interest, to exercise any rights of a holder under the applicable warrant agreement or unit agreement. We understand that under existing industry practices, if we request any action of holders or if an owner of a beneficial interest in a registered global security desires to give or take any action that a holder is entitled to give or take under the applicable warrant agreement or unit agreement, the depositary for the registered global security would authorize the participants holding the relevant beneficial interests to give or take that action, and the participants would authorize beneficial owners owning through them to give or take that action or would otherwise act upon the instructions of beneficial owners holding through them. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">53</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:324pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Any payments to holders with respect to warrants or&#160;units, represented by a registered global security registered in the name of a depositary or its nominee will be made to the depositary or its nominee, as the case may be, as the registered owner of the registered global security. None of Adagene, its affiliates, the trustees, the warrant agents, the unit agents or any other agent of Adagene, agent of the trustees or agent of the warrant agents or unit agents will have any responsibility or liability for any aspect of the records relating to payments made on account of beneficial ownership interests in the registered global security or for maintaining, supervising or reviewing any records relating to those beneficial ownership interests. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We expect that the depositary for any of the securities represented by a registered global security, upon receipt of any payment of principal, premium, interest or other distribution of underlying securities or other property to holders on that registered global security, will immediately credit participants&#8217; accounts in amounts proportionate to their respective beneficial interests in that registered global security as shown on the records of the depositary. We also expect that payments by participants to owners of beneficial interests in a registered global security held through participants will be governed by standing customer instructions and customary practices, as is now the case with the securities held for the accounts of customers in bearer form or registered in &#8220;street name,&#8221; and will be the responsibility of those participants. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If the depositary for any of these securities represented by a registered global security is at any time unwilling or unable to continue as depositary or ceases to be a clearing agency registered under the Exchange Act, and a successor depositary registered as a clearing agency under the Exchange Act is not appointed by us within 90&#160;days, we will issue securities in definitive form in exchange for the registered global security that had been held by the depositary. Any securities issued in definitive form in exchange for a registered global security will be registered in the name or names that the depositary gives to the relevant trustee, warrant agent, unit agent or other relevant agent of ours or theirs. It is expected that the depositary&#8217;s instructions will be based upon directions received by the depositary from participants with respect to ownership of beneficial interests in the registered global security that had been held by the depositary. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">54</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tDOAD">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DESCRIPTION OF AMERICAN DEPOSITARY SHARES</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">American Depositary Receipts</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">JPMorgan Chase Bank, N.A. (&#8220;JPMorgan&#8221;), as depositary, will issue the ADSs which you will be entitled to receive in this offering. Each ADS will represent an ownership interest in a designated number of shares which we will deposit with the custodian, as agent of the depositary, under the deposit agreement among ourselves, the depositary, yourself as an ADR holder and all other ADR holders, and all beneficial owners of an interest in the ADSs evidenced by ADRs from time to time. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The depositary&#8217;s office is located at 383 Madison Avenue, Floor 11, New York, NY 10179. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The ADS to share ratio is subject to amendment as provided in the form of ADR (which may give rise to fees contemplated by the form of ADR). In the future, each ADS will also represent any securities, cash or other property deposited with the depositary but which they have not distributed directly to you. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A beneficial owner is any person or entity having a beneficial ownership interest ADSs. A beneficial owner need not be the holder of the ADR evidencing such ADS. If a beneficial owner of ADSs is not an ADR holder, it must rely on the holder of the ADR(s) evidencing such ADSs in order to assert any rights or receive any benefits under the deposit agreement. A beneficial owner shall only be able to exercise any right or receive any benefit under the deposit agreement solely through the holder of the ADR(s) evidencing the ADSs owned by such beneficial owner. The arrangements between a beneficial owner of ADSs and the holder of the corresponding ADRs may affect the beneficial owner&#8217;s ability to exercise any rights it may have. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">An ADR holder shall be deemed to have all requisite authority to act on behalf of any and all beneficial owners of the ADSs evidenced by the ADRs registered in such ADR holder&#8217;s name for all purposes under the deposit agreement and ADRs. The depositary&#8217;s only notification obligations under the deposit agreement and the ADRs is to registered ADR holders. Notice to an ADR holder shall be deemed, for all purposes of the deposit agreement and the ADRs, to constitute notice to any and all beneficial owners of the ADSs evidenced by such ADR holder&#8217;s ADRs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Unless certificated ADRs are specifically requested, all ADSs will be issued on the books of our depositary in book-entry form and periodic statements will be mailed to you which reflect your ownership interest in such ADSs. In our description, references to American depositary receipts or ADRs shall include the statements you will receive which reflect your ownership of ADSs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">You may hold ADSs either directly or indirectly through your broker or other financial institution. If you hold ADSs directly, by having an ADS registered in your name on the books of the depositary, you are an ADR holder. This description assumes you hold your ADSs directly. If you hold the ADSs through your broker or financial institution nominee, you must rely on the procedures of such broker or financial institution to assert the rights of an ADR holder described in this section. You should consult with your broker or financial institution to find out what those procedures are. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As an ADR holder or beneficial owner, we will not treat you as a shareholder of ours and you will not have any shareholder rights. Cayman Island law governs shareholder rights. Because the depositary or its nominee will be the shareholder of record for the shares represented by all outstanding ADSs, shareholder rights rest with such record holder. Your rights are those of an ADR holder or of a beneficial owner. Such rights derive from the terms of the deposit agreement to be entered into among us, the depositary and all holders and beneficial owners from time to time of ADRs issued under the deposit agreement and, in the case of a beneficial owner, from the arrangements between the beneficial owner and the holder of the corresponding ADRs. The obligations of the depositary and its agents are also set out in the deposit agreement. Because the depositary or its nominee will actually be the registered owner of the shares, you must rely on it to exercise the rights of a shareholder on your behalf. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following is a summary of what we believe to be the material terms of the deposit agreement. Notwithstanding this, because it is a summary, it may not contain all the information that you may otherwise deem important. For more complete information, you should read the entire deposit agreement and the form of ADR which contains the terms of your ADSs. You can read a copy of the deposit agreement which is filed as an exhibit to the registration statement of which this prospectus forms a part. You may </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">55</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">also obtain a copy of the deposit agreement at the SEC&#8217;s Public Reference Room which is located at </font>
          <br >
          <font style="letter-spacing:0.2pt;">100 F Street, NE, Washington, DC 20549. You may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-732-0330. You may also find the registration statement and the attached deposit agreement on the SEC&#8217;s website at http://www.sec.gov. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Share Dividends and Other Distributions</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">How will I receive dividends and other distributions on the shares underlying my ADSs?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may make various types of distributions with respect to our securities. The depositary has agreed that, to the extent practicable, it will pay to you the cash dividends or other distributions it or the custodian receives on shares or other deposited securities, after converting any cash received into U.S. dollars (if it determines such conversion may be made on a reasonable basis) and, in all cases, making any necessary deductions provided for in the deposit agreement. The depositary may utilize a division, branch or affiliate of JPMorgan to direct, manage and/or execute any public and/or private sale of securities under the deposit agreement. Such division, branch and/or affiliate may charge the depositary a fee in connection with such sales, which fee is considered an expense of the depositary. You will receive these distributions in proportion to the number of underlying securities that your ADSs represent. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Except as stated below, the depositary will deliver such distributions to ADR holders in proportion to their interests in the following manner: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;letter-spacing:0.2pt;">Cash.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The depositary will distribute any U.S. dollars available to it resulting from a cash dividend or other cash distribution or the net proceeds of sales of any other distribution or portion thereof (to the extent applicable), on an averaged or other practicable basis, subject to (i)&#160;appropriate adjustments for taxes withheld, (ii)&#160;such distribution being impermissible or impracticable with respect to certain registered ADR holders, and (iii)&#160;deduction of the depositary&#8217;s and/or its agents&#8217; expenses in (1)&#160;converting any foreign currency to U.S. dollars to the extent that it determines that such conversion may be made on a reasonable basis, (2)&#160;transferring foreign currency or U.S. dollars to the United States by such means as the depositary may determine to the extent that it determines that such transfer may be made on a reasonable basis, (3)&#160;obtaining any approval or license of any governmental authority required for such conversion or transfer, which is obtainable at a reasonable cost and within a reasonable time and (4)&#160;making any sale by public or private means in any commercially reasonable manner. </font><font style="font-style:italic;letter-spacing:0.2pt;">If exchange rates fluctuate during a time when the depositary cannot convert a foreign currency, you may lose some or all of the value of the distribution.</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;letter-spacing:0.2pt;">Shares.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;In the case of a distribution in shares, the depositary will issue additional ADRs to evidence the number of ADSs representing such shares. Only whole ADSs will be issued. Any shares which would result in fractional ADSs will be sold and the net proceeds will be distributed in the same manner as cash to the ADR holders entitled thereto. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;letter-spacing:0.2pt;">Rights to receive additional shares.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;In the case of a distribution of rights to subscribe for additional shares or other rights, if we timely provide evidence satisfactory to the depositary that it may lawfully distribute such rights, the depositary will distribute warrants or other instruments in the discretion of the depositary representing such rights. However, if we do not timely furnish such evidence, the depositary may: </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(i)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">sell such rights if practicable and distribute the net proceeds in the same manner as cash to the ADR holders entitled thereto; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(ii)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if it is not practicable to sell such rights by reason of the non-transferability of the rights, limited markets therefor, their short duration or otherwise, do nothing and allow such rights to lapse, in which case ADR holders will receive nothing and the rights may lapse. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;letter-spacing:0.2pt;">Other Distributions.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;In the case of a distribution of securities or property other than those described above, the depositary may either (i)&#160;distribute such securities or property in any manner it deems equitable and practicable or (ii)&#160;to the extent the depositary deems distribution of such securities or property not to be equitable and practicable, sell such securities or property and distribute any net proceeds in the same way it distributes cash. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">56</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If the depositary determines in its discretion that any distribution described above is not practicable with respect to any specific registered ADR holder, the depositary may choose any method of distribution that it deems practicable for such ADR holder, including the distribution of foreign currency, securities or property, or it may retain such items, without paying interest on or investing them, on behalf of the ADR holder as deposited securities, in which case the ADSs will also represent the retained items. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Any U.S. dollars will be distributed by checks drawn on a bank in the United States for whole dollars and cents. Fractional cents will be withheld without liability and dealt with by the depositary in accordance with its then current practices. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The depositary is not responsible if it fails to determine that any distribution or action is lawful or reasonably practicable.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">There can be no assurance that the depositary will be able to convert any currency at a specified exchange rate or sell any property, rights, shares or other securities at a specified price, nor that any of such transactions can be completed within a specified time period. All purchases and sales of securities will be handled by the depositary in accordance with its then current policies, which are currently set forth on the &#8220;Disclosures&#8221; page (or successor page) of www.adr.com (as updated by the depositary from time to time, &#8220;ADR.com&#8221;).</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Deposit, Withdrawal and Cancellation</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">How does the depositary issue ADSs?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The depositary will issue ADSs if you or your broker deposit shares or evidence of rights to receive shares with the custodian and pay the fees and expenses owing to the depositary in connection with such issuance. In the case of the ADSs to be issued under this prospectus, we will arrange with the underwriters named herein to deposit such shares. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Shares deposited in the future with the custodian must be accompanied by certain delivery documentation and shall, at the time of such deposit, be registered in the name of JPMorgan Chase Bank, N.A., as depositary for the benefit of holders of ADRs or in such other name as the depositary shall direct. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The custodian will hold all deposited shares (including those being deposited by or on our behalf in connection with the offering to which this prospectus relates) for the account and to the order of the depositary, in each case for the benefit of ADR holders. ADR holders and beneficial owners thus have no direct ownership interest in the shares and only have such rights as are contained in the deposit agreement. The custodian will also hold any additional securities, property and cash received on or in substitution for the deposited shares. The deposited shares and any such additional items are referred to as &#8220;deposited securities&#8221;. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Deposited securities are not intended to, and shall not, constitute proprietary assets of the depositary, the custodian or their nominees. Beneficial ownership in deposited securities is intended to be, and shall at all times during the term of the deposit agreement continue to be, vested in the beneficial owners of the ADSs representing such deposited securities. Notwithstanding anything else contained herein, in the deposit agreement, in the form of ADR and/or in any outstanding ADSs, the depositary, the custodian and their respective nominees are intended to be, and shall at all times during the term of the deposit agreement be, the record holder(s) only of the deposited securities represented by the ADSs for the benefit of the ADR holders. The depositary, on its own behalf and on behalf of the custodian and their respective nominees, disclaims any beneficial ownership interest in the deposited securities held on behalf of the ADR holders. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Upon each deposit of shares, receipt of related delivery documentation and compliance with the other provisions of the deposit agreement, including the payment of the fees and charges of the depositary and any taxes or other fees or charges owing, the depositary will issue an ADR or ADRs in the name or upon the order of the person entitled thereto evidencing the number of ADSs to which such person is entitled. All of the ADSs issued will, unless specifically requested to the contrary, be part of the depositary&#8217;s direct registration system, and a registered holder will receive periodic statements from the depositary which will show the number of ADSs registered in such holder&#8217;s name. An ADR holder can request that the ADSs not be held through the depositary&#8217;s direct registration system and that a certificated ADR be issued. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">57</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">How do ADR holders cancel an ADS and obtain deposited securities?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">When you turn in your ADR certificate at the depositary&#8217;s office, or when you provide proper instructions and documentation in the case of direct registration ADSs, the depositary will, upon payment of certain applicable fees, charges and taxes, deliver the underlying shares to you or upon your written order. Delivery of deposited securities in certificated form will be made at the custodian&#8217;s office. At your risk, expense and request, the depositary may deliver deposited securities at such other place as you may request. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The depositary may only restrict the withdrawal of deposited securities in connection with: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">temporary delays caused by closing our transfer books or those of the depositary or the deposit of shares in connection with voting at a shareholders&#8217; meeting, or the payment of dividends; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the payment of fees, taxes and similar charges; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">compliance with any U.S. or foreign laws or governmental regulations relating to the ADRs or to the withdrawal of deposited securities. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This right of withdrawal may not be limited by any other provision of the deposit agreement. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Record Dates</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The depositary may, after consultation with us if practicable, fix record dates (which, to the extent applicable, shall be as near as practicable to any corresponding record dates set by us) for the determination of the registered ADR holders who will be entitled (or obligated, as the case may be): </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to receive any distribution on or in respect of deposited securities, </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to give instructions for the exercise of voting rights at a meeting of holders of shares, or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to pay the fee assessed by the depositary for administration of the ADR program and for any expenses as provided for in the ADR, </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to receive any notice or to act in respect of other matters, </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">all subject to the provisions of the deposit agreement. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Voting Rights</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">How do I vote?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If you are an ADR holder and the depositary asks you to provide it with voting instructions, you may instruct the depositary how to exercise the voting rights for the shares which underlie your ADSs. As soon as practicable after receipt from us of notice of any meeting at which the holders of shares are entitled to vote, or of our solicitation of consents or proxies from holders of shares, the depositary shall fix the ADS record date in accordance with the provisions of the deposit agreement, provided that if the depositary receives a written request from us in a timely manner and at least 30&#160;days prior to the date of such vote or meeting, the depositary shall, at our expense, distribute to the registered ADR holders a &#8220;voting notice&#8221; stating (i)&#160;final information particular to such vote and meeting and any solicitation materials, (ii)&#160;that each ADR holder on the record date set by the depositary will, subject to any applicable provisions of Cayman Islands law, be entitled to instruct the depositary as to the exercise of the voting rights, if any, pertaining to the deposited securities represented by the ADSs evidenced by such ADR holder&#8217;s ADRs and (iii)&#160;the manner in which such instructions may be given or deemed given in accordance with the deposit agreement, including instructions for giving a discretionary proxy to a person designated by us. Each ADR holder shall be solely responsible for the forwarding of voting notices to the beneficial owners of ADSs registered in such ADR holder&#8217;s name. There is no guarantee that ADR holders and beneficial owners generally or any holder or beneficial owner in particular will receive the notice described above with sufficient time to enable such ADR holder or beneficial owner to return any voting instructions to the depositary in a timely manner. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Following actual receipt by the ADR department responsible for proxies and voting of ADR holders&#8217; instructions (including, without limitation, instructions of any entity or entities acting on behalf of the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">58</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">nominee for DTC), the depositary shall, in the manner and on or before the time established by the depositary for such purpose, endeavor to vote or cause to be voted the deposited securities represented by the ADSs evidenced by such ADR holders&#8217; ADRs in accordance with such instructions insofar as practicable and permitted under the provisions of or governing deposited securities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">To the extent that (A)&#160;we have provided the depositary with at least 35&#160;days&#8217; notice of the proposed meeting, (B)&#160;the voting notice will be received by all ADR holders and beneficial owners no less than 10&#160;days prior to the date of the meeting and/or the cut-off date for the solicitation of consents, and (C)&#160;the depositary does not receive instructions on a particular agenda item from an ADR holder (including, without limitation, any entity or entities acting on behalf of the nominee for DTC) in a timely manner, such ADR holder shall be deemed, and in the deposit agreement the depositary is instructed to deem such ADR holder, to have instructed the depositary to give a discretionary proxy for such agenda item(s) to a person designated by us to vote the deposited securities represented by the ADSs for which actual instructions were not so given by all such ADR holders on such agenda item(s), provided that no such instruction shall be deemed given and no discretionary proxy shall be given unless (1)&#160;we inform the depositary in writing (and we agree to provide the depositary with such instruction promptly in writing) that (a)&#160;we wish such proxy to be given with respect to such agenda item(s), (b)&#160;there is no substantial opposition existing with respect to such agenda item(s) and (c)&#160;such agenda item(s), if approved, would not materially or adversely affect the rights of holders of shares, and (2)&#160;the depositary has obtained an opinion of counsel, in form and substance satisfactory to the depositary, confirming that (i)&#160;the granting of such discretionary proxy does not subject the depositary to any reporting obligations in the Cayman Islands, (ii)&#160;the granting of such proxy will not result in a violation of the laws, rules, regulations or permits of the Cayman Islands, (iii)&#160;the voting arrangement and deemed instruction as contemplated herein will be given effect under the laws, rules and regulations of the Cayman Islands, and (iv)&#160;the granting of such discretionary proxy will not under any circumstances result in the shares represented by the ADSs being treated as assets of the depositary under the laws, rules or regulations of the Cayman Islands. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The depositary may from time to time access information available to it to consider whether any of the circumstances described above exist, or request additional information from us in respect thereto. By taking any such action, the depositary shall not in any way be deemed or inferred to have been required, or have had any duty or responsibility (contractual or otherwise), to monitor or inquire whether any of the circumstances described above existed. In addition to the limitations provided for in the deposit agreement, ADR holders and beneficial owners are advised and agree that (a)&#160;the depositary will rely fully and exclusively on us to inform it of any of the circumstances set forth above, and (b)&#160;neither the depositary, the custodian nor any of their respective agents shall be obliged to inquire or investigate whether any of the circumstances described above exist and/or whether we complied with our obligation to timely inform the depositary of such circumstances. Neither the depositary, the custodian nor any of their respective agents shall incur any liability to ADR holders or beneficial owners (i)&#160;as a result of our failure to determine that any of the circumstances described above exist or our failure to timely notify the depositary of any such circumstances or (ii)&#160;if any agenda item which is approved at a meeting has, or is claimed to have, a material or adverse effect on the rights of holders of shares. Because there is no guarantee that ADR holders and beneficial owners will receive the notices described above with sufficient time to enable such ADR holders or beneficial owners to return any voting instructions to the depositary in a timely manner, ADR holders and beneficial owners may be deemed to have instructed the depositary to give a discretionary proxy to a person designated by us in such circumstances, and neither the depositary, the custodian nor any of their respective agents shall incur any liability to ADR holders or beneficial owners in such circumstances. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">ADR holders are strongly encouraged to forward their voting instructions to the depositary as soon as possible. For instructions to be valid, the ADR department of the depositary that is responsible for proxies and voting must receive them in the manner and on or before the time specified, notwithstanding that such instructions may have been physically received by the depositary prior to such time. The depositary will not itself exercise any voting discretion in respect of deposited securities. The depositary and its agents will not be responsible for any failure to carry out any instructions to vote any of the deposited securities, for the manner in which any voting instructions are given or deemed to be given in accordance with the deposit agreement, including instructions to give a discretionary proxy to a person designated by us, for the manner in which any vote is cast, including, without limitation, any vote cast by a person to whom the depositary is instructed to grant a discretionary proxy (or deemed to have been instructed to grant a discretionary proxy </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">59</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">in accordance with the deposit agreement), or for the effect of any such vote. Notwithstanding anything contained in the deposit agreement or any ADR, the depositary may, to the extent not prohibited by any law, regulation, or requirement of the stock exchange on which the ADSs are listed, in lieu of distribution of the materials provided to the depositary in connection with any meeting of or solicitation of consents or proxies from holders of deposited securities, distribute to the registered holders of ADRs a notice that provides such ADR holders with or otherwise publicizes to such ADR holders instructions on how to retrieve such materials or receive such materials upon request (</font><font style="font-style:italic;letter-spacing:0.2pt;">i.e.</font><font style="letter-spacing:0.2pt;">, by reference to a website containing the materials for retrieval or a contact for requesting copies of the materials). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have advised the depositary that under Cayman Islands law and our constituent documents, each as in effect as of the date of the deposit agreement, voting at any meeting of shareholders is by show of hands unless a poll is (before or on the declaration of the results of the show of hands) demanded. In the event that voting on any resolution or matter is conducted on a show of hands basis in accordance with our constituent documents, the depositary will refrain from voting and the voting instructions received by the depositary from ADR holders shall lapse. The depositary will not demand a poll or join in demanding a poll, whether or not requested to do so by ADR holders or beneficial owners. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">There is no guarantee that you will receive voting materials in time to instruct the depositary to vote and it is possible that you, or persons who hold their ADSs through brokers, dealers or other third parties, will not have the opportunity to exercise a right to vote. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Reports and Other Communications</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Will ADR holders be able to view our reports?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The depositary will make available for inspection by ADR holders at the offices of the depositary and the custodian the deposit agreement, the provisions of or governing deposited securities, and any written communications from us which are both received by the custodian or its nominee as a holder of deposited securities and made generally available to the holders of deposited securities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Additionally, if we make any written communications generally available to holders of our shares, and we furnish copies thereof (or English translations or summaries) to the depositary, it will distribute the same to registered ADR holders. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Fees and Expenses</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">What fees and expenses will I be responsible for paying?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The depositary may charge each person to whom ADSs are issued, including, without limitation, issuances against deposits of shares, issuances in respect of share distributions, rights and other distributions, issuances pursuant to a stock dividend or stock split declared by us or issuances pursuant to a merger, exchange of securities or any other transaction or event affecting the ADSs or deposited securities, and each person surrendering ADSs for withdrawal of deposited securities or whose ADRs are cancelled or reduced for any other reason, US$5.00 for each 100 ADSs (or any portion thereof) issued, delivered, reduced, cancelled or surrendered, or upon which a share distribution or elective distribution is made or offered, as the case may be. The depositary may sell (by public or private sale) sufficient securities and property received in respect of a share distribution, rights and/or other distribution prior to such deposit to pay such charge. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following additional charges shall also be incurred by the ADR holders, the beneficial owners, by any party depositing or withdrawing shares or by any party surrendering ADSs and/or to whom ADSs are issued (including, without limitation, issuance pursuant to a stock dividend or stock split declared by us or an exchange of stock regarding the ADSs or the deposited securities or a distribution of ADSs), whichever is applicable: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a fee of US$1.50 per ADR or ADRs for transfers of certificated or direct registration ADRs; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a fee of US$0.05 or less per ADS held for any cash distribution made, or for any elective cash/stock dividend offered, pursuant to the deposit agreement; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">60</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">an aggregate fee of US$0.05 or less per ADS per calendar year (or portion thereof) for services performed by the depositary in administering the ADRs (which fee may be charged on a periodic basis during each calendar year and shall be assessed against holders of ADRs as of the record date or record dates set by the depositary during each calendar year and shall be payable in the manner described in the next succeeding provision); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a fee for the reimbursement of such fees, charges and expenses as are incurred by the depositary and/or any of its agents (including, without limitation, the custodian and expenses incurred on behalf of ADR holders in connection with compliance with foreign exchange control regulations or any law or regulation relating to foreign investment) in connection with the servicing of the shares or other deposited securities, the sale of securities (including, without limitation, deposited securities), the delivery of deposited securities or otherwise in connection with the depositary&#8217;s or its custodian&#8217;s compliance with applicable law, rule or regulation (which fees and charges shall be assessed on a proportionate basis against ADR holders as of the record date or dates set by the depositary and shall be payable at the sole discretion of the depositary by billing such ADR holders or by deducting such charge from one or more cash dividends or other cash distributions); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.29pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.29pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a fee for the distribution of securities (or the sale of securities in connection with a distribution), such fee being in an amount equal to the US$0.05 per ADS issuance fee for the execution and delivery of ADSs which would have been charged as a result of the deposit of such securities (treating all such securities as if they were shares) but which securities or the net cash proceeds from the sale thereof are instead distributed by the depositary to those ADR holders entitled thereto; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">stock transfer or other taxes and other governmental charges; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.29pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.29pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">cable, telex and facsimile transmission and delivery charges incurred at your request in connection with the deposit or delivery of shares, ADRs or deposited securities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">transfer or registration fees for the registration of transfer of deposited securities on any applicable register in connection with the deposit or withdrawal of deposited securities; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.4pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">fees of any division, branch or affiliate of the depositary utilized by the depositary to direct, manage and/or execute any public and/or private sale of securities under the deposit agreement. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">To facilitate the administration of various depositary receipt transactions, including disbursement of dividends or other cash distributions and other corporate actions, the depositary may engage the foreign exchange desk within JPMorgan Chase Bank, N.A. (the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Bank</font><font style="letter-spacing:0.2pt;">&#8221;) and/or its affiliates in order to enter into spot foreign exchange transactions to convert foreign currency into U.S. dollars. For certain currencies, foreign exchange transactions are entered into with the Bank or an affiliate, as the case may be, acting in a principal capacity. For other currencies, foreign exchange transactions are routed directly to and managed by an unaffiliated local custodian (or other third party local liquidity provider), and neither the Bank nor any of its affiliates is a party to such foreign exchange transactions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The foreign exchange rate applied to an foreign exchange transaction will be either (a)&#160;a published benchmark rate, or (b)&#160;a rate determined by a third party local liquidity provider, in each case plus or minus a spread, as applicable. The depositary will disclose which foreign exchange rate and spread, if any, apply to such currency on the &#8220;Disclosures&#8221; page (or successor page) of ADR.com. Such applicable foreign exchange rate and spread may (and neither the depositary, the Bank nor any of their affiliates is under any obligation to ensure that such rate does not) differ from rates and spreads at which comparable transactions are entered into with other customers or the range of foreign exchange rates and spreads at which the Bank or any of its affiliates enters into foreign exchange transactions in the relevant currency pair on the date of the foreign exchange transaction. Additionally, the timing of execution of an foreign exchange transaction varies according to local market dynamics, which may include regulatory requirements, market hours and liquidity in the foreign exchange market or other factors. Furthermore, the Bank and its affiliates may manage the associated risks of their position in the market in a manner they deem appropriate without regard to the impact of such activities on the depositary, us, holders or beneficial owners. </font><font style="font-style:italic;letter-spacing:0.2pt;">The spread applied does not reflect any gains or losses that may be earned or incurred by the Bank and its affiliates as a result of risk management or other hedging related activity.</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">61</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Notwithstanding the foregoing, to the extent we provide U.S. dollars to the depositary, neither the Bank nor any of its affiliates will execute a foreign exchange transaction as set forth herein. In such case, the depositary will distribute the U.S. dollars received from us. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Further details relating to the applicable foreign exchange rate, the applicable spread and the execution of foreign exchange transactions will be provided by the depositary on ADR.com. Each holder and beneficial owner by holding or owning an ADR or ADS or an interest therein, and we, each acknowledge and agree that the terms applicable to foreign exchange transactions disclosed from time to time on ADR.com will apply to any foreign exchange transaction executed pursuant to the deposit agreement.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We will pay all other charges and expenses of the depositary and any agent of the depositary (except the custodian) pursuant to agreements from time to time between us and the depositary. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The right of the depositary to receive payment of fees, charges and expenses survives the termination of the deposit agreement, and shall extend for those fees, charges and expenses incurred prior to the effectiveness of any resignation or removal of the depositary. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The fees and charges described above may be amended from time to time by agreement between us and the depositary. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The depositary may make available to us a set amount or a portion of the depositary fees charged in respect of the ADR program or otherwise upon such terms and conditions as we and the depositary may agree from time to time. The depositary collects its fees for issuance and cancellation of ADSs directly from investors depositing shares or surrendering ADSs for the purpose of withdrawal or from intermediaries acting for them. The depositary collects fees for making distributions to investors by deducting those fees from the amounts distributed or by selling a portion of distributable property to pay the fees. The depositary may collect its annual fee for depositary services by deduction from cash distributions, or by directly billing investors, or by charging the book-entry system accounts of participants acting for them. The depositary will generally set off the amounts owing from distributions made to holders of ADSs. If, however, no distribution exists and payment owing is not timely received by the depositary, the depositary may refuse to provide any further services to ADR holders that have not paid those fees and expenses owing until such fees and expenses have been paid. At the discretion of the depositary, all fees and charges owing under the deposit agreement are due in advance and/or when declared owing by the depositary. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Payment of Taxes</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">ADR holders or beneficial owners must pay any tax or other governmental charge payable by the custodian or the depositary on any ADS or ADR, deposited security or distribution. If any taxes or other governmental charges (including any penalties and/or interest) shall become payable by or on behalf of the custodian or the depositary with respect to any ADR, any deposited securities represented by the ADSs evidenced thereby or any distribution thereon, including, without limitation, any Chinese Enterprise Income Tax owing if the Circular Guoshuifa [2009] No. 82 issued by the Chinese State Administration of Taxation (SAT) or any other circular, edict, order or ruling, as issued and as from time to time amended, is applied or otherwise, such tax or other governmental charge shall be paid by the ADR holder thereof to the depositary and by holding or owning, or having held or owned, an ADR or any ADSs evidenced thereby, the ADR holder and all beneficial owners thereof, and all prior ADR holders and beneficial owners thereof, jointly and severally, agree to indemnify, defend and save harmless each of the depositary, us and its and our agents in respect of such tax or other governmental charge. Notwithstanding the depositary&#8217;s right to seek payment from current and former beneficial owners, by holding or owning, or having held or owned, an ADR, the ADR holder thereof (and prior ADR holder thereof) acknowledges and agrees that the depositary has no obligation to seek payment of amounts owing from any current or former beneficial owner. If an ADR holder owes any tax or other governmental charge, the depositary may (i)&#160;deduct the amount thereof from any cash distributions, or (ii)&#160;sell deposited securities (by public or private sale) and deduct the amount owing from the net proceeds of such sale. In either case the ADR holder remains liable for any shortfall. If any tax or governmental charge is unpaid, the depositary may also refuse to effect any registration, registration of transfer, split-up or combination of deposited securities or withdrawal of deposited securities until such payment is made. If any tax or governmental charge is required to be withheld on any cash distribution, the depositary may deduct the amount required to be withheld from any cash distribution or, in the case of a </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">62</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">non-cash distribution, sell the distributed property or securities (by public or private sale) in such amounts and in such manner as the depositary deems necessary and practicable to pay such taxes and distribute any remaining net proceeds or the balance of any such property after deduction of such taxes to the ADR holders entitled thereto. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As an ADR holder or beneficial owner, you will be agreeing to indemnify us, the depositary, its custodian and any of our or their respective officers, directors, employees, agents and affiliates against, and hold each of them harmless from, any claims by any governmental authority with respect to taxes, additions to tax, penalties or interest arising out of any refund of taxes, reduced rate of withholding at source or other tax benefit obtained. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Reclassifications, Recapitalizations and Mergers</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If we take certain actions that affect the deposited securities, including (i)&#160;any change in par value, split-up, consolidation, cancellation or other reclassification of deposited securities or (ii)&#160;any distributions of shares or other property not made to holders of ADRs or (iii)&#160;any recapitalization, reorganization, merger, consolidation, liquidation, receivership, bankruptcy or sale of all or substantially all of our assets, then the depositary may choose to, and shall if reasonably requested by us: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">amend the form of ADR; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">distribute additional or amended ADRs; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">distribute cash, securities or other property it has received in connection with such actions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">sell any securities or property received and distribute the proceeds as cash; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">none of the above. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If the depositary does not choose any of the above options, any of the cash, securities or other property it receives will constitute part of the deposited securities and each ADS will then represent a proportionate interest in such property. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Amendment and Termination</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">How may the deposit agreement be amended?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may agree with the depositary to amend the deposit agreement and the ADSs without your consent for any reason. ADR holders must be given at least 30&#160;days&#8217; notice of any amendment that imposes or increases any fees or charges (other than stock transfer or other taxes and other governmental charges, transfer or registration fees, SWIFT, cable, telex or facsimile transmission costs, delivery costs or other such expenses), or otherwise prejudices any substantial existing right of ADR holders or beneficial owners. Such notice need not describe in detail the specific amendments effectuated thereby, but must identify to ADR holders and beneficial owners a means to access the text of such amendment. If an ADR holder continues to hold an ADR or ADRs after being so notified, such ADR holder and any beneficial owner are deemed to agree to such amendment and to be bound by the deposit agreement as so amended. No amendment, however, will impair your right to surrender your ADSs and receive the underlying securities, except in order to comply with mandatory provisions of applicable law. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Any amendments or supplements which (i)&#160;are reasonably necessary (as agreed by us and the depositary) in order for (a)&#160;the ADSs to be registered on Form F-6 under the Securities Act of 1933 or (b)&#160;the ADSs or shares to be traded solely in electronic book-entry form and (ii)&#160;do not in either such case impose or increase any fees or charges to be borne by ADR holders, shall be deemed not to prejudice any substantial rights of ADR holders or beneficial owners. Notwithstanding the foregoing, if any governmental body or regulatory body should adopt new laws, rules or regulations which would require amendment or supplement of the deposit agreement or the form of ADR to ensure compliance therewith, we and the depositary may amend or supplement the deposit agreement and the ADR at any time in accordance with such changed laws, rules or regulations. Such amendment or supplement to the deposit agreement in such circumstances may become effective before a notice of such amendment or supplement is given to ADR holders or within any other period of time as required for compliance. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">63</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Notice of any amendment to the deposit agreement or form of ADRs shall not need to describe in detail the specific amendments effectuated thereby, and failure to describe the specific amendments in any such notice shall not render such notice invalid, provided, however, that, in each such case, the notice given to the ADR holders identifies a means for ADR holders and beneficial owners to retrieve or receive the text of such amendment (</font><font style="font-style:italic;letter-spacing:0.2pt;">i.e.</font><font style="letter-spacing:0.2pt;">, upon retrieval from the SEC&#8217;s, the depositary&#8217;s or our website or upon request from the depositary). </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">How may the deposit agreement be terminated?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The depositary may, and shall at our written direction, terminate the deposit agreement and the ADRs by mailing notice of such termination to the registered holders of ADRs at least 30&#160;days prior to the date fixed in such notice for such termination; provided, however, if the depositary shall have (i)&#160;resigned as depositary under the deposit agreement, notice of such termination by the depositary shall not be provided to registered ADR holders unless a successor depositary shall not be operating under the deposit agreement within 60&#160;days of the date of such resignation, and (ii)&#160;been removed as depositary under the deposit agreement, notice of such termination by the depositary shall not be provided to registered holders of ADRs unless a successor depositary shall not be operating under the deposit agreement on the 60</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;"> day after our notice of removal was first provided to the depositary. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If the shares are not listed or quoted for trading on a stock exchange or in a securities market as of the date so fixed for termination, then after such date fixed for termination (a)&#160;all direct registration ADRs shall cease to be eligible for the direct registration system and shall be considered ADRs issued on the ADR register maintained by the depositary and (b)&#160;the depositary shall use its reasonable efforts to ensure that the ADSs cease to be DTC eligible so that neither DTC nor any of its nominees shall thereafter be a holder of ADRs. At such time as the ADSs cease to be DTC eligible and/or neither DTC nor any of its nominees is a holder of ADRs, the depositary shall (a)&#160;instruct its custodian to deliver all shares and/or deposited securities to us along with a general stock power that refers to the names set forth on the ADR register maintained by the depositary and (b)&#160;provide us with a copy of the ADR register maintained by the depositary. Upon receipt of such shares and/or deposited securities and the ADR register maintained by the depositary, we have agreed to use our best efforts to issue to each register ADR holder a share certificate representing the shares represented by the ADSs reflected on the ADR register maintained by the depositary in such registered ADR holder&#8217;s name and to deliver such share certificate to the registered ADR holder at the address set forth on the ADR register maintained by the depositary. After providing such instruction to the custodian and delivering a copy of the ADR register to us, the depositary and its agents will perform no further acts under the deposit agreement or the ADRs and shall cease to have any obligations under the deposit agreement and/or the ADRs. After we receive the copy of the ADR register and the shares and/or deposited securities from the depositary, we shall be discharged from all obligations under the deposit agreement except (i)&#160;to distribute the shares to the registered ADR holders entitled thereto and (ii)&#160;for its obligations to the depositary and its agents. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If the shares are listed or quoted for trading on a stock exchange or in a securities market as of the date so fixed for termination, then instead of the provisions in the prior paragraph, after the date so fixed for termination, the depositary and its agents will perform no further acts under the deposit agreement or the ADRs, except to receive and hold (or sell) distributions on shares and/or deposited securities and deliver shares and/or deposited securities being withdrawn. As soon as practicable after the date so fixed for termination, the depositary has agreed to use its reasonable efforts to sell the shares and/or deposited securities and shall thereafter (as long as it may lawfully do so) hold in an account (which may be a segregated or unsegregated account) the net proceeds of such sales, together with any other cash then held by it under the deposit agreement, without liability for interest, in trust for the pro&#160;rata benefit of the registered ADR holders not theretofore surrendered. After making such sale, the depositary shall be discharged from all obligations in respect of the deposit agreement and the ADRs, except to account for such net proceeds and other cash. After the date so fixed for termination, we shall be discharged from all obligations under the deposit agreement except for our obligations to the depositary and its agents. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Notwithstanding anything to the contrary, in connection with any such termination, the depositary may, in its sole discretion and without notice to us, establish an unsponsored American depositary share program (on such terms as the depositary may determine) for our shares and make available to ADR holders </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">64</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">a means to withdraw the shares represented by the ADSs issued under the deposit agreement and to direct the deposit of such shares into such unsponsored American depositary share program, subject, in each case, to receipt by the depositary, at its discretion, of the fees, charges and expenses provided for under the deposit agreement and the fees, charges and expenses applicable to the unsponsored American depositary share program. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Limitations on Obligations and Liability to ADR holders</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Limits on our obligations and the obligations of the depositary; limits on liability to ADR holders and holders of ADSs</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Prior to the issue, registration, registration of transfer, split-up, combination, or cancellation of any ADRs, or the delivery of any distribution in respect thereof, and from time to time in the case of the production of proofs as described below, we or the depositary or its custodian may require: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">payment with respect thereto of (i)&#160;any stock transfer or other tax or other governmental charge, (ii)&#160;any stock transfer or registration fees in effect for the registration of transfers of shares or other deposited securities upon any applicable register and (iii)&#160;any applicable fees and expenses described in the deposit agreement; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the production of proof satisfactory to it of (i)&#160;the identity of any signatory and genuineness of any signature and (ii)&#160;such other information, including without limitation, information as to citizenship, residence, exchange control approval, beneficial or other ownership of, or interest in, any securities, compliance with applicable law, regulations, provisions of or governing deposited securities and terms of the deposit agreement and the ADRs, as it may deem necessary or proper; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">compliance with such regulations as the depositary may establish consistent with the deposit agreement. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The issuance of ADRs, the acceptance of deposits of shares, the registration, registration of transfer, split-up or combination of ADRs or the withdrawal of shares, may be suspended, generally or in particular instances, when the ADR register or any register for deposited securities is closed or when any such action is deemed advisable by the depositary; provided that the ability to withdraw shares may only be limited under the following circumstances: (i)&#160;temporary delays caused by closing transfer books of the depositary or our transfer books or the deposit of shares in connection with voting at a shareholders&#8217; meeting, or the payment of dividends, (ii)&#160;the payment of fees, taxes, and similar charges, and (iii)&#160;compliance with any laws or governmental regulations relating to ADRs or to the withdrawal of deposited securities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The deposit agreement expressly limits the obligations and liability of the depositary, ourselves and our respective agents, provided, however, that no disclaimer of liability under the Securities Act of 1933 is intended by any of the limitations of liabilities provisions of the deposit agreement. The deposit agreement provides that each of us, the depositary and our respective agents will: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">incur or assume no liability (including, without limitation, to holders or beneficial owners) if any present or future law, rule, regulation, fiat, order or decree of the Cayman Islands, Hong Kong, the People&#8217;s Republic of China, the United States or any other country or jurisdiction, or of any governmental or regulatory authority or securities exchange or market or automated quotation system, the provisions of or governing any deposited securities, any present or future provision of our charter, any act of God, war, terrorism, epidemic, pandemic, nationalization, expropriation, currency restrictions, work stoppage, strike, civil unrest, revolutions, rebellions, explosions, computer failure or circumstance beyond our, the depositary&#8217;s or our respective agents&#8217; direct and immediate control shall prevent or delay, or shall cause any of them to be subject to any civil or criminal penalty in connection with, any act which the deposit agreement or the ADRs provide shall be done or performed by us, the depositary or our respective agents (including, without limitation, voting); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">incur or assume no liability (including, without limitation, to holders or beneficial owners) by reason of any non-performance or delay, caused as aforesaid, in the performance of any act or things which by the terms of the deposit agreement it is provided shall or may be done or performed or any </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">65</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:30pt; width:426pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">exercise or failure to exercise discretion under the deposit agreement or the ADRs including, without limitation, any failure to determine that any distribution or action may be lawful or reasonably practicable; </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">incur or assume no liability (including, without limitation, to holders or beneficial owners) if it performs its obligations under the deposit agreement and ADRs without gross negligence or willful misconduct; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">in the case of the depositary and its agents, be under no obligation to appear in, prosecute or defend any action, suit or other proceeding in respect of any deposited securities the ADSs or the ADRs; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">in the case of us and our agents, be under no obligation to appear in, prosecute or defend any action, suit or other proceeding in respect of any deposited securities the ADSs or the ADRs, which in our or our agents&#8217; opinion, as the case may be, may involve it in expense or liability, unless indemnity satisfactory to us or our agent, as the case may be against all expense (including fees and disbursements of counsel) and liability be furnished as often as may be requested; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">not be liable (including, without limitation, to holders or beneficial owners) for any action or inaction by it in reliance upon the advice of or information from any legal counsel, any accountant, any person presenting shares for deposit, any registered holder of ADRs, or any other person believed by it to be competent to give such advice or information and/or, in the case of the depositary, us; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">may rely and shall be protected in acting upon any written notice, request, direction, instruction or document believed by it to be genuine and to have been signed, presented or given by the proper party or parties. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Neither the depositary nor its agents have any obligation to appear in, prosecute or defend any action, suit or other proceeding in respect of any deposited securities, the ADSs or the ADRs. We and our agents shall only be obligated to appear in, prosecute or defend any action, suit or other proceeding in respect of any deposited securities, the ADSs or the ADRs, which in our opinion may involve us in expense or liability, if indemnity satisfactory to us against all expense (including fees and disbursements of counsel) and liability is furnished as often as may be required. The depositary and its agents may fully respond to any and all demands or requests for information maintained by or on its behalf in connection with the deposit agreement, any registered holder or holders of ADRs, any ADRs or otherwise related to the deposit agreement or ADRs to the extent such information is requested or required by or pursuant to any lawful authority, including without limitation laws, rules, regulations, administrative or judicial process, banking, securities or other regulators. The depositary shall not be liable for the acts or omissions made by, or the insolvency of, any securities depository, clearing agency or settlement system. Furthermore, the depositary shall not be responsible for, and shall incur no liability in connection with or arising from, the insolvency of any custodian that is not a branch or affiliate of JPMorgan. Notwithstanding anything to the contrary contained in the deposit agreement or any ADRs, the depositary shall not be responsible for, and shall incur no liability in connection with or arising from, any act or omission to act on the part of the custodian except to the extent that any registered ADR holder has incurred liability directly as a result of the custodian having (i)&#160;committed fraud or willful misconduct in the provision of custodial services to the depositary or (ii)&#160;failed to use reasonable care in the provision of custodial services to the depositary as determined in accordance with the standards prevailing in the jurisdiction in which the custodian is located. The depositary and the custodian(s) may use third party delivery services and providers of information regarding matters such as, but not limited to, pricing, proxy voting, corporate actions, class action litigation and other services in connection with the ADRs and the deposit agreement, and use local agents to provide services such as, but not limited to, attendance at any meetings of security holders of issuers. Although the depositary and the custodian will use reasonable care (and cause their agents to use reasonable care) in the selection and retention of such third party providers and local agents, they will not be responsible for any errors or omissions made by them in providing the relevant information or services. The depositary shall not have any liability for the price received in connection with any sale of securities, the timing thereof or any delay in action or omission to act nor shall it be responsible for any error or delay in action, omission to act, default or negligence on the part of the party so retained in connection with any such sale or proposed sale. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The depositary has no obligation to inform ADR holders or beneficial owners about the requirements of the laws, rules or regulations or any changes therein or thereto of the Cayman Islands, Hong Kong, the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">66</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">People&#8217;s Republic of China, the United States or any other country or jurisdiction or of any governmental or regulatory authority or any securities exchange or market or automated quotation system. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Additionally, none of the depositary, the custodian or us, or any of their or our respective directors, officers, employees, agents or affiliates shall be liable for the failure by any registered holder of ADRs or beneficial owner therein to obtain the benefits of credits or refunds of non-U.S. tax paid against such ADR holder&#8217;s or beneficial owner&#8217;s income tax liability. The depositary is under no obligation to provide the ADR holders and beneficial owners, or any of them, with any information about our tax status. None of the depositary, custodian, us or any of their or our respective directors, officers, employees, agents or affiliates shall incur any liability for any tax or tax consequences that may be incurred by registered ADR holders or beneficial owners on account of their ownership or disposition of ADRs or ADSs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Neither the depositary nor its agents will be responsible for any failure to carry out any instructions to vote any of the deposited securities, for the manner in which any voting instructions are given or deemed to be given pursuant to the terms of the deposit agreement, including instructions to give a discretionary proxy to a person designated by us, for the manner in which any vote is cast, including, without limitation, any vote cast by a person to whom the depositary is instructed (or deemed to have been instructed to grant a discretionary proxy in accordance with the deposit agreement), or for the effect of any such vote. The depositary may rely upon instructions from us or our counsel in respect of any approval or license required for any currency conversion, transfer or distribution. The depositary shall not incur any liability for the content of any information submitted to it by us or on our behalf for distribution to ADR holders or for any inaccuracy of any translation thereof, for any investment risk associated with acquiring an interest in the deposited securities, for the validity or worth of the deposited securities, for the credit-worthiness of any third party, for allowing any rights to lapse upon the terms of the deposit agreement or for the failure or timeliness of any notice from us. The depositary shall not be liable for any acts or omissions made by a successor depositary whether in connection with a previous act or omission of the depositary or in connection with any matter arising wholly after the removal or resignation of the depositary. Subject to certain customary exceptions, neither the depositary nor us, nor any of its or our agents shall be liable to the other for any indirect, special, punitive or consequential damages (excluding reasonable fees and expenses of counsel) or lost profits, in each case of any form incurred by any of them, or liable to any other person or entity (including, without limitation holders or beneficial owners of ADRs and ADSs) for any indirect, special, punitive or consequential damages (including fees and expenses of counsel) or lost profits, whether or not foreseeable and regardless of the type of action in which such a claim may be brought. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the deposit agreement each party thereto (including, for avoidance of doubt, each ADR holder and beneficial owner) irrevocably waives, to the fullest extent permitted by applicable law, any right it may have to a trial by jury in any suit, action or proceeding against the depositary and/or us directly or indirectly arising out of or relating to the shares or other deposited securities, the ADSs or the ADRs, the deposit agreement or any transaction contemplated therein, or the breach thereof (whether based on contract, tort, common law or any other theory). No provision of the deposit agreement or the ADRs is intended to constitute a waiver or limitation of any rights which an ADR holder or any beneficial owner may have under the Securities Act of 1933 or the Securities Exchange Act of 1934, to the extent applicable. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The depositary and its agents may own and deal in any class of securities of our company and our affiliates and in ADRs. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Disclosure of Interest in ADSs</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">To the extent that the provisions of or governing any deposited securities may require disclosure of or impose limits on beneficial or other ownership of, or interest in, deposited securities, other shares and other securities and may provide for blocking transfer, voting or other rights to enforce such disclosure or limits, you as ADR holders or beneficial owners agree to comply with all such disclosure requirements and ownership limitations and to comply with any reasonable instructions we may provide in respect thereof. We reserve the right to instruct you as ADS holders to deliver your ADSs for cancellation and withdrawal of the deposited securities so as to permit us to deal directly with the holder thereof as a holder of shares and, by holding an ADS or an interest therein, you and beneficial owners will be agreeing to comply with such instructions. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">67</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Books of Depositary</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The depositary or its agent will maintain a register for the registration, registration of transfer, combination and split-up of ADRs, which register shall include the depositary&#8217;s direct registration system. Registered holders of ADRs may inspect such records at the depositary&#8217;s office at all reasonable times, but solely for the purpose of communicating with other ADR holders in the interest of the business of our company or a matter relating to the deposit agreement. Such register may be closed at any time or from time to time, when deemed expedient by the depositary or, in the case of the issuance book portion of the ADR Register, when reasonably requested by the Company solely in order to enable the Company to comply with applicable law. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The depositary will maintain facilities for the delivery and receipt of ADRs. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Appointment</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the deposit agreement, each registered holder of ADRs and each beneficial owner, upon acceptance of any ADSs or ADRs (or any interest in any of them) issued in accordance with the terms and conditions of the deposit agreement will be deemed for all purposes to: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">be a party to and bound by the terms of the deposit agreement and the applicable ADR or ADRs, </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">appoint the depositary its attorney-in-fact, with full power to delegate, to act on its behalf and to take any and all actions contemplated in the deposit agreement and the applicable ADR or ADRs, to adopt any and all procedures necessary to comply with applicable laws and to take such action as the depositary in its sole discretion may deem necessary or appropriate to carry out the purposes of the deposit agreement and the applicable ADR and ADRs, the taking of such actions to be the conclusive determinant of the necessity and appropriateness thereof; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">acknowledge and agree that (i)&#160;nothing in the deposit agreement or any ADR shall give rise to a partnership or joint venture among the parties thereto, nor establish a fiduciary or similar relationship among such parties, (ii)&#160;the depositary, its divisions, branches and affiliates, and their respective agents, may from time to time be in the possession of non-public information about us, ADR holders, beneficial owners and/or their respective affiliates, (iii)&#160;the depositary and its divisions, branches and affiliates may at any time have multiple banking relationships with us, ADR holders, beneficial owners and/or the affiliates of any of them, (iv)&#160;the depositary and its divisions, branches and affiliates may, from time to time, be engaged in transactions in which parties adverse to us, ADR holders, beneficial owners and/or their respective affiliates may have interests, (v)&#160;nothing contained in the deposit agreement or any ADR(s) shall (A)&#160;preclude the depositary or any of its divisions, branches or affiliates from engaging in any such transactions or establishing or maintaining any such relationships, or (B)&#160;obligate the depositary or any of its divisions, branches or affiliates to disclose any such transactions or relationships or to account for any profit made or payment received in any such transactions or relationships, (vi)&#160;the depositary shall not be deemed to have knowledge of any information held by any branch, division or affiliate of the depositary and (vii)&#160;notice to an ADR holder shall be deemed, for all purposes of the deposit agreement and the ADRs, to constitute notice to any and all beneficial owners of the ADSs evidenced by such ADR holder&#8217;s ADRs. For all purposes under the deposit agreement and the ADRs, the ADR holders thereof shall be deemed to have all requisite authority to act on behalf of any and all beneficial owners of the ADSs evidenced by such ADRs. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:11.61pt; width:436pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Governing Law</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The deposit agreement, the ADSs and the ADRs are governed by and construed in accordance with the internal laws of the State of New York. In the deposit agreement, we have submitted to the non-exclusive jurisdiction of the courts of the State of New York and appointed an agent for service of process on our behalf. Any action based on the deposit agreement, the ADSs, the ADRs or the transactions contemplated therein or thereby may also be instituted by the depositary against us in any competent court in the Cayman Islands, Hong Kong, the People&#8217;s Republic of China and the United States. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under the deposit agreement, by holding or owning an ADR or ADS or an interest therein, ADR holders and beneficial owners each irrevocably agree that any legal suit, action or proceeding against or </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">68</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:148pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">involving ADR holders or beneficial owners brought by us or the depositary, arising out of or based upon the deposit agreement, the ADSs, the ADRs or the transactions contemplated thereby, may be instituted in a state or federal court in New York, New York, irrevocably waive any objection which you may have to the laying of venue of any such proceeding, and irrevocably submit to the non-exclusive jurisdiction of such courts in any such suit, action or proceeding. By holding or owning an ADR or ADS or an interest therein, ADR holders and beneficial owners each also irrevocably agree that any legal suit, action or proceeding against or involving the depositary brought by ADR holders or beneficial owners, arising out of or based upon the deposit agreement, the ADSs, the ADRs or the transactions contemplated thereby, may only be instituted in a state or federal court in New York, New York. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Notwithstanding the foregoing, (i)&#160;the depositary may, in its sole discretion, elect to institute any dispute, suit, action, controversy, claim or proceeding directly or indirectly based on, arising out of or relating to the deposit agreement, the ADSs, the ADRs or the transactions contemplated therein or thereby, including without limitation any question regarding its or their existence, validity, interpretation, performance or termination, against any other party or parties to the deposit agreement (including, without limitation, against ADR holders and beneficial owners of interests in ADSs), by having the matter referred to and finally resolved by an arbitration conducted under the terms described below, and (ii)&#160;the depositary may in its sole discretion require, by written notice to the relevant party or parties, that any dispute, suit, action, controversy, claim or proceeding against the depositary by any party or parties to the deposit agreement (including, without limitation, by ADR holders and beneficial owners of interests in ADSs) shall be referred to and finally settled by an arbitration conducted under the terms described below. Any such arbitration shall be conducted in the English language either in New York, New York in accordance with the Commercial Arbitration Rules of the American Arbitration Association or in Hong Kong following the arbitration rules of the United Nations Commission on International Trade Law (UNCITRAL). </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Jury Trial Waiver</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the deposit agreement, each party thereto (including, for the avoidance of doubt, each holder and beneficial owner of, and/or holder of interests in, ADSs or ADRs) irrevocably waives, to the fullest extent permitted by applicable law, any right it may have to a trial by jury in any suit, action or proceeding against the depositary and/or us directly or indirectly arising out of or relating to the shares or other deposited securities, the ADSs or the ADRs, the deposit agreement or any transaction contemplated therein, or the breach thereof (whether based on contract, tort, common law or any other theory), including any claim under the U.S. federal securities laws. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If we or the depositary were to oppose a jury trial demand based on such waiver, the court would determine whether the waiver was enforceable in the facts and circumstances of that case in accordance with applicable state and federal law, including whether a party knowingly, intelligently and voluntarily waived the right to a jury trial. The waiver to right to a jury trial in the deposit agreement is not intended to be deemed a waiver by any holder or beneficial owner of ADSs of our or the depositary&#8217;s compliance with the U.S. federal securities laws and the rules and regulations promulgated thereunder.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">69</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tEOC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ENFORCEABILITY OF CIVIL LIABILITIES</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Adagene Inc. is incorporated in the Cayman Islands in order to enjoy the following benefits: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">political and economic stability; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">an effective judicial system; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a favorable tax system; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the absence of exchange control or currency restrictions; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the availability of professional and support services. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">However, certain disadvantages accompany incorporation in the Cayman Islands. These disadvantages include, but are not limited to, the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the Cayman Islands has a less developed body of securities laws as compared to the United States and these securities laws provide significantly less protection to investors; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Cayman Islands companies may not have standing to sue before the federal courts of the United States. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our constitutional documents do not contain provisions requiring that disputes, including those arising under the securities laws of the United States, between us, our officers, directors and shareholders, be arbitrated. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have substantive business operations conducted in China, and a significant portion of our assets are located in China. A number of our directors and executive officers are nationals or residents of jurisdictions other than the United States and a substantial portion of their assets are located outside the United States. As a result, it may be difficult for a shareholder to effect service of process within the United States upon these persons, or to enforce against us or them judgments obtained in United States courts, including judgments predicated upon the civil liability provisions of the securities laws of the United States or any state in the United States. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have appointed Cogency Global Inc., located at 122 East 42nd Street, 18th Floor, New York, NY 10168, as our agent upon whom process may be served in any action brought against us under the securities laws of the United States. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Walkers (Hong Kong), our counsel as to Cayman Islands law, and Tian Yuan Law Firm, our counsel as to PRC law, have advised us, respectively, that there is uncertainty as to whether the courts of the Cayman Islands and China, respectively, would: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">recognize or enforce judgments of United States courts obtained against us or our directors or officers predicated upon the civil liability provisions of the securities laws of the United States or any state in the United States; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">entertain original actions brought in each respective jurisdiction against us or our directors or officers predicated upon the securities laws of the United States or any state in the United States. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have been advised by our Cayman Islands legal counsel, Walkers (Hong Kong), that the courts of the Cayman Islands are unlikely (i)&#160;to recognize or enforce against us judgments of courts of the United States predicated upon the civil liability provisions of the securities laws of the United States or any State; and (ii)&#160;in original actions brought in the Cayman Islands, to impose liabilities against us predicated upon the civil liability provisions of the securities laws of the United States or any State, so far as the liabilities imposed by those provisions are penal in nature. In those circumstances, although there is no statutory enforcement in the Cayman Islands of judgments obtained in the United States, the courts of the Cayman Islands, will, at common law, recognize and enforce a foreign money judgment of a foreign court of competent jurisdiction without retrial on the merits of the underlying dispute, based on the principle that a judgment of a competent foreign court imposes upon the judgment debtor an obligation to pay the sum for which judgment has been given provided certain conditions are met. For such a foreign judgment to be enforced in the Cayman Islands, such judgment must be final and conclusive and for a liquidated sum, and must not be in respect of taxes or a fine or penalty nor inconsistent with a Cayman Islands judgment in respect of the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">70</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:200pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">same matter, impeachable on the grounds of fraud or obtained in a manner, and be of a kind the enforcement of which is, contrary to natural justice or the public policy of the Cayman Islands (awards of punitive or multiple damages may well be held to be contrary to public policy). A Cayman Islands court may stay enforcement proceedings if concurrent proceedings are being brought elsewhere. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PRC</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have been advised by Tian Yuan Law Firm, our PRC legal counsel, that there is uncertainty as to whether the courts of the PRC would enforce judgments of United States courts or Cayman courts obtained against us or these persons predicated upon the civil liability provisions of the U.S. federal and state securities laws. Tian Yuan Law Firm has further advised us that the recognition and enforcement of foreign judgments are provided for under the PRC Civil Procedures Law. PRC courts may recognize and enforce foreign judgments in accordance with the requirements of the PRC Civil Procedures Law and other applicable laws and regulations based either on treaties between China and the country where the judgment is made or on principles of reciprocity between jurisdictions. China does not have any treaties or other form of reciprocity with the United States or the Cayman Islands that provide for the reciprocal recognition and enforcement of foreign judgments. In addition, some of our executive officers and directors reside within China for a significant portion of the time and some are PRC nationals. Further, according to the PRC Civil Procedures Law, courts in the PRC will not enforce a foreign judgment against us or our directors and officers if they decide that the judgment violates the basic principles of PRC law or national sovereignty, security or public interest. As a result, it may be difficult for our shareholders or investors to effect service of process upon us or such individuals inside China, and it is uncertain whether and on what basis a PRC court would enforce a judgment rendered by a court in the United States or in the Cayman Islands. Under the PRC Civil Procedures Law, foreign shareholders may originate actions based on PRC law against a company in the PRC, if they can establish sufficient nexus to the PRC for a PRC court to have jurisdiction, and meet other procedural requirements. However, it would be difficult for foreign shareholders to establish sufficient nexus to the PRC by virtue only of holding the ADSs or ordinary shares. See &#8220;Risk Factors&#8201;&#8212;&#8201; Risks Related to Doing Business in the PRC&#8201;&#8212;&#8201;Your investments in our ADSs, Ordinary Shares and/or other Securities are investments in securities of a Cayman Islands holding company rather than securities of our subsidiaries that have substantive business operations in China. As a result, you may experience difficulties in effecting service of legal process, enforcing foreign judgments or bringing actions in China against us or our management based on foreign laws.&#8221; and &#8220;Item 3 Key Information&#8201;&#8212;&#8201;Risk Factors&#8201;&#8212;&#8201;Risks Related to the ADSs&#8201;&#8212;&#8201;You may face difficulties in protecting your interests, and your ability to protect your rights through U.S. courts may be limited, because we are incorporated under Cayman Islands law&#8221; in our annual report on Form 20-F for the year ended December 31, 2021, which is incorporated in this prospectus by reference. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">71</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tTAX">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:572pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">TAXATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">Material income tax consequences relating to the purchase, ownership and disposition of any of the Securities offered by this prospectus will be set forth in the applicable prospectus supplement(s) relating to the offering of those Securities. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">72</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tSESH">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:448pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SELLING SHAREHOLDERS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Selling shareholders and their pledgees, donees, transferees or other successors-in-interest (collectively, the &#8220;Selling Shareholders&#8221;) to be named in a prospectus supplement may, from time to time, offer and sell some or all of the shares of our ordinary shares held by them pursuant to this prospectus and the applicable prospectus supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Such Selling Shareholders may sell shares of our ordinary shares or ADSs held by them to or through underwriters, dealers or agents or directly to purchasers or as otherwise set forth in the applicable prospectus supplement. See &#8220;Plan of Distribution.&#8221; Such Selling Shareholders may also sell, transfer or otherwise dispose of some or all of our ordinary shares held by them in transactions exempt from the registration requirements of the Securities Act. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We will provide you with a prospectus supplement, which will set forth the name of each Selling Shareholder, the number of shares of our ordinary shares beneficially owned by such Selling Shareholders and the number of our ordinary shares or ADSs they are offering. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">73</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tPOD">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PLAN OF DISTRIBUTION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We and/or the Selling Shareholders may collectively offer and sell, from time to time, some or all of the Securities covered by this prospectus up to US$200,000,000. We have registered the Securities covered by this prospectus for offer and sale by us and/or the Selling Shareholders so that those Securities may be freely sold to the public by us and/or Selling Shareholders. Registration of the Securities covered by this prospectus does not mean, however, that those Securities necessarily will be offered or sold. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Securities covered by this prospectus may be sold from time to time, in one or more transactions, at market prices prevailing at the time of sale, at prices related to market prices, at a fixed price or prices subject to change, at varying prices determined at the time of sale or at negotiated prices. The Securities being offered by this prospectus may be sold: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">through agents; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to or through one or more underwriters on a firm commitment or agency basis; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">through put or call option transactions relating to the Securities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">through broker-dealers (acting as agent or principal); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">directly to purchasers, through a specific bidding or auction process, on a negotiated basis or otherwise; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">through any other method permitted pursuant to applicable law; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">through a combination of any such methods of sale. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">At any time a particular offer of the Securities covered by this prospectus is made, a revised prospectus or prospectus supplement, if required, will be distributed which will set forth the aggregate amount of Securities covered by this prospectus being offered and the terms of the offering, including the name or names of any underwriters, dealers, brokers or agents, any discounts, commissions, concessions and other items constituting compensation from us and any discounts, commissions or concessions allowed or reallowed or paid to dealers. Such prospectus supplement, and, if necessary, a post-effective amendment to the registration statement of which this prospectus is a part, will be filed with the SEC to reflect the disclosure of additional information with respect to the distribution of the Securities covered by this prospectus. In order to comply with the securities laws of certain states, if applicable, the Securities sold under this prospectus may only be sold through registered or licensed broker-dealers. In addition, in some states the Securities may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from registration or qualification requirements is available and is complied with. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Any public offering price and any discounts or concessions allowed or reallowed or paid to dealers may be changed from time to time. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The distribution of Securities may be effected from time to time in one or more transactions, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">block transactions (which may involve crosses) and transactions on Nasdaq or any other organized market where the Securities may be traded; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">purchases by a broker-dealer as principal and resale by the broker-dealer for its own account pursuant to a prospectus supplement; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">ordinary brokerage transactions and transactions in which a broker-dealer solicits purchasers; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">sales &#8220;at the market&#8221; to or through a market maker or into an existing trading market, on an exchange or otherwise; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">sales in other ways not involving market makers or established trading markets, including direct sales to purchasers. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Securities may be sold at a fixed price or prices, which may be changed, or at market prices prevailing at the time of sale, at prices relating to the prevailing market prices or at negotiated prices. The consideration may be cash or another form negotiated by the parties. Agents, underwriters or broker-dealers may be paid compensation for offering and selling the Securities. That compensation may be in the form of </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">74</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">discounts, concessions or commissions to be received from us or from the purchasers of the Securities. Any dealers and agents participating in the distribution of the Securities may be deemed to be underwriters, and compensation received by them on resale of the Securities may be deemed to be underwriting discounts. If any such dealers or agents were deemed to be underwriters, they may be subject to statutory liabilities under the Securities Act. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Agents may from time to time solicit offers to purchase the Securities. If required, we will name in the applicable prospectus supplement any agent involved in the offer or sale of the Securities and set forth any compensation payable to the agent. Unless otherwise indicated in the prospectus supplement, any agent will be acting on a best efforts basis for the period of its appointment. Any agent selling the Securities covered by this prospectus may be deemed to be an underwriter, as that term is defined in the Securities Act, of the Securities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If underwriters are used in a sale, Securities will be acquired by the underwriters for their own account and may be resold from time to time in one or more transactions, including negotiated transactions, at a fixed public offering price or at varying prices determined at the time of sale, or under delayed delivery contracts or other contractual commitments. Securities may be offered to the public either through underwriting syndicates represented by one or more managing underwriters or directly by one or more firms acting as underwriters. If an underwriter or underwriters are used in the sale of Securities, an underwriting agreement will be executed with the underwriter or underwriters, as well as any other underwriter or underwriters, with respect to a particular underwritten offering of Securities, and will set forth the terms of the transactions, including compensation of the underwriters and dealers and the public offering price, if applicable. The prospectus and prospectus supplement will be used by the underwriters to resell the Securities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If a dealer is used in the sale of the Securities, we or an underwriter will sell the Securities to the dealer, as principal. The dealer may then resell the Securities to the public at varying prices to be determined by the dealer at the time of resale. To the extent required, we will set forth in the prospectus supplement the name of the dealer and the terms of the transactions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may directly solicit offers to purchase the Securities and may make sales of Securities directly to institutional investors or others. These persons may be deemed to be underwriters within the meaning of the Securities Act with respect to any resale of the Securities. To the extent required, the prospectus supplement will describe the terms of any such sales, including the terms of any bidding or auction process, if used. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Agents, underwriters and dealers may be entitled under agreements which may be entered into with us to indemnification by us against specified liabilities, including liabilities incurred under the Securities Act, or to contribution by us to payments they may be required to make in respect of such liabilities. If required, the prospectus supplement will describe the terms and conditions of the indemnification or contribution. Some of the agents, underwriters or dealers, or their affiliates may be customers of, engage in transactions with or perform services for us, our subsidiaries, the Selling Shareholders or their affiliates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under the Securities laws of some jurisdictions, the Securities offered by this prospectus may be sold in those jurisdictions only through registered or licensed brokers or dealers. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Any person participating in the distribution of Securities registered under the registration statement that includes this prospectus will be subject to applicable provisions of the Exchange Act, and the applicable SEC rules and regulations, including, among others, Regulation&#160;M, which may limit the timing of purchases and sales of any of our Securities by that person. Furthermore, Regulation&#160;M may restrict the ability of any person engaged in the distribution of our Securities to engage in market-making activities with respect to our Securities. These restrictions may affect the marketability of our Securities and the ability of any person or entity to engage in market-making activities with respect to our Securities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Certain persons participating in an offering may engage in over-allotment, stabilizing transactions, short-covering transactions and penalty bids that stabilize, maintain or otherwise affect the price of the offered Securities. These activities may maintain the price of the offered Securities at levels above those that might otherwise prevail in the open market, including by entering stabilizing bids, effecting syndicate covering transactions or imposing penalty bids, each of which is described below. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">75</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">A stabilizing bid means the placing of any bid, or the effecting of any purchase, for the purpose of pegging, fixing or maintaining the price of a security. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">A syndicate covering transaction means the placing of any bid on behalf of the underwriting syndicate or the effecting of any purchase to reduce a short position created in connection with the offering. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">A penalty bid means an arrangement that permits the managing underwriter to reclaim a selling concession from a syndicate member in connection with the offering when offered Securities originally sold by the syndicate member are purchased in syndicate covering transactions. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">These transactions may be effected on an exchange or automated quotation system, if the Securities are listed on that exchange or admitted for trading on that automated quotation system, or in the over-the-counter market or otherwise. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If so indicated in the applicable prospectus supplement, we will authorize agents, underwriters or dealers to solicit offers from certain types of institutions to purchase offered Securities from us at the public offering price set forth in such prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. Such contracts will be subject only to those conditions set forth in the prospectus supplement and the prospectus supplement will set forth the commission payable for solicitation of such contracts. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Each series of offered Securities, other than the ordinary shares, will be a new issue of Securities and will have no established trading market. Any underwriters to whom offered Securities are sold for public offering and sale may make a market in such offered Securities, but such underwriters will not be obligated to do so and may discontinue any market making at any time without notice. The offered Securities may or may not be listed on a national Securities exchange. No assurance can be given that there will be a market for the offered Securities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Any Securities that qualify for sale pursuant to Rule&#160;144 or Regulation&#160;S under the Securities Act may be sold under Rule&#160;144 or Regulation&#160;S rather than pursuant to this prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">To the extent that we make sales to or through one or more underwriters or agents in at-the-market offerings, we will do so pursuant to the terms of a distribution agreement between us, the Selling Shareholders, if any, and the underwriters or agents. If we engage in at-the-market sales pursuant to a distribution agreement, we and/or the Selling Shareholders, if any, will offer and sell our ordinary shares to or through one or more underwriters or agents, which may act on an agency basis or on a principal basis. During the term of any such agreement, we and/or the Selling Shareholders, if any, may sell ordinary shares on a daily basis in exchange transactions or otherwise as and/or the Selling Shareholders, if any, agree with the underwriters or agents. The distribution agreement will provide that any ordinary shares sold will be sold at prices related to the then prevailing market prices for our ordinary shares. Therefore, exact figures regarding proceeds that will be raised or commissions to be paid cannot be determined at this time and will be described in a prospectus supplement. Pursuant to the terms of the distribution agreement, we and/or the Selling Shareholders, if any, also may agree to sell, and the relevant underwriters or agents may agree to solicit offers to purchase, blocks of our ordinary shares or other Securities. The terms of each such distribution agreement will be set forth in more detail in a prospectus supplement to this prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In connection with offerings made through underwriters or agents, we and/or the Selling Shareholders, if any, may enter into agreements with such underwriters or agents pursuant to which we and/or the Selling Shareholders, as applicable, receive our outstanding Securities in consideration for the Securities being offered to the public for cash. In connection with these arrangements, the underwriters or agents may also sell Securities covered by this prospectus to hedge their positions in these outstanding Securities, including in short sale transactions. If so, the underwriters or agents may use the Securities received from us under these arrangements to close out any related open borrowings of Securities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">One or more firms, referred to as &#8220;remarketing firms,&#8221; may also offer or sell the Securities, if the prospectus supplement so indicates, in connection with a remarketing arrangement upon their purchase. Remarketing firms will act as principals for their own accounts or as agents for us. These remarketing firms will offer or sell the Securities in accordance with a redemption or repayment pursuant to the terms of the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">76</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:360pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Securities. The prospectus supplement will identify any remarketing firm and the terms of its agreement, if any, with us and will describe the remarketing firm&#8217;s compensation. Remarketing firms may be deemed to be underwriters in connection with the Securities they remarket. Remarketing firms may be entitled under agreements that may be entered into with us to indemnification by us against certain civil liabilities, including liabilities under the Securities Act and may be customers of, engage in transactions with or perform services for us in the ordinary course of business. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may enter into derivative transactions with third parties or sell Securities not covered by this prospectus to third parties in privately negotiated transactions. If the applicable prospectus supplement indicates, in connection with those derivatives, such third parties (or affiliates of such third parties) may sell Securities covered by this prospectus and the applicable prospectus supplement, including in short sale transactions. If so, such third parties (or affiliates of such third parties) may use Securities pledged by us or borrowed from us or others to settle those sales or to close out any related open borrowings of shares, and may use Securities received from us in settlement of those derivatives to close out any related open borrowings of shares. The third parties (or affiliates of such third parties) in such sale transactions will be underwriters and, if not identified in this prospectus, will be identified in the applicable prospectus supplement (or a post-effective amendment). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We and/or the Selling Shareholders may loan or pledge Securities to a financial institution or other third party that in turn may sell the Securities using this prospectus. Such financial institution or third party may transfer its short position to investors in our Securities or in connection with a simultaneous offering of other Securities offered by this prospectus or in connection with a simultaneous offering of other Securities offered by this prospectus. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">77</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tEXP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:420.5pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EXPENSES</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth an estimate of the fees and expenses relating to the issuance and distribution of the Securities being registered hereby, all of which shall be borne by our company. All of such fees and expenses, except for the SEC registration fee, are estimated. </font>
        </div>
        <table style="width:416pt;height:100.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:371.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">SEC registration fee </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">18,540</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:371.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">FINRA fees </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">30,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:371.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Legal fees and expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8203;</font><font style="position:absolute;"><font style="font-weight:bold;"></font>*</font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:371.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Printing fees and expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8203;</font><font style="position:absolute;"><font style="font-weight:bold;"></font>*</font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:371.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Accounting fees and expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8203;</font><font style="position:absolute;"><font style="font-weight:bold;"></font>*</font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:371.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Miscellaneous fees and expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8203;</font><font style="position:absolute;"><font style="font-weight:bold;"></font>*</font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:371.29pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8203;</font><font style="position:absolute;"><font style="font-weight:bold;"></font>*</font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:5.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">*</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:10pt; text-align:left; margin-left:20pt;font-size:8pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.16pt;">To be provided by a prospectus supplement or as an exhibit to a report on Form 6-K that is incorporated by reference into this prospectus. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">78</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tIOCD">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:248pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We incorporate by reference the filed documents listed below, except as superseded, supplemented or modified by this prospectus: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1818838/000110465922050329/adag-20211231x20f.htm">our annual report on Form 20-F for the fiscal year ended December&#160;31, 2021, filed with the SEC on April&#160;26, 2022 (File No. 001-39997);</a> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;letter-spacing:0.2pt;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;letter-spacing:0.2pt;">
          <!--blacklining:none;-->
          <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1818838/000110465921011303/a20-29876_128a12b.htm">the description of our ordinary shares contained in the registration statement on Form 8-A filed with the SEC on February&#160;3, 2021, and any other amendment or report filed for the purpose of updating such description;</a><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any future annual reports on Form 20-F filed with the SEC after the date of this prospectus and prior to the termination of the offering of the Securities offered by this prospectus; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any future reports on Form 6-K that we furnished to the SEC after the date of this prospectus that are identified in such reports as being incorporated by reference in this prospectus. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Potential investors, including any beneficial owner, may obtain a copy of any of the documents summarized herein (subject to certain restrictions because of the confidential nature of the subject matter) or any of our SEC filings incorporated by reference herein without charge by written request directed to 4F, Building C14, No. 218, Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu Province, 215123, People&#8217;s Republic of China. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You should rely only on the information incorporated by reference or provided in this prospectus or any prospectus supplement. We have not authorized anyone else to provide you with different information. We are not making an offer of these Securities in any state where the offer is not permitted. You should not assume that the information in this prospectus or any prospectus supplement is accurate as of any date other than the date on the front of those documents. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Any statement contained in a document incorporated by reference herein shall be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained herein, or in a subsequently filed document incorporated by reference herein, modifies or supersedes that statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute part of this prospectus. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">79</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tLEMA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:500pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">LEGAL MATTERS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are being represented by Davis Polk &amp; Wardwell LLP with respect to certain legal matters as to United States federal securities and New York State law. Certain legal matters in connection with any offering made pursuant to this prospectus will be passed upon for the underwriters by a law firm named in the applicable prospectus supplement. The validity of the ordinary shares represented by the ADSs will be passed upon for us by Walkers (Hong Kong). Certain legal matters as to PRC law (excluding the laws of Taiwan, Hong Kong and Macau) will be passed upon for us by Tian Yuan Law Firm and for the underwriters by a law firm named in the applicable prospectus supplement. Davis Polk &amp; Wardwell LLP may rely upon Walkers (Hong Kong) with respect to matters governed by Cayman Islands law and Tian Yuan Law Firm with respect to matters governed by PRC law (excluding the laws of Taiwan, Hong Kong and Macau). </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">80</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tEPTR">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:528pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">EXPERTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">The financial statements incorporated in this Prospectus by reference to the Annual Report on Form&#160;20-F for the year ended December 31, 2021 have been so incorporated in reliance on the report of PricewaterhouseCoopers Zhong Tian LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">The offices of PricewaterhouseCoopers Zhong Tian LLP are located at 42/F New Bund Center, 588&#160;Dongyu Road, Pudong New Area, Shanghai 200126, the People&#8217;s Republic of China. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">81</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tWYCF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:396pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">WHERE YOU CAN FIND MORE INFORMATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have filed with the SEC a registration statement on Form F-3 under the Securities Act with respect to the offer and sale of Securities pursuant to this prospectus. This prospectus, filed as a part of the registration statement, does not contain all of the information set forth in the registration statement or the exhibits and schedules thereto in accordance with the rules and regulations of the SEC and no reference is hereby made to such omitted information. Statements made in this prospectus concerning the contents of any contract, agreement or other document filed as an exhibit to the registration statement are summaries of all of the material terms of such contract, agreement or document, but do not repeat all of their terms. Reference is made to each such exhibit for a more complete description of the matters involved and such statements shall be deemed qualified in their entirety by such reference. The registration statement and the exhibits and schedules thereto filed with the SEC may be obtained from the SEC&#8217;s website that contains reports, proxy and information statements and other information regarding registrants that file electronically through the SEC&#8217;s Electronic Data Gathering, Analysis and Retrieval (&#8220;EDGAR&#8221;) system, including the Company, which can be accessed at http://www.sec.gov. For further information pertaining to the Securities offered by this prospectus and Adagene Inc., reference is made to the registration statement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We furnish reports and other information to the SEC. You may read and copy any document we furnish at the SEC&#8217;s public reference facilities and the website of the SEC referred to above. Our file number with the SEC is 001-39997.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">82</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style=" width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 0pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:2.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 2.5pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:143.06pt; text-align:center; width:456pt; line-height:15.5pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">Up to US$100,000,000 of</font>
          <br >
          <font style="letter-spacing:-0.28pt;">American Depositary Shares</font>
          <br >
          <font style="letter-spacing:-0.28pt;">Representing Ordinary Shares</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="position:relative;margin-top:47.45pt; text-align:center; width:456pt;">
          <img src="lg_adagene-4clr.jpg" alt="[MISSING IMAGE: lg_adagene-4clr.jpg]" height="44" width="204" >
        </div>
        <div style="margin-top:61.56pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 55.06pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:13.62pt; text-align:center; width:456pt; line-height:14pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:12pt;">
          <font style="letter-spacing:-0.24pt;">Prospectus Supplement</font><font style="font-weight:normal;letter-spacing:0.24pt;"> </font>
        </div>
        <div style="margin-top:15.943pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 15.9433333333333pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:54.06pt; text-align:center; width:456pt; line-height:20pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:18pt;">
          <font style="letter-spacing:-0.36pt;">Leerink Partners</font><font style="font-weight:normal;letter-spacing:0.36pt;"> </font>
        </div>
        <div style="margin-top:92.8pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">March&#160;29, 2024 </font>
        </div>
        <div style="margin-top:143.36pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 143.36pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:2.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 2.5pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
      </div>
      <hr >
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>lg_adagene-4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lg_adagene-4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ + #, P$1  (1 0,1 ?_$ /@   ,!  (# 0
M      @)"@<"!@ $!0,!  ,  @,! 0$           8'" 4)  ($ 0,*$
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M>GNTG_.*)^+J]T6&?I%?T*2?Y9@_@XEAEHNP:5[^U>T<,&I%JKMS+UI6]/'
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M@$=G5AH':RTP0:C+55 8(J"A5V].SVK,7PVUOBJ!-T&(>W+1GTAMY3$%YO\
MA!EUB][A^>._F6B\D%1=M7-*(0$K1;*>,$[3999R+Q60?-%CIN1=(;*( T
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M8" @.F*U&)&;8Y&UB?<LP_!$A$3PYTE"P\A428!!O!!7>#U$766<F=;MW]Q
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M/YQPY7N-]O/]D;>S\N&C[R3WN[L2O+.!X)D1W$Q'_G5M>9=M:SX++:@?%/\
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M#Y?VOAH]/[^[N6[?\[;4N/U.]_?;9_H/[/);C_\ GQ_.K_P9:??[^_\ IO\
M&VZ_\'7_ -W_ / V/+_XF?9^?^NOI-ZP?]B>N>?[7_,O*MK_ %7#0%_O3W\_
E['S;A?AX;OQGO:M67_#]^J'_ +2^KCO#_HW&\0]_!87W3+?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm2213007d1-pc_neobody4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2213007d1-pc_neobody4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@#1@,X P$1  (1 0,1 ?_$ 0<  0 " @(# 0$
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MDL@Z)>PNL99BI_'&PM6O_N][X,'%6?8>T4!GRK,GZED):)256SXN,P+RE=3
M/DK$BR)_03Q,"9Q.K%LL-]ZQ=<KS;I-6:M=TT/J&V6>862;(+2UAL>OJ],34
MFJ@S1;-$57\D\55,1)--,HGX*4I> #!O*L3'P.3[E@XBA,2'/R(T47.E$E=5
M6Y))L !U)/Q-37[8[KG[YVVX]O>ZR&;=,S8\">:0@ O++BQ22.0H"@L[%B%
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M>9?5:NT&,:"F/F!C L?8SIS[A1 ."B@ " _S (<975[(<GU6DRL +;Q#3'_
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M!O#:.?\ ,]C*C;MQR1$@L$=O5C Z]!'+K0>)\%!OU'7K6).5]ANSW-1(V_\
M'MN;*F<.\T,?TN0[#39GR,4PS/T500SL"HT,"MQ46^X_]G[T58P<OM);=ONL
M9!0XJIP]N91VQJP0 *;Q9LQ2/5+(Q2./'*J[Z0.3U'Q-Z%#*.S^X'?<:T>]X
M>/E1@6U1EH7^\W]1#]RJ@^T5&CEOL,X5N!:?AF[Y^VS,U_3R$3+A M;0EOIY
MD%['5)).1UZ&XTZQ#U<^ZGI6<CG3.SYC<U)CR'$D+6+BCL:%:QK4P*)LRZRV
MXT;R#)R_2.8IB0#5=8HE$ 6 03.-T?VI[*<U&G><5,/-8_BDC,+ECXGU\<D$
M*?\ 2L!UOIMJ QC_ *LO>1V:82<0W&?=MFC0_)CY(S(4CC:ZH,'/575Y%8W&
M)"[#25]6XB+=YH/WM;?UA.(4CN)U=D(B::G*$Q(51O.Z\MD>S\52IN%M:;#2
M<ED7BZA  P_JT8CR!A*4/0@>#/[$;/NF.<[A^Z!X"/E$FF:-C<7'KPD:0!_N
M<A\+^-ZK^Q^]_E_&MP78^[7&6BS%8>JT'JXF1''I-F^CR@WJ.S #K/CI8L1U
M729:]"_9WTK[#&81]3W)#U6UORM +2-GD'7]B!X]Y!&+9K3:A*U89/S*)12B
M9&0X'CU$!*(XEW_M?S7CNJ3*PWFQ%)_-@_-2R^+$+^8BVZWD1/\  ;2GX)[F
M.S?<#T\?;=VCPMVD6,_39P^EE#R$A8E=S]/-+J&DIC3SV-NMF4MOV4Q3% Q1
M Q3 !BF*("4Q1#D! 0]! 0S']9Z!!%QX5_<5]IBE,4IBE,4IBE,4IBE,4IBE
M,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE
M,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE
M,4IBE,4IBE,4IBE,4IBE,4KH>P]I:WU) GM&S[W4Z!7R&,F65MT]&P31=<I?
M,&C,\@X0%\^4#^1!$%%E!$ *41$ SW;?M>X[M/\ 3;9!+//_ !8U+$#XFP-A
M]IL!\:MOD_,>*<*V_P#5>7[EA;9MUR!)DS1PJS $Z$UL"[V!(1 SGR!J'[>W
MWC: I/RHO1U0LVZ)@@>*4](E<:_HQ3'(7A5)>8CW%OD#ME!'S1-%,TU/'@CC
M@WD&6MD[*[[EVDWN:+#B_B+:63H?/21& ?(B1_M6H0]P?[P;MULI;$[>;?F;
M[E6%IY0V#B_,MP5$J-ENR'H\;XT /[LOF-.T=G?<3WL*FI18F>TQK*;*V41E
M:TT-I>J_IZBP^$JQO$^Z5V79&9RB!5PB'CU)0I1 $./,,O!]L[2<&8KG&/*W
M*,L-,A^IDO;\#1*/11AY&1$()OJ\+8'Q^8>][W&11R\>3*VCB>2D+"7$7])P
MRA-Q/#F3.<[(B;IZB8V3DJR#3Z1!?5G/4_T41+IV6R=E=[3ULFWZQW\U":X;
M?#3<2*JAUG"CN^W%"4EYQ-XJ8!5.,2P7'\W!P,('+0]U[W2*OT_'<%(X5%E:
M8W^4   11D!;#P_,8>'2PM61^%?W=^/*_P"I=T^0S9&;*2\L.WKIO*S%G8YN
M4KO,')NY.'$Y)8Z[FXE<TWT7ZFZ%.U=ZWTA2V,XS52<-[7/LUKG;F[M- $#N
MF%EMZ\W+0YUP 1.FQ5;(>1AX3 /3,7;OSCE>^*8]PS9C PL40B*,B][,D857
ML? N&/0=>E3'X+[<^RG;F1,KC''L%=SCD$BY.0&S,E) GIEXI\MII,<LM[KC
MF*.[,0@U&^V66I6;*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3
M%*8I3%*8I3%*8I3%*8I3%*8I70=B:JUGMV"/6=IZ_INQ*^?W!+$72MQ%D9(*
M*E*4SAHC+-'0,GA?$HD61\%2&*4Q3 8H"%0V[==SVB?ZK:LB;&R/XT;LA(^!
M*D7'Q!N#YBJ#R'BW&N68/Z;RC;\/<<"]_3R(8YE!_C*)%;2PZ$,MF! (((%1
M%;Y^BCJ=LDCZ2U'*6_0=D7\SMT8AXM>*(#A0?-15U5K0^&<*45/Y$V4TR;I
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M%=!A\DR*B-DW%)E;S%B>M2&%%TR@2H?(2$?<CS%YXRRG'NVW;M!/O<BY>[
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M#=)GFRW-RS'[;V4"RJH\E4!5'10!6RKA_"^*\ V&#C'#L&#;]CQU"I'&#UL
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MJ@8??3LEN&2F%@<QXK/F2&R1Q[M@.['QLJKD%F/V &LHP5PJ5I*)ZS::Y8R
M50XF@IN,ER@1(Y$U3":/=.  J:BI2F'\ ,8 'U$,H\^'EXIME121G^4K+_C
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M),]B?PEJD*HFT-:;1C0F=:;#H^PXGQ\OU.D6N"M;  \S)_F=P3]\@004()1
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MQ7)Q@<5&,S R;V'E62@@)14:2,>NW=MCB41#DAP'C.F?'@RH6Q\E$D@8696
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MI0Z_(VN[V6!J%8B$07E+#9I9A!PL>B)@(4[R2DEVS-N!U# 4OD<!,80 .1$
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M+CHP!-F%F'D15;X]R3D'$]T3>^,YN3@;M&+"6"1HWTZE8HQ4C5&Q5=<;71[
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M%),HF,8P@4I0$1'C/JJSL%4$L38 >)/P%<)98X(VFF94A12S,Q "@"Y))Z
M=23T J&7MO\ <OI?3GZE3]!-X_>>PT/?:GGT'BJ6IZ\[*FY(59:=9&*[O*K=
MR1$PMXDZ;)PBH;B224)X#F'BG:#=]VTY>_EL' -CHM^>XN.FD](KC5U<%PP%
MXB#>H']Z??7PCA8DV3M@D/(>1BZG(UD;;"=+V82I\^<5<1DICM'!)&[%<U70
MQFMCV![3[V[/V(;!N2_RUE(@Z7<PM:24_3:=606\B^U7JNS%.*8&(W$$C.1(
MH]<$(7WUE3!Y#(?8N,[)QO'^GVB!(K@!G\9'MYNY^8]>MKZ02=( Z5JV[D=V
M^X/=G=?U7G.Y3YA5F,4-]&-CAOW8,=+1Q]+*7TF60*IEDD8:JU\RO5C>F*4Q
M2F*4Q2F*5,QU.Z.ZTU3KEKW0[].$ZMI]BDQDM9ZB?I&/8]J3+DJ[N#+,U]0J
M;IY&2B+7WH^'*)32:7+I\=O%HJ_+Q+RCF.X[IN#<.X*/5WDW$\X-H\=!8-9_
M ,";,_[ALD8>9@$FQV?[$\5X=QB/OU[CG&'P!-#;=MI!.3ND[W:$/#T9H75"
M\4%Q]0FK)R7@VZ"1LG7CN)]C>W>T9%J%!)I:DZ_, 9L8'4=3.DS:O8Z)/S&*
M7*08H-#39T1(F9./3*C$-!00%-L*R7R5*[Q+@&U<8MG2DY6_MJ+Y#W+7<681
M@DZ01<%NLC:F#/I.D8Y[W^YCF?> 'CN*%V?ME$(E@VK'TK%I@;5$V2ZJAF96
M"%8OEQ83%"T4 EC,SQW9?M1MIBE,4IBE,4IBE,4IBE9ET=V!V]UQN;:]Z=NT
MO3YM,422"#185H2Q,4C&/^DV>"<>Y%V"+,)S""3E(_M*""J0IJE(H6D;SL6T
M\@PS@[O"DT!\+CYE/\9&'S(WVJ1<=#<$@WMP+N-S3MCOJ<CX1N$^#N*V#!&O
M%,O7\O(A-XYX^MPDJL%:SKID56$TC">Z\_;]47%<GXZHZ![[0,4NZK4XR37;
M57;J,5&H'<M7JWQW,G*1A$&I@,R54>S<$W)\IHH^:)/6XXB;'W[M1DC)A:;/
MX([ .IL9,;4QL5%P ;G\0"Q2L=#B-VC>IQ1[IVW]ZNU'9\^+ XS[E(86?&F4
M,N)NPBB77'(VEI& 1#:)FFS,2)/J,=LO'AR\>H/=M:DV#HV_6#66SZV^JUPK
M3LS9_'/"<IKHB(BUDXMX3EM*0TDB *M72!CHKI& Q3"&9DVS=,#><&/<=MD6
M7$D%PP_P@CQ5AX,IL0>A%Z@9R_A_).!\AR>*\LQ)<+?,1RLD;C_8NC"ZR1N/
MFCD0LDB$,C%2#6.,J%6U3%*8I5M+ZD>^2^_Z0.A-KSJC[<NMX@JT!.2JHG?[
M'H+,R;9)TZ>&#_/[74@42;/3*#\E\T,B[,*ZP/EBQ:[J\&78\S]?VJ,+L^0]
MG1?"*4W/1?*.2Q*V^5&NGRJ8U.Y'V6^XN7N'LG^K+FF2\W.ML@+X\TMRV;A(
M0OSR :7R<74D;ER)IX=$Y,\B9<HDJ[*=?:+VBTM=])["0,,';XWVVDJW3(>3
MK%@9*%>5^TPYC&3\9*#E$DU@()@3<I =NKY(+*D-COC7(<_BV]0;WMQ'KPMU
M4_A="+.C?8RDB_BILRV901+KN/P#8^Y_#<WA?( WT.6@TNMP\,J,'AFC((.J
M.158J3ID75%(&C=U/S\-S:CN>AMIWK3^PF)8^X:_L#N F$D15,S="CX+,):,
M571;K.8><C%T7K)8R9!6:.$S^(>7 ; ]FW?"W[:X-XVYM6'D1AUO:XOXJP!(
M#*0587-F!%^E:&^6\5WKA')<WB?(8Q%O.!.T4@%RI(ZJ\995+12(5DB<JNN-
ME:PO:L994ZMRF*4Q2F*4Q2F*4Q2F*4Q2NQ5*X6RA6*+MU'LT_3K5"./E0]DK
M$N_@IV+<^!DQ682L8X:OFBADCF*(D.7R*80'D!$,\^5B8N=CMB9L4<V*XLR.
MH=&%[V96!!%P#U%>W;MRW'9\Z/<]HR,C$W.$DQS02/#-&Q4J6CEC99$;2Q&I
M&!L2+]:L"]0OOBN]84CJ9V[KPWV!$S=JEMBEQ[&,ND8F)C)F<6BJMP90%H;D
M Y!,LP".=))IF,*3Q4X<1^Y?V'P<H-F\0D^GR.I]"0EHV^Q'-W0^/1]:DD=4
M J>7:;WP;YMC1[/W8@.X8!*J,['1$R4!)N9X1HBG4 KUB$,BJK$K.["K*>F]
MYZC[!TUI?M,W^N[ JSKVR*/H)X"CJ+=JH)N?TNP1#@J$Q6YI-!8AU&3]!LZ3
M*8!,F " C&K>MAWCCV8<#>L>3'RA>P8=& )&I&%U=;@@,A938V-;%>'<YXCW
M V@;YPW<,;<-M) 9HFNT;E5?TYHS:2"72RL8ID20!@2H!%97RDU=E,4IBE,4
MIBE,4IBE,4IBE,4IBE,4IBE,4IBE,4K7GM!UEUAVTU'/ZBVE& XC9(OS(&?:
MI-QL%+LS=)4D9::T[73/\238BJ8IR_Y)TV45;K =%50@W%Q?D^Z<2W>/=]J>
MTJ]'0WT2(?Q1N/-3XCS5@&6S &L?]S.VO&>ZO%)^*<HBU8TGS12J!ZN/,H(2
M>%B/E=;D$?AD1GB<-&[*:V/6O?NX?IZ[+SG6'LC^HS/7BV2I99M.,FKUXS81
ML@LX8P^X* Q*LN<\5(BV*E8(M+W7)#-S@0%';4$G$D^2\?VCO#QF/D_&]*<A
MB325) )8 %L>4V'S+>\3FR_,+V1[KKJ[=\^Y5[2.Y&1VT[A^I-P+)E$@D168
M(CEDCW#%2Y)C?3IRH5U/>-@H::+1); A)N&LL-$V*NRT=/0$]',IB$FX=ZVD
MHF7B9)LF\CY.,D&:BS1\P?-%B*HK)',FHF8#%$0$!R)\\$^+.^-DHT>3&Q5T
M8%65E-F5E-B"""""+@]#6TK;]PP=UP8=TVN:+)VW)B26*6)UDCECD4,DD;J2
MKHZD,K*2K*002#7*9U5ZZ8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%
M*8I3%*8I3%*8I3%*8I6O/:#LKKWJGJ.?VOL)V4R+%,[&LUQ%P5"6NEK<-UU8
MBKQ'*3@Q5WQT#&67]LZ;-J11=0/!,<N#C/',_E&[1[7@ ]>KO:ZQQ@C4[=1X
M7Z"XU,0H-S6,.[O=;C79SA63S'D;J= *8\&K3)EY)5C%CQFS$%])+OI811AY
M6!5"#7QZD=:]K?9[ON8[:]HUW)].Q4V1NSADBJLHVW'A''N1VKJ8T^0#B(U[
M7"K<2;THF6=*F52*JH_</'C;/W*^2;1VUV->+\94?JS)T)ZF/4+&>4V^>9K7
M1;!1T)41*D;ZR.RW:3G/NU[BS=X>[TSGA460 P4&-<HPL#'MF$A8F# A!MD3
M!FD:[HLLF;/D9D%HE@P8Q3%E&1C)I'1L<T;L(^/8-T6;%@Q9HD;M&3)HW(FW
M:M&K=,I$TR%*0A"@4H   &1DDDDED:65BTK$DDFY)/4DD]22>I)\:V_XN+C8
M6-'A84:0X<**D<:*$1$0!51%4!555 "J      !7MYPKOIBE,4KC9@)<8B5"
MOGC4YX8U\$(I,).5HA.7%LJ$:>519*H/%8TKSP%<J)R*F2\@*8#<#G9#Z/K)
M]1J./J&K38-IO\VDFXO:]K@B_C7DSQGG G&UF%=S]%_1,H9HA+I/IF0(5<QA
M[:PK*Q6X4@V-4GZ[V][9:'[?WO=]PD)><VO V&6KVZ:M,KJ_H4G"QLRG 2=,
MDF\891A%5^)?E1;Q2C<HMF#@C8Z '#@JDS,KB?&=[XI#LF*J)M+QJ^.ZCY@6
M76LJZK,6926?5\SJ6U>)(T$;+WL[M]O.].=W#WF6?(YM!ES0;I#,UXY%CE$$
M^'-Z),4<<4BK%"([Q021Q>B"$53;LZR=F]8=K=81>SM8RGNMU?!E9*V].B6P
MTRPE1(H[@)]HF<WM.$O+R16+R@[0$JJ1C$-Z1.Y)QO<N+[DVV[DO7Q1Q^"1/
M)E/^,>*GH:W:]I^['$N\?$HN6<3EO&;+/ Q'K8LUKM#,H\"/%''R2)9T)!Z;
M#90*R;3%*8I3%*8I3%*8I3%*8I3%*T][8=X=$=0*^9YL:P!)W1\S!U6M7UI5
MH^N\^5551!N\.Q4722@H 5D5/.0?'10$$5"(>^N4$#7?Q7A.^<MGM@1Z,$$A
MYW!$2D"Y4$ EWZCY%N1J4MI4ZA@OO/[A^W/9#;RW)<GZCDCHK0[=CLCYDJNQ
M1961F408]U<F>8JK"*181-,HA:J?V^^QSL!VZ</H.:DRT#4IW/FQU547;I.*
M=-T'IW4>K<Y<WLOKI)MP*B)A6*A' N@19!DW4Y')/\3[?[#Q,+/C*9MUTV,\
MEM5RNEA&!TC4_-T%WTL59W%:=^]7N;[E=[9)-OWF9<#AIDU)MV,2(2$E,D+9
M,A^?+F2T5W?1#ZL2S0XV.Q(K0#+YJ.],4IBE,4IBE,4IBE3%=!NINM*KKU[W
MY[>*I,-$:^=&?:ZIJR'S'>S+9%2@1[%VZB#% LM")6)$6C&.$Y22<@D8SL4X
MY!4'6*.;\IW*?<!P7B@OO^0MI9/ 01LNHV/[KE#J+V)1"/3!E92DT/;QV;XE
M@\8D]QW>EPO;+:Y2V'B :WW++AE]-0R @20)D*85QRRKD3HPRF3"AF7)TD[@
M=O=E]Q-I/+[=EU8JN1YW#+7^O6CY=U 4: .9,/CM?,J!)"=DP0(K)R1DDU7J
MX !2I-DFS9"\.*<5VWB6V#;\ :IFL992 'E<7ZFU[*+D(ER$!\68L[8+[T=Y
M^6][^7ORCDQ$6''J3#PT=F@PH&(/IH6"ZY9-*-DY!5&R)%!T11)#!#JAESUB
M.F*4Q2F*4Q2F*4Q2F*4Q2F*5R$1+RL!*1TY!2<A"S4.]:R<3+Q3QQ'R<9(LE
MB.&;^/?M%$G3-XT<)E.FJF8IR'* @("&<)(XYHVAF57B=2K*0"&4BQ!!Z$$&
MQ!Z$=#7?C9.3A946;A220YL$B21R(Q1XY(V#I(CJ0R.C@,CJ0RL RD$ U/Q5
M)JF?;YH *!=GD)5.]VC*\NO3+8<&T<TVY6D"$,JG)-DS)%,UE'292R:21!+#
M22I)!F4K5TZ89@[+CRNT^]_6X(>7@^=(/5CZDX\GQ4_8/P7_ *1 8Y+O''+6
MQ#9<K:?>OV]_L_R)\?"]Q?',9OH\H$1INN+8$I.G079Q:<*",6=AF8VC'R<K
M!$"5FK4]3+'/5&TQ;N#LM7F9*OV"&?D!-[%34.\6CY..=)@)@*X9O&YTS\"(
M<E]!$/7,W8\\.5CQY6.P?'E171AX,K ,K#["""/LK7KN6W9VS[ED[/ND30;G
MB9$D$T;=&CFA=HY8V'DR.K*P\F!%<)G=7BIBE9&U%M2X:1V92ML4&0-&VRBS
MS.=BE?<<D;.O8,)'L1)D:+M5W4+.QRJK)\W!0@.&;A5(P^)QSP;IMN)O&W3;
M7G+JQ)XRC#I<7\&6X(#*;,C6.E@&'4"KCXARO>^#<HP.8<<E,.][=DI/$UW"
MDH>L<GINC/#*FJ*>+6HFA>2)OD=@;Y6@=U53L1IZA;EI9C%@KS!I20,552K.
MH64056CYZOO5"D3(H]@)MHX9JG*4"*'1$Y.2&*(P>W[9LKC^[S[/F=9H'M<>
M#*0"CC[&4A@/$7L>H-?HH[:<^V?NAP7;>=[%=<#<,</H;JT4BDQS0L;"[0S(
M\18#2^G6EU928'/OOZH?JM>IG;RI1O+VL? USMKXR7JK7I!XI^Q+2Z\1(F7]
M*G'BD4NJ8#JJA(,B>B:'IGKL'RSTLB?B&6WR2WFQ[_QP/S8Q_.0"0#H!HD/B
MU0G]]/:[ZC!P^[.UQ_FXVC#SK?Z)V/TLYZ@#1*S8[&S._K0+T6.JN62CK6A3
M%*8I3%*8I3%*8I3%*8I3%*8I67-+;YV_UWN;6_Z7OT]0+0V B:CR'73.RE&I
M#@K^G3\(]2=PECBC* !A:OF[AN)@ WAY  A2-YV'9^0X9V_>L>/(Q3Y,.H/Q
M1A9D;^4C*UNEZNGB/-N6\"W==]X=GY&W[JHMKB(LP_BRQN&BF2_7TYD>/4 2
MMP+6B^E'W?ZOVR>(U]VC:Q6G-@+%2:-=B-E3):FL;H!(F!I9=ZNJ\UX_<"?G
MET=Q%<$.<[QMRF@,7>:]C]TVD/N'%B^;@#J82/ZP@Z_A %I@/Y(63J $;JU;
M+^S?O3XWRAHM@[GI%L^^$6&8IM@2D6 ]0NQ?$=KGJY?'LK,TT5TC,\C=PW=M
MT';1=%TU=(I.&SENJ19NX;K$*HBN@LF8R:J*J9@,4Q1$IBB @/&8%961BC@A
M@;$'H01Y&IRQR)*BRQ,&C8 @@W!!Z@@CH01U!'C7FSY7.F*4Q2F*4Q2F*4Q2
MF*4Q2F*4Q2F*4Q2F*4Q2M,N\/2S7/=G4#RA6Q-"'N<(5]*ZOV$BU34E:79E6
MP$*"AP)[[ZJS1T4DI:/\BD=(ID4(*;E!LNC>G!N;;EPC=QG8A+X,EEGA)^61
M ?X!(ER8W\5)(-T9U;#?>OLOQOO1Q8[/NRK#OF,'?"S H]3&E8"X)\7QY=*#
M(AOID"HXTS10R1P=_7%W-OG1S<TQT [AG5K=7CK0K"4RPRJZCACK>T3:B3^.
M9J21S F;5=^!^F\9/2E!!DX>E<J>#1PX6;9R[C\+P><[,G<#A]I,IH=<B 6,
M\:7!('^GBTE63Q<(4%W55>%'M[[R[MV0Y?/V([LGZ?:HLPQ0RL2RX61,5=%8
M^6#E^HLR2V"Q&59WTP2RRQ6D<BS6SNF*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2
MF*4Q2F*4Q2F*4Q2F*4Q2F*4Q2ND[(V-2]1T6T;*V'/,ZS3*=%+3$],OCB"39
MLD8B22*"1 ,L]D9!VJFV:-42G7=NEDT4B'54(4?=MNVYN[YT6V[=&TN;,VE5
M'GYDGR"J 69C8*H+,0 35N<NY;Q[@G&\SEW*\J/#X_@Q>I-*YZ 7"JJ@79Y9
M798H8D#232ND4:M(ZJ:P<+"[9^YGMH\L$RK-4GK1JQ8C<$2+EYJ=/>NQ40AH
MA(_RXQ?:>Q2QP*O77@JBU20 3BJBS:-U9*RS[3V@XJL$:I/R#)N?#^ED ZLQ
MZ-Z$5[*MP3>PTM([C4?A[;S;WU]YYMRRI<C;>V6U:5\03AXCL2(X$.N$[CG>
MF6DF971= 9_6AQ8,=K1E,IM7UY4Z]1J3",:W4JI$LX.OP<<0Q&<;&,$2HMFZ
M?N&465.!2\G54,=5903'4,8YC&&,N9F96X9<F=FN9,N5RSL?$L>I/3H/L
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M6>TV:[3\I:KC8)JU6:;=&>S%@L4F\F9F4=G I3.'\E(+.'CI;Q*!?(YQ$"@
M!Z  9(?'Q\?$A7&Q8TBQT%E1%"JH^"JH  ^P "M6VY;GN>\YTNZ;SDY&9ND[
M:I)IY7FFD:P&J261FDD:P +.Q8VZFN!SNKPTQ2F*4Q2F*4Q2F*5N3T3ZHO\
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MBU%BF*4Q2OR)R%'@3% ?[!, #Z_AZ"/\>,^$@>)%<@K'J ;5_0$! ! >0'U
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M265]UPZH$^=-XZJ#PRAC',W!->,6.H<RC45C L3&O-^V&P<S1LDCZ7>[=)T
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MOWN6],W9_N&S1\JP%*8<DVI)YDAU"7#R$D 896*%^4GYY80RR(LF.TD\_68
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M;=,W)%6KM$QDEDU$S&*/@W+;-OWC"?;MTACGPI!9D<7!^T>88>*L"&4V*D$
MU6^/<CWWB>\0;_QK+GPMXQW#1RQ,58'S!\F1A\KQN&21"4=64D&U]]?_ -S=
M$WD,)JCLTM":RV^Z42C(2[)A^FZXV"[.(E:H.%5U%$:/:'9>"^RX4_37BX<-
MU45546611[@=F,[8]>[<7$F3LX&IXC\TT0\R+6]6,>-P-:C\08*TE;1.POO
MV?FAAXKW,:#;N6NVB+)4%,/*-_D5KEAC3D?*0S>A*XO&T;21XXG9S!%3AIBE
M,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4JO%]PG0N:%T'?#KF61@=E:^4C+%M
M:/K)E6DDZ;UA1!S$[>KBC$I';.T4\K5,94Q#>*K!NF[+[2K1P9U(GL[SV'3_
M &"Y#IDV[(U) 7ZB\EPV,X/0I)<^F+7#L4.H.H37U[O.QF0';OIP9I,?>L 1
MS9Z1?*UL<AH]QA9 'CGQ]*F=M5O2C2=?2>&5IM__ *U>]\+W8TP1S-JLHS=V
MO4F$-M2NH@BW3?K*(^$;?8)JEXE+7[5["@F2*4HL'Z:[<2BD#=9?'W<O@<W"
M=YTP7?9,F[0/U^7K\T3D_OQW%CUUH5:^K4JY\]N/?'%[S\0+YP6'F>W:8\V+
MY0)+K\F7"!X13V8%2%,4RR1V,8BDED>S&]2)IBE,4IBE,4IBE,4IBE,4IBE,
M4IBE,4IBE,4IBE,4IBE,4IBE02?;GW6F(%NATOT:=W,;.V:W91.R5*Z"S^:B
MH&T^PVAM;Q+*/!5TM:-A(/"@Y1X!0D4LFF5-09 IT<X]I^&Q3-_;'>;)@8S%
MH==E4LERTS,U@$A(^4^&L%BR^G9M='O:[]YF!#_J&X&&R.1[K&L>X&'5),D6
M1I6+;XHHPSO/G*X]5/Q?3O'&L<OU>J+<[ZZ>D,3TWU&"<V1I([FOZ,?*[,G$
MO973C5$D14CZ-".4A.0\+6S.% 46*8WSGIU5^?:]A-&SNX/-)>7;K^1==GQR
M5A7K\USUE8']Y["PZ:5 %M6HMGGVO>W[$[&\,+;E:7GFZ+')G2?*1#873#A*
MW'I0%F+N"QFF9WU>D(8XI#<Q_4GJ8I3%*8I41?:'Z]ME=L^X5$O&V-BQ\IU6
MJ-?(LRU]%J2$//QLBT,R-*5;XY#+M' 7J2 KE[.I*I//@-_A FB9!HN;+/&>
MX&W<5XA-@[5CE>3RR]96"LC WTR$^/Y2W58F!0,==VUR+4(>[WM@Y3WH[Z8/
M).:;HDW:#$PP$Q(WDBGB*E3-C*HNH^LDM)-FQND[0H,<B,X^+(=%.WOUP[6Z
M@W)OVIZ(2UO;Q%9>K3$M2X-9U+V_7C<QQ4<KPR:P/7%]UPJ@)D)"/>INW"#3
MD70/6AG"C:^.(]Q-LY=C-QGFR0>O*ND.P"Q3?8? 13?O(RE06_H]$@16CMWR
M]K'+NQVZQ=V_;W-N0V[#F]1X(6>;,V\7Z.E];YN!8^EDQS"9UA).6,G%;)DB
MD1Z"?9OKWMFSC=>WG]-U_P!@&[ YEZX946]<OP,4P,\DZ"Z=K**&>@B47"\.
MJ<[Q!(JBB)G*"*RJ6/>==ML_BQ;<<'5/L);\7B\5_ 2@#P\A(!I)L&"LRAI2
M>W#W:<:[R)#Q3DGI[;W*$))B_#CYN@?.^&S$D2 ?F-BNQE5-3Q&:.*9X]WHO
MK;HZ%W5-=B(O7-?:;BL$,G!R=T205^8HV*4Z3AX@S%48QI.2+0Q6SJ021(]<
M-4RHG5%/R*:RY.1[W-LR<?DR)#M"/J$?E?Q )_$5!^94)TAOF N 1(#%[4=O
M,+G\W=#%VK&3G,\'I/E '58C2SJE_369T_+DG5!,\8],OH9@V<,HE9#IBE,4
MIBE,4IBE,4K4_MQW&U)TZU^-OV*]4D;!+%=-Z-KV(60_<]UE&X) J1H18?:C
M82.,X3._D5@]EJD8 *59PH@V6NOB?$-UY?G_ $F  F,EC+*U]$:G_"SM8A$'
M5CU)5 SKA7O=WVX9V+XT-YY(S3[OD:EP\&(CU\J06O8GI%!'<-/D.-,:D*BR
MSO#!+3A[7=N]N]OM@'NNRY7V8J.,[;TJB1:JY*K2(IRH0RC6*:*&_P YDWI4
M$Q?2"P"Z>'3(!A*BD@BE+CB_%MKXGMWT.VK\[6,DA_'*PO8L?@+G0H^503;J
MS%M'G>'O'S'O7RH\EY9+:&(,F)BH3]/AQ.5+)$I\7D*H9YF_,F*)J.B.*./5
MS+DK%%,4IBE,4IBE,4IBE,4IBE9?Z_ZJ>;QW=JO4;)15 VP;S7JV[>(%*=6-
MB'T@B$[+%(<0*?\ 2(4KAT)?Q,"7 <CZ92M\W--EV?)W60 C'@=P#X,R@Z5_
MRFLO[:O'M[Q#)Y_SK:.%8I=)-SW"#'+J 3%')(JRS6;H?1CURD>80BQ/0R"_
M<9MAE<>T[?5%;!-I2>O-(@->0\4Q.3](;33UDVL$^K'MT_RM#-&KQA$JI_XI
MH@ _AEA]I=K?$XQ^J9/S9NX3/,S'\14$HH8^=[-(#_NE23][G,8-\[P_V/VD
M"/CO&-O@P(8D(]%9"@FF:-1^ J)(L5U/@<0= /&)O,HU#NF*59G^A_4.M7.M
M=J;S<13*0VPVV5):T:RKDP+NJW2FE1I%C2;QC901!@I/RTVX,X<D #."-DTO
M+A$P#&7O7N>>V]0;278;:N.L@7R9RTBEC\;  "_AUM^(UMW_ +O?B'&8^ ;E
MSA((WY9+NDN(TQ!+QX\<.-*L27Z*&D<NY2WJ$(&)]-0L@'V/].H/MCH2PI14
M.P_ODH;!Q9-7V$R7MOC/&/BZE*BY<)"11Q$VR,15:@DH)DD7AT'(%$R( -B\
M%Y3-Q;?8\HLWZ?(=$RCP*'IJM\4/S"UB;%;@,:D?[CNS6W]Y>W&7M"11_P!J
ML5#/@3&X9)T%_3N"/DR%!B8-J52RRZ&:-+8,^H#MBKNG1HZ1N[@R&U>O[9I6
M!:/S^U+3.MVA$6%4E'+)1JT6;/*X*9H1V0WO*\LD5UE/<="4M:[H\;39]]_4
M\+KM>>/54C\(=NKJ#<W!)UKX"S6 LMSC_P!G'=C)YYVX_LCR'\OF/&F&%*C7
M$KX\2A,>5T*J5=0#CR ZB7A]1R&DTK(CV+T;5.R&F+]IJX$\8NYP;EDTDB))
MK.:_/HE^37;,P36*9(S^O3*2+M(# )#&2\3 )1$,L79MURMCW2#=<,VGAD##
MR!'FIMY,+J?L)J1_/N%;/W$X=N'"]^0-MNX8S1$V!*,1>.5-0($D,@62,D&S
MJI\JH6;%H%HU3?;CK2[,?TVVT2QR]6GVA?<,@$E#/%62SABLJFB9W&/?:!=H
MN!0*X;*)JE_*<,G)M6Y8V[[=#N>&;XT\:NOA<7'@;$@,IN&%^C CRK\Y_,>*
M;OP;E6X<0WY/3W;;LJ2"0 -I)1B Z%U1FBD6TD3Z0)(V5P+,*Z;E0JVJFQ^F
M#J2IM7<#SL7;X\3T#2[H6E52<  M[%M%^P$R ^V!^56E*AWH/5 .4"B]=,Q(
M)O:5*&$.\O*!A;>G&\5OZSD@/+;]V('Y1X?OL/(W 4W%F%;#O81V>;D'*<CN
MSO$9_1]H+08=[6DS)$_,<?->V-"X_$FEGG0HVJ)P+7QSD2(=10Y4TTRF.HH<
MP$(0A $QSG.80*4I2AR(CZ &1GK;J2 +GPJL$[%;[9/L<3;A[DCU<T*H!0.F
M0BD;-4N#DT#/D3O6QDQ..YK2P."9RG!4L&0OB(*(@;) K_\ ZU[?:K:.2[G?
MXADN/V$&)&!^R5NMQTK6%*/_ 'MO=#Z889':+B!'@$:*?2X)!/SJZYV1&0"#
M9L.'Y=+W8V=FC-HP:-F#)L@T8LFR+-HT;I$1;-FK=(J*#9!$@%32112(!2E
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MR."&4_:#_"#X$=1TK:_LV];3R';(=ZV/(AR]IR$#QRQ,'1U/F&'P\"/%2""
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M4?!%>.F5 9.%AX(1@_6.IS[1!)BSNMQ==[V!MQQD4[EA@O?]YH@"9$OYV_&
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M7;VLVB,*HHO"6*,3>)^^V4_Q3D43,HBHFH>$^_\ ']VXSN3[5O,3192]1?\
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M!.83+*ECRJJF.HH8YK [S<=Q=@YDSX*A,7-A$^D= KLS+(!U\&9#)Y %RJ@
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MZUB8PB=158XB=98WFLJ<1,JL?Q OFJH/)U#^)0#D1$> RX(HHH4].%51!Y
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M;"[F=R.,=I^&9?-^6R,FUXJ@*B --/,YM%CP(2-4LK=!<K'&NJ69XX8Y)$I
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M%M,4IBE,4KV&C1T_=M6+%NL[>O7"+1FU;IF6<.73E0J+=N@D0!.JLLJ<"E*
M")C" !G%F55+,0% N2>@ ^)/D*YHDDKB*)6>5B %4%F8GH JBY))Z  $D]!4
MUGVK&8:.TWTRZ41*Z0O-8:X"^WXK,1&.>V>72- MY1 0-^59]86]E=&*</(J
M;Q,0]#>N'^V1?>]VWCF<H)7)R?2BO^(1I\VD_8$,*@^%T(\JG3[NDQ^W?">"
M=@L$JLVS[2<W.$:VBDRL@F/U5-_Q-D+N$K*;MIR$8GYKF$O,Q5!.F*4Q2K7?
MT5Z_- =9=A7]TQ^,\V%MAZU9NS)@!I&MTR AV#!4JO/DHBWL4I+I 7C@IRG'
M_&'B+_>W/,_(<;;U?5'CXNHB_P"%Y';5T^)1(ST\1;X5N$_N\N-+M_:_=^42
MP&/,W+>3$LA !FQ\2"/TR&!)*)//EH P&EQ)86:YWX[_ -M1I/27M+.K+_&%
M32-_KK9<%_C'2D;E!.J?%G16]Q(2. DIU+VO$WD*GB!0$P@ V1V_Q&S>;[5
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ME+F(V"F>T&JW3^5D644V-5YE:\QR#M^LF@B,K-4EI8(:#9)**![[EZX;MFH
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MDOJ9ZD_ZN'7EO=;3'*--J;Q1B;;947:2J3NOU5%%PI1ZH=%4_+=RA'R*K]X
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M7D7*V:4Q2F*4Q2OX8I3%$I@ Q3 )3%, "4Q1#@0$!]! 0Q7P@$6/A53M9/\
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MU?P!-NW3 RSA<Y$DRF.<I1]FWX&5NF=%MV$I?+FD"(/B6-NI\ !XDGH "20
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M MUOK(/YA!O=(NC-\I!8HA*ZP1('VV=E,OO?W'AV28,G$\#1D[E+IET_3B0
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M !-@*A1S+F_+.X>_2<HYMGS[COTJ*AEETBR*6*QQHBI%#$K.[+%"D<2L[LJ
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M0B:9"IIIE*0A"% I"$* %*0A2@!2E*4.  /0 R,9))N?&MP"JJJ%4 *!8 >
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MIEZO(RDBZ,4I"F</7KDZAQ  #R,/ !DV,>"'%@3%QU"8\:*BJ/!54 *!]@
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M&0F7A%';DP 'FX6.8?41S!&\;G-O.ZY&ZY'27(F9R+DA=1)"BY)TJ+*MST
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M2T_]L7U(?9E_^U#ZRCIW_P!?64M_778CG_U"DO*5=)'_ *0BL_ _[P/6:?\
M5N[?;/\ <_4VC^P>GEPC_P 57/[1%+\:TZ?](^U/W'?YT\;CG^TG(VG+/[/4
M>$#[%.7C? 5:Y[3:)J'<7K+>=6'?1KMAL&JH3-"M21RNV,;94$49ZB6MFZ;"
M8ZT<223;G6%$P"Z8*JI ;P5'F*/%=]S.&\G@W72PDQY2LL?@60W26,@^#:;@
M7'RN WB*VB]S^$;3W=[;9W&/4C:#/Q1)BS@ZD28 2XLZE3=DUA"VDCU(F=+Z
M7-01_16EV2UAMO=FI[)J^\(:==K2[*V6%_'*M*U1-RZ^D%(-W'HR;Q9"-?24
MDV(XCI)O'BZ=@LV9'4*1!(QPSOWU/&]SVC"W;&RH#O "F- ;O+C3#4#I U!0
M=+H7TK9I +LP%0>]D8[B\<Y;O'&<_;,T<0<R)D2,I$.+N.(YC*AV<1EV&N&=
M(1)*67'+6CC+5)7V9^IS1_:7LS$]AKK9[376X5V&C[G3:6FSB'-ZL%<7!*#L
M#^W*"Y?1()P**$<Z3:M@<KMVR HN6JB9CJ8TXQW:WSBO&7X]A112/ZC&*20E
MA$CCYD$?0-\Y+J2VD,S:D<$ 2+[E^U7A?=#N1'SW><K)Q\<XT:9.-CJB'*EA
M8".5\@ZF0&$""55CUO&L9CE@9"SRE-@033!J@J*H,@2:G!1RH[<)F(@D<A'2
MZZJSE1P9!0AQ,J85#@<#"(^7(XL;43J86U=?"P\?(#I:_P .GE4GX]"KZ:&^
MBR]26(Z#\1)))L0;DW-[GQKV,XUV4Q2F*4Q2JKOVDP\ITM^QW0_="GM%4X>]
MNH>USC5D=))65GJ :-J6SX!,ATSH-$+7KB68)&5]#J+OG)_0Q?,95=K)8N:]
MM\_AF81ZN.&C4D&RK-JD@<D&Y,<RN0/@BCJ.E:OO<YC979SW$;)W>V@$8^>8
M\ET1E#RR89CQ\Z$*RE52?$D@1G\2\\K?*P#&TA#3$988>*GX1ZC)0TY&L9B)
MD6PB9N_C)-JD]8/4#"!1,BZ:KD.41 !$I@R+4T,N/,^/.I6:-BK ^(938@_:
M"+5LXP\O&W#$BS\)UDPYXUDC=>H9'4,K#[&4@C[#7)9U5Z:8I3%*8I7K/7C2
M.9NY!^Y09,&#9=X]>.E2(-FC1JD==RY<+*"5-%!!$AC',80 I0$1],Y(CR.(
MXP6D8@ #J23T  ^)KJR,B#%@?*R76/&C0N[,0%55!+,Q/0  $DGH +FJQWUY
ML7W<[[*MP=KK"W?.ZQ0W=@NL&+Y%J<C-W.>]1=05J23$@@"T%1&KA=%1/@Y7
M4,F<1Y$>9*=P'BX?VZQ>+XQ09$P2)M.KJ%_,R)%OY/)8,#Y2D!?AJ0]L6/E]
M]O=3O'>'=4R&VO >?.3U! ?3:8G$VO$F"W^:#$UM$\=SKP%+2DG\RSUD::VZ
M4Q2F*4Q2F*57M^];KS/3\#K+LE78X[YA2&;O7NQ540$ZT7"RTLG(4J64(4GY
M8Q&>D'[1=0QOR+OFP '!S"&?>R6_PQ29/&YVM)*WK0CR+!;2B]_Q:%1@ .JJ
MY)%A?63_ 'AO;/-S,?:>[6VPA\;#A.!GO<ZHXWFUX+$:;>GZ\V3&S%QIEF@1
M58R$KTWZX_MGH=&UU6=!=G7KJNM:1'LJ[KW:3:.?RT4>JL4OC1%9N;&,2>R<
M>YK[<B;1D^;-U&RK$J9')4#MS.'7K[A=K,S/SY-]XR \DS%IH"P4ZSU9XV8A
M2'ZLZ,00URI8,$2B>U[WF[%QGC6/VY[NR/!A[?&L6#N*1O*OTZBT>-EQQ*\B
MM  L<$\4;(T.E)DB:%I\B<IKVHZS/:V>X-NPFE5:PD4AEYO^\^EECVISIHJ@
MV=K'F2@T>@5PF MU?!<IC@42 80#,*MQ7DR9 Q6V[-&01<+Z$ER!?J/EZKT/
MS#IT/6M@D/>GL]/MC;S%RKCIVM&"M)^HX@5'8*1&]Y1HD(=/RVM)=E&FY JK
M3]F':N/[R]AM=T71R#^TTVFC^Q]=K%8N63V\WB^RT4A+R,6PD$FCULQE'3"-
M8M$W"::IQ:BJ8"E5 I9,]NN+/PG8<C+WHK%FRGU)OF!6..)6T@LI()4%W8J2
M/FL+VN=1'NI[S8_N$[D[9LW %ER^.X2C%P/RWCER\O,DC$CI'*$D02LN/!%'
M(BO>(NUO4T):UT)K!+2VDM4:F3<(/#Z\U_5:F\?MDC((2<I#P[1I+RJ:!C',
MB65E"+./$3")15XY'(O;]N7ZSO65NMBJY&0[@$W*JS$JI/2^E;"]AX5N.[;<
M1_L%V^V7A9=))=LVS'QW=%*K)+'$JRRJI+%1)+KDTEB1JM<^-9;RDU>U,4IB
ME5*/NH[)FVGV&CM)P+T%:?H9DJQD?85*=O);'LK=B^LJQCH+F3<$KT8DRC2$
M5("K1ZD^* \*#DJNSW'!M?'SO$X_KF>=0O>ZPH2$'4=-9U27!(9&C\Q6ESWV
M=U6YGW17@NW/?8.-H8F((*RYTZH^2UU<AA HBQ@KJLD4\64.JR"\,N9=J#U,
M4IBE,4IBE;]?6MIMIMOM13I"?(B6D:B;.]PW)T[."+-!G2U&Z\"FX4525:JH
MK6UPP,X14$H*L4W _@4<L+N1O#[1Q6=(+_799&/& +DM+<-Y@@B,/I(O9]/Q
MJ2GM-X'!SCO3MTVY:!QW8U?=<MF;2JQX95HKW5E93E-CB5&TAH/5-_EL9>-;
M6[IKOO:W9BDUKM%,;'LW=B#=02M*E]776!:U]>I5B<_:SNO3E@JD7& [I=;3
M4^,5RJF9PHT1XY5*0AL2;EC<SV':=KS<G:TQL38Y _J+/&VL2.@D#(DA:TKV
MU:0;!F\%N1.+BFZ=@>Y?-^9;!M',YMUW[N/C- <>3;,J'T#B09#8;13SXJ1$
MX,&OT!,5UM''^*0A6TVT9J?9#KZU^\.H(RF6&=V9%;^JU;=4NOQCN<GS3-5N
M&I/W S:QT6DZ<O#1:42Y45%(IBE21,?GQ 1R\=\W/;E[F;'NLD\2;:^!(XE=
M@B:7CR-#%GT@!M2VO8DD#Q-JP+VXXGRJ7V@]Q>'8^VYN1RZ#DN+ ^%CPODY(
MFQ\O;1D1B+&$K2-#Z<AD]/6JJCO?0I:O7Z6:7V3U;UIVS[#[YJ$QK*L!H&TZ
MWK,'>6:E<FKE:;4Y:JL(]C%R!0E&I%)*(:LB*+M0374D2F2$Y4EO'NYGO>V\
MEW':>,['-'E91W**>1X6$BQ1Q!@264Z2=+LU@]QH(-BRU3.P/;SEO:;BW->\
M/<3 R=GV=>(9VV8T&?#)B39F5FR0-&BQRJ)XU]3&CAU/CE9#DJ\998I /%OS
M7=S[==).F^Q=#UZ0OSG0U+?Z?V90ZLF:;N,)+QT?3X%I*MZM%)NI%V62"K?,
M7*D!W7Q)!HO[0I>\=+AL&?A<2YMO.V[[*L"Y\PR8)9/DB=29'93(]@"NO0+_
M "ED=0U](;U]S>.\A[X^WG@/+.V^%/N3\:P7VG<<+&!GS()D&)CQ3#%@$CLD
MP@]>0C\Q(9\>5XQ'ZSPY3M6GM96'I3V V7<NB#3JK9:-5*^VH4_:;))K6:SS
MB\@BQ?OTX28AZG-5]5N[*V33*Z;JDD#/_!(3^V<!IV)O&Z8_-=OVW"W[]6@R
M)9#+''&NB- FI?G5I$:X+$Z2#'HN;7%KIWS@O#MS]OG*.6<A[:_V(W#:\3#3
M!R<K+G^HRLEL@12$031XL\.EUA5?51TR_J=$9<*^K7GZOK%8+#?>Q 3\Y,38
M0G3#85?A0EY)[)!$04;+U%..A8P'BRP,(E@0P@BW2\$4P$?$H<CEQ]S<>#'V
MG ]!$37ON.[:5"ZF9)M3-8"['S8]3YFL3^T3<MQW+G7)FW+(GR&@[9[M!$99
M'D].&/(V[TX8]9.B*/4=$:V1+G2!>O%TN@YG:W1SO?I:D1ZLUL%=+6%XAZZT
M\G$M8(V'G22DDU@XQN15])2"*-3,D1)(AS*N7;=(/S*EY<OR,?:.<[#O><VC
M;_ZS"SGHJ,\91"[$A54F2Y)(LJLW@*^]C]JW7G7MR[E]O>-PG(Y-?9\^*%;M
M+D18V:,C(2"%%>665(\72B(A,DLT,0LSBMJJ?**=9.M?UL4C<;)2BVQ_VT5V
M%+05L,:O2%7J R&P*^\F+$@^2\XE*-9[(CGK@KGV3H$4]M4$S%4%.TLB <HY
M-R3-V9O7Q1M'HJT8UB24K$ZHEC\VIH60%;@GJ+BU\X[;N;]F>SW:78>>Q?IN
M\OSH;A-%EM],<7"6;+@FR,@R*1"(8L^')99=#!;H^A@Y3:05]K;)W3VLT5V/
MT94ZCTSC:K?;7%WLU+_2(5NZ4?M9I'8,=>#",1+VV89R3Z;DU$"F>Q\DD)SG
M1425!:V"NU[=LVT;[QK/FR.:/)#&8O5U.1I*&!HOQ+&A588P;*\=K JRVS"D
MO,>5<\YSVW[N\9P-K]OF/B[CE+F?1^C C&49 W*/.($,N5/'-+GY3IJE@R@Y
M9XY(9@]4W)35IGIBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4K).N--[:W!(
M'B]5ZTO.PWJ*B";I.GU>9GTV'R3"1%23<QK-PUBVYA*/*K@Z290*(B8  1"G
M[ANNV;3$)MSR(<>(WL9'5-5NI"ZB-1'3H+GJ.G6KDXSP[EO-,M\#B&V;ANF9
M'HUIB8\N08Q(2$:3TE;TU8AOG?2ME8DV4D2(ZZ^F;NY> (K/5NBZK:G(54BU
M_N[%=91(Q2G#Q84)O>'Z"XE-Q[;E-N8#!P;Q_'+!S^[O"L*PAEGRC?J(HCT_
M;*8E/[":DUQKV-^X+D 9LW!V_:$TW1L[,CL]Q<#3A#-E0^1$D:$&_2MY]=?0
M8S(=F[VUV'<KI\_\(0&NJ6DT/QP4?\SMUEEGI>1,)@_/"?@ #_'@+)W#OF;,
MFU;?\W[KRR?XXT7_ !2U(3B_]W(=<.1S3D_Y?7U8,+$ZGH+>GESRV%C>^K"-
MQ8].HJ1C47U3=)-1JLWZ>JB[(FV0"!9G;4FM=2K\AP)G57538T)8X#Z@;])
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M*5%=]QNA3;MZ27N5C68.;/I1ZSW%#"4I@5&+K;=XSNZ)E2%.H#5.DRC]X8G
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MR@KL=(D* AB0K8V^FS28:MZ@15SD&8(6/=UCE+ZZ.JB*;Q*M-#?MNGL5#"
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MT?-R'R;#H:S\0J2QCBN;75]4?S4*0%%E#J/#1=H:S" ^'Y&S4S1+@H>',/\
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MW9,VQ!5<.W:Z39L@F7^919=8Q$DB!_$3" 8I6N]P[.T"O&5:P8.K<_3$Q?\
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M2)/)P]4D-?/3V:OQIR!ZFD6['R /4N9&P^:\%Y1!]))D8SJUB8<E0ESY#3,
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MHX_$PXP=04@5B/E5I6EE!D.Z&6=6>:_)C%(4QSF*0A"B8YS"!2E*4.3&,8>
M*4H!R(C^&*5K!LCLU7*T9Q%4Y-"TS*?DF=_[A@K[)4.0_P"R$1!26,4?Q*@8
MJ0@/^6Y 2YV*A/CX5Q+?"M([AL&WWMU\JS33I^0AQ.W8E,#>,9\\@'Q8]'P;
M)F H\"?Q%0P!^8PCZYV  >%<"2:Z7GVE,4IBE,4IBE;L].__ *XO_P!"/_TS
MYUR>5<EK@#D.F<R:A#)J$,)#D.42'(<H\&*8I@ Q3%$.! ?4,5QK\XI3%*8I
M3%*[' VR>K:@&BWZB:/EY*,U?ZS)7UY'S;G'Q*8W^^)XG_L'! -?0;5L)5=I
MPTX*;.3 D-)&X*4%E %@Y./H (.3>/M',/X$4X]1  ,8<X%;?=7(-\:REG&N
M5,4J!W[(OI^J^[T+)N[K+%1M0W4<SR=L]#141C*EM-Q[)UWBT:D8$V%7OLBJ
M3R!8!1CY)R<QG7M+*J/!SSVW[PY6R-%L?)W:;9  B2VU20#RU><D2^%NKHM@
MEU54J#7N']I.U\PCRN:]M(4Q>9LS33XH;1CYK6^<Q@_)CY+VO<:(9I26FT22
M23FI+.P4W5YJ6K=EB).OV& DGL/.04TQ<QDO#RT<X4:2$9)QSU)%VQ?LG21D
MU452%43.42F !#C);0S0Y,*9&.ZR8\BAE92&5E875E87!4@@@@V(-Q6JO)QL
MG"R9<+-CDAS8)'CDCD5DDCDC8I)'(C ,DB."CHP#(P*L 017%9VUT4Q2F*4Q
M2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2O8:.W3!TV
M?,7"[-ZR<(NVCMLJ=!RU=-U"K-W#=9,Q5$5T%2 8ABB!BF ! ><XLJNI1P"A
M%B#U!!\01Y@USCDDAD66%F252"K*2&4@W!!%B"#U!!N#U%?1 ZE;P:]D.MNG
M-U('0%W>:5&O+ DV$@H,[A&^[!W2.1]LJ902C[9&/$2?E(/B0!\2_@&N_ENQ
MMQODF9LC7T03L$OXF,_-&3]\;*?VUO\ >U7-8NXG;O:.9(5]7-PT:4#P7(2\
M>0@\.B3I(HZ#H ;5L3ENUD"F*55Y_P!H5VO81L^@M'MGCMM5DJ]-[2F&1.2L
MIB<>2;BJ5]=P;_JJ\ RC9$$RAP!0D3"//)?&47MZVF 8FX;XP!RC(L"GS5 !
M(X^YRR7^U!;P-:S/?URG+DWC8>$HSC;XL>3/=;#0\LCOCPM>U]<2).HL199V
MO?4+;7=//I/ZTUG654M/8R%D=O[+L]=C)J8B7-BGJ_2J@ZEV2+T8:%8523AG
MTPXBTW MUG;YRX2<*%%5)!#\H!:G,.]O)<G=)<7C;KA[9%(RJP1'DD"FVIC(
MK!0Q&H*J@J#9F:LI=IO9CVYP>,XVX]Q8IMVY%E8\<DD?K2P8^.SC7Z<0QY(Y
M'9 VAY))75RNI(X[VJ-3[?NBVJ.FT[I_;?78TI1(F[S4TP=5 EAEWYZO::NE
M$S,38J=*R;M[8&R#GY"IER*.S_"<I(BW$I%/;2R5V@YWNW,H,S:>1:)YH$4B
M30H#H^I6215 0D6%K*-2EM747,=/=EV0XOV@SMHY/V^,N%@YLDB-!Z\CM!-
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M]5T[6\1\2$ 1X 1'@H"(?0"385\)M4=&UM\6/8:B\9'BM 5/R$I(M%7AW)$
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MJ"68GR  ))\A7JP<',W/.@VS;HGGW')F2&*- 6>265PD<:*.K.[LJHHN68@
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M=0J@.E&S4OBDGY+SKD6Q2ML^7M^9M\ZRY61-&T2D(4+)$S+=E< Z4-S=P"-
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M41$<4K86C4EI668VZUF(V6;I?(;-W'H6.3$."KN">HG?J>7":8 (D$0#@5!
M"\2;]!7("W4UP#G;\B-D2>MT1+7T1,W&-,!/><MCG+YNU#_XKW\H&( #X$#\
MOKR8PM(M]M-1O?RK8:/D&DJR;2#!8J[1VD55%4O\2C^)3 /J10A@$IBCZE,
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M1+6T$S8V'7$GMRQ$:JHR%LV%:;"=P]5=(G2<F;UZMR4!58]$@JF^-XLSNFX
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M)ZFS3%*8I3%*8I3%*8I3%*8I3%*8I3%*KT??I?5&U2Z[ZO0<>24S8KM?95J
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M[]2GD&R**?FJJL^\?03''GD<\.X<QYER*7T,S.S)VE:WI*S*K$GH!%'I2]_
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MI:4(HD9>GRF2VLK\J_*3;H.G056)>1<BGV6/C4^X[A)QJ&8RQX;9,[8D<IU
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MF"G+U!:_G7S2:WBIU&K%#C"Q=:C$620@7Y+HP K(2"I0_P N_>&#WG"@B(B
M>A"<\$*4O 9U$D^-<@+5V!_),(Q'WW[M%JEZ^(JFX,<2AR)4DPY45, #^!0$
M<^5]K'DCLUFD)B1C%5T(#Q[SHP-TO_3%3*"BIP_W? <Y::5U1QL6QK"(I&9M
M _@"+4#\!QP'(N3K\C_^/_T,^Z12O2_?=J__ 'I_^HQW_P J8L*5R#?8]A1$
M/>!D[+_$%6XIFX_Z4S=1( '_ '0'%A2NW1NRXU<2IR319B8> %9(?E-_\(F
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MW3YPJY7/^*BAN> _@4A0X(F0/X%* %#^ 9RKY7J8I3%*8I3%*8I7(1LJ_B7
M.8]RHW4#^8"CRFH7_>*I&Y34+_@$!X_AZXM2LY5>Y-9XH-G $:292\BCY?TG
M(!^)VQC#SS_$2#R8 _ 1#D0X$6K[7<%D$7!0(NBDN0ITU0(LF10H*(G*HDH!
M3@8 .DH4#%'\2F !#USY2M==Q/Y_]1;Q[@OL0(D*LP]DQA3>KE*4%U'1N Y7
M;G-P4@^A2B!@Y$PCG-;6^VN#>-85SE7&F*4Q2F*4Q2F*5MKK"<&9JS5-4_DZ
MB3#&+\B'D9-$A3-%!#\>!:F*7D?YC$-G!O&N:^%9$SC7*JT7^T%Z!248Z8[-
MQ#(WR6R[G3=X<)E.<#M%RR=LH3E4A/R(%:N"3:"JQ@_J&<-TQ,'B0HR7]OO(
M&#YO%YC\A R8AT\?ECE%_$W'I$#RLQMU-:XO?IP)"FS]R\13ZH)V[)-V(*_F
M9&*=/X5L?JE=[7;5$I)"H!6+R3M:W*8I3%*8I3%*8I6PEX[(6Z^Z)U+U^DZS
M0HZJ:=D)Z2K]@A(63:7696L+V1?/26B6<3KR-D445I,X) @R:B4I2^0F$!$;
M<P>-8>!R#,Y''+D-F9J(KHS*8E$:JH]-0H8&RB]V;SM:K_WCN)NN\\!VGMW/
MBX$6T;/-/)%+'&ZY,C9$DDLGKR&1D<:I&TZ8T/07+&Y/9=H]N;YMG8NE]F3M
M.UC$36CH2DP-:C:U7IEA SS2ASI[!%*V]F\LLD[E'3UVH*;LS=PT*HB/B0J8
M_FSR[5P_ VC:\W:<>?*?'SY)7=G=2Z&9 C>F0BA0  5N&(/B3X54^3]V=\Y7
MRC9N6YV%M<.X;)C8D$*0PR)%*F',TT7U"M,[.69V$FEXP5-E"FY..-_;KLG8
MK;=LW';H2IURPW#]!_4(:CQK^(JS/]OUF&JS3]+CI.5FWS?Y#&$257\W2OFX
M.H8/$I@(6I<=V+%XUL\.R8<DTN-#KLTK!I#K=I#J*JH-BQ LHZ #J>M6_P!P
M.;[EW&Y=E\RW>#$QMQS/2UQXR/' OI0QP+H1Y)6%UB5FN[7<L18$ 8=RMU9M
M,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE;O_6Q<S4/O?U=G"J'2%]M6&IGDF*@&
M$NQT'FO#)B*1BF\%BV@2& ?RB4P@8!+R&6/W)POU#@FZ0&WRXC2?^9M-_P#(
MZ?;X=:S/[=]Z.P][^,YPU7DW6+&Z7O\ UR^)Y>7Y_7RM>]QTJ_ED ZWLTQ2M
M0-W]!^H/8A>0DMI:)I4I8Y,3*O;C!-7%,N;IU[9$D7C^TT]S!S,NNV*F3P!Z
MJY2\2@0Q#$Y*-X;)S[F''56+:\^=<9.@C8B2,"]R%20,J@DF^D*;F][]:Q)S
M/L1VCY]++E<EV+"DW*9M3Y$2G&R'?2%#R3XYBDE*JJ@>JSBR@$%1:HD-S_[/
MCKJ5^5(Z"WA9Z>Y,999&M;-B&-PB#G4, ILVUCKY:U*Q+-OR(%.LSE%A*  8
M1'DXY<V;W";C%:/?\&*9>@UP,8V^TE'UJQ/V-&/ATZ5%/E_L(V'(U9'!=\R<
M5_F(AS8TG0DFZJLT/H/&BBX!:*=R+78D$M&M8_K=^T#J!+/[)JEA>)!!L1-1
M:W]8M@3+MU)E(!@^,%8B5ZYL:3*4AS%.F>&.D<IC%_, B&9+QNY/:_E\*XVZ
MO I)-H\V)0%\.NM@\*WMXB2_3RZ5'#<?;M[E.T^;-N/&8<Y@(T#96RY3LT@N
MWR"*)H<YPES<-C:+.=)-VM.=]/'8KL+O'6VY:]V4L4Y/7[5M\@HEJE;H&.KE
MQB(&=KH.FS"=CVL/"R+@!?QSE1)R_35=*B=0GN&(F4I,%=XN.<?V+<L+)XU$
MD>WY>.S7C9GC9D>Q*,69? J"J$*+ VN3>;GM'[B<ZYOQ_>=L[AY,N1R':LZ*
M/3/&D61%%+#J5)D6.-^K([*\H+M=AJ(4 3$YAVI=4Q2F*4Q2F*56(N &UC_M
M"-:E^#-X^]OX 44A,H9-P6Z==5*2L)N'2BBA5+,DHJ4#^!2*%#@G@0OE)[#/
MZG[>I81UD@5[_9Z>9ZH\OXEO#Q'G<FM:F[*>/>_K'RY%T8^7-$4ZW#?4;/\
M3%O&_68O8&UB+@:;5V7[:VZFP?L#Z>ZC7(1S'RL1K%H#7P]SW%]A[JFJV]14
M*HX31."S:"0#Q'V_0?S'$!#QIW:J1=NX%NN[QDC(CEG:_P !%CHZD=+W!9OC
MY6'C>S?>GAS<L]RW#N"Y2I)M&5A;?&$M<E\[=,G'F5@6"E6CCA 'R_O:C:UK
M*61RK:[3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I5!7MW*$F^UO9>62\O8?[]V^
MX;^9 34!J;8%@!J"A ,8"J W OEZC^;G)U<65DXQML;_ (EP,<']D*#_ ,%?
MG![PR0S]W>5Y./?T9N3;K(+^-I,_(?K_ ++P\JUXRNUCFF*4Q2F*4Q2F*4Q2
MF*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*5>A^O+5)=-]--!U-1(Z4G(T
M=E>ITJR!F[M.;V*HM=WK)\F<I#@ZA@G2,!\@Y K4H?PR%7<'<SNW,<_)%O32
M8Q+8W&F&T5P;D68J7Z=/FZ5^@CVO\0'"NPW&]J;5]3D;>N;+J0QN),\G,,;J
M0K!H5F6 A@& B ;J#6Z&6;6?*C'['V7]P[0E6Z:@G:5QNV@&X>0^/NM@,YD#
M>'/B4Y9%TJF(_B()AS^  '>@LM=;>-8&SE7RF*4Q2F*4Q2NRT^K25TLD36HH
MO+N4=%1%42"=-HW* J.WJP%$!]EHW(90WJ B!> ]1#!-A>@ZU+95JU%T^ C*
MY#(@BPBVQ4$^0#W%U!$3N';@P  '<NUS&44'T 3F'@ #@,\Y-S<UVCI77+Q:
MQB4?TR/4 )%RGRLJ4?5DW. @ E$!_*Y5 ?R_Q*7\WH(E'/H'G2L&"(B(B(B(
MB/(B/J(B/XB(_P 1'.5?*A:^WW[2+U]:W^KS^RM55/9O]]'][/ZE^Z)R8AOT
M3^[G^[/X?P?TE%;Y/ZE^^U?=]SCP^.3Q_F',I]M.WV)SOZWZK(DQ_I?1MH56
MU>KZM[W(M;TQ;[S6.^?<XGX;])Z..D_U/JWU,5T^GZ?A8&]]?[+5'Y8/O)^Q
M_648O=-O?4]LFI:]A0.YL4Y8*KO?7\8S9D254.=>W6?6KZ$A@(5,3BJNBJ0"
M%-Z?Q"\H>TO!\^08NV\CQY,U^BJKX\A)_F)*&;[@15K2]S>6X<9R,[8,B/%4
M79F$R #[6:&P^\U./T*[[Z9^P73I]J:G_4H23@I(M?V%KRQ&;#9J)8CH?);M
M7JC0QFDI#R[0!7CI!#^BZ2 Y3%2<(N&Z.)N8</W3AFZ?IVY:61UU1R+?1(OA
M<7Z@@]&4]0?BI!.2N,<GV[E>W?7[?J4JVET;\2-XV-NA!'52.A'P(($!E4^_
M[O)M2VWRKZ-^O0VZU:#,.6$[_=?';>O[N(:#)R,=%O9UM4*W,&B"2IHQ;V16
M\"J&2.!!'P-QF'([-\3V_%AR-WWL8@G0%?5,,8)L"0I=UU6N+V\+B_C6+XNZ
MO(LO*FQMLV=LHP.5;TO5>W4@%@D;:=5C:_P/PK8;K7]^5JF>QU.ZU=UNIEEZ
MN638$Q#5V"GY)>T1"L)-V.04BJZ6X4>_5F G8RO3$IXM?U1-PHFV6 3*(^R"
MJJ-%W[L[CP['+OW%=RCW#'A5F91H.I5%VT21NREE'700"1X&]@:KL_=&:7>8
MMEY%M\N!/,RJA8L+%C9=2.B,%8] PN+^(M<C:GN=]I%ZZO?8EU0Z4P>JJG::
MSV(_N*_6+O+3DPQG:Y_>WO*TZFD/TV-9HGCW?Z1'U\CM'W3![BR@E-P4 '+?
MXMV^Q.0<)W'E4N1)'/A?4:8PJE6]&!)A<DW&HMI-O "]5KD7.)]DY;@\;3'2
M2+,]&[EB"OJS-$;+8@V"W\1>]JFDS%E9$K]IJ'2.15(YDU$S%.FH0PE.0Y1Y
M*8I@X$IBB'("&*5L!3K06>:B@Y$I9-H4/>* >(.$O0I7*9?[>?0X!Z 80'\!
M ,X$6K[7(VJNMK/#.8Q<"E5,7W63@0]6KP@#[*O( (^ B/B< _$AA#\>, V-
M?"+BM,7;1PQ=.&3I,R+EJLHW72-QR15(XD.7D.0'@P?B'H/\,[*ZZ]?%*8I3
M%*8I3%*R]IN5%I8746<W"4LS,)"\A^9TP\ET^ '^QL9;\,XMX5R7QK9O.%<Z
MTU^P;3)-]=-M^Z]28C(3)J')6NJ-TRE%TI;J)X7*NM6:@G3]E>4DH0C,3>0
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MO(K)CJRM^ZRAA<@"KN>0PK?[6-MPR0Q6K[P[*82&-7WK$I@'@2FE2EBRB40
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M*8I3%*8I6.-QJJH:BVHN@HHBLCKB\*HK)',FJDJG6)0Z:B:A! Z:B9P 0$!
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M7N:RKI3^!SB)?(H;!, #Q_#D<RS_ *C.;_'"_P#.M_\ 1UCG_6_P_P#C9/\
MYK_]ZM\^FGV8=1>]R\W#Z%O[UQ=*W')3,WKNXP;RJ75I"J';(&F6L>[%>/G(
MIH^=D;N5XYT[(U7.F"PD!9 5;,Y1P3DO$ DF\0@8LC:5D1@Z%NORDCJI(%P&
M )%[7L;75Q[F&P<G+IM,VJ=!=D8%7 Z=;'Q )L2I(!\?$7\=!^R+KQL?N3=^
MB]>:[#+NR@$L)YY>1K4<VI1BUEBPD)$6,\G8'#UQY-Y)/VO)F3R-R ^/'.,S
M@^]X/&(N6SF'])F*Z;,2_P Q(%UTV'4&_6ON-RS:<OD$O&8O5_4X02UULM@
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M51KZ;>S?U::BZ=R=7[CO="H[6';5XEBM]CZ94V#9%*>ZA:HG$^W*):_M"BK
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M3C\0_$.<9LX^^OC>%0,Y[JZ:8I3%*8I3%*_9#G2.11,YDU$S%.FH0PD.0Y!
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MH+7OXU0)=Y?D'*<_!Y5NN3MVVP/(L<<;&-2%<J%/0J6TB_S*Q<DZ;#I7<O\
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M#'*R@,UP+EHF _:H)'Q\NI%99^W#_P _7]8__P!Q=_\ %E[)RG]MO^Y[?_\
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ML@#%E*]"&(TJ"7+_ ( %\>M=W<?F6P[QQP;1LTPRL[*DCTK&&)4!@W46N&)
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M.O&GMIN)H&O&Q95T>H LR*3Z4B'K4S47L#H=]MQ65;VQ%1W4GNQ)ILXZ'O\
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M#NV(0CF0TIN&H7YN0'*Y("\1;^B3GM%\C-F#&2CU;5"2KY0."BHX&*0$?4?
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MBQT@%G;Q9V)=SU9B234%/^T#[)UHAI74FI72L1(;<DMBH7N(9D,V5G*U18R
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M1V#7)2GWNL0-QJLVW,TEZY9HEC-PLDW-P/M/(V10<-%P*8 ,43%$2F !#@0
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M>VZ>Y,R#Z$;FHVIXYT5"P[7L$<Y5B?<*L*;B*J$?[C-2Y6%$I#"H@BLDU:\
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MC >(K0S.^N%,4IBE,4J7#I-IP]1J3C9,ZU]N>NS9(D,DLF +1]4*<%D%@$0
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MO*YW$I$4)&;L(NA;B;QT>F1!!\9=P2GWR370\1!21.X)"N5E2CY*%8$\O(W
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MHQEM2FQ),F/)&Z^"QM?IP6U_K=KUXJ3[<71S9<=NRBE*=V[H"L@U5O,*)O\
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M@0PZ@W<:;6)-@""0:^>UFPFM"5,4IBE3H?;V!ZQHKZS]6D.#8E0ZW)N7<6D
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M&:A6[UI1H5146JETL#(YQ ZJAB*IQ390@IN721E% ,B@=-3-G9CM)/W!W/\
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MN&/:GLO(PE9?_*U-I!Q-T:AF*!BHRTL9RS0O=L3YX!1";F89)!J< X48L4%
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M)Q^%8)U9<Y(4-I ;T$8V 9EZN_A%'\Q()0-D_N[WA)LE,>OW7TJ%'ZT4M)O
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M]Q2NL7&EU/85=D:G=J_%V:N2J7M/HF6;$<ME>/5-9/RX4;.VY_SHKI&(LBH
M'3,4P (?02#<>-" >AJ%;L7]7MBA%']HZ^/CV:'$RKE77LX\00L<>03&4,E
M33DZ#&<:HE$0(BZ,@[*0H "CI0V>E)P>CUTM'_%J)J;@YJM2CR#L41)P,U'+
M"W?Q,PQ=1LDR7+P(I.F3Q)%RW4 !YX,4!X'/0"#U'A777%Y]KY3%*8I3%*V
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MRVUBB5N8N%SGHJL5>OLE)&:GIMZA'Q<:S2$H&7=.W!R))@8YBD('/D=0Q2%
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M@ <\?AD:,K)ES,F3+G-YY9&=C\68EB?VDUL>VS;L3:-MQ]IP%T8.+!'#&O\
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MQY%;\9C6ZQ,U^NI=+1/YW2YZM60_<GP''XQS!.3[* >,[ZAR(V7\"S&S2JI
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M$8U)'J#ZH()@=M*;NO:T\L02*'JE$*M&Q G+XF,D]LTDW++/FR@B)1*W:,%
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MNW[*DQ[:^]^]=^N/[KRW.V_&VW:<7<AB011RM/*&3'AGF]:5EC#&T\133!$
M";AO&M]\L2I(TQ2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2JHOWAZ'/1^PE4WA%LQ)!
M;JK*;*;7(910"WV@-V,*\,J4" @R1D*>M$>P7R\EUFSH_')3#DH^R^^#.X])
MLTA_K&%*=(L!^5*2Z];W8B3U+]/E!07Z@#3;[_>WC\=[I8O/<2.VV<@PU$C:
MF8_6X2I!)==.F)&Q3AE &_,D7(;2"&9H2,S)4#:WH^MK39-W=S=+5M\V4<0%
M;GS;(LOBFDJ@$7KY ]E:-GR2H&*I'S-@9,8Y8.!$2/!_#\0LKN%N_P"B\0S<
ME"!/)'Z2=2#JE.@D6_>52SC^;^RL_>U[@XY_WTX_L\ZN=MQ\OZV<@*P$>$#D
MA9 P(].:6.+&>P)M-TL?F%XG(6U^@:JMOW=;H5M>^*7I5@Z,,/J>II3,RW*K
MP4;C?"H2)B+HE#@PLJHTC3HG,(B'S%0   1$T[?:_P 97 XIE<FE7^L[AD%$
M-O\ ,P77H?Y4ID!'\A?'RUU^[[EK[CR_#XA W]5V[&]607_S^1UL1_)A6,J;
M_P"<;H/$PFY)ZHA5D34>NI7;NT*#K&%\RR-YM<+6TER)BJ#%"2?)(OI14@>H
MMHIB*CE4?X))&'^&43DF]X_&]@S-^RK>CB8[RD7MJ*J2J#[7:RC[2*N+B/'<
MGEO)\#C6)?ULW*CBN!?2K,-;_=&FIS]BFI&_M>V<P6VE1^N%,.5EK[K[2X.&
M1AVJGDT2L<G$,5"IF$@^#C]&J2<<V3\O(Z*IG)?03G#,(>W78)DX_E\XW0:]
MYWG*D<N1\QB1V%_LUS&5C;HP"'K85(;W3<F@?DN%V\V@A-BV/$C7TU/RB9T6
MP^!].#TE7S4M(.ES44&2*J*],4IBE,4K\'215\ 700<D3536!%T@DY0,9(P&
M*"J"Y%$E2"(>I3 ("&=4\9FA:(/)'J%M4;%''VJZD%3]Q\.AZ$UW8TJ09"3O
M%!.J,#Z<T:RQ-;R>-P58?81XV(L0"/8J5OI#1ZX26A'B[]%^9(T<S(="'3_S
MLQ#>RNJLY6*FDD;W#E4'PY 0* %X -/7N([^>Z>#N%N_;[C'(9MLX;C3%(<F
M#$5\T*L*N+RP1)*Y9SIU*U[&[7ZUX<S:.QN/S^3(Y?BR8L#&)S&-9P4>2.-F
M"1B1I @9B2LA]-;%5 0 5*KJMOKY\T8H,-GK0J#@4T$T"5>P&+R1(!\/;9O4
MO<!(@?@ >@!SD3,?MC[GN]F.TF5SGE>X0HUF58<MBA8W^8/^$D_&IQ\*E]L_
M$(<6?!Y'QO G>PA#S1P2$*OX55Y UU4?A\@/#I7K]<4;D_G+.R+JU]J=DE%G
M<-YQ"H6(B5D65?II'C1.R30_G2,*X@<3 /C^&7AW _NU]_Y%MV$G.^Y?.MR1
M@I]'&*J8 $%E;U]5K&ZBUN@-ZO3A7>#9<[*S8=@GV/#@B)$<TTNI<@ZV^9?1
M()!%GZDWU"O'O.)V! MB.&<Q&$!V[$HJ*Q1FKILF#==8YCDDRK_G,9("\"7R
MX,(AQQSDANPW]UO[=?10\RCY%N1BANT^;N,L32D,  R8TT>GH2200.GAUJ$'
MNJ]S7/."J$V'D6!+E3YRQ"+%VXMZ::&=F6?)$L3BZA;:"UF)%B+C4)IVLW[3
M*3LG1\?=H!>C;-;-FUH/&1:99]1@W]Q)>'_5B.U$F<?)M_%)RBBBEYI@8@\%
M.<II]\)]JO9;M7N.'D<#Q,F/!BE>1(I,F3)C$B!=#EIFDD:W32#):X!ZUR[>
M>Z;N7S'MMF\6W+Z6(-!"),A8]&1,LZLK@E&6)6*K9PD:Z=14 > UNR1E6;3%
M*8I3%*8I3%*FCTPLKVS^M7;.HI(Q9K8_6%^C<* *@E6DT:JU;.IN.:HF5$%G
M JQ*%@B4$RF\2)%:D /R$+D6N4JO;COKMO)(/RMCW]##D6Z(920C$VZ"SG'F
M8^9]0^9-3*X:S]UO;ING$\FTW(N..)L7S<1*IDC OUZH,G'4 ]%"#R J%S)2
MU#6F*5L#U[[0;KZP6LMJU#<7<(*YT_UNMO/*2I]H;IB7EK8:ZLH5F\Y3 2$<
M)^T];E,84%TC#Y9:',."\8YU@?0<BQEEL#HD7Y9HC\8Y +CKU*FZ-8:U8=*O
MG@W<?EW;K<OU'B^4T08_F0M=X)1TZ21$V)L+!UTR*+Z'6YJR]U1^V[1&]"1]
M7VHJTT?LE8$T/;GY!/\ N^GG1A33*,);70H)Q3APH81!I)E0\>2D37<&$<A)
MS_V]\KXJ7S]A#;IL@ZWC4_41CJ?GB%]0 _?CU>99$%;!.VWN9X7S,1[=R!EV
MCD!L-,K#Z>1N@_+G-@I)/1)0I\E9S4L*2J3A))=!5-9!9,BJ*R1RJ)*I*% Z
M:J2A!$BB:A! 2F 1 0'D,C^RLC%6!# V(/B#\#4DU974.A!4BX(Z@@^8KR9\
MK[3%*8I6([IH/2FQ5%%[MJNB6)ZL;R4E'U:BPF1$>1$ FD&Z,L4IA'D0!8 ,
M/ C^ 9R#L/ FOA53XBM:[#];?5&<,H=E3IZKJ*B<QC5ZXV 2@<YC&$R:$^\G
M6R0 )O0A" F4   * 9S$T@\ZX^FM=+@_K T;5[;6K? 7':2+RLV2*LK9C(RM
M5?L%5X>3;2C1F((U%@\*U]UL!#B*QU#$'^8#?F'D9V(L0*^", WZUEKLETJH
M79JTP5LMEJM\ ]@*^%>;-JZ:&*U6:A(O9+WUPDHM^K[_ +KXQ?RF OB >G/(
MYQ24H+"U?60,;FL)1WU2]=VO@9]:MMRB@)B50BD_56C4QQ$!]U-)K2TW*8E
M.  5CAZCSSZ<<OJ'^ROGIK]M9=KGUX=3J\<BQ]<.+ X3,4Q%K':K0^)R50ZG
MYV"$LSBURB!@*(*(& 2D#^(F$W$S2'SK[H7X5LM3=1:LUV4H4775*J1RAP+F
M K,1&/E1\?#S</VK1-ZZ4$GIY**&,(>G/&=99CXDUR  \*R)GROM,4IBE<!:
M+76*1!2-HN5BA*I6XA SF4G[%*,H:'CVY?057DC(+-VC<G(\ )CAR(\!ZYZ\
M' SMTRTP=MAER,V0V6.-6=V/P55!)_8*\>X;C@;3AR;AND\6-@1+J>25U1$
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M!%,B2***1 (DDDD0"D323(4 *4    . S7NS%B68DL3<D^=;[T1(T$<8"QJ
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M/ER1OCN[NBV].'$P-PB5&!$BN9]3!NB@ ,<N<>[0=H>WL^;%S/<N/QM*6:"
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MCW*?UW<ZI?:L[%A9*988>SP3O\_BA*P;]"19&5*FHD=1 5VY04)Y!YD$2B/
MYX-UVW$WG;,C:<]=>%DPO$X^*NI5K7O8V/0VZ'K53V7=\[8-WQ=\VUM&X8DZ
M31GK8/&P87L02"19A<7%QYU?*TGM:O[QU+K_ &W6#E&&OE9CIY% %"+'CGBZ
M?M2T,Y.F8Q/FP<NBNS7 !'Q60,'\,U0<GV#,XMR#,X]G#^LXD[1DVMJ -T<7
M_=="KK_)85N>XIR/!Y=QO"Y+MQOAYN.DH'B5)'S(;?O1N&1AY,I%:\_85UF3
M[8=4MEZO9M4W%S9,BWC6:IB%,JCL"I).7L,T0.H($0&R,U'4,JJ(#[3>24,
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M?8^>;-NR-I]#<\9F^U/54./N9"RGSL>G6MP?M?JB5;[EW&11*)"7:JT>UB0
M3 A52P2567,F"9S" ++U<RAO,"F%0YAXX$##C/VZ[BV=VPQH&ZG$R)X?/P]0
MRB]_@);"UQ8#[JRU[IMJ3;N[N5DQ]/K<3&G/WA/0-OO]"YO;J3]YC<S.=1TI
MBE,4IBE,4KFJ_9+%4Y5M.U6?FJS-LC =G,5^4?0TJT.!BG [:0CEVSM P'(
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M0 U8DU5JG37TYZM;[_[$&@M@=XKQ6Y$-1:@8/$9)MKUO)M31ZYE7C8#IMEB
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M&.NDTL#(@"<#<))I\?REXGEV"XOB[KVBGP=V77A[CEY)%_W4*)CG3\/FC<_
MDL#<$BM7_NO;;Y>]V)N^&HBWS:<; =9X[+*L\$TF7$VHAAJ42(/F4C2%Z?*M
MK '3_N?JSN%1OUZGN2PEUAF[8MZUQ(NTE)RL/52$*9RV-X(#-5ITN(@UD4DR
MD4_D5(BL!TBQ2[B]M-^[<[I])N2^KMDI/H9"@Z)5'D?'1(!^*,DD>*EE(8SQ
M[7]UN-]TMF^NVAO2W2(#ZC%8CU(6(\1X:XB;Z)5%F\"%<,HW S'59/IBE,4I
MBE,4IBE,4IBE,4IBE,4IBE,4J%[[JNM8[1Z_1>[Z]'JN;?HEXLYEP9MO><R&
MMK&LT:V'WBHI&<K%K,FDTD2G,;VFC('R@@ &,8,Q=F^1?IN^OLF0P&+FK\MS
M8"9 2MKD :UU+;Q9_34>0J!GOV[6GE7;G'[B;9$[[SQZ0^J$4LSX.2R)*6"(
MSM]/*(IM1(CA@.5(UA=AM5]7\ >M]#>NL<H/)G-:L4^ ^"A/R6N^6NT)AXJB
M)AX3F #D/RF_$OY1#+9[FSID\YW"1!8!XU\;]4AC0G]I4FWEX5E_V@;9D;3[
M<>,XN4VN1X,J8&VGY,G/RLB-;?R8Y56_[UM0\:[YWY?*1W3'LDX2(0YE-4V5
MB)5/+Q!.40+&K'#Q$H^::3LQB_P\@#GD/3._M+$)NY6R(Q( W")O]B=0_P (
MZUDCO-*8>U/('4 D[7.O^R0J?\!JCMFTBM/5,4J8&$\87Z<+A[0G,-NWBU^3
M[8@B!#-K75O$%O'GY9!+6$Q#RXX,)?\ >!S&?+OE>YW&U?\ U;:3;S\89?#X
M?TI_P_&I=88&)[0<HKXY6[B_E:V5".O\;^A'C]GPJ'[),5$6F*4Q2F*4Q2F*
M4Q2N8-89\T06OFG)@T"18'!(0TF]&(*X 1$%RQHK_"*L B(^0$\O7\<IHV;:
M%S?U-<7&&Y?Z7TD]3_SFG5_AJL-R'?VV[]';.S#M'^@,TGH_^:U:/_%KC6SE
MPS<(NVBZS5TW4(LW<ME3H.$%DQ R:J*R1BJ)*$,'(&*(" Y[)\?'RH6Q\I$D
MQW%F5E#*1\"I!!'WBJ?BY>5@SKE84LD.4ANKHQ1E/Q#*00?N->[)RTS8'POI
MF3DYN26!-(SR3>NI)\J!>"))BX=*++J 4/0H<CQ^ 9T86W[=M</H;=!#C8][
MZ8T6-?OLH _;7IW#==WWO(&1NV3DY>7;2&ED>5[>0!<LWCY7K9]GT2[A/Z@>
M\M>N^S3UTC+]1!0\"="768BBHX*Y:U=PJE:'B9T$A.7VF9_(HE$.?,O-ER=U
MNW$6XC:GWG!^L+:?QW0-<"QE ,0ZFQNXMU^!M?\ %V6[JS;6=XCV+/\ H0FO
MJ@$A6Q-Q"2)CT%P!&2>EAU%]3C%,0QB'*)3%$2F*8!*8IBCP)3 / @("'J&9
M!!!%QX5C @J2K A@>HK^8KY3%*8I3%*8I7NQC]:*DH^4;E2.XC7S1^@18#&1
M.LS73<)%5*0Z9S)&.F & #%$0_ 0_'.K(A7)@?'>X21"IMXV8$&WCUZ_"O1B
M9+X>5%F1 &6*17 /@2I#"]B#:XZV(^^I8ON;8E;=I*:Z(FH 2.CJNNJH;R%,
M[E"[[%9F*F80\0%-LW2\B@/IY<C_ #9'3VO2F3M_E1DBZ;M* /.Q@QFZ_M)_
M^ J4GO A]/N9AR@'3)LL)OY$C)RP0/N 6X^V_G42&20J*=,4IBE,4IBE,4IB
ME,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4KL%3M5@HUGKUSJDHY
MA+-59F.GX&69G\',=+13I)ZQ=HCZE$R+A$H^(@)3!Z" @(AGCW# P]UP9MLW
M"-9<'(B:.1#X,C@JP/W@_>/$5[]JW3.V3<H-WVR1H=QQI5EC<>*NA#*?X1U!
MZ$=#T-7<NE_::N=M=(5_8T:9DRM;(J<%L>L-U?(]<N#-!,7I4T3F,N6'F""#
MQ@<PF\FZH$$PJI*@76!W+X'F]ON43;-/J; ;\S'E(_I(2?EZ^&M/P2#^,+VT
MLM]O/:KN+M_<SB$&_P"-I3<% CR8@>L4Z@:A;QT-^.,GQ1@"=08#(O8O0=$[
M-Z<NVEMBM#+5ZXQAFZ3]N1,TG79ML8KJ"L\*HH E2EH*32372Y_IJ@4R2H'1
M44(:V^.;_G\8WF#>]N-LB%KV/X74]&1OY++<'S'B+, 15>X?!-C[E</S>&\@
M4G S([!U_'#(IU131D^#Q. P!NK %'#(S*:!W8_KWL/J]N"VZ:V7&J,YVM/3
M_ D2)*$B[577"JOZ';8!8_(.8:<:)^XF/(G14!1!8"+HJIDGYQSD&W<HV>'>
M=L<-CRKU'[T;V^:-QY,AZ'R(LRW5E)T3=P."<@[;<LR^(\EA:+/QI"%:WR3P
MDGTLB(W(:*91J7KJ4WCD"2I(BX,RN59E,4IBE3%=3OLXAXK6S3JGWAH"/83K
M.[(C$1\I)%4D;]KB/ JB;$S)PJNB]G8JO&4_S R#IE-0R(C\%T<B#9F7#W+.
MV<TVYGEG!\C].Y.OS%5L(IVN+ZAU56<?CNKQRD?F)=GD,K^U?N*Q,+C0[4]Y
ML'^T';*4F-7=F.7@QE2%$3"TDD<3'\G3+%DXB,?II]$,&,.Z[[^I ERJ9>P'
MUX7Z.[&:4G$E))O2R2S;^\:N<@"SJ*CS.THQ.P'BP$Q5(]ZG'6%J($;G:NUP
M.H/AV'NV<+,/'NXF.VV[Y&=)DT_DOY!C8MHU>3J7A;JP=%L*KW-O:L-ZVD<_
M]O\ G1\AX5D+ZBX^K3F0@@$Q@.$]4I\VJ&58,N,Z8FAED#-4+%@KT_4YJ2K=
MJ@YBM6*&='8R\!8(Q[#344]2X]QI)1<B@V?,72?(>2:J93ASZAF:<?(Q\N%<
MG%=)<=Q=71@RL/B&!((^T&H?9^!G[7F2;=N<$V-N$+%9(I4:.1&'BKHX#*P\
MPP!%</G=7CIBE,4IBE,4IBE2+=2/K![/=LS,+#%5P-9:E6%NY=[8V,W=Q$*Z
MBSF(HNZIT.=,DS=E?A^X=%1L1.+,JG[:[YN)@-F.N7=SN+\2#8\TOU.[BX&/
M"0SANMA(WX8NM@0Q,EC=8VK/W:KVW=R^ZK1Y^#C?IW%&TLV?EAHXC&2I+8Z6
M]3))0LR&-1CED*29$)(-2#S'9GHS]7T1(4GIO 0W9CM =FO$V?L#:5D92KUE
MTLU/\I*(E8PI&;]E[K@$QBJXL@W42_(_E%W#<4SX^AXSSKNA*N;S*1]LXOJ#
M)B1C2[@'IJ5NH/2_J3 D'K'"JO<9ZRNX_9/VU8K[3V?@AY+W+*&.?=9V#P0Z
ME+'TG0:'6[*I@Q&1&7ID9<DL.AH(=H[3V!NF^6/9FT+3*7&[VM^I(34Y*J@=
M950X\(M&C=(J;2,BH] "HM&;9-)JT;D(DBF1,A2AG?;-LV_9L&/;=KB2#!B7
M2J*.@'Q)ZEF)ZLS$LS$LQ+$FH0<@Y#OO*]XR.0\ERYLW>\J0O+-*;LS'X  *
MB*++'%&J111A8XD2-54= SWU1J]M@P?2KYE%Q;)W)2<D[;,(Z.8-EGCY^^>+
M$;M&3)HW(HX=.W3A0J:::93'.<P%* B(!G"22.*-I96"Q*"220  !<DD]  .
MI)Z 5W003Y4Z8V,CR9,CA41069F8V5547+,Q(  !))L.M7?/JNZ()=-M+'FK
MLQ;COC;#:,F-A*^2;D]1BT$U%X'7+%RF8Z'_  (#LZTFH@(D<R:AR@HN@V:'
M"$/=7GAYEO7H8+'] Q"RP]+>HQL'F(\?FL!&&_"@!LK.XK<Y[7^QR]HN'G<-
M[C YWNR1OE_-J^GC74T.(MCH!C#EIV3I),2NN6.&!A*5F+*D]3%*8I3%*8I3
M%*8I3%*8I3%*8I7Y.<B1#J*'*FFF4QU%#F A"$( F,<YC"!2E*4.1$?0 SZ
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MZ^2FFQO#^)/Q#5OZ,-%!K+J$YVA(LB(6+?EPD+(5<Z*B#P*34%753J3%T50
M$Z7ZFVEY%N</RG;R9#!R \C='?3?3N?+UVJ-B<;;X0EKW'JR6DD(M_),:,/$
M,AO\*QG[(^$+QSM3)RG(0+N._9CR!M)5_IL8MCP(VKJP]49,T; !2DZE;@ZF
MFES"M3)IBE,4KKMOD96'J5HEH*,<34W%UV;D8>':$*H[EI5E&N7,?&-4SF(1
M1P_=I$2(41 !,< $0SV;=#!D;A!CY3B+%DF17<] BLP#,?L4$D_8*\>XS9&-
MM\^1BHTN5'"[(@\7=5)51>PNQ  ZCJ:J]Z@^EGLKL-R2;W+:JKJ!@_7,[?ME
MW!;]=U%'!Q755/&03U&ME.N8X^0J3'ND./YDQX$,G3R+W,\)V=#B\:Q\C<94
M%E('H06'0#5(IDZ?9#8CP:M=W&/:7S[?9?KN796-MD<C:F6_U.02QNUUC81
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M1MUU*.B9B=I#R350BIPCDT9(,IR!E:Q,LUQ9KMW**B\--."HJE,/LK"102G
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M8J7L3,VY2$I?$HB03<>1A$;%]ONUG;>U^%(W23*DFG(M_&D9%^^Z1J;GXV\
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M V7;,C>-TE2#;,2"2::1S98XHD+R.Q\E1%+$^0!JL7]4=<FNXW?W?_>6\,W
MQU.D9B5K+=Z)U2Q]GV*G)UVGPB"QQ,@];436,>Z9^("<S<QF2G(#X&&3O=?)
MAX=V_P!OX-@D>I,JJY'FD.EY'(\5,LY5O*_Y@\+BM:_M;VW-[N]]]][U;ZKF
M'"DDEA#$_)/F>I#CQ @!9$Q<)9(K&Y0_3N?FTM5H_(MULVIBE,4IBE,4IBE1
M]_9EUU'L1U6N;.(8 [O6MRFV52/;3 SMPZKS9<T_!H"4AEU33U94=I)(E$H*
M/BMA-SX!F7>R/,O['<]QI<A].U9O]6GZ] )"/3<^0].702?)-=O&L*=_^"GG
M?;?+QL5->\X0^JQ^G4M$"9(QYWEB+H!>Q?03X5BSZB.Q@;GZRLZ!-/@<771*
M[2E/2J*)BZ=4MPDNO0I(R93>946\<V6BBB)0\OTSR$1,81RO^X?AG]FN<-NV
M*FG;-U!F6PZ"8$"=;_$L1+_Y6W@*MOVQ<\_M=V]39\M]6[[,5QWN1J,!!.,]
MKWMH!BN?$PD^)J5?,!U(^F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2JFOW
M/Z;4H':9GLIFT%*#W74H^:%P "5 UMIZ#2K6-HD7^4#IQ2$2Z4$/YE'HB(<B
M(CL"]M/)!N_ VV21KY6V9#);S]*8F6,G_+,JCX! /"M:7NSXH=E[BQ\AB6V)
MN^*KD_&> +#* /+\OT&-O$N3X]3$+DB:BW7::/;Y?7]SJ=ZKZOL3E-LD):(A
M7D0*61@I)M)M//CU%(R[8H'#\#%$0'T'*?NVV8V\[7D[1F"^)E021./Y,BE3
M^VQZ?;55V+=\OC^]8F^X)MF8>3',GE\T;AP#]A(L?B"14J?VGTB)NRVF^XVO
MTQ=4/=M*@XR7>)D_.SLS"..]A/U4WXI2#ZM\LC)"'*2L*J4W!N R//M[W;)V
MI=T[9;R=.\;5E2.B_&)FTR:/BJR_/?S$ZD=*E#[G]DQ=Y.T=V]A&O8]WPXT=
M@/"4*7B+^89XB8R#^$P$&QZ5H%U>WY8.L^\*+MZ!*HZ)7I1-*Q0Y%SMB6&IO
MS$;V*#46(13VS/(\3"B<2*%2<D34$A_#Q'+G<?AT'.N)96PRV&05UPL1?1,@
M.@_<;E6_DL:PCVHYYD=NN;XG(H[G#U>ED+>VJ"0KZ@^];!U\M2BKFFQ*7K;N
M=UKD8#Y24C2=O4AO)UN=2335<1#Q^S(_KU@9@<!!.1@Y+VU!)Z<F3.D;\IC
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M<'J+G(T@6_$F.2/C4S$@;M#[;)FR#Z7*N5N %(^=8)5 *VL" ,4.QO\ @DR
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M2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2HS_M;Z]J[SZIV*8A&)7=STVX/LR#
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M_P#ZL.-_U@__ #B2K3P__P!;;-_ZGC_X&&MCONR_YIT#_I5K?_@V:RVO;?\
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MA[W=U>.*L>V[WF- MK).5R5M\ ,A9=(^Q;6\K5N=4?NX[7P9$T++5]/W9(I
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M'.@D9)$869'4D,K ^!!!!KB\[Z\M;-]4NT-XZJ;.9WFK'4D8)_\ 'CKU3E'
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MLJJHL /_ (SU)ZDDFH4;INFX[WN,V[[M,^1N61(7DD<W9F8W)/\ B %@!8
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MIY]V61A'!MV0C9<(%@JA;LDN-!&/G?TI\>&-0TDI5 [5=HH+V[R-+K3[9$%
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MW$LBS<I1+Q=PV35<%/#R*J3Q+Q .5D"<CQSEN<NX^>5<<R^._4/BIEQ^FTB
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M\16^JU UCFAJ2K=S,J2+FI!&G=*-TZ^JP5,Q H$\TVX@)1 X 8*!+VRXI)Q
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M#@.3'-R8QA*0A0$QA*4!$/'N&X86TX,NY;E*D.! A>1V-E55%R3_ /$.I/0
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ME%S3J)TET9TPI0UG54#\BQ2J*'[SV/.D;N[K<G20%$ ?R)$B%CX1NJ7EK&-
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M%NJ[>OGKM4C=JS9M6Y%%W+IRNH4B:9"F.<Y@  $1 ,ZY98H(FGG94A12S,Q
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M%3@*RZKLRJAC*',8=>7>_9I-E[F[G"VHPSR+/&3<_),@:POX*C:HU Z )86
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MBZ#IJNLV<MEDW#9RW4.BNW71.51%=!9,Q5$EDE"@8IBB!BF ! ><XNB2(8Y
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MD!E6R:1E%5 BI(JI'K XF,)F;@@''W2J%+@KN3P;,[?\JGV.?4V$3ZF/(?\
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M54F",[3II=J=5)VM#+G2\5?(P\J&2$ZHI"LIC;FG/<OG/9K.&YM#)NFW[S%
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M+5HT:HJ.'+IRX4*D@W;H)%.JNNNJ<"D(4!,8P@  (CG"21(D:65@L2@DDFP
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M1X6&C29<SJB(HNS.Q"JH'F22 !\:\^7EXN!B2YV;(L6'#&SR.QLJ(@+,S$]
M% ))\@*K+.%+E]O7=)-!#]8B.L&H%#F]PY5F8L*49^0%5?0OMM[YM5W'E I!
M$56;)'G^H5B;SF\@VWV[=LR[^G)SK<1]AU3:>@^V#%#&Y\'<^7JBVOYVW/W0
M]V B>K'VWVD^/5?R=74_9D9A4 "]XXEOU,1U6:8&"AZO"0]:KL:SAH"OQ;"%
MA(B/1(V81<3%M4F4?'LVY  B+5FT1(FF4/0I2@&0AR\K)SLJ3-S':3+F=G=V
M-V9V)9F)\R222?C6P'$Q,7 Q(L'"C6+#AC5(T465$0!550.@"@  >0%<MGGK
MT4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2H0OM@Z82MF9MNW^D6SN-V
MKK1-C+7U.O\ NM9B:@*R*#J)O48JT$BP6B@$9E,HJ']96-2*(' 621%)0=@.
MY>/@R-VZY0ROL&<62 R6*))+</ P/3TLB]@/ 2$]/S6(B-[D^T^3N4*]T.(*
MT?*-N"O.(KAY(HB&2=;?Y[&TWN/F:(>-XD4[<?7CW4BNW>I$?UURQ9;FHC=I
M%['@TA20_4ORBC'7B):%\?\ @BQ%2$5B$*!6;X%$> 3]@ZN/>\/;/([=\A(Q
M59N-99+8SFYT^;0.?X\=^A/XTTMXZ@N3>QW=G&[H<7#Y11.4X85,J,=-1\%G
M0?Z.6UR!T234G@%+2"YB&LV4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q
M2F*5&3WG^M77':]J^NU2/':ZWFBW 4+6DT$(*Y_&2\&\;>V3,H++*&(0J24J
MB4[UL0"@<CE),B(9P[6=[-Z[?R+MFX!\SBI;K$3\\-SU:!CT'F3$;(QO8HQ+
M5'[O%V"V#N9"VZ[>4P.8*ORSA?DFL.B9"KU;IT647D06N'4!*JB[CTIL[05X
MDM>;7J<E4[-'")R(O$_-A+,#'.1"8@)1+S83<,Z$@@FY;G43\BF(82J$.0L_
M.-\GV/EVUIO''\A,C"?S'XD;S213\R./-6 -K$7!!.M7EG#^1<(WB38N2XSX
MV>AZ7%TD7R>)Q\LB'R92;&ZFS @8KROU;-,4IBE,4IBE,4IBE,4IBE,4IBE,
M4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,
M4IBE,4IBE,4IBE,4IBE,4IBE;U=-N@NX.W\XD\AFQZ=JJ/>@A8]FS+14T:04
MC!\F+J[,11/9I\"^@I)G(W;B("NLGR0I\5=R>[?'.W6*8LEOJ=_=;QXR$:NO
M@TIZ^E']I!9OW%/4C,_:CLERCNCEB> '$XRCVERW4Z3;Q2%>GJR>70A$_?8&
MP-M?KAUBU'U9HB-%U37DV":P-U['9'WMN[3;Y1%,2?J=BEO;(HY.43G%%NF"
M;1J!S%023*8P#KXYGSCD//-U.Z[_ #%V%Q'&O2*%2?PQIX#RNQN[V!9B16S3
M@G;[C';K9EV;C4 C0V,DC?-+,X'XY7\6/CI461 ;(JCI6P>6A5[4Q2F*4Q2F
M*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2J\OV9=I+AV#VA"]!>M9EYY])V1K"[,>
M1"_].?M#94'1*/\ -2$46]<IOQC/IY<PB1-PW%-04R,G *S"[(<$V[B&Q2]V
M^;6BBC@+XP<?T<1%O7TGJ9)KA(%\2K7%S(FF#_N![B;IS;D4/9/M^3-DRSB/
M+9#T>0?-]/J'A%" 9,EO %=)L(Y TO/4+J_4>I>F(#6-=^/(31BEF+Y:R-P0
M<6VX.T$BR4D8!#WDHQK[8-F"!A$4&:1 ,)E!4.>._<3G6X]P>2S;YFW3&_!!
M%>XBA!.E?@6/XI&'XG)(L+ 2>[8]O-K[:<3@X[M^E\D#7D36L9YV UN?,*+!
M8U).E HN3<G:'+%K(5,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE?D
MY"*$,FH4IR'*8AR'*!B'(8! Q3%$! Q3 / @/H(9]!(-QT(KX0"+'J#59KN'
MHN_?6WV0K?;KK@T.AJ>RSJJ4Q6T06+!5]_*J%<S^MY]! W/[(N"2)UHLX  ,
M5TO;)[:K9HHK-WMSRK:>]/"YNW?-&OR""(%)#;7(J"T>3&3_ )^&X$H_?4ZC
MJ5Y L .Z7#]Z["<]@[I<"0CC61,1+"+^G&SD&3&D \,>>Q:(VM$X"C24BU3^
M=>]]T+LKJFL[:UV^^1#3R I2$8N=/]6J]A:D2"8J\\@F8P-I:)74 #?]371.
MFNB)T%DE#1(YAQ/=N$[_ #\>WE+9,1NK"^B6,WT2QD^*.!]ZD%& 96 FIPCF
M>R\^XWC\FV)]6'.OS*;:XI!^.*0"]G0]#Y,+.I*,K'->6Q5V4Q2F*4Q2F*4Q
M2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*5@CL#ULU!V<I:M'VY5D)MDG[RL+--A39
M6>K/UDP3&3K4V"2J\<ZX*7S((*-G $*5=)4@>.77Q'FO(N#[F-TX].8I38.A
M^:*50;Z9$N P^!Z,MR593UJS^:\#XQW V@[/R?&6:#J4<666)B+:XI+$HWQ\
M5;P96'2JJG<_ZU-Q]4EI"VQ*;C9>E@<J&;WF&8G_ %*LME#<MF]^A4/=/#F+
MS[?Z@D)XY8_CR=!14C<)[]M.]G&^?*FW9!&#R;3U@=OEE/F8'-M?Q],VD O8
M.JEZUN]V?;[RGMNTFZ80;<>):B1.B_/"OD,F,7T6'3U5O$2.IC+!*C=S--8
MIBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4
MIBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE>[&1DE-2+&(AX]]+2
MTF[;L(V+C&B[^1D'SM4J#5DQ9-4U7+MVY6.!$TTRF.<P@  (CG5//!BPODY+
MI'CQJ69F(554"Y9F-@ !U))L!7?C8V3F9"8F'&\N5(P5$12SLQ-@JJH)8D]
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MIILF5LC(=I)W8EF8EF8GJ22;DDGQ)-S4M(8(<:%<?'18X$4*JJ JJ!T 4"P
M Z  6%>[G57;3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I6$>PN_\
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M\$1?,GQ-E4%B ;:Y;R[8.#[)+R#D<ZP;?$/O=V/X8XU\7=O)1]I)"@D5RO\
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M2[WL:@:O@E[/L>Z5>C5]OY@>7M4Y'0;$RA$S*?';K2+A '3Q0I1\$4O-50>
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MI3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I7\$
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M@;8Y;S+C?!MI;>N3Y28V$O07ZO(UNB1H+L[GX*#;Q-A<BO/L;L+VX^U6[O\
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M;;QPV-V%IYE_W-&'R*1_G9!;J"B2"Y$:NZWN1XUP?U-EXUZ>Z\K_  Z4:^/
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MD96YZR/3G,K(76Y1]HM)$Q5,7AV[7:5MXX<B!N4Q.F(A_4#)ZQ9NV86=!QN
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MSJH^Z[FG*./<OVW X[NNX8*-MOJ21XV3- "6FD5798G4$G00"039;>5:X4N
M^XZ_U*N7:FV??LY5+5#L)VO3"6UX%%.3B)%N1RQ>D2?VYN]3*X0.!@!4A%/7
M\P .7GN>7[;MHW";:]R@VF+<,>1HY$.+(=+J;,MUB*]#TZ$CX58NTXGNMWK;
M,?=]JR-WFVW)A62)QEP#7&X#*UFF#"X(/S 'XB]=+LO:[[.^HMNA6VV+ELN'
M=/SKR#&%VJSCKA6[2S8N$&\DV:2;U.12>-$S F188U^DN@58IRG3%4AS5/!X
M!V-[A[=*_'\;"D1 %9\5FADB+ E25!4@GJ5]2,JUB"&TD"D;EW,]Q':_<X8^
M496;&\EW6/+6.>*95(# /9K@=-0BE5EU W74"9[8WM MV'^NK:/8*GNI*BW%
MIHS;;][^@O56C^H[%HM0G'+O]'D"G5<I- E8]-TS4\_?^$NF)A*KSXQ-FX*O
M#^\F!Q#<E3*VYMUQ%7U%!6;'GF0#6O0$Z&*N+:=:M:ZVO,^'N&W-^Q6X<YVE
MI,/<UV;-<^FUF@RL>&0MH;QL)$#(?Q%"I-FO:.+Z9-[;JV?N?;4!LS;6RMC1
M+/6#:78,KY>K3;V\;(H6N(9 ZCD;!*R"3%95L_4(H9,I3'+P CP&9G]RO%.,
M[%QK;\O8]OPL+(;.*,T$$4)93$[68QHI8 J" ?#K6!_:?S+EG(N3[KA\AW//
MS\=,!'5<G(FG",)0MT$KL%)#$&UK]+^%6+<AM4Z:8I6/]@[7UAJ>-1F-G["I
M>OHQR<R31Y<;+#UU%ZL0"B=!B,J[:F?+E X")$@.< '\,J^T;!OG()SC;'AY
M.9.HN5AC>0J/BV@'2/M-A5&WKD?'^-XXR^09N)@XQ-@T\J1 GX*78:C]@N:Q
MQKSMIUFVO+HU[7F\]:6>PNE!19U]G:8Y"=?J% AA+'0[Y5I)2/ *!ZH)*!^/
M]@\5G>.WW-]@QSF;QM6=!AJ+F1HF,:_SG4%5_P HBJ%L?<G@'),H8.Q;QMV3
MG-X1I.GJ-_-0D,WC^Z#6P^6?5[5"[V#^Z73FJKG*4O5VO)7=BL ^<1DS94K6
MVI51.^:+*(.TJ])C7[6]GT&ZZ8D^2#1!JL(>2"BJ8E4-)?A_MGY)O^VQ[GON
M9'M:S(&2,Q&:;21<&1?4B6,D&^G6S#P95:X$4.=>['BG&-UEVCCV%+N\T#E)
M)!,((-2DAA&_IS-)I(MJ$81O%&8=:B ^PCN;0>Z1=,7&O4R=H5VJ,5<*_=H&
M5>-9J.!F]=5^1K:L#8VI&(RS8CC]2*K[[!@JF82CXG*?DDBNS_;7=^V9W/;<
MS)BR]LR)(9()$!1KJ)%D$D9U:#;T[:9) 1?J".L7.^7=C9.[4>T;I@8LV'NV
M+'/'D1.0ZV<Q-&8Y5"ZU!$H.J.-@;?*0>F^,SM_M= ?5WUPW)UUV"ZK<'1H>
M8HFW8B+K->E)YK"UVVS-2K]G92LO&R[V-CXTL4@F]!L8B@).T%N4DDW 9BC&
MX[P#+[Z[UQOF6&LV5E2)/B.TLBQEY(DFDB949%9FUL4U7%T9?F9DK-67RGN3
MA^W38.6<"S6Q\7"A;'S46&)Y!'#*\"2JSK(51/37U--CI=7NBJX.W/U/]U9;
ML7KZ=U;M&PK36X]<&6E0F9-?W96[4:4?F%"87-P4%G]:DWA6#H2@  W49F_,
M<Z@ACSO_ -LL?AF\1;[L4(BXWFV70HLL,ZKU0?!9%'J+_*$@\ *R;[:^[>3S
M[8IM@Y%,9>5X!+%V/SY&.[?+(>@&J)CZ;VZ:3$?%C41?V1I'VS]ETW0$?)5-
MQ8-*ZR:"FH4#*&FZ_4#.2)^1&OLF2D[(LG^8Y@\B>0' H@!9#]EF''^R4>[M
MT80YN2?LT236^-[K$I\/.UK^,8>_8_M1[@VV(@F,S[?ACKX^HD):W06LTS#Q
M/A>]C86EMUZQCMNZ:V5J=TDV2:7FB6*J-14)X-X]W(Q+AK$/B%3(8$AB9$45
MT_$H^!D@$ 'CC('\9WR;CW),+D$98R8N7'*?BP5P77[=:W4]>H)K8QRK8,?D
MW%\_C<P AS,.6'X!2Z%586\-#68? @5JK]=W4S8O3W4EDU[L"\UNWJS]N&X,
MV56;2HQ==>/(6,BI=JVE9A%@\DV[PT2@<O+-H!#%,;Q$RAN+^[Q]P=F[C<AA
MWC:,6;&6'']$M*4U2 .SH2J%@I&M@?G>_07L!6-^QO;3>^UO%IMBWK,@RWFR
MO7"Q!]$3-&B.JN^EG4E 0=$?6YTW8ULHSZYZ18[CE.P*&N*Z.Y)=!NW=7Y=%
M=U,HD;P(5@JD85RNJRAW2U> 6:Z[5)%=PV,*:ISD$0RR9.9<HEXW'Q!\V;^S
M<9)&." AO)ZOS6 9P)/G57)56^90#UJ_H^#<1BY1)S5,#'_M5( #DE;R"T?I
M?*22$)B_+9D"LR?*Q(Z5FO+9JZZ8I3%*8I3%*8I3%*8I3%*8I6OW8'M#I+K%
M636;;]U8P0K(**PU;:\25OLRI!$A6]?KC<POGODMP0S@X),T!$!762)R8+NX
MCP7D_.<[Z'CN*\MB \A^6&(?&20_*O3J%%W;P56/2K*YKW"XEV^VX[ERG+2!
M2/DC'S32GX11#YFZ]"U@B^+LJW(@4OO;#NK]EUED]3=7Z?,:TU *WPK%)-9)
M:-.I'J@KRKLK8[=))&,9/F0B8T'&^1W!!.D(/PXR6.T]O^V79+"3D'.LF/.Y
M';5&I4-9A;IC8Q)+,K?Y^2P4V8>E4,]Y[E=V_<!G2<;[<8LNW<5OIED#E"5Z
M_P#&<I>B*RVOCPW9A=3ZRFI,^FWU?Z8ZP#&W.TE;;8W(W!%PG:YI@0*_4WA?
M$X_L>O+BNFT=(J  %DG0JO\ DODB+8ISI#A'N3WSY+SK7MN#JV_C9N/21OS)
M1_N\@MJ!_P!&MH_)M9 :L_\ :KV\\2[=>GNN<%W+E0L?7D4>G"W_ /#Q&X4C
M_2-JD_BE 2M2<Y@ZI!4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q
M2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q
M2F*4Q2F*4Q2M:>Q_4?1?:BNC";8I[=[)MFRK>!NT1[,9>*P*@^?E#3Y4%E!;
M K^<S1T1RQ5, "HB80 0O;AG<+E7 LSZKC^2RP,P,D+W:"6W\>.X%[= ZE7
M\&%6#SOMGP[N-@?1\FQ%DF52(YTLF1#?SCE ) OU*,&C8_B0U!G9NK_?+ZTI
M^4V%UJM<CMK3(N59"<@V4:[EVHL4@%03;!U>1T=;S;-$?$\U"J^ZDB0QCK,R
MG]L938/.NT_>S$CV?FV.FW<EL%20L$.H]/ZOE6MU)Z0S"Q) "R$:JB!G]N^]
M'8',DWKM[DONO$M1:2$*SC3U_P",8@:Y( %Y\=@U@23$ITU(/U2^VG0F^OTV
MJ[)50TALQR*+4C&QR*:E%L#Q0PID+7[BL1LW9.%S@'#23(T/YJ%215=&Y-F(
M.?\ M]Y;Q/7G[*#NFQK<ZHU/KQ@=?S(1<D#^/$7%@698QTK-O;;W+\)YMZ>V
M[V1M'(6L DK#T)&)L!%.; $FUDE"-<A4,AZU*R0Y%"%43,4Y#E*<AR& Q#D,
M "4Q3 (@8I@'D!#T$,P&00;'H14CP01<=0:_6?*^TQ2F*4Q2F*4Q2F*5CR>U
M)J^T6RNWRQ:^ITS=JD]3D:U;I"O1CBR0KQ)$[=)9C-G;#(I DD?\I?<\"F I
M@#R*40K&)R#?<';YMJP\S)CVS(73)$LC"-P3<ADOI/7SM?Q'@35%S..;!N&X
MP;OG86++NN,^J*9HT,L;6(NLA&H=#\;?P"LAY1ZK5,4J)'[BM 6+<'6Z,O%1
M9.I6<TG8'-J?Q+-$[AT\IDLQ+'6EPU02 5%%H8S=H^4]! K-LN;\0#)">W'E
MV'QSFK[7N++'B[G"(E<FP$R-JB!)\GNZ#^6R"HS^Z7A.?ROM^FZ;6C2YNTSF
M=D479H&71-I \T^20^/R(_2]JT%^I_O_ *TTG5ICK]N^92J%>=6)U9J'>'B*
MRD(R=2Z""<U7+$LU14/%MSNF9'+1VH4R/FNL18Z12I>66N__ &CWOD^?'R_B
M\1R<Q81%/ "-9"$Z)(P3\YL2KH/FLJE0Q+6PK[:>]O'^*[9)P?E\RXF'Z[2X
MV0U_3!D_I(I2!\@U#6CM\I+,K%;+>83<WV+]2-04B2M:6YJ!LF62:+C!4S65
MN@KI/STH"0F:QYPKKN4;P""ZG *.WYD$$B@/J<_BF:.?&NS7<+D6Z)M[;;EX
M6.6&N;)ADACC6_5OS ID(\DCU,3\!<B4?*N^O;'C&T2;F-VP<_(53Z<&)/'D
M2R/;Y5M$SB,$^+R:57XWL#6(T31+MW][JMEK"V5=A?[Z^V+M!TW(JHPK]&:2
M1)*;:$6X_P U9DC@2AX[S]/>6;IC^.3DY7NNU]H^V13#8*<3$7'Q0;!I)RNE
M#;S.J\TEO(.:UZ\,V?=^]W=T39ZEDS,TY660+K%C*P9DOTLN@+CQW\V0?&IA
M/O7@"J:7T984TB%3AMES$ 7Q]P@)%GZHX?$2(D0GQ_ 2UC^(@8OB % 0$W$<
M_:KED<FW7#).J3!23[_3E"WOX_YW_#U\JE)[R,,-P[:,T#I%N31^?3U(':UO
M#_-??TZ>=0S[+[+J3O2_K=U>A7KD6M*GMC7F\I@"1&YY&4NUH5ID451(_O*
MP8S4@\634#Q$SU P /ME$))[)P@8O<S>N=92KKR8L>" ];Z5@B$S]>GS,D:
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M%0J >*2A! I@DSQ79H<_M=MVPS,8X<C88(7:/2&'JXJH[KJ4KJ^8L"RD%NK
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MD1**Y3G,E;/:COLO<#=VXQO^)%C[G+&[1&,LT4H4%GC9'N58("U]3*X#7"D
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M8)6)O_3O8.MK*S9S,9#;.MU?DH2022=,7U4N%7KK]1F];* (*MI!X\D4SD,
ME,4!]1Y$ I?N6Q\C:.X^)O6$S13RX,,BNI(99899%!4^14+&01X&JO[3\O'W
MOM5E[%GHLN/!N$\3(P#*T,T43D,#Y,SR @]"/X!$IN&A[!^KGNS"6BF@]?U)
MA*GM>O73U90C:YZVESJ,IVES+I/S(J_8-'"T8[.)?,JI$7I4R>XCQ(/CF[;1
MWV[82X&Y:4W%H_2R H%X<E/FCF0>2L0)%'A8M$2;-49N5;-O7MS[NP[IM(=]
MH$AFQB2;3XK_ "RX[GS9 3&Q-S<1S:1=:YW4-IA^T7VSU.^U\'3JOV?>Y[]
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M^76QCEMU_P![OTZ]/A>L4>['!7+[3MD$7.+N6/*/'H2)(;].GA,1\W3K\;5
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M3]'WQKGU(%'HNQOUDQ[JG4FY,1B8GJQ:H[?U#[._K34]IZFOO+0,(0036/\
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MN7K7HGL#'&CMOZOJEU,#8[1K,/H\K6SQB!P-RG$6N-,RLD23R-Y>+=TF43
MB \!ET<;YKROB$WK<<SLC%^:Y16O$Q_EQ-JC?_*4U:/*N!\/YMC_ $W*-NQL
MP:2 [K:5 ?\ 1S+IEC_R''6H?MN?2:WC)/\ >/5?=,[1K#'JJOH>#N[EV)63
MWP.*)8>_U5!I/0J9!'P(*C%ZL!3<F6'@>9%\>]SKSP?IO/=LBR\-P%=X /F7
MSUX\I,;GS-G07\%J+W)O:1#CY/ZMVVW:? W!"6CCG9B%:QL(\F(++&/*Y25K
M'J3YXB3[#?;%TD/\7<=&E-U:YB0\5K!88U2]QQ8\I@,9Z&T::I^OQSA8"B!#
MV ZYR@(\H?AQ<1X?[?\ N>-?&\I-LWF3PCC;T&U?Q?I9ORV \QCZ0?XU6TO.
M/<OVD;T^583[SL,9L974SC3_ !AE0?F(3\<H,?'Y?"MOM+_=7ULO0-(_:\!;
M=+3*H)E7>N&ZEYIA53F @%3FJ\S3L1.3#R(K0Z:1"C^93T$<QWR;VR\VVK5-
ML$N/N>,/!0?0FM]J2'T_X)B3Y"LF\3]VG;[>M,'(XLG:,PVN6!G@N>EA)$OJ
M?>7@10/$^-2E:YW#JG;T:,MJ[8U+O[ A0.NK5+'%S2C/D0+X2#5DY5=1RP&$
M $BY$S@(AR'KF"-YXYO_ !V;Z??<+)Q)CX"6-DO_ #2P 8?:I(J1>Q\GX[R;
M'^JX]G8F;C^9AE22W\X*25/V, :R/E%JN4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q
M2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2M7MP=TNKNB/DH;
M*W/38N8:D4,I6(I\>TVP#D$Y"I*5JL)2\PS%95,2%.X212\@'DX 4PA?7'.V
MG.N5Z7V3;,F3'8_TK+Z47W^K*40V'4A23;RZBL?<I[J]O.&:DY#NV)#E*+^D
MK>K-YC^AB#R"Y! )4"X/7H;19;/^[-M,21JEU=T39;W8'JBC6)E[J1P073@I
M# 4\=0:@>4FYA)0_YB :09*^!?S)@)A N>-C]L4F-!^H\[W6#$PU%W2&W0?R
MIYM*(?C:-Q?P/3K'/D'NWAR\D[7VYV;)S\]B0CS BYMXICPZY7%^O5XS;Q O
MTQ(.A_MG[O&]S;ES?Z/UM)&*1Q7IMXKKV.-&J 05VAM<5)(UHG%"%.)B)V$2
M>1^2^^4"_EN'^U?M][7BW'L9-UWI/"1%&0VH>!^HF/I)]IQ[].NDWZVU_8WW
M,]W#JY/F-LNP2'K$S''&@@7'TT%YI/YN4PZW&H6Z;HZ)^FCK)K3X4KL]U/[Q
MLK?V55$YU4]:I";I($S@HVJD&[%ZZ3]XIO)*0D7S=0@@4R7H(CC3E?N3YQO>
MK'V-8=KPC<?ECU)[&_C*XL#:W6.-&!ZAJRKPWVJ=N^/:,G?S-O&XK8GU3Z>/
MJ'F((S<B]_EEDE4CH1\96*O4ZM2(1E6J96X&I5V-3!&/@:U$,(.'8I%*4H$:
M1L8W:LVY?$H!P4@?AF L[<,_=,ILW<II<C,<W:21V=V/VLQ)/[34D-OV[;]I
MQ$P-K@AQL&,62.)%C10.@"H@"@?<*[!GDKVTQ2F*4Q2F*4Q2F*4Q2F*4Q2F*
M4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*
M4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*
M4Q2F*4Q2F*4Q2F*4Q2M1]T=$^J>^OENK_IVL!/O/=.I;JJ@>FVLSE3D?F.YB
MM'CE9A=,P\E"0*[2_M((>F9"XSW5Y]Q/3'M&Y3_2+_F93ZT5O@$DU!!_O>@_
M;6-.6=GNW'-=4F^[5C',;QFB'H37^)DBT,Y'PDUCXBHM=B_2*^K\F%HZR=@Y
MNJS;$55XAA?4W31ZU=")A2,AL&B),I".3*4?#DD.LIQZ^0_AF=]F]S\69!]!
MSG9XLC%>P=H+%2/.^/.65CY]9E'V5'3?/:+)@Y'ZEV[WR?$S4N47(N"&\K9.
M/H=!Y'\ESYW/A6.OW+]SO4A(2RL3,[UID6F E7=L&F[6JZ"/@"CEQ(0*[7;R
M+=)/_*&=JH$*0#''@ $P5GZ+VT]PFO!)'M6Y2'P#'"()\@L@.(2?(("2;#SM
M5#.?[L.V49&1$^][3$HL2HSP0/,M&4SNG[Q<@ 7/D364->?>1$,WOZ%OW0%F
MJLFS.1O*2%#E49%9)SP4%06IUN3KSV,*GSY"4TFX4\1_ 1_&A;Q[6LF6+ZOB
M6[P9$#"ZK.I4$>5IH?45K_'TU%7!LGO PH9S@\VV3*Q,I" Y@8.0>E]4,PA9
M+>-O4<V^/G(5K/[+.E>T2HI1N[Z]5)%7Q \7LA)[0%4#F#DJ9Y.RH,JXN<?P
M_H/5@Y].><P_O?9/N;L5VGVN;(A'[V,5R ?MTQ%I!_E(*SCQ_OYVFY& N+O&
M/CSGIHRM6,03Y:I@D9_R78>5;KPD]!66/1EJY-1,_%./\A)PDBSE8]?\I3_T
M7K%9=LI^0X#^4P^@@/\ ',99.)E84QQ\R*2&<>*NI5A]X8 C^"LLXN7BYL(R
M,*6.;';P9&#J?N920?X:Y;//7HIBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,
M4IBE,4IBE,4IBE,4IBE8XOVXM3:K;&=[*V71*$@5+W@&W6N#@%5B"/!?C-Y-
MZV<.CJ&'@I4BG,<P@!0$1XRM;3QSD&_2>GLF%EY;WM^3$\EOO*J0/M)( \ZH
M>\\GXYQR(S[_ )^'A1 7O/-'%?[M; F_@ +DGH*C]V=]P?3.@?);P%CMNUI-
MN(I_%H-6=D8^_P#XH&F[<K5HM=N'("95J=T''\H&$/',N['[=.Y6[Z7RX,?;
MX#UOD2C5;^9")7!^Q@OVV'6L)<B]T7:?8]4>'DY&Y9*]-.-"Q6_^^3&*,CXE
M&;[+GI6C\U]P'9C<TDYKO5+J\J\<^X5$KUU&VK:LZDD<  '9XJJ,X*+A50,8
M!$7)WB"9 $3"(#R7*&-[=.$<:A7,Y_OH5+7TAHL5"?@'E+LX_FA&)\/MQ%E>
MZ+G_ "N=L+MIQMY'U !V6;+< ^92!8TC/VL[J!U/V<7_ *J?VU]L>#;QVZYU
M339,QCNX*5M;.!;*QZOJ1$NOM3H&9/E$BJ>)49<[9;@HBH?RX$WH_M][?.W_
M $XMMPW#<D\)%B,AU#S^HRSJ6]KDPAAUZ"WAT#MQ[F^Y/7F&[':]JD)U1F98
M_E/D,?"&E_&P6=U:W5C?QV=T]])772G"T?[:MUTW#*(F*=>-24+0*<X !*84
MU(V$=/K280$!+Y%FB%,4?4@#^%C<C]SW,MRU1<?Q\;;8#X,1]1,/\IPL7_H3
M;XU?_%?:/P+:=,W)<C+W7)%KK?Z> _Y$9,O_ *>Q'E4J&LM*:BTQ&?I&J=;T
MV@LC)@DX_;,#'QKQ^4#%,!I6321_4Y=;DH?U'2RR@^(>OH'&!=\Y-R'DL_U.
M_P";DY<M[CU9&8+_ #5)TH/L4 ?94CM@XIQKBN-])QS Q<*"W40QJA;^<P&I
MS]K$G[:RAE#JX*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8
MI3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8
MI3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8
MI3%*8I3%*8I6-=A:;U+MEI\'9VM*+?FX)>RE^[:O#3J[8G)A#X3N09KNF)R&
M,(E.B<ABB/(" Y6MGY)R#C\GJ['FY6(][GTI7C!_G!2 WW$$&J%O?%^-\EA]
M#D&!AYL5O":&.2WW%U)4CR(((\JCYV7].W32^&<.:]!W/5,@L)E/=HEK<+QX
MKB \">(N3>ULTFWEQRDU^*7@."B7\<R_LGN.[E;2 F9+C9\(Z6GB :W\^$Q,
M3]K:OMO6$.0^UOM1O9:3#Q\K;<AC>^-,=-_][F$R ?$($^RU:5S?TN;KUQ(.
M9[K=VF-%R)@*=L261M.M95/VBJ>V@K:*/*3YW9@,81*?X;<I?,0\0X$QLFXO
MN7XSO4*XG-=A$D/F4,62G7S$4ZQV^T:V\/'R&)\KVG<KV"9\SM_R5X9S;2'$
MV*_2]@TV.[ZNM['TEM>UO,\8,5]WN@A,#21E-O5]F F.<'NO]J ^!,H>A2S1
M$-FG'Q+^!"IB<1_B;.[ZCVO<M_I$3;LQOY.1BZ?]A?&_AO;[JZ?IO=[PMORY
M#NV$@_C8V4&M_/"99/W>/VFO.3[>.WVI!!#L-U'0:>P**:BBT-L73[A7S4$A
M3J*VMA<&@J..."F32*03>I2B'IG$^W?MUR'YN'<B+7O8!\?, Z?")H3T\[DF
MWB?.OO\ [SW='C"6YSQ;1I(!;1E85^MO&9)UZ^ (Z$^ \JSS3/O,Z]ROL)7G
M5>UZ>X5$P*+0P5>X1;;@"B4RKE29K,D8AOS!_39', \>@@(B6T]R]K/,,>[;
M7G[?DH/ /ZL+'[AHD7^%QY_MO+:O>%P/)*INVW[GBL?$J(9D7[R)(W(^Z,GP
MZ6N1M/4OM5Z,6TR:(;F"MO% \OB6VG7:$*0/),G*DH:OKP)!\E0]/E^7 ";C
MQ*(A8>X=A.ZFW@L=L]:,><4T+_']WU!)Y?Q/@/$UD;:_<=V=W1A&N[K!*1X3
MPSQ#R'XVB]/S\-=_$VL":V3J_:OK+=!(2K=@M-33A3Q$K%ILBH_J8 ;^7SBU
M99.12\OX>20<B A_ <LK/X%S?;+G/VC<HD'[QQIM/^R":3^PU?\ MO<3@.\'
M3M>];5/)_%3*A+?M37J'[16;HZ5C)AL5[$2+"49F$ *[CGC=\V,)DR*E J[9
M15(1%)4I@]?Y3 /X"&6O-!/COZ>0CQR?!@5/P\#8^((J[89X,A/4QW22/XJ0
MP^/B+CP(->_G57;3%*8I3%*8I3%*8I3%*8I3%*ZE8;]1*D!QM=UJ58!(/)0;
M#8X>%!, (FH(G_4GC;P $U2&]?\ %, _@(94,/:=UW"WT&-D3W\/3C=_L_=!
M^!_@JGYF[[5MP)W#*QX /'U)$2WGUU$>1'\-:]V?O;TYJ/N!,=DM2+'1-XJI
M5^VQ]N7(<#>)B&0J9YM8%"&]#%\>2B \@' Y>&#VJ[D;C;Z;9=Q /@9(6B'\
M,N@58^?WA[6[9<96_P"UZE-B(\A)2#\+1%S<>8M<5K/;ON)Z15HJPQ%LO%^.
MD!Q!*HZ_G&IEC$2]P$T5+P%,0$3J?TRB8Y2>8<^0$X/E[[=[<>Z&<1]1CXN(
M#YS9"&W7S$'K'[?"]O*_2L?;G[I>T&WJQQLO*S66_2'&E!) \ 9Q O4] 2P%
M_.W6M4[E][E+2,9MK7KU;; LLH5%HO<KA$UDP"H40*<T9 15Q,Y4]\0*")7)
M/(!Y\P'\HW]MOM3W-AKWO>,>%0+D0PO+_P"-(T-A;K<J;?#SK&VZ^\G9@?3X
M]L>7D2LUAZ\R0^/A\L2Y!8WL-(87_C>1Q\'?_P"TK=XE2TOUD&KQ3LAE&,_'
M:IN$HF!%/ ""M;KR_"D*" & Q ^,D)@\A$#%#\M7_P!4?8CBXU<EWSU\A39H
MVRH5_@A@7UQ]OS'R\#XT?_75[C.7/HXGQOZ;&8763Z2=OA_G\AEQSXBPT"_4
M]1X?C_52^XC?Y"_WJ;Q<ZVBWYCJ/HZ0V:UKB!VZ@' 2*UO2#![$+@JF;DK9;
MVR%$0 X$$!\?O]O_ &X\1)_0-J7-G3\++C&0W^R3-8.+>;"Y^%QX\1VW]T_-
M57^TF]';L9S=E.4L1MU\8]O0HU_)&8 =+V(Z9)HGT75([G]4W-V M]J>NE1<
MR#6CP$?7E3KGX,KYV*SN;@X?F.KY"94S)$Y@'\ 'URB[K[J-P">AQK:,;'B4
M64SR-(+>5HXA"%Z>6MA5=V?V=[4TIRN6[WF9<[-=A!&L1)\[R2G(9KGQ;2I^
MX]:W\UE]9G2K5WL+L-*PMODT1()I79+I]?%%SI_R'4AYY=Q5TC /K_18) (_
MCSP'&)-\[W]S=]NLVYRX\!_<Q@L '^7&!*?VR&LU\>[ =I>.6?&VB#)R!8Z\
MHMDDD>!TREHQ_DHM;P0T'"UR.;P]>AXN!B69?!I%PT>TBXYJ01Y$K=DQ10;(
M%$?X%* 9B[)RLG,F.1F222Y#>+.Q9C][,23^TUEW&Q<;#A7&PXXXL=1T5%"J
M/N50 /V"N4SHKOIBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4I
MBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4I
MBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4I
MBE,4IBE,4IBE,4IBE,4IBE,4IBE,4KPN/C_'7^7[/Q?95^3\CP^/\?P-[WO^
MY_3]GV^?+R_+X\\^F<DUZQZ=]=Q:WC?RM;S^%<7T:#ZEO3L;W\+>=[]+6\:T
M4W/_ /&V_-U_?5_JE?JO#KWOU[^[3]W\^T/ROC_$_P#;5[GCQS[7YO<\/\?P
MS*G&O]=-E_LQ_:'Z?I;T_J?1\>E[_E6^_I:_E>L0\M_U$ZO_ &Q_LU]3U_IO
MI/6\/FT_YWX7T^=O.U1I7Z+^B25D'B"MB3K<EYB"[R@H=BUX_P A,D8!9E90
M4_4_ I4Q*'QTO#@YN>1\1+FW:)_=9!"K+"9H/(9!VX-Y^.IXY?\ 9&_0?;>/
MN^0>S6?)=)9D@R/,XPW,I_D^FDD'^Q'GU\K:PV72?TW2!SJUCN-N:N'.)1]A
M]KV\6%BD >V @@F.C8E\ &*4PC[CE0?(W(< 'CE]87)_<E" N=QO;9@/-<B"
M-C]Y^N9?X%'0?'K6.L_B?M1G<O@<IW;'O^Z<?(D4>'A?;E;X^+GJ?ATK#QNN
MW2;]0!36/V)RPR?L* 1H;JSO<L@"8)B*YPD:^V,X% Y_$#%!J %+ZB8WH W'
M_;+N=Z-M]X;'Z%_']4P=-_+Y9#:_C^]U^ JV5X+VD.5JXQSK(&1I/RC:-Q+V
M\SJB4'3X7&CIYDUE**T5V40$/[GN[.Z)4WOG!#]*UA]AT (F%N OS!^U]'V4
M2KD3X P!R)D_4PE_#*#/RKA+_P#:/C&V1BW75E<>D\_E_I<V+I_B/A>KE3AG
M<&/_ +,<PWJ5K]+87)XO+YOZ+!FZC_"/&U93A];_ &SL4VX5_?\ M:8(9DF4
MIIB&['I*$:D*C[*CC^\W2<6X%ZJ AY>0"\ 0-[H /EE R=Z]OLK-]9M&!&=1
M_ ^W$7ZWM]-FL-(\K?)X:;]*N?"X][FXD7Z'?<R1= MZD>Y Z>EB?J]N5M1\
M[_F>.JQO7=FD-]XK-!HK$6RP2QTC-RLFSMMJI-=T JD3(=V:[UJ-0*4I!\U/
MU!1,WB ^8>7Y1IDF3[6Y79<C'BC!OJ(.40.GEZ$K'[!Z8/7PZ=:J8PO>##&'
MQLQYF!&E=.&"W4#K]1 B_:?4(Z WZ]*[!_\ Y^/_ ,/]2[/+_P#\D_\ P_6:
M[O\ _M?_ .'Z#7923OWRD(0IJ96E#%*4HJ'==7@.H(  "<X)VM-,#''U'Q*4
MO/X  9X3B>U DD94X'PMN?\ X8KU5!N'O,  .#BDV\=6U=?X,@#^ 5Q\C(??
M:^*D#:"BH<4Q,)SQRW4I4RX& H 54)>9E"@!..0\ (/J/(CZ<=T$/M-B),DT
MDM_XPW86^[0B?X;UYLG)]Z$X BQX82#XH=F-_O\ 4ED'\ %=:E ^^XS,X/32
M!&XG2 YXO_5'%X7E0H%,0( II3P*/J?VP'\O/(<<Y[8/_=,$EXM!>Q_%^K6_
M])\OW7JG3#WIE+2EPEQU7]%N.O\ N=WM\;#PKKTA5_NG=.T$I?8UQC>$%#)N
M(]BS4:" '*'MKEI%$?C[YA'DONDY\0'U ..?7#G^V:.,MCX6._7J&9K_ 'CU
MYUZ?<:ZY-J]VTD@7(W*6/IXA4(^X^ABMU^\?MK%4SJG[,Y!ND-L[,;W@VAV#
MU1P"<#WO69I-@*0'2$Q_=[U^F&H@9$1'E<3)^ &X-QY!E?Q=_P"R$+G]/V/:
MI9 ZVO)L0)/D4^HW!#X_Q;&]NGA5K;AQGW"S(OZGR+=HHRC7T1\A*@=+B3Z3
M;''AX:[BU['QK%D[H)ZN93^^SO?>(KDY/G#.Z0[KV Q1_3A'E0+;K:M>X<&O
M!2@<2\M_S>@?ERO8O+8D _LQQ3$D_BZ,[98_WO+TLF7S^%_FZ>/6J#E\)RW!
M_M7S3<HQ^]ZFW;_)^[_NV-%Y?']WKX=*XBM]>?K8;^!K?]A5AEN1*91&M]9M
MKU[P 2)^21',G#6;W!*H!N%!1+Y (?D 0'GTYO,.];W&W</AC^V3<L63]ME>
M*WETN?OJF;=P?V^QB^[<XR)3\(=JS(O(=+O%-?K?K87%N@\]@JMJSZ1X,2J3
MO93<%T5'@5$IBM;.C&/(&-Z(HUG1\*]3*8H@!O)RH/(<@(<\9:&?OWN?RNF+
MLFW8R_%),5F_:9<UQ_ HJ^-LX][0L+KF[]N>8W^Z19B+^P0X$1_A8_LK<'5:
M?T<I&*G65]6.5R*B4[C:@;7*598$VX&4,7;B+>-!(P>(_P!,A$/+S\0 ?/,<
M[^?=(PU9PSU4CPQ?I>@Z_P#V0EK^/B2WA?RK*G&1[0%&G;3M;,&ZG-^JZFP_
M^W "WA^$!;WMUU5*IJ#_ %7O91_N"_N$^/PI\?\ N@_N\]GCV/ZOL_LO\G'Q
M?YO'_J?X^F8$Y%_;K6?[6_JVOS^K^HOX]+^M]O\ AJ2'&/[ ^BO]C/T?T+?+
M]%]-I\/+T.GX?AY?96>\M.KPIBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4I
MBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4I
(BE,4IBE?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>tm2213007d1-tbl_program4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2213007d1-tbl_program4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!L .4 P$1  (1 0,1 ?_$ 0<  0 !! ,! 0$
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M!WM7:(]9J4>2V.?,T.&.!-GQ^O+K!XC]]>WI]#2Z@VYP=VDVMZ5::M;<W?\
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M>_\ >K*Q080_=*Z_V=3?B6%[WK?WHXD_;]X?I<QK&,B,!
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M2PO>];^]'$G[?O#]+F-8QD1@(
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M[<L.'KWO":>Z($8C6.S;5;$BMC;)(C4EE9&B^@R5[V-5&JU$5K537L7LPX
M                                       #>_\ [8W_ #W_ /X^C"O\
M1?ZE_P!J-Q?X ?\ 6/\ RTT0&:FG0                  _0B_[4G_(U_\
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M&J.>_P!)(T=<O:=3_23EARA4_P!-N0K)[+7>7Y*=LRN\FKE%?D!R>I-;%%C
MWMLAGD*BY3WAO'S>UF-$8N4<&=R4]UY9R:A=MEUOPW?T.)[MCFHK_@YFE9%$
MV!K.92)&LST<JLCD?FSRJO.366QJMBHZU;%K=^-];M\0STE[8&K'5=Y3U%5+
M6OF;6+4.?-S+HVI+44\*.I*9K>8I6OS)VLM:Z/-;:G5$-CF@0    #>[3=_9
M [1G^K33I_U08X&%8@_>JX/RBJ_0Y3<.!?[L,<?D-V?\5IS1$9J:>
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M^:V*-'7==KU1D=3*QB*^2D<]ZHU$17/<Y[ERN<JJJF >\IU?_GKC3]&;2_\
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M_P">N-/T9M+_ -#0</L*_$U'6ZS7CCSO/Z90^S+J[$.\IU?_ )ZXT_1FTO\
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M_P">N-/T9M+_ -#0</L*_$U'6ZS7CCSO/Z90^S+J[$.\IU?_ )ZXT_1FTO\
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MN:]'WG=$[&K"KFU#/DS+7?\ E4;4,8K48[.DLB18;955JJY7G7\,V-/@
M  91P=_MJP__ %HX_P#];&D6R^?]SU?Y-+_$<9'@_P#>VZ_VC3?CF&2];/\
M;,U<?\3F>_\ >K*Q080_=*Z_V=3?B6%[WK?WHXD_;]X?I<QK&,B,!
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M6T==4U=13.B2]8:R>62CBBIFK,K6Q2T>;;1STE<UK&QQ*Z+.8]J'1.-PG5$
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MW4HS'H"4VQ7<+"J5KLT-1@?#%4L?/4[E2.F93HB33M:L,?WD;VME1LC4M_\
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M&L;UPC.S2@    !O=V8W]OC2]_66E_R2ZC"MXO[DWE^3_P#::;AW _WQX?\
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M:^/\Z=,?_ CH]_W.L@PK!/\ -KQ_;5=^/<;AWR?S_#W_ -GW-^AL-$1FIIX
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M;&.+;II[CQ!5MJ+JI9,^&/F*>-(W6.;:QT43'):CW9R(ZQRK:Y%7*:T"_F$
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M*Q6OD:])%MSGK*UZ2N5UJY^<]V=DSK;$L-WJX_2]ZN_'7@Y]=6TB4LR/B@?
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MHS_5IIT_ZH,<#"L0?O5<'Y15?H<IN' O]V&./R&[/^*TYHB,U-/
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MN)^9%Z%16JJU4J)S>:JRJJVHY%:VU<QK3::;]HXVR[2ZAT^W8M?59J;3YCS
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M"_((=YL1[0K=/+RAP^P%L.Z.IT^K'J=Z4>K=@WT4P7Y!#O-B/:%;IY>4.'V
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MOR'FH_D7-\WS>:F9F69N9F69N9F^CFV669++"[$/OET_AEGP4@?(J"2$
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MG\I+_A%PE020@                  !&_??\6_QH3YOM@DA
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M6(4T%-)QQE62QJ.\RHTCJ\G%-A\<0IC4ARD^]0M27EJ+ZUJ;LU [#
M %M3/_,^5_Z-/O\ DM4*FC_G<7\HW^,A9,3?NW>'Y#/^*>>#H=VC\FP
M
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M?V'ZJ"MN6JC22&>![9(I6+Y',>Q5:Y/-D7(J*BY44F1\2Z
M $:V?6+/Y27_  BX2H)(0                   C?OO^+?XT)\WVP20@
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M[6LL5DF)CRJ6EWT, [@0     !;?WN_''\Z"?."20^^73^&6?!2 !)"
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MD#8:O.)<9SD:1+Y7,7NM7!6L,2VNCZY'&EI2:EHD9=UI*8DDBRPNT#*0
M   "VIG_ )GRO_1I]_R6J%31_P [B_E&_P 9"R8F_=N\/R&?\4\\'0[M'Y-@
M
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M-9A;D<K34K3A5I=JVM5-0-I      !;?WN_''\Z"?."20^^73^&6?!2 !)"
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M5M:6EL0D6$ITR<LLDDJRVRRVEM*4 $T         "-5^_FK[,J^!G"020@
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M$1$1$1$1$2PYQQ/L                !&MGUBS^4E_PBX2H)(0
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MDG+PJ?DP <WW]).7A4_)@ YOOZ2<O"I^3 !S??TDY>%3\F #F^_I)R\*GY,
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MQ%A-!)[88ORA/ID^)T)+&1*;H]+.8T;%&RG)^<%-K:N,*:FA5<60<;2PNX#
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MV*8MJATVIS84F76VI:D*.$_OBA=@&TH
M       @I2<:GC,C4)S3"#R&)W.).)ON*-)-*;U%Y9I1EE;;RS"[[:5MNI6E
M:5ILT%12-1U5$UR(K5D:BHOGRH6?$,LD%P5TT+G,F91S.:YJJBM5(W*BHJ94
M5%RHJ944\5_K7:I.LGGWTQ9$\XQV_P"[&&MG4.@BY!^8_P 0&_GWVQ=[8O'M
M(]:[5)UD\^^F+(GG&'=C#6SJ'01<@>(#?S[[8N]L7CVD>M=JDZR>??3%D3SC
M#NQAK9U#H(N0/$!OY]]L7>V+Q[2/6NU2=9//OIBR)YQAW8PULZAT$7('B W\
M^^V+O;%X]I'K7:I.LGGWTQ9$\XP[L8:V=0Z"+D#Q ;^??;%WMB\>TCUKM4G6
M3S[Z8LB><8=V,-;.H=!%R!X@-_/OMB[VQ>/:1ZUVJ3K)Y]],61/.,.[&&MG4
M.@BY \0&_GWVQ=[8O'M(]:[5)UD\^^F+(GG&'=C#6SJ'01<@>(#?S[[8N]L7
MCVD>M=JDZR>??3%D3SC#NQAK9U#H(N0/$!OY]]L7>V+Q[2/6NU2=9//OIBR)
MYQAW8PULZAT$7('B W\^^V+O;%X]I'K7:I.LGGWTQ9$\XP[L8:V=0Z"+D#Q
M;^??;%WMB\>TCUKM4G63S[Z8LB><8=V,-;.H=!%R!X@-_/OMB[VQ>/:1ZUVJ
M3K)Y]],61/.,.[&&MG4.@BY \0&_GWVQ=[8O'M)\VZJ]4-M;KK=2.>[:WUVU
M];<PY#I6^[8I;MKJTD6S=7:TI39K^Q0.[&&MG4.@BY \0&_GWVQ=[8O'M!]>
MM=JDZR>??3%D3SC#NQAK9U#H(N0/$!OY]]L7>V+Q[2/6NU2=9//OIBR)YQAW
M8PULZAT$7('B W\^^V+O;%X]I'K7:I.LGGWTQ9$\XP[L8:V=0Z"+D#Q ;^??
M;%WMB\>TCUKM4G63S[Z8LB><8=V,-;.H=!%R!X@-_/OMB[VQ>/:1ZUVJ3K)Y
M]],61/.,.[&&MG4.@BY \0&_GWVQ=[8O'M(]:[5)UD\^^F+(GG&'=C#6SJ'0
M1<@>(#?S[[8N]L7CVD>M=JDZR>??3%D3SC#NQAK9U#H(N0/$!OY]]L7>V+Q[
M2/6NU2=9//OIBR)YQAW8PULZAT$7('B W\^^V+O;%X]I'K7:I.LGGWTQ9$\X
MP[L8:V=0Z"+D#Q ;^??;%WMB\>TCUKM4G63S[Z8LB><8=V,-;.H=!%R!X@-_
M/OMB[VQ>/:1ZUVJ3K)Y]],61/.,.[&&MG4.@BY \0&_GWVQ=[8O'M(]:[5)U
MD\^^F+(GG&'=C#6SJ'01<@>(#?S[[8N]L7CVD^:ZJ]4-UUM]VI'/=;[-MM+J
MYAR'6ZS;4V+MK=61;-NVI]78^J'=C#6SJ'01<@>(#?S[[8N]L7CV@^O6NU2=
M9//OIBR)YQAW8PULZAT$7('B W\^^V+O;%X]I'K7:I.LGGWTQ9$\XP[L8:V=
M0Z"+D#Q ;^??;%WMB\>TCUKM4G63S[Z8LB><8=V,-;.H=!%R!X@-_/OMB[VQ
M>/:1ZUVJ3K)Y]],61/.,.[&&MG4.@BY \0&_GWVQ=[8O'M(]:[5)UD\^^F+(
MGG&'=C#6SJ'01<@>(#?S[[8N]L7CVD>M=JDZR>??3%D3SC#NQAK9U#H(N0/$
M!OY]]L7>V+Q[2/6NU2=9//OIBR)YQAW8PULZAT$7('B W\^^V+O;%X]I'K7:
MI.LGGWTQ9$\XP[L8:V=0Z"+D#Q ;^??;%WMB\>TCUKM4G63S[Z8LB><8=V,-
M;.H=!%R!X@-_/OMB[VQ>/:1ZUVJ3K)Y]],61/.,.[&&MG4.@BY \0&_GWVQ=
M[8O'M(]:[5)UD\^^F+(GG&'=C#6SJ'01<@>(#?S[[8N]L7CVD>M=JDZR>??3
M%D3SC#NQAK9U#H(N0/$!OY]]L7>V+Q[2?-^JO5"9;=89J1SW?9=38NLOS#D.
MZVZG_I=;=(JTK0.[&&MG4.@BY \0&_GWVQ=[8O'M!FO _:%ZE\,3UOE+SDJ<
M9:C5UUB620?)$TD$G;7AINNKN]C6M?5;LIC#R5MMT3K4M*5M-LMH>6H(VY%]
MJOC F&KVH7TC*:&FG5/0EAC:QS'>951J-1[?,YCLBM5<U6/S7MV)NO\ I@[]
M]VV+:?$55?UZW_=+7(VIH+SK:BJ@J8%^_8Q\[IGTLR??PU,"(Z.5K.=944_.
MTTWJ;P-G[&FH^ -^0\8O5'%L4["=T:E>XIY#&':VW94,DD;"SU%S<XD?5IL7
M7DGE5M-(,-)OL,NZS7[<-XX=KW4%Y,LD3*UR6JQ[?,YCE1+47^!%1<CD145#
MWSW0[X<#[[<'PXRP-4\[1OL;-!)FMJ:2:RUT%5$US^;D;YE1SHY&V20R21.:
M]<TBS&T0                (UL^L6?RDO\ A%PE020@
M  !&_??\6_QH3YOM@DA                   "V_O=^./YT$^<$DA]\NG\,
ML^"D "2$       #5;4!I*@6I;(.#97E!WDRR*X)59&DS!CYC>G>*HG3)<VC
M2*!L>0UDIB[FS2U Y0;'[K*FA*G2*B251$L5<(VU"K++@-7()V;#OA1ZQ\NT
M_:E95C!MQI$]1V+X:@<L?QO)"Z)X@U#YTC>=;8-%G.:.:U.G/Q(Z1LEGC"MT
M2/!!#*60G5)%5"-F\";+[-.'P&/$QS3QE*28F;G?#$,P;DYLE<4B6:&3+3'
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M_%//!N.[1^38
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M?DU=AO*DHQQ9E"+1!0['Q=NE5&-3:>W.[ 6_KTZ5_8S&>3%)%6X4<=Q)2V$
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MO\FJ14T?\[B_E&_QD+)B;]V[P_(9_P 4\\&X[M'Y-@
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MZCVH^*&ULD%THJ*F8QS7.CGK,U?PU0W.BB=^"I'.:UU34=K8U<>@X
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MM(;"[BVY.L*;RC[C3K";3CS[S ,D
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MQ-QMTQN@IM2/ 1]$_P!UY/:]]_.17=V;H>^8M%Y=9/\ /81Q-QMTQN@IM2/
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MZ(C7JYJ(ALH,:-\                  !&MGUBS^4E_PBX2H)(0
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M4>\@#B_?B=8A+,77J"U%Y]E]EY"<O_\ AIS#+:TN++MNV=M;3]D 2X@
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M1=TJ=Q5'O( <$7=*G<51[R '!%W2IW%4>\@!P1=TJ=Q5'O( <$7=*G<51[R
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MSC#NQAK9U#H(N0/$!OY]]L7>V+Q[2/6NU2=9//OIBR)YQAW8PULZAT$7('B
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MP?#C+ U3SM&^QLT$F:VII)K+705437/YN1OF5'.CD;9)#))$YKUS2+,;1
M              C6SZQ9_*2_X1<)4$D(                   1OWW_ !;_
M !H3YOM@DA                   "V_O=^./YT$^<$DA]\NG\,L^"D "2$
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M(]0YT<U\A<5*V^I)-NX)DB<FP#<        !&J_?S5]F5? SA()(0
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M_):H5-'_ #N+^4;_ !D+)B;]V[P_(9_Q3SP=#NT?DV
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M;54U+4I+317V+>9H               1K9]8L_E)?\(N$J"2$
M        (W[[_BW^-"?-]L$D(    4;@O1M2!<Z.*@M(WMJ-2O7JSJUH4E1H
MR;U"I0;6E*UH6207===[%?8H .L/&VON:9'(QA(CV72_CUFSWAM[SUB#%$SU
M,F6:M5N'UF/)K/\ &.05F 2\;I$\A.EB*,%5>69N?J%QLBB^[G5>:W'$W 3^
M#>THP],,8:>W/)S@[MV0LCX_TJ796>(/BG*;GA'%F:=4\ QW*(!C>4Y((:))
M$X&Y3)UR4SEM:!U>C525.^L]5QI='1 :K C=+G:20C++ :S90:IFPY9M?]75
M6AIB6 \ZF1+($7TP:@I9BQU28F=[HY)TN4YVSQ,IB5.;6PK7%8K6*5MR)-N:
M)<0@ O,G7.SSO*VE^'8E1**LN3=16:M/^;&;)D!G4&R1CJ28KTU9!S@2S$1^
M25C2EG>%:ED9%-%*A(XH5S$YVFI:_P!^*46 =A       MO[W?CC^=!/G!)(
M??+I_#+/@I  DA         #3;7]FO+VGS2I/LG8#18Z7YC3RC"\(Q\GRVVR
M1WQO:_Y<SEC;$A*N7MT0D,5DJIJ0$3@P^M$:].;2\NV[]W;2I=X'6E.NUIRH
M\MTB<<51:'PRUMBO9GIG9FF>'LKYVR!BO+FJG6KK"TF:I\<2O&&'I[%93DB1
M81==-1;>TM;!P94<]E+C+C7!,>E*) W%9L]ZI<E9'A. ,93/"K).$.G\K4/E
M;,>4]*.?(DUJ&F=9.F>/\20:*Z4I9G['^480\'D09X4OJ^03(TU-<UD4);+K
M7:ES6!LWI&S@^ZA<'-D_EC U1J;LN0\[86R&TQ]6K71JW)6FO.^2M.>2'"**
M7"RQRNB#W.<5N"UIM5;946W*";#KKS;;[J@;+          C5?OYJ^S*O@9P
MD$D(         :N9;TSF3S*#%F_'F7L@8)RXUP-PQ8\2F#MT!DC=-L<K'NR3
M-\<E\3R5$)DP+%$1DM3U[&X)BDB]O.7K"JFG)%BE,:!@%5V=#<\OV82I5J0S
M=*,6Z@LG8GR[G+%:]LPXC1Y=EF*<(X P71!-I<TXO0R@F&9"8-.3$MDK2QFL
MA+BJ.6)K+B&M4>WF 91/TFRPS4KDO4BCU+Y-8G;(V&D6#R8RQPW#-4,(B\?<
M,AR"%/$5<)'CR2'*93#I;DI>YIS7@IU0JS2B"5J12EMO), M5PT&MLEQ[JDB
M\YSSE^33C6#%(QCW+^6$)&/(/*$V.8NQ+XDFAT";8-"6!@BU%D6?WDDYV,(7
M/U%+R<:6M+*3-B= !O4TM+8PM38QLC>C:69F;T;2T-3>G*2-[8V-R8M&@;T*
M0BVPE*C1I2;"RB[*4MLLMI2E*4H )        !;4S_S/E?\ HT^_Y+5"IH_Y
MW%_*-_C(63$W[MWA^0S_ (IYX.AW:/R;
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M(8:K>H]J/BAM;)!=**BIF,<USHYZS-7\-4-SHHG?@J1SFM=4U':V-7'H.
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MC3(4A*JUPOVRE2JK4R\T#L>      %M_>[\<?SH)\X))#[Y=/X99\%( $D(
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MW&W3&Z"FU(\ _P!$_P!UY?:]^?.0[LW0]\Q:+RZR?Y[!Q-QMTQN@IM2/ /\
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MG>1ZPYBO1$:]7-1$-E!C1O@                  (UL^L6?RDO^$7"5!)"
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M9RD,@&Y.OC:/BAG*0R ;DZ^-H^*&<I#(!N3KXVCXH9RD,@&Y.OC:/BAG*0R
M;DZ^-H^*&<I#(!N3KXVCXH9RD,@&Y.OC:/BAG*0R ;DZ^-H^*&<I#("A0%N-
M;%.YJ4MM*+EE+]LFONV3*'7;>ZFP?;L6W7?4I^P"V KMR=?&T?%#.4AD W)U
M\;1\4,Y2&0#<G7QM'Q0SE(9 -R=?&T?%#.4AD W)U\;1\4,Y2&0#<G7QM'Q0
MSE(9 -R=?&T?%#.4AD W)U\;1\4,Y2&0#<G7QM'Q0SE(9 -R=?&T?%#.4AD
MW)U\;1\4,Y2&0#<G7QM'Q0SE(9 4.YN/.>QPE+NO -G;\&OVFY\(^MVF[[.V
MVWL[.S]3]@/,"NW)U\;1\4,Y2&0#<G7QM'Q0SE(9 -R=?&T?%#.4AD W)U\;
M1\4,Y2&0#<G7QM'Q0SE(9 -R=?&T?%#.4AD W)U\;1\4,Y2&0#<G7QM'Q0SE
M(9 -R=?&T?%#.4AD W)U\;1\4,Y2&0#<G7QM'Q0SE(9 -R=?&T?%#.4AD!%;
M!G-.QMK=UYUV-OM:[3=.<OKMIMMG:[;V=C9^I^R'G!*H??+I_#+/@I  DA
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M (Y"\-:IO1N*)_2HH!D#(2=M1J"UFY7HW,Y \)%!1A2I$1?;L5 RN
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M6?8:_MT$IY020@                    $:V?6+/Y27_"+A*@DA
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M$,&/HW#WL^-.3W$\<V.,BR._,Y[R\'(HQ'TFW,(+N3J51:EQ6@;S
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MM,Q?H_!\FQ67*H= 5CO"\M19I2R9B,4-"%3>RNJ6XXDHVZ\NP#9\
M 'Y-4W_SSEW^D[__ )55CVJH?YE#_),_BH>,Y:XJB0
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MBHMBHJ+E147(J+Y#O$R1DK&RQ*CHW(BHJ+:BHN5%14R*BIE14\I-#YG,
M              (UX^YBS[#7]N@E/*"2$                     C6SZQ9
M_*2_X1<)4$D(                   1OWW_ !;_ !H3YOM@DA    "G5JTJ
M!*I7+E*=$B1)SE:Q8K.+3)4B5,7<<H4J5!UUA)"<@FRM]]]]:6VVTK6M:4H
M.O\ QGK/R'E6-1'*C-@R.Q_"65,=/N4<5/,GS8T(LWN$ MA,DFT"R#-=/Y\.
M1?DW#\D-K(FN1$().\21OL=".=6IN,(<2T(%7ACM#L#SB!:<%>09>W0[)^<<
M9Z<)*]1YLC\Y>H)!,A:E(?&'['6-)5E!)'%D!@LIGSQ)2$,6:I"ZMSK(3%":
MQ$0H,4$VW@0.F?M(<+YICSPFF3X1#LG,#OJ@-6P]#%,C+&UWB&FO/<GP](W*
M"2,Z+7,F2I$RHD[&H?F>/*G1S:%CT02>F*J:5;<!>=FM^$S#(NF&+XCI^5+!
MFO..7\(3\R4QR<X[G&,)-BK 60\R+&1]Q[/(_%YC&Y151$T)1R%X;TAO-[C8
MILMNL,)OO WH      %M_>[\<?SH)\X))#[Y=/X99\%( $D(       &I>N/
M40Z:5=,TWSBSVPNU=&I)B&/479&<%#5!&))DS,^/L6N4IEC@E6-QR5CB3;-#
M7-1=PA/;6Q)6EQI=M;KZ ::XH[0?,.=)>Q8)Q3%<'2S)K[-]0);/G]IE,L=M
M+DXP9ISB^F1TFN;\5T0([G_(%UN2=64;Q\8RI7FU(GD;3(%%CPH3M5"5(%PL
M_:./,6F<>CV?85#,?L4;ENK["N=97'Y,Z/;)',VZ<L21+5!!+X4O>&UAJZP?
M*6E!/*Y8J+5DE+V-8U6-]UZG<E*D :ZF]KEF.W1\GS:MT\1R+YVA&E3M(M16
MH/#+_)G<]!BAVT!M?,5L,.>$2,I2:=DS)$LBQB'=[25!\;6JU9!=]R>ZM@&7
MLO\ :#3C$N+,"3=1EO2(]-N;=4[_ ((<<PT9,IM.'\:1R-:4]0>HA<YR)M/E
MZR2.3^I><))FFVXM80E))>;3KK+KB:VW@=B.E[+<ESSIYP[F:80)1C&29+@3
M#+W6#J%;@NYC.>$MJDJB14\,D9?#6MQ376*T?.#8VN-J0\NBM(F44-(+ SP
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M=_\ \JJQ[54/\RA_DF?Q4/&<M<51(
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MU5L1/*JJJ^555<I?HH2M                  "->/N8L^PU_;H)3R@DA
M                  (UL^L6?RDO^$7"5!)"                   $;]]_
MQ;_&A/F^V"2$    *5<B2.2)8W."8E8@<$JA$M2*++34ZI(J*O(4ICR[J5M,
M)/),NMNMK[%;:UH .JUA[,>]ID.FI(XYE9)#C71ZFEK3I]M<\*M-=0C5#7G3
MQG#33$,69"U#6S>O](&+\:P'/#B8WI*1EN>'!P;D*MT=%RJU6>K H8)V7!L
MBS=B-JS\K48%?G[1MD+,T)58R0W3:?91T88YTZXQB3Q$<D63.B?'$(R/'-*4
M(+DC*8R/BW:H556MT;3EIA]H$73LLY6HC+E#ENK>:(&2-H=7*C!+C!H&FQ_.
M,8RW6)DASR'.7^139AFU'2;H8@2[*F5B2MUL85%-;BMO5K%:ZJ!8W 9!T_\
M9KLV#93 )@5DAN6KH;JBR?JD4L,2QM2$0P^0Y5TKD:9WF&1ME5SB8.D<BC32
MPQY0W*7%V74I=:D4'J+[;UIH'9Z      +;^]WXX_G03YP22'WRZ?PRSX*0
M)(0       ,/YVPI%=0F.5&,9FX2!L85,QQ;-KU<85-R)WHZXDRE#<MQM/8H
M=6IZ14;ULD@Z0A=95/4PQ"8=8482;=8<6!:^;=.3-F21XXG[=D+(^&LL8GI+
MD,'RQB@V!WRQNBV0TS(1D&"N#1E*!9/QY(8=-#8JSJEB5P8U1A2]E0JTIJ=2
MF+-H!KIDGLRL Y:TZ+-.4ZDN6GALD&85>=I]E R2QNF6LE9%D9[BDR0NESS?
M#3(F4R94@;ZYPUX:FEE:VQ-#'$UH:2&Q*6EM3@5,R[-/ 4W>>T$>W.0932J>
MT=PZ;A3,2=!(8UP#'<;<L0KL,2AXP6D<(:X60F1S>/'(W!YN7\\H%SVUI5ER
M2EW";5 &6BM*EKN\X-D>4<]9LS3(-/><'W.V/W:>(L#,1ES[(-.^:=-2V*/R
M'$6#<8-#K"RX;GA[<"[*)BG2CS8EON77(RKT1H&2=/6#(EIIP[#,&0!PD*Z!
MX[)>&F#II,J:U:R,PY7(G=XC$ :S&=G8T94/QLQN1$?8";B+E*=B;$A2@]4H
ML-4G 9G                                      >*F1?\ C/:MG>0/
MKLFSMITL3.;RYN">P]9DNT^PA:M/4E6G6EX_-+M-M+-I2ZEMUU*5^I6OU1Z
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M$\BGU)(0                   C7C[F+/L-?VZ"4\H)(0
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M<Q9]AK^W02GE!)"                     1K9]8L_E)?\ "+A*@DA
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M2/G^4U0]JZ+^9P_R3?XJ'C,W[U/X"VQ4G(
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MS%GV&O[=!*>4$D(                    !&MGUBS^4E_PBX2H)(0
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MJT#+DO.LT,B[#%X<3(K\:QA,T-1;.W-Z--;)I#;8D((/3%V ;<
MX5'O<_[";_<7 #\FR9?YWRK_ $D?/\IJA[5T7\SA_DF_Q4/&9OWJ?P%MBI.0
M                                      =[O9.=C1-M:;JUYJSLB?\
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M20@                    $:V?6+/Y27_"+A*@DA
M"-^^_P"+?XT)\WVP20@   !'NS6@?&IS970CA38\-ZQK<4VZG$<(0."8Q(K(
MW9.82H)W9.==;MB[[;[=G9MK2NQ4 =0D6[.;,C*]:46%RR9BQ9#-'47D^.(5
MDUMC<U9\UY;PJ7IJSMIWQ9AW+C2GD5T!H3#S,Q(9,\/:.IQ#\_QDA0G9FFBF
MVU$!;6.NS"R_!8*VX/,RQC)SQ-*9AV?&6<F291$I*;E6.SW0ECO2M";(QB@V
MKN4P%0W(*W2,QN*!<NJ2NBZY\>%):9>:<1N0%&U]FGJ;;6$EE9-0&)L>.F+2
M-=CO@&?0+&S_ /EH3+-:V8EN3E-,@&OS^M;DC7"&U4<B/4-1=RIV<%"5S+M;
MSFDHM:!DS3OV=4^Q#D#'T_D.161U-C6LG,6JIW:KI)EO(KG5ORQHV3:;+(19
MD;,4IE^09>Z1R2VWKKG=W6[*U!9;0M.CI6Q(0!VX      "V_O=^./YT$^<$
MDA]\NG\,L^"D "2$         ,+9LQO/,EQ],RP?*]V-+3;79NDR%PQS!LG1
M6:1Q];#6MP9Y%')@@W>ZY,4;4Q+<G7)TU;[KK%J=<1=N- .MQ!V*VF]!B&?8
MS_+C+*N1.D'PC <092.E2YODV"&C3-C.!Q/3VJC$=C:I@Q_(U^*\FPL_(#?1
MS:34I$F>5=B8A,WV)4B<#8U[[/Z"/&F[5)@"R4&MSCJFD>HJ2R;)Z.*,=)/'
MU.HB>/L_=V]O*,ONN<VB,.;U0I&0J4W;J2F+W2[;4V0!MQB^/Y+CC L0Y4R,
MSY.D)KPH5HW]D@!6.4J1FO1-Y*=H,9"9-*[52A.N(4'55<(LK?:HM+W.FY;:
M\#(X         (U7[^:OLRKX&<)!)"                          <*CW
MN?\ 83?[BX >*AY_\:'5J^.[J])<ZZ=2TKPY+G1,6H69+M4%IW!4:K)L/M+Q
M^:7:=:6=2EU+;KK:7;.Q6M/9'H#3?2UP/#3QQ/NZ]L]K&HMC:>RU$1%L_#ID
M^TAT"=]%/> URMCK;G6-%R*LM2BJGF542E<B*J>5$5;/):OE(W]6-U>?/QIO
MX[D[Z/!]O%S@79U[>K3]H./A5WA],N735/9!^K&ZO/GXTW\=R=]'@>+G NSK
MV]6G[0/"KO#Z9<NFJ>R#]6-U>?/QIOX[D[Z/ \7.!=G7MZM/V@>%7>'TRY=-
M4]D'ZL;J\^?C3?QW)WT>!XN<"[.O;U:?M \*N\/IERZ:I[(/U8W5Y\_&F_CN
M3OH\#Q<X%V=>WJT_:!X5=X?3+ETU3V0?JQNKSY^--_'<G?1X'BYP+LZ]O5I^
MT#PJ[P^F7+IJGL@_5C=7GS\:;^.Y.^CP/%S@79U[>K3]H'A5WA],N735/9!^
MK&ZO/GXTW\=R=]'@>+G NSKV]6G[0/"KO#Z9<NFJ>R#]6-U>?/QIOX[D[Z/
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M<Q9]AK^W02GE!)"                     1K9]8L_E)?\ "+A*@DA
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M]D,@*[=77Q1'QLSDP9 -U=?%$?&S.3!D W5U\41\;,Y,&0#=77Q1'QLSDP9
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M7(S61GDZ1GF>.<EQR(3Z)+7.+R%O=$5KBVIN'-B].K3[HG/*-N S"
M C5?OYJ^S*O@9PD$D(                         !PJ/>Y_V$W^XN '5[
MWS/9F-7Q6OU5QA.N;?W@M(_(O*INXJT?[W4E;H3 S"3-S.+NIMK+KK:[&S2M
M:>R-PLW!;W96)*RYI58Y$5/PU,F1<J9%FM3[9IM_T@-T4;U8Z]T56JJ9*:L<
MF3["I3JBI]A4547RHJH.^H[,'K81CR'RSY@#EX?][^Q9=-2Z\X^(/=#M?\UK
M>S#OJ.S!ZV$8\A\L^8 >'_>_L6734NO'B#W0[7_-:WLP[ZCLP>MA&/(?+/F
M'A_WO[%ETU+KQX@]T.U_S6M[,.^H[,'K81CR'RSY@!X?][^Q9=-2Z\>(/=#M
M?\UK>S#OJ.S!ZV$8\A\L^8 >'_>_L6734NO'B#W0[7_-:WLP[ZCLP>MA&/(?
M+/F 'A_WO[%ETU+KQX@]T.U_S6M[,.^H[,'K81CR'RSY@!X?][^Q9=-2Z\>(
M/=#M?\UK>S#OJ.S!ZV$8\A\L^8 >'_>_L6734NO'B#W0[7_-:WLP[ZCLP>MA
M&/(?+/F 'A_WO[%ETU+KQX@]T.U_S6M[,.^H[,'K81CR'RSY@!X?][^Q9=-2
MZ\>(/=#M?\UK>S#OJ.S!ZV$8\A\L^8 >'_>_L6734NO'B#W0[7_-:WLP[ZCL
MP>MA&/(?+/F 'A_WO[%ETU+KQX@]T.U_S6M[,4*3MH^S%+/<+K]5T8MM-4VW
MEUK",L?NK*)R;*UIL0'_ /FMK03X?][^Q9=-2Z\>(/=#M?\ -:WLQ7=]1V8/
M6PC'D/EGS $>'_>_L6734NO'B#W0[7_-:WLP[ZCLP>MA&/(?+/F 'A_WO[%E
MTU+KQX@]T.U_S6M[,.^H[,'K81CR'RSY@!X?][^Q9=-2Z\>(/=#M?\UK>S#O
MJ.S!ZV$8\A\L^8 >'_>_L6734NO'B#W0[7_-:WLP[ZCLP>MA&/(?+/F 'A_W
MO[%ETU+KQX@]T.U_S6M[,.^H[,'K81CR'RSY@!X?][^Q9=-2Z\>(/=#M?\UK
M>S&9L$=I/H<U,3Y-BW".HB(37("]O7N;;%JMTKC;D[IFLKA+C8RTET>8"'E<
MC1TO47I4MYRFB4HT[<]R)-OLL.)-TV\7"-V.OG$-UST]UL<UKI,Z*1K%<MC<
M_FGO5C5=8U'.1&YRM;;G.:BW[#>]W=SBV]&7+<-YQ2WI(CE9&Z.:%TF:BN<D
M?/Q1I(Y&HYZL8KGHQKGV9K7*F\0UT;(       C5/W0;/\=_P%HE/(H)(0
M                 C7C[F+/L-?VZ"4\H)(0                    "-;/
MK%G\I+_A%PE020@                  !&_??\ %O\ &A/F^V"2$
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M +";_<7 #\FR9?YWRK_21\_RFJ'M71?S.'^2;_%0\9F_>I_ 6V*DY
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M\!:)3R*"2$                   (UX^YBS[#7]N@E/*"2$
M         C6SZQ9_*2_X1<)4$D(                   1OWW_%O\:$^;[8
M)(0     #3F&ZV\8Y%(3/T"A6;93C5[;I:Y0K-C?B:44PW.DL-89%(EKFP30
MTBW@L/>V^,*.8I.XID,6DMQR/FAR74<$%5(&4,1:B<9Y=Q]@F<(GYJBSEJ%Q
M3#,NP''TI?F!%/5<=F42;9@404P%.9Y[FJ9F]RI8LO1<((+,+OK2^MM-L (;
M 6J3%FH.&.4MCCR@853&^Y3:)!$I _1VR5QY!BG*\ZQ(Z2=\:T#JL,:HV\O,
M 5JD2H_:67I+[*W[2^E]EH'.^ZF<;-TQTY15@<$\]1:F)K.H1")A!WAAD$21
M.$ Q=/<IO"MR=D3F84H1F-N/E:*S@G"+[5U]EM]MMM+[K0-B      !;?WN_
M''\Z"?."20^^73^&6?!2 !)"       !@74QGANTTX<?LO.<4?IP6TR/&L30
MQ.,J65$]/;]E3)\-Q1&4J9;(7!J949-LCFR6]0:H4%V%)K#+O9K2EM0-8FCM
M$F&1R4_#\=P/EQYU/MF3LB8ODFGE*YXKM>(J;BS'6%\L33(#UD4S(-N+[L8-
M\%U'X_.L7I'14OJXS!O;3$);A:N3HP+H@NO[&4MF4'@[_#9YC!ZDGK),$Q(R
M!;%4_P#1)E33"7 7N8XJG2N-R62,I[Y*L<S8Z71YP9UCFSN4::%*OA1=;TUA
MP& $W;"8+<M)T&U:-.,,R*H[,-/VLW4:Y8[6M$<9<E0.%:%65YOS<CFC*Z2)
M.E:WI).D;=%TY5IYEM'=\1;O<23<886!L-D+5]D+&#?AI'*]*N0B,B9[SLY8
M+QQCM'DG#"I4O<&;3]F?46ZRMUE59J5$V5A2P[!3TFH6<JHKO75(MH7N9E3+
M0-A-/><(EJ4PGC3.\%02!KB>48LAE3,URM(W(I$UDJ]T+/;7<ME=7YA.6(%9
M!A-RAN<'!L54LH<C5J4QA1Y@&9        $:K]_-7V95\#.$@DA        Z
M:]2O9@N.?"NT??C5T;MGVJC\C/Z!W)1DS+D<C\6_);3QC#%M?Z4([%R2X\?L
MS.&K5-NT;G_=6XTG=/W5;DQ0$M$-$><8S,-<=M\+PN>UZI)!J6=8IE>S4QG*
MZ1LK5F*$)&F*,<CT\'8/NQ:B4(7]N)L<')#(5"LI)=<<5P@S937@4F(-%&J7
M1U"\O-FDI1@%SD>3<$:6V)J-S1/\GG?D?G_&C8[8YS#):34W&.29C(\2&XXY
MJ=8A'E6U1H9.D<+>"H4CRI,* Q+.^S+SC-Z:6'AACFG[&#II:D<DRBZ,BC,^
M4<MJM5N1)OJ,QYG/(,=U#Y.K@3$*\^"Y!D\373IT-+CCGNF3[V9?:WT;68]
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M_P"PF_W%P _)LF7^=\J_TD?/\IJA[5T7\SA_DF_Q4/&9OWJ?P%MBI.0
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M4_=!L_QW_ 6B4\B@DA                   "->/N8L^PU_;H)3R@DA
M                 (UL^L6?RDO^$7"5!)"                   $;]]_Q
M;_&A/F^V"2$    (UX:TKXT.K(NJ=1$\-JYK653FW$**)7!*:D45(/L_=DG4
M*.KM;Z>S;=L5H .G*$Z(-7\9-TBXXOF\.:L8Z2X&_8773V):H-1[,5J3PK']
M+^<<%8DCF5-%*+'[;IPCTSLFF18S*GR06/CZJ*7Q JB LM.8C1MH&*\<]E[G
M^&QN+XT>2--TA;7"5=FSD:0:A#Y9-[\V83=M#F,],,,D^+L)195A@Y%)8-*7
MW3:O<F%U4RR*WMRO(SVH4LY]2KT[H!$,G9BZJ6%H>B8FDT>XVFD,:^T&5X\R
MC'[G28OV:7O6?FNF3H_'LXQ:::=C8G&HW#&E,DM7*%A>2TJU^;&Q?<SFIV_@
M*H#-NF#L]L[8CG^+YM-7[&M$L3UOYTU0O;,TSI[F;@FB.7-%5-/Z9A;7PG!V
M'69]E*;**A2O5W<R,B0UK,JJVUZV\Q-4#N=      %M_>[\<?SH)\X))#[Y=
M/X99\%( $D(       &LNL#3JFU6X$D&#5SLA9FZ2S/#,B=5+DV'/"%8SXQS
M5CW*CNPJ$)"YN-OMD[9"C6VAE#:;A<KH;6V^EE;+@,42S1:WPN8X3RAI LQ1
M@2:859\X0PN,.6,E#QC">0'4:Z8OE666Z0L\.E$">T,Z>)_A&)/94EX4M4U-
M;%!"E.IHOO-) UQS;V7+]FG3I(\=NF>"&C.^1-1TSU#Y&S0Q0)0SLAJK,6+Y
M%IHR_"8'"BIBK>(C'S])TQ7Q!C./?')<E5D)716<K4VF;8#BGW96GR]3VFY2
M'+;6V1S6[ITRS@O T7K!*VMNE<_43B5%#]0[LFX$_IK)HTY5R=%6"6J4I9;6
M<4I0FD5.,MO)O) O)Z[-J'92B>GG'.7\4:-4>(L+:H)5GZ38,Q5IU0L6&,HM
M,DTF:AM.MK-(8"_N3NP5E*639K1/W.9B<^E2V$DJTJT[<U!(&Z^E_$DGP+@3
M&N%97.S\EK,6LJB#,DU7$.13R\0&..[BVXQ+DRAX>'YS>)@TXW(:D3RYG*S+
MW5U3*%E:6;ON=H&>P       $:K]_-7V95\#.$@DA
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M^RQ9)7(B6N7S(B(QB>BQK6Y#:48<9>     1JG[H-G^._P" M$IY%!)"
M               $:\?<Q9]AK^W02GE!)"                     1K9]8
ML_E)?\(N$J"2$                   (W[[_BW^-"?-]L$D(
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M+7=%'<:1[\ '"UW11W&D>_ !PM=T4=QI'OP <+7=%'<:1[\ '"UW11W&D>_
M!PM=T4=QI'OP <+7=%'<:1[\ '"UW11W&D>_ !PM=T4=QI'OP <+7=%'<:1[
M\ '"UW11W&D>_ !PM=T4=QI'OP <+7=%'<:1[\ .(]4MJ2=2K6=;2I1E*W55
M(Z[6E;*[-=BANS78 '$B5++422VUL-,MM2IZ6WT4I+:7VT*LI2^EMQM+K:74
M]G8K[- 7R@JN%KNBCN-(]^ #A:[HH[C2/?@ X6NZ*.XTCWX .%KNBCN-(]^
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M+KJT4);=I?<==6XNNV-ILULK[&S3V*_L H*[A:[HH[C2/?@ X6NZ*.XTCWX
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M%M5$M2VSR&RPQ(RH      "-4_=!L_QW_ 6B4\B@DA
M "->/N8L^PU_;H)3R@DA                     (UL^L6?RDO^$7"5!)"
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M?YWRK_21\_RFJ'M71?S.'^2;_%0\9F_>I_ 6V*DY
M          %V02=S/&$PCV0,=RA[A<VB;D0\1N41QQ4-3TS.2?9H6J0KDMY9
MQ5UUE]UE]NS6PPN^ZR^EUEUUM:*\;MH+WH9;LO2&.HN^9BMDCD:CF.:OF5%R
M+]E/L+8J94*N@O"NNJMCO&[99(*^%R.9(QRM>UR>=')8J?\ ZID7(>Z;LF>V
M<B&LU"UX.S\J8H'JD0I[BFM050AGB&;4J>AE_#HD0:=4IIG25+9MG!DI=M5%
M+;E;?LDU/2H/.O?7N$K<!2/Q%AA):G!SE])%M=+2*OFD5$M?"J_>2V6MR1R^
MEFR2]_-RV_2''#4PYBM8:?%S;>;<WT(JMGF5B+DCJ&IDDB15;)9ST-C5?#!W
MUCK8=D     "-4_=!L_QW_ 6B4\B@DA                   "->/N8L^PU
M_;H)3R@DA                     (UL^L6?RDO^$7"5!)"
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ME!)"                     1K9]8L_E)?\(N$J"2$
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M"4\H)(0                    "-;/K%G\I+_A%PE020@
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M7]&N7@D_*0 YPOZ-<O!)^4@!SA?T:Y>"3\I #G"_HUR\$GY2 *%0MON6M]_
M%UNTX5L67%DTO,VQ5M/[W2BBM*[7ZM=FM/8#S KN<+^C7+P2?E( <X7]&N7@
MD_*0 YPOZ-<O!)^4@!SA?T:Y>"3\I #G"_HUR\$GY2 '.%_1KEX)/RD .<+^
MC7+P2?E( <X7]&N7@D_*0 YPOZ-<O!)^4@!SA?T:Y>"3\I #G"_HUR\$GY2
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M)(B0N(,?V.(S]VF[%"9&YMMM]5*1GE3SC60)4)]]M+%!S.KLLK6I%^P!=
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M^#\15:T%Q7G15=:C%>L<4S'OS$5$5V:BVYJ*YJ*MEB*J6^5#9 8H92
M!&J?N@V?X[_@+1*>1020@                  !&O'W,6?8:_MT$IY020@
M                   $:V?6+/Y27_"+A*@DA                   "-^^
M_P"+?XT)\WVP20@                  !;?WN_''\Z"?."20^^73^&6?!2
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M_MT$IY020@                    $:V?6+/Y27_"+A*@DA
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M-7-CPM_*1^BT(D>1GU!PYO;U;:S\!AL2<%FZKSDI)O!]R+OO/O+*O R
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M\[Y5_I(^?Y35#VKHOYG#_)-_BH>,S?O4_@+;%2<@
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M6VRV]*XNQY)G]\LN &T8       "-5^_FK[,J^!G"020@
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M"                   $:\?<Q9]AK^W02GE!)"
M1K9]8L_E)?\ "+A*@DA                   "-^^_XM_C0GS?;!)"
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M*MZ"P#G1-[6LXDJWH+ .=$WM:SB2K>@L YT3>UK.)*MZ"P#G1-[6LXDJWH+
M.=$WM:SB2K>@L YT3>UK.)*MZ"P%"@<2"[%-+K%5=NN6&4VJ11?^YO.NK2E=
MJ77:W4I]6E?9I^R"H"NYT3>UK.)*MZ"P#G1-[6LXDJWH+ .=$WM:SB2K>@L
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M-MG5'^1O*'&_=1MRC_[SD#O8^SDZW.)^/NWR2'#O&VSJC_(WE#C?NHVY1_\
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M4_=!L_QW_ 6B4\B@DA                   "->/N8L^PU_;H)3R@DA
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M;:UB_P#%/J#_ -[4N'>["/[IW7^SJ;\2P\A-Y?\ >/B#]MUWZ5*:L#(3"0
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MY%!)"                   $:\?<Q9]AK^W02GE!)"
M    1K9]8L_E)?\ "+A*@DA                   "-^^_XM_C0GS?;!)"
M     609DS'!3^]12^?0RDJC;68]R&+VR=EODC&SE)^%F.CLPV+;G5O;[4O]
M\W8TFTO:>SL[  F8K*(Y.(Q')K#WMMDL2E["SRB+2-F5E+V=_CD@;T[LR/;4
MN(NO(6MKJV*RCR#;*UL,*,MNI6M*@"EATVB.0F*R3P:1L\LCICI(F0MZ85Q#
MBVWN\1D3K$9.VVJDU]Y55C#)V-8@5%[.V)5)C"[MBZRM  >IM$8X^PZ,/TC9
MVB19"='1D@S*X+B$SE+'=DCKM+G=M84IM]IKDL;8PQ+5YQ9=+KK$J4PRO[FR
MM: 70      +;^]WXX_G03YP22'WRZ?PRSX*0 )(0    Z8IAB+/^5(!K Q=
MD<[/,+T!9GP;J"PV^1O*-UFH36*E/RFTNL",FVG)BQ:SY#G#=C2QCDC@Z(FN
M<NDXF"C]ZIR65C)37(C@,*FN.9WMPP?,\R8@R9E#2;@SM 9*X-J]JT7Y-A64
M)[B=^T+SZ.17*N2-&T:A+ADN2MN.=54Y51XE>7#6VXRJ=M?RV>U$@L?K@,F?
MT(98B'90X:AQ&+)G>_XIU.:7-1:#"S"QG.60XMI[PUVG.+M5;9C5AA".XQ:?
M,\=:8XB6VHXRFVRJU<W6-9%M3:66@"WYRAS[EG47DO,>$6G4YB;%^9\U=GO@
M]QFR7%DSQ1DQXQQC C46_P"=WRD)RI B9Y"\9)2\LM#2;(G5C;+:K"E5Z ZS
M<$ZVX#3/5M=K?G6D;5=@W)R/73(4*[25VI6'=.R/%N"YI.Y!G:?134]JIP=A
MIHU!JHEB.3GJ$N0-)+-CX^..3M8SM\Q121U>FY0H=K6]8C VUU)2?5M LAZK
MI? V;40X)&?7:TO^.L5XJP[E9&YZEL8,W9KZ-4K1&(OG?'N&\EQZ$-[;J,=I
M#P%VFB?^C]U?&QQ9'QT;TB-08B C\Y),]91Q/K(A\[;-84DSV9E7*+:PXQ:L
M1S]1IE4:?X]JYB9VG!UQK($6/3,=RV6K-/2-@=W&]C?5TCM>%3]8Z%%DH[DZ
M,"]85.=8:K,S0:X/^K-GR*FS?K?:=2[(^X%F3MIIANEV/QK4,=I3EVGQ4=CA
M%C+)D\+?&G$IK0DC#\ZR9_2.[Z2_$U6E*2&\#4)QR;VE*N!XIBB9?JIB$.9V
MO4)%'34.7B+57)I7D7.3)%-,CSB#,%^(+-(LAU+0'%[@Z2/(54L1FD3_ "1,
M?V)P;U#NX,ET7HX 9ZR&GU19!U38[9\LI-43U)<>Z^=+,DBK)!<)30O2&9IG
M:]/<%6RG)UTVLQ^\P]L=TNH-YE%'$I?*"9DV&VE)SD]&$LN\T#T(     C5?
MOYJ^S*O@9PD$D(     !QFFE$%&GGFEDD$EWFG'&WVEE%%%VUO,--,OK2PLL
MNRE:W75K2E*4V:@"Q<59,B69\:0'+L 6J7."9.B$?GD*=5;>L:CGB)2ML3/<
M;>>;7$E.X(B7AF6DJ2BSRRSK2C;=O99=LVT OX  !@*?ZI-/N+9HEQ[/LJ1F
M.2\\EC5K&E28M4TC:&3KSVJ,.<W<4"-6U0!IDKDE.3MRM[/;TRXXDRPB^^XN
M^EH$'CO61ICRM.OZ,X)F&,.\Z/<IJSM$=5EN\?5RMSQJ[.;'D1% S9(V-"/(
M)T$=6942\49#'"C;4BZJC<[=BM0(YCUPZ2I)&I_+V3/< 6QW&""&N\T<:.1Y
M'-['DES5LF,I W)%24A=)8YE%^0*&^+N+64M121Q(,2MIJI07>70"Y(-JJP/
MDM_@,<@D]0R5=DQMRLMB1J%&Y%I3W#"#[%HYE*(O!BQ(F-B\_B+I+TMJEA<[
M$CMM"5=]I%;4*NI(&PP      X5'O<_[";_<7 #\Q371_;:UB_\ %/J#_P![
M4N'>["/[IW7^SJ;\2P\A-Y?]X^(/VW7?I4IJP,A,)            O3'6.9U
MER;QK&V,XJ\S6=3!T(9HW&&!)>L<W1>HK6M+"R[=@LE.05;<:>>;<60F(LO-
M-OL*LOOI2UM;27=2R5U=(V*DB;G.<Y;$1/\ VR(B95541$551"NNN[+POJ\8
M;INF%]1>50]&1QL2USW+EL1/@1%556Q&M17.5$153]'OLYL$:@M..E>!XOU*
M9;.RSD-ILO.*O,NHX%8^CQR9(6TXT1RH_P"-)DCB]I-]+%RKV2]VJD3UJC3)
MJCI1C>^+FOS$$MX7'3)34;LB^;G7(JVRJSR,5]J6M3RV9[O3<X]5=T6%L4X/
MP7!<V+J]U=>37*YJ*N<E-$K6HVE;*OIS-C5'.1S[<S/YF->9BB1-Z1B)LX "
M-0^^73^&6?!2!()(0                   C5/W0;/\=_P%HE/(H)(0
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MDF;DRNKAM6NXPP\BVP =_H      MO[W?CC^=!/G!)(??+I_#+/@I  DA
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M/@I D$D(                   1JG[H-G^._P" M$IY%!)"
M       $:\?<Q9]AK^W02GE!)"                     1K9]8L_E)?\(N
M$J"2$                   (W[[_BW^-"?-]L$D(
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MUM?_ *A8H*[G=O\ &/<C]Z"Q0.=V_P 8]R/WH+% YW;_ !CW(_>@L4#G=O\
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+C;;&U]GZ@><'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>tm2213007d1-fc_corpobw.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2213007d1-fc_corpobw.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!N@.: P$1  (1 0,1 ?_$ :(    & @,!
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M;^_=>Z]_PU#V+_WN%_F_?^CJ^+'_ -QO[]U[KW_#4/8O_>X7^;]_Z.KXL?\
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MQMN]>Y_9>[]LT6Z-G9[#[<P<F)S.U=[86GKJ3*XJ5*!%?&[DP5=&Y( $]/(
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M4#_Z31\S_P#[K+W[KW7O[N?S\_\ G\O\H'_TFCYG_P#W67OW7NO?W<_GY_\
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MZ]U[^[G\_/\ Y_+_ "@?_2:/F?\ _=9>_=>Z]_=S^?G_ ,_E_E _^DT?,_\
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M7F)K*C'93?FS,;D*20Q5=!D-T8.CK*64 $Q5%+45T<\,@!!TLH//OW7NH?\
MI7ZM_P"?E; _]#+;O_UQ]^Z]U[_2OU;_ ,_*V!_Z&6W?_KC[]U[KW^E?JW_G
MY6P/_0RV[_\ 7'W[KW7O]*_5O_/RM@?^AEMW_P"N/OW7NO?Z5^K?^?E; _\
M0RV[_P#7'W[KW7O]*_5O_/RM@?\ H9;=_P#KC[]U[KW^E?JW_GY6P/\ T,MN
M_P#UQ]^Z]U[_ $K]6_\ /RM@?^AEMW_ZX^_=>Z]_I7ZM_P"?E; _]#+;O_UQ
M]^Z]U[_2OU;_ ,_*V!_Z&6W?_KC[]U[KW^E?JW_GY6P/_0RV[_\ 7'W[KW7O
M]*_5O_/RM@?^AEMW_P"N/OW7NO?Z5^K?^?E; _\ 0RV[_P#7'W[KW7O]*_5O
M_/RM@?\ H9;=_P#KC[]U[KW^E?JW_GY6P/\ T,MN_P#UQ]^Z]U[_ $K]6_\
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M /6KW[KW7O\ AE/^4A_WKE^'_P#Z([8__P!:O?NO=>_X93_E(?\ >N7X?_\
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M[JT+_AE/^4A_WKE^'_\ Z([8_P#]:O?NO=>_X93_ )2'_>N7X?\ _HCMC_\
MUJ]^Z]U[_AE/^4A_WKE^'_\ Z([8_P#]:O?NO=>_X93_ )2'_>N7X?\ _HCM
MC_\ UJ]^Z]U[_AE/^4A_WKE^'_\ Z([8_P#]:O?NO=>_X93_ )2'_>N7X?\
M_HCMC_\ UJ]^Z]U[_AE/^4A_WKE^'_\ Z([8_P#]:O?NO=>_X93_ )2'_>N7
MX?\ _HCMC_\ UJ]^Z]U[_AE/^4A_WKE^'_\ Z([8_P#]:O?NO=>_X93_ )2'
M_>N7X?\ _HCMC_\ UJ]^Z]U[_AE/^4A_WKE^'_\ Z([8_P#]:O?NO=>_X93_
M )2'_>N7X?\ _HCMC_\ UJ]^Z]U[_AE/^4A_WKE^'_\ Z([8_P#]:O?NO=>_
MX93_ )2'_>N7X?\ _HCMC_\ UJ]^Z]U[_AE/^4A_WKE^'_\ Z([8_P#]:O?N
MO=>_X93_ )2'_>N7X?\ _HCMC_\ UJ]^Z]U[_AE/^4A_WKE^'_\ Z([8_P#]
M:O?NO=>_X93_ )2'_>N7X?\ _HCMC_\ UJ]^Z]U[_AE/^4A_WKE^'_\ Z([8
M_P#]:O?NO=>_X93_ )2'_>N7X?\ _HCMC_\ UJ]^Z]U[_AE/^4A_WKE^'_\
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M[_TICI?_ .S7W[KW7O\ APSX!_\ ><?P^_\ 2F.E_P#[-??NO=>_X<,^ ?\
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MGP#_ .\X_A]_Z4QTO_\ 9K[]U[KW_#AGP#_[SC^'W_I3'2__ -FOOW7NO?\
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MFOOW7NO?\.&? /\ [SC^'W_I3'2__P!FOOW7NO?\.&? /_O./X??^E,=+_\
MV:^_=>Z]_P .&? /_O./X??^E,=+_P#V:^_=>Z]_PX9\ _\ O./X??\ I3'2
M_P#]FOOW7NO?\.&? /\ [SC^'W_I3'2__P!FOOW7NO?\.&? /_O./X??^E,=
M+_\ V:^_=>Z]_P .&? /_O./X??^E,=+_P#V:^_=>Z]_PX9\ _\ O./X??\
MI3'2_P#]FOOW7NJL/YSFX/@O_,._E[]V]#;+^>?Q-P_<F)Q\?:G0&8QORMZ?
MPM13=R[ H\C6;:P\F0@W]31TN/WYC*ROVU5S2ZXZ:DS,DX4R1(1[KW51'_"3
MC#?$OXB?$'>7R/\ D+\P_CKM'NSY)9ML/MKKOL#Y&]:87.]5])]?97)8_$8R
MJVEN#>-+6[4S>_MW_?96L@:"-IL;!B7(5@P]^Z]UMC?\.&? /_O./X??^E,=
M+_\ V:^_=>Z]_P .&? /_O./X??^E,=+_P#V:^_=>Z]_PX9\ _\ O./X??\
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MZL?:"_&P;CH,!L3L)ZO?E!6)0P8>"G7%XJ%YFCJDB]U[K<8_X?<_EG_\_/\
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MEJRCI<MO'=%#2/63)'14GG$E1+%"K2+[KW0G?\-Y_ /_ +P<^'W_ *3/TO\
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MO"9:EBK<;E,;74^S'@JJ.MI)EDC=205;W[KW2@_X;S^ ?_>#GP^_])GZ7_\
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MW7NO?\-Y_ /_ +P<^'W_ *3/TO\ _85[]U[KW_#>?P#_ .\'/A]_Z3/TO_\
M85[]U[KW_#>?P#_[P<^'W_I,_2__ -A7OW7NO?\ #>?P#_[P<^'W_I,_2_\
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MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JH'<?\
MV_SZ:_\ &0/R7_\ @S_B;[]U[JW[W[KW7O?NO=>]^Z]U3C_,9^.??_RVVMWN
M>JY*#9>Z_CSL?:6Y_BW-N[JW+Y_,[I^1_7V\MF_);:N^.MMVXCL?:]-@,94]
MG=2[0VO)/6T%;5TZT.7_ ,G&.KXY:_W7N@#^6&!^47R*J:VOW)\7?DA5U&[,
M5_+D[0Z/V=MG=E!0;4ZEW%UG\GMM;Y^5G7'9U''VGMG9X[*P$-*)Y<E6PU6
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M:%2B1K%'[KW5A?OW7NO>_=>Z)]_,,_[(#^<?_BGWR8_]\OO7W[KW7OY>?_9
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M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJ@=Q_]O\ /IK_ ,9
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MGP>V_P#'6J[-WOV!L/I/.]U;Q^2?R][GV[V[MK;5%DM_;?V5\JN_][=X577
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M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJ@=Q_]O\ /IK_ ,9
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MEOACMC,9'/=VUN4WSO#(0T7?M%DCBLA5TE'C\-MN#!QU53YCE(_=>Z0O6_\
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M_P!')UU_]D?OW7NO?[-A\6?^\E>@/_1R==?_ &1^_=>Z]_LV'Q9_[R5Z _\
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M_P#;M]^Z]U[_ (9*^(O_ #]3Y_\ _IQ_YL__ &[??NO=>_X9*^(O_/U/G_\
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MZ]_PVW\NO^]TOS__ /0&^$W_ -RY[]U[KW_#;?RZ_P"]TOS_ /\ T!OA-_\
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M_P#N7/?NO=>_X;;^77_>Z7Y__P#H#?";_P"Y<]^Z]U[_ (;;^77_ 'NE^?\
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MQ5U(M*]5122QLB5=,E=35M$]13,P=!-#+$64:T9;J?=>ZJ,Z,^2O>G:/4GP
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MP];0;CP6\ML5M+5$4Z4U2\7W%*TM)+!-)[KW5;/\F_\ YEU\]O\ QK]_,_\
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MFJ(Y!6, (O&-?NO="E_LF7\V7_O='_[3G^-?_P!E/OW7NO?[)E_-E_[W1_\
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M[,?=>Z<O]DR_FR_][H__ &G/\:__ +*??NO=>_V3+^;+_P![H_\ VG/\:_\
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M9_\ MV^_=>Z]_P ,E?$7_GZGS_\ _3C_ ,V?_MV^_=>Z]_PR5\1?^?J?/_\
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MD=;;:R>\^Q=X[5V#L_"0FIS.Z]Z[AQ&U=M8BG'UGR>=SM908N@A'^KEE1?\
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M]Q)O[,MF*C)U=8^2?(2&4$",)[KW0,;=^ '5FP<_\?MR=4[_ .W>JLE\8OC
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MN>PU0V]_CEM/"[3VK5=&;RW/X(\]D-[U&XJ+$4NX<+E(J&CR,U9[KW0Q;S[
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M2U\__P#T.?A-_P#=1^_=>Z]_PY)\NO\ O2U\_P#_ -#GX3?_ '4?OW7NO?\
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M_:<_QK_^RGW[KW7O]DR_FR_][H__ &G/\:__ +*??NO=>_V3+^;+_P![H_\
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M["[#J>PNO/BQB^T*:GH3U/AMF=R=MY[86;JF%1_$D[#W+F^B=M[AVO3PL(O
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M '_I&_QU_P#M<^_=>Z]_PT[_ "LO^]:?P _](W^.O_VN??NO=>_X:=_E9?\
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M?/\ _P#3C_S9_P#MV^_=>Z]_PR5\1?\ GZGS_P#_ $X_\V?_ +=OOW7NO?\
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MI4XO-4\Z!$E6-?=>ZL.]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=$^_F&?\
M9 ?SC_\ %/ODQ_[Y?>OOW7NO?R\_^R _@Y_XI]\9_P#WR^RO?NO='!]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=5,_+3XE_-K/?-KJ_YJ?"
MOM#XL;1W3M'XL=B_%W<^V/E%UUVUV!@,C@.P.VNN^V*C/8&GZG[$ZUR-'F*/
M(]:T5.CU%;-"(9IP8&9HY(O=>Z9_[N?S\_\ G\O\H'_TFCYG_P#W67OW7NO?
MW<_GY_\ /Y?Y0/\ Z31\S_\ [K+W[KW7O[N?S\_^?R_R@?\ TFCYG_\ W67O
MW7NO?W<_GY_\_E_E _\ I-'S/_\ NLO?NO=>_NY_/S_Y_+_*!_\ 2:/F?_\
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M 55  %O?NO=9O[N?S\_^?R_R@?\ TFCYG_\ W67OW7NO?W<_GY_\_E_E _\
MI-'S/_\ NLO?NO=>_NY_/S_Y_+_*!_\ 2:/F?_\ =9>_=>Z]_=S^?G_S^7^4
M#_Z31\S_ /[K+W[KW7O[N?S\_P#G\O\ *!_])H^9_P#]UE[]U[KW]W/Y^?\
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;^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
